Studies on asymmetric approaches to (-)-cytisine and related molecules by Bisset, Alexander A.
  
 
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap  
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
http://go.warwick.ac.uk/wrap/58474 
 
 
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to 
cite it. Our policy information is available from the repository home page.  
 
 
 
 


1Studies on Asymmetric Approaches to (-)-Cytisine
and Related Molecules.
Alexander Arnold Bisset.
Ph.D.
University of Warwick.
Department of Chemistry.
February 2013.
2Table of Contents
Acknowledgements.....................................................................................................5
Declaration and Inclusion of Published Work ........................................................6
Abstract .......................................................................................................................7
Abbreviations .............................................................................................................8
Section 1: Introduction ............................................................................................11
Section 1.1: Chirality..............................................................................................11
Section 1.2: Asymmetric Synthesis .........................................................................13
Section 1.2.1: Aldol Reactions ...........................................................................14
Section 1.2.2: Heck Couplings ...........................................................................16
Section 1.2.3: Sigmatropic Rearrangements.......................................................17
Section 1.2.4: Asymmetric Alkene Hydrogenation............................................18
Section 1.3: (-)-Cytisine..........................................................................................25
Section 1.3.1: Introduction .................................................................................25
Section 1.3.2: The Synthesis of (-)-Cytisine.......................................................27
Section 1.3.3: Related Syntheses ........................................................................41
Section 1.3.4: Pharmacological Studies..............................................................48
Section 1.4: (-)-Sparteine and Related Compounds ...............................................49
Section 1.4.1: Introduction .................................................................................49
Section 1.4.2: Synthetic Approaches to (-)-Sparteine and Related Compounds 50
Section 1.5: Asymmetric Syntheses of γ- and δ- Lactams  ...................................... 60
Section 1.6: Conclusion..........................................................................................60
Section 2: Results and Discussion ...........................................................................61
Section 2.1: 1st Generation Formal Synthesis of (-)-Cytisine: AH of Enamide 1...61
Section 2.1.1: Introduction .................................................................................61
Section 2.1.2: Synthesis and Hydrogenation of Enamide 1................................65
Section 2.1.3: Completion of the Formal Synthesis of (-)-Cytisine ...................73
Section 2.1.4: The Attempted Synthesis of (-)-Sparteine ...................................78
3Section 2.1.5: Future Work.................................................................................80
Section 2.2: ATH of Enamides, β-(Acylamino)acrylates, Tetramic acids and 5-
Acetyluracil.............................................................................................................81
Section 2.2.1: ATH of Enamides........................................................................82
Section 2.2.2: Synthesis and ATH of β-(Acylamino)acrylates. ......................... 86 
Section 2.2.3: Synthesis and ATH of N-Boc Tetramic Acids. ...........................88
Section 2.2.4: ATH of 5-Acetyluracil.................................................................96
Section 2.3: 2nd Generation Formal Synthesis of Cytisine: AH of Pyridone 2.....101
Section 2.3.1: Introduction ...............................................................................101
Section 2.3.2: Synthesis and AH of Pyridone 2................................................102
Section 2.3.3: Completion of the Synthesis......................................................107
Section 2.3.4: Synthesis and AH of 5-Substituted Pyridones...........................108
Section 2.4: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine): AH of
Pyridone 3 ............................................................................................................115
Section 2.4.1: Reduction of Imide 235 .............................................................115
Section 2.4.2: Synthesis and AH of Pyridone 3................................................117
Section 2.4.3: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine) 6 .122
Section 2.4.4: Synthesis and AH of Enamide 301............................................123
Section 2.5: Asymmetric Synthesis of Alcohols 7a and 7b ...................................125
Section 2.5.1: Introduction ...............................................................................125
Section 2.5.2: Preliminary Synthesis and ATH of Ketones .............................127
Section 2.5.3: Synthesis and ATH of Pyridyl Alkyl / Aryl Ketones ................132
Section 2.5.4: Asymmetric Synthesis of Diastereomers 7a and 7b..................136
Section 2.5.5: Synthesis of Bromides (D1)-306a and (D2)-306b ....................141
Section 2.5.6: Synthesis of Amines 308a and 308b .........................................145
Section 2.6: Conclusion........................................................................................148
Section 3: Experimental Procedures ........................................................................149
Section 3.1: Procedures from Section 2.1 ............................................................150
4Section 3.1.1: Synthesis and Hydrogenation of Enamide 1..............................150
Section 3.1.2: Completion of the Formal Synthesis of (-)-Cytisine .................161
Section 3.1.3: The Attempted Synthesis of (-)-Sparteine .................................169
Section 3.2: Procedures from Section 2.2 ............................................................174
Section 3.2.1: ATH of Enamides......................................................................174
Section 3.2.2: Synthesis and ATH of β-(Acylamino)acrylates. ....................... 179 
Section 3.2.3: Synthesis and ATH of N-Boc Tetramic Acids. .........................183
Section 3.2.4: ATH of 5-Acetyluracil...............................................................193
Section 3.3: Procedures from Section 2.3 ............................................................196
Section 3.3.1: Synthesis and AH of Pyridone 2................................................196
Section 3.3.2: Completion of the Synthesis......................................................200
Section 3.3.3: Synthesis and AH of 5-Substituted Pyridones...........................203
Section 3.4: Procedures from Section 2.4 ............................................................213
Section 3.4.1: Reduction of Imide 235 .............................................................213
Section 3.4.2: Synthesis and AH of Pyridone 3................................................213
Section 3.4.3: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine) 6 .217
Section 3.4.4: Synthesis and Hydrogenation of Enamide 301..........................219
Section 3.5: Procedures from Section 2.5 ............................................................220
Section 3.5.1: Synthesis of Ketones .................................................................220
Section 3.5.2: ATH of Ketones.........................................................................228
Section 3.5.3: Asymmetric Synthesis of Diastereomers 7a and 7b..................238
Section 3.5.4: Synthesis of Amine 308a...........................................................243
Section 3.5.5: Synthesis of Amine 308b ..........................................................246
Section 3.5.6: Attempted Synthesis of Pyridone 307 .......................................250
References ................................................................................................................252
Appendix I: NMR Spectra .......................................................................................264
Appendix II: X-Ray Crystal Structures....................................................................272
Appendix III: Chiral HPLC and GC Traces.............................................................280
Appendix IV: Catalyst and Ligand Structures from Section 2 ................................288
5Acknowledgements.
First of all, I should like to thank Martin, for your devotion and persistent help
throughout this project. Thank you for teaching me to aim higher and reach further
than I thought was possible. I should like to thank everyone from the Wills group for
always being supportive during my time here: thanks to Zhijia (Amphy) Fang, Andy
Rawlings, Charles Manville, Charlotte Zammit, Dave Morris, Eduardo Martins, Jon
Hopewell, Katie Jolley, Mofta Darwish, Rina Soni, Tarn Johnson, Vicky Marlow
and Vimal Parekh.
I should like to thank everyone at AstraZeneca for my time on placement in Alderley
Park, and for financial support. In particular, I should like to thank Allan Dishington,
Gail Wrigley and Teyrnon Jones for supervising me.
Thanks to everyone who contributed towards this project. In particular, thanks to
Akira Shiibashi, for your work during the preliminary study; Jasmine Desmond, for
your work during your MChem project; Guy Clarkson, for X-ray crystallography;
Per Ryberg, for carrying out the asymmetric hydrogenation screens; and the EPSRC,
for crystallography.
Thanks to all the support staff at Warwick and AstraZeneca. In particular, thanks to
Ivan Prokes and Edward Tunnah in NMR; Phil Aston and Lijiang Song in MS; and
Rob Jenkins for technical support.
I should like to thank my Mum and Dad, my family and all my friends for your
support during this time. And lastly, I should like to thank God, for always
encouraging me to carry on no matter what.
6Declaration and Inclusion of Published Work.
This thesis is submitted to the University of Warwick in support of my application
for the degree of Doctor of Philosophy. It has been composed by myself and has not
been submitted in any previous application for any degree, apart from the
asymmetric transfer hydrogenation (ATH) of enamide 1 in Section 2.2.1, which was
previously submitted as part of Jasmine Desmond’s final year MChem research
project. The work presented (including data generated and data analysis) was carried
out by the author except in the cases outlined below:
Section 2.1.1: During a preliminary study, the synthetic route and AH of enamides 1
and 227 was initially developed by Akira Shiibashi, a visiting PhD researcher who
also obtained the X-ray crystal structures of these compounds (Figure 2.1.2).
Subsequent work during this PhD project further developed and optimised the
synthesis and hydrogenation of 1. Section 2.2.1: Jasmine Desmond contributed
towards the ATH of enamide 1 as part of her MChem project whilst under joint
supervision with Martin Wills and the author. Sections 2.3 and 2.4: Per Ryberg
undertook the AH screen of pyridone substrates 2 and 3. The synthesis and
characterisation of these compounds was carried out by the author. All X-ray
structures in this thesis were determined by Guy Clarkson, except compound 269
which was determined by the EPSRC Crystallographic Service in liaison with Guy
Clarkson.
Parts of this thesis have been published by the author in the following publication:
Bisset, A. A.; Shiibashi, A.; Desmond, J. L.; Dishington, A.; Jones, T.; Clarkson, G.
J.; Ikariya, T.; Wills, M. Chem. Commun., 2012, 48, 11978-11980.
7Abstract.
In this project, the asymmetric pressure and transfer hydrogenation of a number of
substrates was carried out in attempt to asymmetrically form 5-substituted 6-
membered saturated heterocycles, directly applicable to the asymmetric synthesis of
(-)-cytisine and other related compounds. The hydrogenation of N-acyl-
aminoacrylate-like enamide 1 was successful, resulting in the formation of 5-
substituted glutarimide 218 in up to 94 % ee. Unfortunately, subsequent reduction
resulted in epimerisation and loss of ee, preventing an asymmetric synthesis of (-)-
cytisine precursor 5. The asymmetric reduction of pyridones 2 and 3 (featuring
proximal coordinating groups) did not proceed with any enantioselectivity; however,
the racemic reduction products were successfully utilised in novel syntheses of
cytisine precursor 5 and bispiperidine 6 respectively. The ATH of pyridyl methyl
ketone 4 with (R,R)-RutethTsDPEN, (R,R)-248 resulted in the formation of pyridyl
alcohol 303 in 78-83 % ee. This compound was converted to diastereomers (D1)-7a
and (D2)-7b which are derivates of a cytisine precursor and other therapeutic targets.
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MS mass spectroscopy.
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Mp melting point.
μL     microlitre. 
mmol millimole.
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N/A not applicable.
N/O not obtained.
nOe nuclear Overhauser effect
ppm parts per million.
Prep preparatory.
q quartet.
quin quintet.
RT room temperature.
s second or singlet.
SAR structure activity relationship.
t triplet.
TFA trifluoroacetic acid.
TLC thin layer chromatography.
TMS trimethylsilane.
TsCl tosyl chloride.
νmax absorption.
w/r with respect to.
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Section 1: Introduction.
Section 1.1: Chirality.
In 1815, the French scientist Biot made the observation that certain substances (such
as solution of sugar) had the ability to rotate a plane of polarised light to a certain
degree. Biot attributed this phenomenon to be a property of the individual molecules
of the substance; however, due to the limited understanding of the time, the origin of
this effect was unknown.1 2 In some cases, two ‘forms’ of an identical compound
were known to rotate plane polarised light in different directions, an example being
lactic acid (Figure 1.1). One was known to be isolatable from muscle during
exercise; this was observed to rotate light in a positive direction (dextrorotatory). A
second form was known to be isolatable from fermented milk; this was observed to
rotate light in a negative direction (termed levorotatory).
Figure 1.1: Enantiomeric ‘forms’ of lactic acid.
In 1860, Pasteur went on to suggest that this type of observation resulted from the
asymmetric arrangement of atoms in a molecule. Following the concept of the three
dimensional tetrahedral carbon atom by van’t Hoff 3 and Le Bel 4 in 1875, these
combined ideas brought about the realisation that it was the asymmetric arrangement
of four inequivalent atoms bonded to a carbon atom, that resulted in optical activity.
For the example of lactic acid, this is the origin of its optical activity. The two forms
(or enantiomers) of lactic acid shown are non-superimposable mirror images of each
other; each has the affect of rotating light in the opposite direction. As a general rule,
12
it is found that when mirror images of a molecule are not superimposable, the
molecule will be optically active.
When two chiral centres are present in a molecule, a different type of isomerism
occurs, due to the multiple arrangements of adjacent stereocentres that are possible.
These isomers are called diastereomers. An example are tetroses, the four carbon
sugars (Figure 1.2). Due to the two asymmetric carbon atoms, there are four possible
arrangements or isomers, as shown. Isomers a and b of erythrose are mirror images
of each other (or enantiomers). Isomers c and d of threose are also enantiomers of
each other. However, isomers a and c, (-)-erythrose and (-)-threose, are not mirror
images of each other. The same is for isomers b and d. These are both called
diastereomers. Diastereomers often have completely different chemical properties
(such as the melting point), whereas enantiomers have identical chemical properties.
Figure 1.2: Enantiomers and diastereomers.
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Section 1.2: Asymmetric Synthesis.
Due to the prevalence of chirality in nature, a major theme of organic chemistry has
been asymmetric synthesis. As a large proportion of biological molecules found in
nature are chiral and present as a single enantiomer; consequently, enantiomers of
drug molecules can have drastically different physiological and biochemical effects;
for instance, the thalidomide tragedy.5 Chirality is therefore a crucial consideration
in the development and synthesis of drugs.6
Single enantiomers of compounds have traditionally been obtained by the resolution
of racemic mixtures by chemical or chromatographic means. The chiral pool of
organic starting materials has also been an important contribution to synthetic
chemistry. However, now, asymmetric options for many important synthetic
transformations are available, enabling the selective formation of one enantiomer
over another.7 Asymmetric transition metal catalysts are commonly used, and
asymmetric organo-catalysis is developing rapidly.
In this section, instead of reviewing well known asymmetric transformations, such as
Sharpless’ asymmetric dihydroxylation, a selection of recent asymmetric
developments of important catalytic transformations will be briefly illustrated, to
show the utility of these modern methods in the synthesis of therapeutically
important compounds. The main topic of this theme, asymmetric alkene
hydrogenation, will then be discussed in more detail.
14
Section 1.2.1: Aldol Reactions.
Aldol reactions have been a powerful tool in C-C bond formations because two
chiral centres may be formed in the transformation. The control of the
diastereoselectivity of the reaction has been widely studied to enable the formation
of syn or anti products, through the use of specific reagents. This is related to the
geometry of the intermediate enolate, which may be influenced by the base and
conditions used in the enolisation reaction. Early enantioselective modifications of
this transformation were achieved by use of chiral auxiliary templates, but
asymmetric transition metal catalyst-based methods were later developed. An
example is a process developed by Carreira, 8 which catalyses the asymmetric aldol
addition of dienolsilanes to aldehydes, utilising a chiral copper based Tol-BINAP-
CuF2 complex (Scheme 1.1a). The aldol addition of dienolate 8 to furfural proceeded
to form the adduct 9 in 94 % ee and 95 % yield. In this case, adduct 9 was then used
in the synthesis of the polyol subunit of the natural product, amphotericin.
More recently, asymmetric organocatalysis has risen to prominence. Following the
first report of an asymmetric intermolecular aldol reaction by Barbas and List,9
proline derived organocatalysts have become highly effective in this
transformation.10 An interesting example is the proline-based aminoboronic acid,
homoboroproline (S)-12, developed by Whiting et al (Scheme 1.1b).11 Bifunctional
catalysts of this type enable formation of aldol products with a similar magnitude of
enantioselectivity to that observed with L-proline. The system operates through
combination of the catalytically active proline-derived unit, (S)-12 with a chiral diol
such as (R,R)-tartrate, resulting in the in situ formation of the active catalyst, 13.
15
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14
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c.
R=(R,R)-diethyl tartrate.
Scheme 1.1: Examples of asymmetric aldol reactions.
In the example shown (Scheme 1.1b), the reaction between p-nitrobenzaldehyde 10
and acetone was catalysed by 20 mol % of the precatalyst, (S)-12 and (R,R)-diethyl
tartrate, resulting in formation of the adduct (S)-11 in 78 % yield and 90 % ee. The
combined nucleophilic secondary amine and Lewis acidic boronic acid groups have
been shown to be a necessary for activity. A bifunctional catalytic process involving
the active catalyst, 13 and a six-membered transition state have been suggested to
explain to the observed configuration in comparison to L-proline.11a Other interesting
recent work in this area includes the chiral cis-diamine-based Tf-amido
organocatalyst, 14 by Moteki et al 12 which has been used in the aldol reaction
between cyclohexanones and α-keto esters in up to 94 % ee and 8 : 1 dr. Chiral 
aminals have also been used in the organocatalysis of the α-amination of 
aldehydes.13
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Section 1.2.2: Heck Couplings.
Asymmetric Heck couplings have enabled the formation of otherwise difficult chiral
centres 14; for instance, the synthesis of α -arylated 15 or -benzylated furans 16, 16 or
18. An asymmetric Heck reaction with a benzylic electrophile was recently
published by Zhou (Scheme 1.2a).17a Problems with isomerisation and slow olefin
insertion encountered with benzylic electrophiles had previously prevented success
in this area. The reaction between benzyl trifluoroacetate and 2,3—dihydrofuran 15
with phosphoramidite ligand 20 proceeded to form 2-benzyl-2,5-dihydrofuran 16 in
72 % yield and 94 % ee on a 10 mmol scale. The product 16 has direct use in the
formation of analogues of adenophostin A, a potent IP3 receptor agonist, useful in
the investigation of IP3-mediated Ca2+ signalling pathways.18 In a second similar
example, the asymmetric palladium catalysed phenylation of 2,3-dihydrofuran 17
with the novel phosphite-oxazole ligand 21 resulted in the formation of the arylated
product 18 in high regioselectivity and 98 % ee (Scheme 1.2b).19
Scheme 1.2: Examples of asymmetric Heck reactions.
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Section 1.2.3: Sigmatropic Rearrangements.
In the following examples of sigmatropic rearrangements, these transformations
proceed with retention of existing chirality. Asymmetric sigmatropic rearrangements
have however been studied, 20 and recently the first example of an asymmetric Cope
rearrangement of an achiral diene was published.21
In the first example, a thermal uncatalysed aromatic Claisen rearrangement was
employed in the formation of a benzylic chiral centre, during the synthesis of the
aromatic bisabolene sesquiterpene, (+)-7,11-helianane 24 (Scheme 1.3a). The
starting material, ether 22, was asymmetrically formed in 82 % ee with Trost’s
palladium catalysed allylic alkylation. A subsequent Claisen rearrangement resulted
in the formation of the product 23 in up to 80 % ee.22 An interesting synthesis of
oxindoles was achieved through the reaction between an enantiomerically pure
nitrone (25) and an aryl-alkyl ketene 26 (Scheme 1.3b). The reaction proceeded
through what was proposed to be a 1,3-dipolar cycloaddition and subsequent hetero-
[3,3]-sigmatropic rearrangement to form oxindole 27 in 96 % ee and 84 % yield.23
Other interesting examples include the asymmetric synthesis of allenes from tertiary
propargylic alcohols and methyl aryl-diazoacetates via a rhodium-catalysed tandem
oxonium ylide formation and subsequent [2,3]-sigmatropic rearrangement.24
18
Scheme 1.3: Examples of asymmetric sigmatropic rearrangements.
Section 1.2.4: Asymmetric Alkene Hydrogenation.
Heterogeneous hydrogenations have been widely known for a long time, 25a but it
was only in 1965 that Wilkinson showed the first case of homogeneous transfer
hydrogenation with the rhodium catalyst RhCl(PPh3)3.25b The iridium catalyst,
[Ir(PCy3)py(COD)]PF6 (Crabtree’s catalyst), was later developed by Crabtree in the
1970s. Later work by Knowles and Horner involving chiral phosphine analogues of
Wilkinson’s catalyst started the initial development of asymmetric alkene
hydrogenation.26 27 An important development was the asymmetric synthesis of L-
DOPA 31, a rare amino acid used in the treatment of Parkinson’s disease, using a
complex of the chiral diphosphine, DiPAMP 36 (Scheme 1.4a). Enamide 29 (a direct
19
precursor of L-DOPA) was reduced in up to 94 % ee.28 This process was used in the
industrial large scale synthesis of the amino acid. The use of enamides in the
synthesis of β-amino acids sparked further research into this area, and enamides have 
subsequently become a ‘benchmark’ in the rating of catalytic activity. In the mid-
80s, Noyori and Takaya achieved the highly successful asymmetric hydrogenation
(AH) of α,β-unsaturated carboxylic acids with ruthenium complexes of 2,2’-
bis(diarylphosphino)-l,l’-binaphthyl (BINAP), such as (S)-RuBINAP)(OAc)2 37a.29-
30 An example is the asymmetric synthesis of (S)-naproxen (S)-33 (an useful anti-
inflammatory agent) via reduction of the α-naphthyl unsaturated carboxylic acid, 32
(Scheme 1.4b).29
CO2H
MeO
CO2H
MeO
(S)-33
97 % ee
32
0.5 mol % (S)-37a
MeOH
135 atm H2
12 h, rt
PPh2
Ph2
P
Ru
O
O
O
R
R
O
(S)-RuBINAP(OR)2
NHCOMe
CO2H
NHCOMe
CO2H
OAc
OMe
OAc
OMe
NH2
CO2H
OH
OH
L-DOPA 31
0.1 mol % [RhCODCl]2
0.2 mol % DiPAMP 36
3 atm H2, 50 °C, 1h
29 30
94 % ee
(R,R)-DiPAMP 36
P
P
Ph
Ph
OMe
MeO
HBr
O
O
O
O
34
35
a.
b.
37a R = CH3
37b R = CF3
c.
Scheme 1.4: a. Synthesis of L-DOPA; b. reduction of carboxylic acids with Ru(II)-BINAP.
Using 0.5 mol % (S)-37a with a high pressure of 135 atm H2, (S)-33 was obtained in
97 % ee (Scheme 1.4b). Hydrogenation of oxygen-functionalised unsaturated
20
carboxylic acids has also enabled the asymmetric synthesis of otherwise difficult
targets, such as the substituted lactones 34 and 35 (Scheme 1.4c).29
Following these two examples of initial advances, a plethora of asymmetric ligands
were developed for the hydrogenation of a range of substrate types. The C2-
symmetic bisphospholanes, DuPHOS 40 (Figure 1.3) and Me-BPE 53 (Scheme 1.5)
developed by Burk have been two of the most successful ligands in the
hydrogenation of (E)- and (Z)- amino acrylates. The Josiphos ferrocene-based
biphosphenes 38 originally developed by Togni and Spindler were a unique class of
ligands, due to potential modulation of the side chain through an alteration of the
synthesis.31 This enabled the fine-tuning of these ligands to acquire the properties
necessary for optimum interaction with the substrate, enabling the ligand class to be
used in multiple applications. From this class, the Mandyphos 39 and Taniaphos 41
types were later developed (Figure 1.3).32
Figure 1.3: Ligands developed by Solvias.
The term ‘privileged ligand’ was coined to ligand families which had high success in
certain transformations. The further development of ligands has generally involved
the further modulation of these privileged ligand families to generate a diverse range
21
of sub-types with steric and electronic diversity, with the intention that a suitable
ligand may be available for any transformation.33-34 The fine chemicals company,
Solvias have taken this approach in preparing libraries of different derivatives of
privileged ligands, including those based upon DuPHOS, BINAP, PAMP or
JosiPHOS ligand backbones.
AH of β,β-disubstituted acylamino acrylates. 
Despite there being many good examples of the AH of unsubstituted acylamino
acrylates, there are relatively fewer examples featuring β,β-disubstituted substrates, 
since these have proven to be more challenging. Reactions 1-5 (Scheme 1.5) show
five examples of the hydrogenation of β,β-disubstituted substrates. Wada 
35 achieved
the reduction of cyclohexene-fused β,β-disubstituted acylamino acrylate 42 to give
43 in 89 % ee, using the [Rh(COD)2]BF4 complex of chiral diphosphine 55 (reaction
1). However, with the chiral phosphine tBu-MiniPHOS 52, Imamoto 36 achieved the
reduction of 42 in 97 % ee (reaction 2). Two excellent examples by Burk 37 feature
hydrogenation of the similar ring fused β,β-disubstituted acylamino acrylates, 46 and
48 in 98 % and 99 % ee respectively with 0.2 mol % of the Rh-Me-BPE complex 53
(Scheme 1.5, reactions 3 and 4).
It has been shown that the mechanism of hydrogenation proceeds through the
coordination of the alkene and acyl carbonyl groups to the rhodium atom (Figure
1.4). This co-ordination is very important in the mechanism and generally reductions
without the acyl group have low enantioselectivities.38
22
Scheme 1.5: Reduction of β-disubstituted aminoacrylates.
Figure 1.4: Coordination mode of acylamino acrylate reductions with Rh(II).
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However, in some cases, enantioselectivity has been observed without the N-acyl
coordinating group being present in the substrate. Collaboration between Rosner and
Solvias achieved the reduction of β,β-disubstituted unprotected enamine, 50. Using
the Rh-ferrocenophosphine complex derived from [Rh(COD)Cl]2 and ligand 54,
reduction in methanol at 50 °C, under 90-100 psi of hydrogen, resulted in the
formation of amine 51 in over 95 % ee.39 Limited evidence suggested that the
mechanism proceeded through reduction of the imine tautomer, involving 1,5-
chelation of the catalyst. The product of this reduction, i.e. 51, is ideally suited to the
synthesis of β-amino acids without the necessity of acyl removal. 
In contrast to amino acrylates, there are a limited examples of enantioselective
reductions of olefins with aprotic oxygen or nitrogen groups; for example, α,β-
unsaturated esters and lactones. Takaya achieved the enantioselective reduction of a
number of cyclic α,β-unsaturated ketones, alkylidene ketones and alkenyl ethers with 
Ru(II)-BINAP complexes (Scheme 1.6).40 The enantioselectivity of such reductions
has been shown to be dependent on the relative position of the alkene and oxygen
functionalities. Substrates (such as 56 and 58) with adjacent oxygen groups to the
alkene are thought to enable intra-chelation to the Ru(II) centre, resulting in good
enantioselectivity. However, endocyclic substrates such as 65 are reduced almost
racemically and it is thought that the corresponding co-ordination mode is not
formed. An example is 2-methylene-γ-butyrolactone 56. Reduction with (S)-37a
under 100 atm H2 resulted in the formation of lactone (R)-57 in 95 % ee (reaction 1).
Similarly, hydrogenation of α-methylene carbonate 58 was achieved in 95 % ee with
trifluoroacetate-derived Ru(II)-BINAP catalyst (S)-37b (reaction 2). This method has
been applied to the asymmetric synthesis of substituted diols.41 In a third example, α-
pyrone 60 was reduced with MeO-Biphep catalyst, (S)-68 in the presence of aqueous
24
HBF4, resulting in formation of 5,6-dihydropyrone 61 (a direct precursor to the anti-
obesity drug, tetrahydrolapstatin) in 94.7 % ee (reaction 3). Brief experimentation
with the pyridone analogues, 67 resulted in low enantioselectivity; the tautomeric
nature of the compounds was considered to be a contributing factor.42
Scheme 1.6: Reduction of aprotic functionalised olefins.
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A final example is the asymmetric synthesis of paradisone 63 ((+)-cis-methyl
dehydrojasmonate), a perfumery compound which is made on an industrial scale. β-
Oxoester 62 was reduced with [Ru-(-)-Me-DuPHOS(H)-(η6-cot)]BF4, (R,R)-69 (a
catalyst formed from (R,R)-MeDuPHOS, [Ru(1,2:5,6-η-cod)(η3-methallyl)2] and
HBF4) (reaction 4).43 Paradisone 63 was formed in up to 90 % ee as the cis
diastereomer only. The high enantioselectivity of this reduction in contrast to the
poor selectivity observed for 63 has been proposed to arise via the coordination
mode 66, in which the ruthenium centre is chelated between the alkene and ester
carbonyl groups.44
Section 1.3: (-)-Cytisine.
Section 1.3.1: Introduction.
(-)-Cytisine, 70 is a naturally occurring lupin alkaloid, found in the seeds of the plant
species Laburnum anagyroides, commonly known as ‘Golden Rain’.45 The alkaloid
consists of a piperidine core framework of two fixed piperidine cycles, A and B,
which are fused to a 2-pyridone ring (C) (Figure 1.5). Its absolute configuration was
established by Okuda et al.46
Figure 1.5.
Physiologically, the affects of (-)-cytisine are similar to (-)-nicotine; the alkaloid is
highly toxic and active at nicotinic acetylcholine receptors. (-)-Cytisine is only a
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partial agonist at these receptors, however it has a higher affinity than nicotine, with
higher selectivity towards the α4β2 type receptor and sub-nanomolar affinity, yet
exhibits comparable efficacy and potency in stimulating dopamine release, a key
factor in the feeling of pleasure associated with tobacco use.47 Consequently, it has
been used as a smoking cessation drug; in therapeutic administration among
smokers, cytisine is found to outbind nicotine and effect receptor stimulation
sufficiently for the user to overcome cigarette cravings.48 The drug varenicline 71 49a
was developed by Pfizer through structure-activity relationship (SAR) studies with (-
)-cytisine. The drug, ‘Tabex’, contains (-)-cytisine, for the same application.
There is also potential use for (-)-cytisine in the prevention of neurodegenerational
diseases such as Parkinson’s or Alzheimer’s diseases, in which nicotinic receptors
are altered in some way. Nicotinic acetylcholine receptors have been linked to many
diseases. There are many different subtypes, which are all involved in different
modes of action. However, their development as therapeutic targets has been limited
by the inability to target selectively the individual subtypes. There is a lack of
understanding of the SAR and specificity of active ligands to each subtype.50
Consequently, research into this area has been driven by the need to determine these
properties, and further discovery of highly selective subtype ligands.
(-)-Cytisine has been so widely studied because it has a uniquely high selectivity
towards the α4β2 type receptor with sub-nanomolar affinity, whereas generally
amongst the known ligands, selectivity is poor. It has a longer in vivo half life than (-
)-nicotine and crosses the blood brain barrier making it particularly advantageous
over other ligands. (-)-Cytisine has been routinely used as a benchmark in the study
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of these receptors in the brain via positron emission tomography (PET).51
[3H]Cytisine is commonly used. A synthesis of [F18]aryl cytisine has been developed
and is shown in the next section.
These combined issues have driven a large amount of synthetic research into the
alkaloid. There are now over ten total syntheses, although only three are asymmetric.
There have been may direct derivatisations of cytisine and synthesis of modified
related structures. In the following section, these synthetic strategies to (-)-cytisine
will be reviewed in detail, followed by a summary of the progression of the
pharmacological studies of derivatives.
Section 1.3.2: The Synthesis of Cytisine.
The past retrosynthetic approaches to cytisine have been thoroughly reviewed by
O’Brien 45, who categorised them according to the retrosynthetic approach taken for
the deconstruction of the bispidine core framework of the A, B or C rings. Although
there are few asymmetric syntheses of the alkaloid, the racemic strategies still
required careful diastereo-control to achieve the formation of the bispidine core
skeleton. In this review, the syntheses will be listed chronologically in accordance
with how the key diastereo- (and, if applicable, enantio-) selectivity was achieved.
These generally fell into four categories.
Routes involving hydrogenation of a pyridine intermediate.
The majority of past synthetic approaches to cytisine involved the hydrogenation of a
substituted pyridine intermediate to achieve the required 3,5-cis geometry of the
corresponding piperidine. During the hydrogenation, hydrogen addition to the same
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pyridine face resulted in formation of a product containing the required cis geometry.
All of the syntheses in this category were racemic. They also produced poor
precedent for any future asymmetric modification - the AH of pyridines has
generally resulted in poor enantioselectivity,52 with the exception of a number of
methods.53
Govindachari.
The first total synthesis of (±)-cytisine was achieved by Govindachari in 1957
(Scheme 1.7).54 The first step involved the condensation of 3,5-substituted pyridine
72 and diethyl ethoxymethylenemalonate in alcoholic potassium ethoxide to give
quinolizinone 73. Following multiple reductions and decarboxylation, amino alcohol
74 was obtained in 24 % yield over three steps. Chemoselective reduction of the
more reactive quinolizinone heterocycle with PtO2, under an atmosphere of
hydrogen, resulted in the 3,5-cis piperidine 75 which was directly treated with
phosphorous pentabromide and potassium carbonate, to give a crude material which
upon sublimation and recrystallisation, yielded cytisine 70 in 4 % yield from 75.
Scheme 1.7: Govindachari’s synthesis of cytisine.
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Bohlmann.
At approximately the same time, Bohlmann also completed a synthesis of cytisine
(Scheme 1.8). Homologation of 3,5-substituted pyridine 76 with formaldehyde
resulted in formation of vinyl pyridine 77, which subsequently underwent Michael
addition with diethylmalonate. Hydrogenation with Raney nickel under 200
atmospheres of hydrogen at 185°C resulted in formation of the key 3,5-cis
substituted piperidine, which spontaneously underwent cyclisation and
decarboxylation to give quinolizinone 79. Conversion of the ether groups to the
corresponding bromide was achieved with HBr. However, under these conditions,
ring opening also occurred, resulting in formation of carboxylic acid 80. Assembly
of the A ring was achieved by treatment with ammonia in ethanol at 0°C. Ring
closure of the lactam was then achieved by heating the compound at 200 °C.
Following protection of the basic nitrogen with acetic anhydride, oxidation of the
lactam was achieved by dehydrogenation with palladium on carbon. Most of the
yields were not reported. 55-56
Scheme 1.8: Bohlmann’s synthesis of cytisine.
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O’Neill.
O’Neill’s synthesis was published in 2000 (Scheme 1.9).57 The first step was a
Suzuki coupling of pyridines 81 and 85 to give bispyridine 82 – a transformation
which was not available during the work to the previous two syntheses.
Scheme 1.9: O'Neill's synthesis of cytisine.
Lithium-halogen exchange of bromopyridine 81, followed by trapping with
B(OMe)3, formed the corresponding borane which was coupled to pyridine 85 with
Pd(PPh3)4 to form bispyridine 82 in 50-55 % yield.
By reducing the ester group of 82, it was found that regioselective N-protection of
the less hindered pyridine was possible. The resulting pyridinium salt, formed in 70-
80 % underwent mild reduction with PtO2 to the desired piperidine alcohol cis-83,
obtained as an 85:15 mixture of diastereomers. Attempted hydrogenation of the
corresponding pyridinium salt of ester 82 resulted in poor diastereoselectivity.
Mesylation of the alcohol 83 resulted in spontaneous cyclisation to 84. Oxidation
and debenzylation was achieved by transfer hydrogenolysis with Pd(OH)2 and
FA/TEA. Overall, (±)-cytisine was obtained in 25 % yield from 81. A modification
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by Plaquevent afforded bispyridine 83 in 79 % yield, following a Negishi cross
coupling with Pd(PPh3)4 and ZnCl2.58
Routes involving assembly of a cis-piperidine intermediate.
van Tamelen.
Van Tamelen’s synthesis was completed alongside Govindachari and Bohlmann’s
initial routes (Scheme 1.10).59 Substitution of acetate 86 with diethyl malonate
resulted in formation of pyridine 87. Hydrolysis to the carboxylic acid was followed
by Mannich reaction with benzyl amine and formaldehyde to give the piperidine cis-
88. A process involving an initial Mannich condensation to form the malonate
enolate and concurrent decarboxylation, followed by intramolecular conjugate
addition was proposed for this transformation. Carboxylic acid cis-88 was directly
converted to the ester cis-89, as an mixture of isomers (the ratio was not stated).
Scheme 1.10: van Tamelen’s synthesis of cytisine.
An attempted epimerisation with an alcoholic base did not successfully convert the
mixture to the desired cis isomer. Reduction to the alcohol was followed by
treatment with HBr and subsequent cyclisation to the pyridinium intermediate, 90
which was then oxidised with alkaline ferricyanide. Debenzylation could not be
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achieved catalytically and required the harsh boiling of the alkaloid in HI with auric
chloride.
Lesma.
Lesma’s group derived an asymmetric synthesis of (-)-cytisine conveniently starting
with all required stereochemistry in place through the use of cis-piperidine-3,5-
dimethanol monoacetate, cis-92. This compound was formed in > 98 % ee by the
enzymatic resolution of alcohol cis-91 with the lipase Pseudomonas fluorescens and
vinyl acetate (Scheme 1.11).60 61
Scheme 1.11: Lesma's asymmetric synthesis of (-)-cytisine.
Ester cis-92 was oxidised under Swern conditions to give the configurationally stable
aldehyde 93, which was subsequently allylated with (-)-allyldiisopino-
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camphenylborane, to give alkene 94 in 85 % yield as a 10:1 mixture of
diastereomers.
Through use of the corresponding the (+)- borane reagent, access to the (R)
configuration alcohol diastereomer was achieved in a similar yield and dr. Control of
the chirality at this centre was not necessary for this synthesis and the allylation was
equally successful with non-chiral reagents, however the step was studied for future
asymmetric application to non-aromatic alkaloid derivatives. The alcohol 94 was
mesylated and subsequently converted to the azide 95 in 87 % yield. Following
reduction to the amine with PBr3, this amine was acylated with acryloyl chloride and
NEt3, resulting in a 59 % yield of 96 over two steps. This alkene then underwent a
ring closing metathesis reaction with Grubb’s 1st generation catalyst, forming the
lactam 97. The remaining ester group was converted to mesylate 98, which,
following nitrogen deprotonation with NaH, cyclised to give the desired
diazabicyclo[3.3.1]nonane framework. Dehydrogenation with DDQ gave N-
benzoylcytisine in 50 % yield which then underwent deprotection with HCl, to give
(-)-cytisine in 7 % overall yield after 13 steps.
Honda.
Honda’s asymmetric synthesis was the first to derive a route to (+)-cytisine, the
unnatural form of the alkaloid (Scheme 1.12).62 The synthesis utilised an
enantiomerically pure proline derivative and featured a samarium diiodide mediated
pyrrolidine ring expansion to a key 5-subsituted lactam intermediate which was later
converted to the cis piperidine. A variation of the synthesis also provided a route to
the alkaloids (-)-kuraramine, 99a, (-)-isokuraramine, 99b, and (-)-jussiaeiine A, 100
(Figure 1.6).
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Figure 1.6.
To begin with, the starting material, 4R-hydroxy-L-proline 101 was converted to
triflate 103. Conversion to ketone 102 was achieved under Swern oxidation
conditions, and the corresponding enolate was triflated, giving 103 in 81 % yield.
Stille coupling with 2-tributylstannyl-6-methoxypyridine and Pd(PPh3)4 was
followed by alkene reduction with Pd / C, to give 104 in 88 % yield. Only the
desired cis isomer was observed, presumably due to hydrogen addition to the least
hindered face. Ring extension of 104 was achieved by a samarium diiodide-mediated
reductive deamination and concurrent cyclisation of the resulting δ-amino ester to 
give δ-lactam 105 in 78 % yield. This compound was a common intermediate in the
synthesis of the other featured alkaloids.
Following N-protection, ethoxycarbonylation was achieved with LDA and ethyl
chlorocarbonate to give 106 in quantitative yield as a ca. 1:1 mixture of
diastereomers. Isomerisation to the more stable 3,5-cis compound was not possible,
resulting in only half of the piperidine being viable for the final cyclisation.
Following ester reduction, alcohol 107 was obtained in 91 % yield as a separable
mixture of diastereomers (1.1:1). Thermal cyclisation was achieved via the
corresponding mesylate of cis-107, which was followed by hydrogenolysis of the
benzyl group to give (+)-cytisine in 72 % yield over three steps. Overall the
synthesis proceeded in 19 % yield over 11 steps.
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Scheme 1.12: Honda's asymmetric synthesis of (+)-cytisine.
Routes involving cyclisation of a 6-membered intermediate.
Gallagher.
Gallagher’s 1st generation approach to cytisine involved the synthesis and cyclisation
of a 5-substituted δ-lactam via a Buchwald-Hartwig coupling (Scheme 1.13). An 
asymmetric variant of this synthesis was later published.63
Enamide 109, prepared via Stille’s method 64 was used a starting material of this
synthesis. The AH of enamide 110 with Ru(R,R)-Me-Duphos]COD.BF4 proceeded
with poor selectivity and lactam 111 was obtained in 24 % ee (Scheme 1.14a).
Alternatively, reduction with palladium on charcoal gave the lactam in 95 % yield.
Ester reduction and subsequent bromination with PBr3 gave bromide 112 in 57 %
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overall yield. Alkylation with 6-bromo-2-hydroxypyridine initially resulted in poor
yields of the desired N-alkylated product 113, with the O-substituted isomer 114 in
the majority alongside the elimination product 115. Optimisation of conditions gave
no further improvement; instead, a factorial experimental design method 65
investigating a number of parameters enabled conditions favouring the desired N-
alkylation to be determined. This resulted in an overall 2.4:1 ratio of N- to O-
products in 61 % yield with elimination product 115 isolated in 14 % yield. The key
intramolecular Pd(OAc)2 mediated α-arylation of 113 with 2-bromopyridone resulted
in formation of the arylated adduct in 44 % yield. 66
Scheme 1.13: Gallagher's first synthesis of cytisine.
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Similarly, the Buchwald-Hartwig intramolecular arylation of 2-piperidinones has
been developed by Maier 67 for application in the synthesis of related alkaloids
(Scheme 1.14b).
Gallagher’s synthesis was completed by selective lactam reduction with BH3.THF
and the product was subsequent deprotected with Pd(OH)2 on charcoal, giving (±)-
cytisine in 44 % yield; with an overall yield of 4 % from 109.
.
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Scheme 1.14: a. AH of enamide 110; b. Maier's Buchwald-Hartwig arylation of piperidinones.
Gallagher’s 2nd generation asymmetric synthesis.
A modified asymmetric variant of this synthesis was later developed by the
Gallagher and coworkers, who completed a route to (+)-cytisine and also the lupin
alkaloids (±)-anagyrine and (±)-thermopsine (Scheme 1.15). The desired chirality
was achieved in the first step by the enzymatic resolution of ester 111 with α-
chymotrypsin.68 The resolved ester was obtained in 42 % yield and > 98 % ee (R).
The configuration was retrospectively assigned following competition of the
synthesis. The unwanted carboxylic acid was obtained in 48 % yield and 64 % ee.
Through the same method as previously, ester 111 was converted to the bromide
112, then coupled with 2-hydroxypyridine to give the N-substituted product (R)-5 in
38
66 % yield. In this synthesis, cyclisation was achieved by treatment with LHMDS or
LDA via an internal 1,6-addition to the pyridone, forming the single diastereomer,
116. This was the first intramolecular variant of this type and a later detailed study
into the process was carried out. Oxidation by MnO2, followed by lactam reduction
and debenzylation, was achieved in 60 % yield over two steps. Overall, (+)-cytisine
was obtained by 10 steps in 3.7 % overall yield. It was later shown that during the
cyclisation of (R)-5, if the intermediate enolate was trapped with
bis(trimethylsilyl)peroxide, the oxidised product pyridone product could be directly
obtained in 60 % conversion.69
Scheme 1.15: Gallagher's asymmetric synthesis of (+)-cytisine.
Coe.
Coe derived a route to cytisine (Scheme 1.16).70 The synthesis also provided a route
to derivatives of cytisine 70 and varenicline 71. The forward synthesis started with
the N-substitution of cyclopentene 118 with glutarimide, giving N-substituted
glutarimide 119 in 78 % yield. An intramolecular Heck coupling was used to achieve
B ring closure. Conversion to the enol phosphate 120 was achieved with LiHMDS
and diethylchlorophosphate in quantitative yield. A subsequent Heck coupling with
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Pd(OAc)2 and P(o-tol)3 enabled cyclisation to the key tricyclic dihydropyridine 121
in 57 % yield. An asymmetric variant of this coupling was carried out with the
phosphinooxazoline ligand, 117 and Pd(OAc)2 resulting in the formation of 121 in
22 % ee and 52 % yield.
Oxidation was achieved with MnO2 in refluxing benzene,
giving 122 in 74 % yield. This was followed by
dihydroxylation with catalytic OsO4 and (CH3)3NO.2H2O,
resulting in an 85 % yield of 123. Conversion of the diol to the amine substituent of
cytisine was achieved via oxidative cleavage with NaIO4, and subsequent reductive
amination with NH4OH and Pd(OH)2, under an atmosphere of hydrogen, giving
cytisine in 57 % yield. Overall, (±)-cytisine was obtained in 16 % yield from
intermediate 118.
Scheme 1.16: Coe's synthesis of cytisine.
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Section 1.2.4: Route involving the synthesis of bispidine.
O’Brien’s synthesis was the first to start with a completed bispidine core, which
negated the need for diastereoselective control (Scheme 1.17).47 Although
asymmetric Mannich reactions are known, no reference to any attempt was
mentioned.71 Construction of the bispidine core was achieved via a double Mannich
reaction of N-Boc-piperidone 124 with benzylamine and formaldehyde followed
NaBH4 reduction of the corresponding tosyl hydrazone intermediate to give 125 in
47 % yield. Allylation of 125 was optimally achieved through a lithiation –
transmetallation sequence. Lithiation of bispidine 125 was achieved with s-BuLi and
TMEDA at – 78 C in EtO2 following a reaction time of 7 h. Transmetallation was
then achieved via addition of 1 eq. CuCN.2LiCl in THF which then underwent
allylation with allyl diphenylphosphate to give allylated bispidine 126 in 60 % yield
as a single diastereomer. Boc deprotection followed further reaction with acryloyl
chloride, to give the diene 127 in 99 % yield.
Scheme 1.17: O'Brien's synthesis of cytisine.
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This underwent ring closing metathesis with Grubb’s 1st generation catalyst,
resulting in the formation of lactam 128 in 89 % yield. Simultaneous
dehydrogenation and benzyl group hydrogenolysis was achieved with palladium on
charcoal in a solution of toluene and cyclohexene, to give cytisine in 76 % yield.
This 6 step synthesis gave (±)-cytisine in 19 % overall yield from 124.
Section 1.3.3: Related syntheses.
Due to the pharmacological interest in cytisine, there have been numerous syntheses
of derivatives and structural variants of cytisine. These are listed in the following
section.
Gallagher’s 3rd generation synthesis.
The application of Gallagher’s 1st and 2nd generation routes to the synthesis of
pyridone core-modified derivatives 129 and 130 was not successful. These
derivatives were found to decompose upon cyclisation to the bispidine adduct
(corresponding to the transformation of (R)-5 to 116, Scheme 1.15). These
compounds were of particular pharmacological interest for reasons to be outlined
later in the next section. Instead, an alternative convergent synthesis was completed
involving a late stage intermediate 132 which was used in the synthesis of the core-
modified cytisine via coupling with the desired pyrazine or pyridine (Scheme 1.18).
The starting racemic lactam 131 was prepared through the method of Park et al.72 An
asymmetric synthesis of this lactam has also developed by Park and Gallagher (see
Gallagher’s 2nd generation synthesis of cytisine, in the last section). Following O-
protection, introduction of the alkene bond was achieved through a selenide
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oxidation-elimination sequence. Treatment of the resulting alkene with bromine,
followed by NEt3, furnished the common intermediate of the syntheses, bromide
132, in 28 % overall yield. For the case of 4-azacytisine 136, bromide 132 underwent
Stille coupling with 6-methoxypyrazine tributylstannane 137 with Pd(PPh3)4, to give
adduct 133 in 86 % yield. 6-Methoxypyrazine tributyl-stannane 137 was obtained
from 2,4-dichloro-pyrazine via two consecutive substitutions with NaOMe and
Bu3SnLi. Reduction of adduct 133 was achieved with LiAlH4 to give lactam 134 as a
2.7:1 mixture of diastereomers in 89 % yield. Further lactam reduction with LiAlH4
and subsequent deprotection with TBAF achieved the diastereomerically pure
product, cis-piperidine 135 in 49 % yield.
Scheme 1.18: Gallagher’s synthesis of core-modified cytisines.
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Cyclisation of the corresponding mesylate of 135 was achieved with NEt3 through an
N-alkylation - O-demethylation sequence to give N-benzyl-4-azacytisine in 73 %
yield. Deprotection was then achieved via treatment with 1-chloroethyl
chloroformate followed by subsequent methanolysis, to give 4-azacytisine 136 in 61
% yield.
Norbispidine.
The novel 5-membered cytisinoid, bispidine 142, was synthesised by Gallagher via
the sequence shown in Scheme 1.19.69 The initial pyrrolidinone 139 was formed via
treatment of carboxylic acid 138 with benzylamine by conjugate addition and
subsequent cyclisation, resulting in pyrrolidinone 139 in quantitative yield.
Following reduction and bromination, bromide 140 underwent reaction with 2-
hydroxypyridine to give N-pyridone 141 in 61 % yield. LiHMDS mediated
cyclisation resulted in formation of the intermediate adduct in quantitative yield,
which upon oxidation with MnO2, gave norbispidine 142 in 68 % yield. Overall
norbispidine was obtained in 19 % yield.
Scheme 1.19: Gallagher’s synthesis of norbispidine.
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α-Hydroxypyridone.
The natural product hydroxynorcytisine 148 was isolated from the legume family,
Laburnum anagyroides by Hayman and Gray in 1989.73 A total synthesis of the
alkaloid was carried out by Caldwell to assess the selectivity profile at the α2β4
receptor (Scheme 1.20). The synthesis involved the isolation of the intermediate, (±)-
norcytisine 146b which was also pharmacologically interesting as it would enable
direct comparison with (-)-cytisine.74 Ring opening of N-Boc pyrrolidinone 143 with
6-lithio-2-methoxypyridine resulted in ketone 144 in 55 % yield. A reductive
amination cyclisation with TFA and Pd/C, followed by reprotection with Boc2O
gave pyrrolidine 145 as one diastereomer in 74 % overall yield. Following ester
reduction, cyclisation was achieved via the mesylate, to give the key compound 146a
in 83 % yield. Deprotection then gave norcytisine (±)-146b in 41 % yield.
Conversion to hydroxy-norcytisine 148 was achieved in 3 steps from 146a.
Bromination at the 3-position was achieved with NBS and CCl4 in 54 % yield.
Following Stille coupling with tributyl(1-ethoxyvinyl)stannane, acyl 147 was
obtained in 70 % yield, which then underwent Bayer-Villager oxidation with m-
CPBA, followed by hydrolysis with KOH to give the target compound following
deprotection.
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Scheme 1.20: Caldwell’s synthesis of α-Hydroxypyridone.
These compounds were determined to have an affinity to α2β4 nAhC receptors that
was 4 orders of magnitude less than (-)-cytisine.
Cyfusine and cyclopropylcyfusine.
The novel fused ring variants, (±)-cyfusine 153 and (±)-cyclopropylcyfusine 155
were synthesied by Yohannes et al. (Scheme 1.21).75 These convergent routes
involved the common intermediate 151, simply constructed in 2 steps from 149.
Following treatment of alkyne 149 with the dipole precursor 150, the [3+2] adduct
151 was obtained in 85 % yield. Multiple reductions gave alcohol 152 as a single
diastereomer, which then underwent cyclisation with methanesulfonyl chloride to
give cyfusine 153 in 16 % overall yield. The cyclopropyl variant 154 was prepared
via cyclopropanation of intermediate 151 with dimethylsulfoxonium ylide, to give
the product 154 in 61 % yield.
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Scheme 1.21: Yohannes’ synthesis of cyfusine and cyclopropylfusine.
Following reduction and cyclisation, 155 was formed in 38 % overall yield. The
nAChR binding assays of these analogues were evaluated; interestingly, (±)-
cyclopropylcyfusine 155 and cyfusine 153 showed similar selectivity to the α2β4
receptors to cytisine, but with much weaker binding.
The total synthesis of the saturated derivative, tetrahydrocytisine has been also
reported.76
Direct derivatisation of (-)-cytisine.
9-(4’-[F18]fluorophenyl)cytisine.
A rapid synthesis of 9-(4’-[F18]fluorophenyl)cytisine was developed for application
as a radioligand for PET studies of α4β2 nicotinic acetylcholine receptors (Scheme
1.22). Cytisine is particularly suited to use as a radioligand due to its high selectivity
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to the α4β2 receptor subtype, and relatively higher in vivo half life in comparison to
other radioligands.77 During the synthesis, (-)-cytisine was directly N-protected with
NaNO2. Treatment with iodine in the presence of silver trifluoroacetate resulted in
the formation of N-nitroso-9-iodocytisine, which was then converted to the
corresponding stannane 157, following treatment with hexamethylditin in dioxane in
the presence of Pd(PPh3)4. The Stille coupling of 157 with readily synthesised 4-
[F18]fluorobromobenzene 156 78 and PdCl2(PPh3)2 followed in a short reaction time
of 15 min at 110 °C. Subsequent denitrosation with 3M HCl at 110 °C for 2 min
gave 9-(4’-[F18]fluorophenyl)cytisine 158 in 6-10 % radiochemical yield (RCY)
overall (% yields were not stated).
Scheme 1.22: Lasne’s synthesis of 9-(4’-[F18]fluorophenyl)cytisine.
Other derivatives.
Following treatment with Lawesson’s reagent, thiocytisine 161 was obtained and
characterised by X-ray crystallography (Scheme 1.23b). Halogenated derivatives at
the 3- and 5- positions of cytisine have been prepared via treatment with NCS, NBS
or iodine mono chloride. The functional activity of these derivatives on cultured cells
expressing three major types of nicotinic receptors was studied and suggested that
halogenation at the 3-position imparts greater activity that (-)-cytisine.79 Access to
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derivatives at the 6-position were serendipitously discovered following the attempted
benzylation of N-propionyl cytisine 159 with LDA (Scheme 1.23a). Instead of the
expected benzylation, an unusual type of nitrogen to carbon acyl transfer occurred,
forming 6-derivative, 160. This transformation was then applied to the synthesis of a
range of other 6-substituted derivatives.80 Cytisine derivatives of flavonoids have
recently been carried out.81 The 4-substituted derivatives, 162a and 162b have been
synthesised through an alteration of O’Neill’s synthesis and were determined to be
the most discriminating nicotinic ligands derived from cytisine.82
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Scheme 1.23: a. LDA mediated carbon acyl transfer; b. derivatives of cytisine.
Section 1.3.4: Pharmacological Studies.
Following all the studies of the derivatives, the halogenated and methylated cytisines
162a and 162b; and cyfusine 153, were the only ones to show any improvement or
matching activity to (-)-cytisine. Derivatives in which the bispidine skeleton was
altered in some way, such as norcytisine or α-hydroxypyridones 148, actually
showed decreases in activity. A later in silico study by Abin-Carriquiry 83, on the
interaction between cytisine derivatives and α4β2 nAChRs, achieved the development
of an accurate model, which could accurately predict the interaction of modified
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cytisines within the binding site of the receptor. This was able to account for the
limited effects that were observed for structural modifications to the cytisine
bispidine scaffold. Significant bonding interactions exist between the charged
bispidine nitrogen atom which is surrounded by what is described as an ‘aromatic
box’ of tyrosine and tryptophan side chains. Any alteration to this bispidine region
disrupts these important interactions. Derivatisation of the pyridone region was also
considered most likely to result in improved interactions, and a key target for further
study.83 This rationale motivated Gallagher’s 3rd generation synthesis, which enabled
the previously unreachable azacytisines 130 and 136 to be accessed. The available
synthetic strategies to cytisine had not provided any means of accessing this type of
derivatives.
Section 1.4: (-)-Sparteine and Related Compounds.
Section 1.4.1: Introduction.
The lupin alkaloid (-)-sparteine, (-)-163a is found in numerous species of plant, such
as Lupinus caudatus, commonly known as Kellogg.84 The alkaloid was first isolated
by Stenhouse 85 in 1851, but it was not until 1931 that the structure was determined
by Clemo.86 Sparteine consists of a bispidine of equal chirality to (-)-cytisine, which
is fixed to a further two piperidine rings. Due to isomerisation between these
heterocycles, there are four naturally occurring stereoisomers; the enantiomers (-)-
sparteine and (+)-sparteine, and the diastereomers α-isosparteine 163b and β-
isosparteine 163c (the latter of which was unusually discovered synthetically before
its isolation from a plant) (Figure 1.7).87 (-)-Sparteine is pharmaceutically active as a
hypoglycemic agent and has been used in the treatment of diabetes, eczema, and as
an anti-inflammatory agent.88 Pharmacological study of derivatives is ongoing.88 The
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alkaloid has had large attraction in asymmetric synthesis as a chiral bidentate ligand.
89 Other similar lupin alkaloids containing the piperidine core framework are known,
such as (+)-anagyrine 215 (p 59) and aloperine 214.
Figure 1.7: Isomers of sparteine.
Section 1.4.2: Synthetic Approaches to (-)-Sparteine and Related Compounds.
The alkaloid (±)-sparteine, 163a was first serendipitously synthesised by Clemo in
1928, who formed the alkaloid through reduction of l-lupanine, 164. This established
their close relation as lupin alkaloids and began many fully synthetic approaches to
the alkaloid.86 The relationship between (-)-sparteine and its naturally occurring
stereoisomers was established through resolution with base, during early
investigations. The diastereomers 163b and 163c were also observed as racemic side
products in early synthetic attempts towards (-)-sparteine.90-92 In this section the
synthetic approaches to sparteine will be reviewed in detail, followed by syntheses of
some related compounds.
Leonard.
In 1950, Leonard completed the synthesis of a mixture of sparteine (±)-163a and α-
isosparteine (±)-163b from two different precursors 165 and 166, both derived from
ethyl 2-pyridylacetate (Scheme 1.24). Hydrogenation of these precursors resulted in
subsequent cyclisation to the alkaloid. Precursor 165 was formed by the combination
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of ethyl 2-pyridylacetate with ethyl orthoformate and acetic anhydride. Alternatively,
precursor 166 was formed by the condensation of ethyl 2-pyridylacetate with
formaldehyde. Hydrogenation of both precursors with copper chromite formed a
mixture of sparteine 163a and α-isosparteine 163b.93 In 1947, Sorm derived an
almost identical synthesis to Leonard’s glutarate 166 synthesis, except it was less
efficient, forming lupanine, 164 as a side product.91
 Scheme 1.24: Leonard’s synthesis of sparteine and α-iso-sparteine.  
Bohlmann.
Bohlmann derived an early synthesis to sparteine 163a from enamine 168, involving
a key ring closing reaction between the enamine and iminium intermediate (Scheme
1.25). 94 Reduction of amide 167 gave enamine 168, which underwent dehydration
and subsequent cyclisation and reduction with NaBH4 to give (±)-sparteine.
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Scheme 1.25: Bohlmann’s synthesis of sparteine.
Oinuma.
Oinuma derived a diastereoselective, three-step synthesis of α-isosparteine 163b
starting from the N-oxide, 169 (Scheme 1.26). Following a 1,3-dipolar cycloaddition
dimerisation between 169 and 4H-pyran, the product, 4H-pyran 170 was obtained in
70 % yield, with high regio- and stereo-selectivity. Further reaction with N-oxide
169 was reported to form a 2:1 adduct containing what was characterised to contain
the exo,trans,exo-addition product 171, as determined by 1H NMR. Hydrogenation
with Pd(OH)2 formed α-isosparteine through the suspected intermediates 172 and
173 (some yields in this synthesis were not quoted).95
Scheme 1.26: Oinuma’s synthesis of α-isosparteine. 
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Biogenic related syntheses.
There has been much interest into the biosynthesis of the lupin alkaloids 96 97
resulting in a number of biogenic syntheses to sparteine 163a and other related
alkaloids. These alkaloids have been shown to originate from cadaverine 178. Radio-
labelling experiments have shown that cadaverine (itself derived from lysine) is the
source of carbon and nitrogen atoms present in these alkaloids.
Van Tamelen.
Early study proposed sparteine to be derived from γ-keto-α-α’-diaminopimelic acid, 
174 and lysine, through the intermediate 175 (Scheme 1.27). Based on this route, van
Tamelen derived a biomimetic approach to sparteine 163a via intermediate 175.98
Scheme 1.27: Proposed biosynthesis of (-)-sparteine.
The synthesis formed 176 via condensation of acetone, formaldehyde and piperidine
(Scheme 1.28). This was then dehydrogenated with mercuric acetate to form the
proposed intermediate 177, which underwent ring closure to keto-sparteine, 179.
Following carbonyl removal with hydrazine, a single diastereomer of sparteine was
reportedly obtained in 57 % yield.
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Scheme 1.28: van Tamelen’s biomimetic synthesis of sparteine.
Koomen.
A key component in the proposed biosynthesis of the lupine alkaloids is
quinolizidine 183 (Scheme 1.29). The formation of quinolizidine 183 is thought to
proceed by the oxidative deamination of cadaverine to 180. This compound is in
equilibrium with 181 and has been shown to rapidly dimerise in water and neutral
pH, to form tetrahydroanabasine, 182. Further oxidative deamination is then thought
to form quinolizidine 183, a key component of the alkaloids.
Scheme 1.29: Proposed biosynthesis of sparteine via intermediate 183.
Based on this pathway, Koomen developed a biomimetic synthesis
(Scheme 1.30) to a number of different lupin alkaloids, involving
the key intermediate, oxime 184, a close derivative to 183.97
55
Koomen initiated the synthesis by the synthesis of tetrahydroanabasine 182, via the
procedure stated by Schöpf.99 Treatment with NH2OMe afforded oxime 186 in 98 %
yield as a mixture of diastereomers. Deamination was achieved with o-quinone 185
to give the key intermediate, oxime 184, in 54 % yield. For application to the
synthesis of sparteine, the oxime 184 was subjected to further reaction with
dehydropiperidine, 181 to form 187 in 80 % yield. Removal of the O-methyl oxime
was achieved via treatment with O3 and HCl at -45°C for 7 h. Hydrolysis of the
resultant product formed 188, which spontaneously undergoes cyclisation in NaOAc
and AcOH to supposedly form intermediate iminium species 189, which was
reduced with NaCNBH3 to form sparteine as a single diastereomer in 21 % yield.
Interestingly, if the oxime deprotection was carried out with TiCl4 and HCl at higher
temperature, following the cyclisation and reduction procedure, the alkaloid was
obtained as a 1.2:1 mixture of diastereomers β-isosparteine and sparteine. This has 
been attributed to the mildness of the ozonolysis process, which must proceed
without epimerisation.
Scheme 1.30: Koomen’s biomimetic synthesis of sparteine.
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Configurationally, the β-isosparteine isomer is more thermodynamically favoured 
and may be formed via epimerisation during the harsher conditions of the TiCl4
process.
Wendt.
The first asymmetric route to (-)-sparteine, (-)-163a was developed by Wendt 100 in
2002 utilising the chiral (bis)hydrosilation of norbornadiene 190, developed by
Hayashi (Scheme 1.31).101 Norbornadiene underwent (bis)hydrosilation with
[(Allyl)PdCl]2 and HSiCl3 with (-)-S-MOP 193 to give disilylnorbornane 191 in > 99
% ee as a 18:1 mixture with the meso isomer 192. Oxidation under Swern conditions
gave (+)-194, which was used by Wendt as the starting material of the synthesis.
Following monoketalisation, aldol reaction with aldehyde 203 gave enone 195 in 64
% yield. Alkene hydrogenation and benzyl deprotection was achieved with Pd/C,
resulting in formation of the desired endo orientation, due to hydrogenation of the
least hindered exo face. The resulting hydroxide group was converted to azide 196
by a modified Mitsunobu reaction with Zn(N3)2.2Py in 78 % yield. Cyclisation of the
C ring was achieved by an intramolecular Schmidt reaction with TiCl4, which also
deprotected the ketone, giving 197 in 62 % yield. Chemoselective removal of the
amide carbonyl was achieved with Lawesson’s reagent and Raney nickel. The
resulting ketone was alkylated with LDA and I(CH2)4Cl, followed by iodination to
give 198 as a single diastereomer in 76 % yield over 4 steps. Cyclisation of the D
ring by a second Schmidt reaction was not possible, and so an alternative photo-
Beckmann rearrangement was used. Reaction with BocNHOBoc then resulted in the
formation of 199 in 95 % yield. Subsequent deprotection yielded the free
hydroxylamine, which underwent intramolecular ketone condensation to give oxime
200 in 74-98 % yield. Photolysis initiated rearrangement to the lactam, 202 in 76 %
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yield via proposed intermediate 201. Finally, use of LiAlH4 achieved conversion to
(+)-sparteine in 95 % yield; an overall yield of 15.7 % over 15 steps. In addition,
Other racemic syntheses have been completed in the literature.102-105
Scheme 1.31: Wendt’s synthesis of (+)-sparteine.
Miscellaneous syntheses.
The low availability of the enantiomer, (+)-sparteine has been problematic to its
further investigation as a chiral ligand.106 To overcome this, (-)-cytisine has been
used in the synthesis of a ‘(+)-sparteine surrogate’ (204). This surrogate models the
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D ring of the alkaloid with a N-methyl group and has been used experimentally as a
readily available mimic (Scheme 1.32). Following extraction of (-)-cytisine from the
seeds of Laburnum anagyroides, N-acylation was carried out. Multiple reductions
gave the surrogate 204 in 86 % yield.107
Scheme 1.32: O’Brien’s synthesis of the ‘(+)-sparteine surrogate’ from (-)-cytisine.
Aloperine.
A synthesis of aloperine 214, a member of the Lupine alkaloids, was completed by
Overman et al to enable further study of its cardiovascular, anti-inflammatory and
anti-allergic activities (Scheme 1.33).108 The starting material, 206 was obtained
from (±)-3-cyclohexene-1-methanol. Treatment of 206 with TfOH and Bu4NI at
room temperature resulted in formation of tricyclic iodide 207 as a single
diastereomer in 73-92 % yield. Elimination with DBU followed by epoxidation with
m-CPBA achieved epoxide 208 as a single diastereomer in 95 % yield. Epoxide
substitution with NaSePh, followed by selenide oxidation / elimination furnished the
allylic alcohol 209 with H2O2 in 81 % yield. Oxidation with TPAP-NMO followed
by iodination with I2 and CCl4 achieved conversion to α-iodo enone 210 in 84 %
yield over two steps. Suzuki coupling with the 9-BBN derived borane 205 and
PdCl2(dppf).CH2Cl2 gave chain extended amine 211. Subsequent intramolecular
conjugate addition, followed by sequential treatment with TFA and NaOH resulted
in formation of the cis fused product 212, after a reaction time of 5 minutes.
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However, if the mixture was left for several days, the 1,2-addition imine product and
trans fused products were obtained as a 4:1 mixture. Reduction and N-protection
with 2,2,2-trichloroethyl chloroformate (Troc-Cl) afforded alcohol 213 which then
underwent elimination with POCl3 and deprotection with Cd-Pd and ammonium
acetate to give aloperine in 73 % yield.
Scheme 1.33: Overman’s synthesis of Aloperine.
The alkaloid (-)-anagyrine has been prepared via a number of
racemic syntheses which share similarities with van Tamelen
and Gallagher’s routes to cytisine.109-111
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Section 1.5: Asymmetric Syntheses of γ- and δ- Lactams.  
Enantiomerically enriched δ- and γ- lactams are key components in the synthesis and 
constituents of a number of natural products 112 113 and pharmaceuticals, 114 a key
example being (-)-paroxetine, used in the treatment of depression.115 Methods of
synthesis have involved a number of transformations. Enantiomerically pure cyclic
sulfamidates have been utilised in the synthesis of δ- and γ- membered lactams and 
piperazines.116 In one case, AH was utilised in the synthesis of a key sulfamidate
which was used in the synthesis of the natural product (-)-aphanorphine.117 There are
a number of examples of transition metal catalysed asymmetric 1,4-conjugate
arylations.118 Ag-catalysed asymmetric Mannich reactions of enol ethers with
various imines were employed in the asymmetric synthesis of various lactams and
piperidines.119 A number of organocatalytic methods have also been developed.120
Section 1.6: Conclusion.
Although many derivatives and routes to cytisine have been achieved, there are still
limitations to these syntheses. Few are versatile for derivatisation, and most are
racemic. In a review 45 of the synthetic strategies to cytisine, O’Brien had concluded
that, “there is a need to develop an approach to cytisine that delivers a late-stage
intermediate that is equipped for analogue preparation.” This statement has been
quoted numerous times in syntheses and derivatisations. And so, through the new
pharmacological insights into the SAR of these receptors, gained from the study by
Abin-Carriquiry; and, these limitations in the majority of the available synthetic
strategies, it is clear that further study into versatile syntheses of cytisine and its
derivatives, is still key to the further development of this therapeutic area.
61
Section 2: Results and Discussion.
Section 2.1: 1st Generation Formal Synthesis of (-)-Cytisine: AH of Enamide 1.
Section 2.1.1: Introduction.
At the outset of this project, the main goal was to complete a divergent asymmetric
synthesis of the lupin alkaloids: (-)-cytisine and (-)-sparteine, using transition metal
catalysed asymmetric alkene hydrogenation as a means of inducing the desired
chirality. More specifically, it was to complete the synthesis and hydrogenation of a
common precursor to the alkaloids, which resembled β-disubstituted acylamino 
acrylates; a class of AH substrates which were reviewed in Section 1.2.4.
The topic of the AH of β-disubstituted acylamino acrylates is an established field 
with many good examples of substrates which may be reduced with high
enantioselectivities. The mechanism of this process is well understood to proceed via
the coordination of the chiral catalyst centre to the alkene bond and the carbonyl of
the N-acyl group, which in the chiral environment of the catalyst may result in
enantioselective reduction of the alkene (Figure 2.1.1a). This N-acyl group is
required for activity; substrates without any coordinating group are reduced with
little enantioselectivity. Within this context, the synthesis and hydrogenation of
enamides 1 and 216 was investigated as a novel route to a number of potential
alkaloid precursors.
Enamides 1 and 216 have the crucial N-carbonyl group (within the pyridone ring)
adjacent to the alkene bond, and would be predicted to coordinate to the catalyst in a
similar manner to β-disubstituted acylamino acrylates (Figure 2.1.1b). This class of 
62
intermediate was to be key to the synthesis of the alkaloids, through the proposed
retrosynthetic analysis shown in the next section.
Figure 2.1.1: a. known coordination mode of acylamino acrylates to Rh(I) catalysts; b. proposed
coordination mode by enamide 1.
Retrosynthesis of cytisine.
The proposed retrosynthesis required disconnection the B ring at the C(5) – C(6)
bond of cytisine precursor 217 (Scheme 2.1.1a) in a similar manner to the
approaches carried out by Gallagher and Coe. This disconnection reveals glutarimide
(S)-218 as an intermediate, and may potentially be achieved through a nucleophilic
ring closing substitution involving the formation of an enolate at C(6) in analogy to
Gallagher’s method, which involved the corresponding lactam 5. However, due to
the potential for regioselectivity issues upon enolate formation at C(6), involving
competing deprotonation at C(9), it may be necessary to carry out the cyclisation
through lactam 5, following the conversion of 218 to 5. Enantiomerically enriched 5-
substituted glutarimide 218 would be formed through AH of the aforementioned
enamide 1.
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Scheme 2.1.1: proposed retrosynthesis of: a. cytisine 70 and b. enamide 1.
It was envisaged that enamide 1 could be assembled via Michael addition of 2-
hydroxypyridine to enamide derivative 219, where X is a leaving group such as a
halogen or tosylate group (Scheme 2.1.1b). This compound should be readily
available from the corresponding precursor alcohol, 220. Formyl addition was to be
achieved from the reaction of N-benzyl glutarimide with an appropriate source of
formate.121
Retrosynthesis of sparteine.
In a similar manner to the proposed (-)-cytisine synthesis, retrosynthetic analysis of
sparteine (+)-163a gives compound 222, through disconnection of the C(5) – C(6)
bond (Scheme 2.1.2). The D ring may then be constructed from glutarimide 224 by a
known literature method involving imide reduction and subsequent substitution of
the N-acyliminium intermediate, forming 223, which may then undergo subsequent
ring closure by RCM.122 (R)-224 may be formed via AH of the aforementioned
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alkene 216, formed from allyl glutarimide 225. When multiple olefinic bonds are
present in a molecule, catalysts such as Rh-Et-DuPHOS, 229 are known to have high
regioselectivity towards enamides over other relatively less chelating alkene bonds.
This gives some precedent for the selective reduction of enamide 216 to 223, without
unwanted overreduction of the allyl group.37
Scheme 2.1.2: approach to the total synthesis of (-)-sparteine and (-)-anagyrine.
Underlying methodology – synthesis of 1-(piperidin-3-ylmethyl)piperidine 6.
An underlying theme of this project is the methodology of forming enantiomerically
enriched 5-substituted glutarimides or lactams. This has been briefly reviewed in the
introduction. An interesting extension of the asymmetric synthesis of glutarimide
218 may be the further reduction to 5-substituted piperidine, 1-(piperidin-3-
ylmethyl)-piperidine 6 (bispiperidine) (Scheme 2.1.3).
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Scheme 2.1.3: formation of 5-substituted piperidine 6.
Section 2.1.2: Synthesis and Hydrogenation of Enamide 1.
The work in this section began with the synthesis of the key enamide 1.* Synthesis of
the starting material, N-benzyl glutarimide was carried out. Ring opening of glutaric
anhydride with benzyl amine, in the presence of triethyl amine, formed the
intermediate amide-acid, 123 which was subsequently heated in acetyl chloride to
promote ring cyclisation, providing N-benzyl glutarimide 221 in 90 % (Scheme
2.1.4a). This method was preferred over others.124 125 The alternative N-alkylation of
glutarimide was avoided due to the higher price of glutarimide. A microwave and
solvent free SiO2-TaCl5 promoted synthesis with glutaric anhydride and benzyl
amine was considered but the procedure required the meticulous drying of the
reagents and was limited to smaller scale reactions (< 300 mg).126 Treatment of the
sodium ethoxide-generated enolate of glutarimide 221 with ethyl formate, resulted in
the formation of enol-imide 220a, observed (1H NMR, CDCl3) exclusively as the exo
resonance form.127 This assignment was made based upon the large J coupling
observed between H(1) and H(2) (J = 12.3 Hz). Only a trace signal of what may
have been the aldehyde proton (H(1) or H(3)) of the endo (220b) or aldehyde (220c)
isomers were observed (1H NMR, CDCl3, δ 9.96, s); no other accurate assignments 
were possible (Scheme 2.1.4b). A similar transformation with triethylorthoformate
was unsuccessful.128 Tosylation with tosyl chloride and NEt3 in DCM resulted in
* The synthetic route to enamide 58 was initially developed by Akira Shiibashi, a visiting PhD
researcher, during a preliminary study. Subsequent work during this PhD project further developed
and optimised the synthetic route.
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compound 219 as one isomer; presumably the Z alkene isomer based upon the
assignment of 220a, although this was not fully established.129
Scheme 2.1.4: a. synthesis of hydrogenation substrate, 1; b. isomers of 220.
The formation of enamide 1 was achieved through a 1,4-addition-substitution of
tosylate 219 with 2-hydroxypyridine and NEt3.130 Due to the binucleophilic nature of
2-hydroxypyridine, substitution at both oxygen and nitrogen sites was observed.131
During initial reactions (toluene, 110 °C, 10 h) the isomers, N-addition product 1 and
O-addition product 227 were formed as major and minor products respectively in
varying yields (Table 2.1.1, entries 1 and 2). These compounds were separable by
chromatography, however their 1H NMR spectra were ambiguous (these spectra can
be seen in Appendix I). These isomers were assigned as the N-substituted and O-
substituted products 1 and 227, following X-ray diffraction of the two samples
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respectively. These structures are shown in Figure 2.1.2. These structures were
obtained by Akira Shiibashi.
Figure 2.1.2: X-ray structures of: a. N-substituted product 1; b. O-substituted product 227.
Table 2.1.1: 1,4-addition-substitution of tosylate 219 with 2-hydroxypyridine and NEt3.
entry scale / g 1 / %a 227 / %a time (h)
1 0.45 32 12a 10a
2 0.28 75 0b 20
3 1.32 65 0b 20
a. isolated yield; b. determined by 1H NMR of the crude reaction mixture.
Interestingly, lengthening the reaction time (20 h as opposed to 10 h) was found to
result in an absence of O-addition product 227 (entries 3 and 4). It is possible that
this is the result of a thermodynamic preference towards N-substituted product 1,
resulting from isomerisation between 1 and 227 during the reaction. N-substituted
pyridones are known to be thermodynamically favoured over O-substituted isomers.
Selectivity towards the formation of N-substituted pyridones is also known to occur
when the formation of the pyridone is reversible, as is so in this reaction.167
To confirm this, an isomerisation experiment was carried out (Scheme 2.1.5): A
mixture of 1 and 227 (1.5:1 ratio) and 2-hydroxypyridine, was stirred at 110 °C.
After 20 h, the mixture was found only to contain only the N-substituted isomer 1 (as
determined by 1H NMR). This showed that during the reaction, isomerisation of 1 to
227 occurs with a preference for the formation of thermodynamic product 1. During
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the reaction, the O-addition product 227 may be initially formed as a kinetic product
which then isomerises to the thermodynamically favoured product 1. Upon shorter
reaction times there is not sufficient time for complete isomerisation to 1, hence a
mixture of the two isomers is observed (entry 1).
Scheme 2.1.5: isomerisation of N- and O-substituted products
AH of enamide 1.
With enamide 1 in hand, the AH was carried out (Scheme 2.1.6, Table 2.1.2).
Enamide 1 underwent Pd/C mediated hydrogenation under 5 bar of hydrogen
resulting in complete reduction of the alkene bond and pyridone ring to give the fully
reduced imide 228 (entry 1). This overreduction of the pyridone ring was overcome
by ceasing the reaction after 30 min under a balloon of hydrogen (entry 2). Due to
the high polarity of the two products, some difficulty was experienced in the removal
of palladium from the sample following silica gel chromatography (it was necessary
to prepare metal-free samples to prevent high performance liquid chromatography
(HPLC) column damage). These racemic hydrogenation products were later used as
standards in the chiral HPLC analysis of AHs. Noting this potential overreduction,
the AH was carried out with, [Rh((R,R)Et-DuPhos)COD]BF4 ‘(R,R)-RhDuPHOS’,
(R,R)-229).37 The 1H NMR spectra of the crude reaction mixtures obtained with this
catalyst were clean, with only trace amounts of side products. The catalyst is easy to
handle and air sensitivity is only an issue when the catalyst is in solution. It was,
however, necessary to dry the substrate with MgSO4 before use.
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Scheme 2.1.6: hydrogenation of 1.
Table 2.1.2: hydrogenation of 58.
entry
scale
(mg) cat.
mol
(%)
P
(bar)
temp.
(°C) time
218
(%)
228
(%)
ee of 218
(%) c
1 50d Pd/C 5 5 RT 12 h 0 100 N/A
2 30a Pd/C 10 1 RT 30 min. 100 0 N/A
3 70a (R,R)-229 3 25 30 5 d 89 11 89 (S)
4 110a (R,R)-229 3 25 30 5 d 60 40 93 (S)
5 140a (R,R)-229 3 25 30 5 d 89 11 94 (S)
6 800a (R,R)-229 3 25 RT 5 d 100 0 90 (S)
a: [substrate] = 0.25 M; b: determined by 1H NMR; c: indirectly determined by analysis of 228;
d.[substrate] = 0.06M.
The optimum reactions conditions to achieve complete conversion of the starting
material and minimal overreduction are shown in entries 3-6; however fully reduced
lactam 228 was generally always observed as a minor product in varying amounts. In
the case of entry 6, only a trace of lactam 228 was observed.
During analysis by chiral HPLC it was found that the two compounds, 218 and 228
could not be resolved, preventing accurate determination of ee. To overcome this,
steps were taken to indirectly determine the ee of 218 through a new procedure. The
inseparable reaction mixture of 218 and 228 was hydrogenated with Pd/C, resulting
in the full conversion of 218 to lactam 228 (Scheme 2.1.7). The ee of this new
sample of 228 was then determined by HPLC, and taken as an indirect measurement
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of the ee of compound 218. This method assumed that 218 was a precursor of lactam
228 during the AH, and that the two products were formed in the same ee. This
procedure was routinely used as the indirect method of ee determination of imide
218. In each case the ee was consistently high, ranging from 89 – 94 % ee even at
larger scales of 800 mg. This was very encouraging and showed that this class of
enamides could be enantioselectively reduced in the way predicted.
Scheme 2.1.7: Method of indirect ee determination.
A sample of 218 (90 % ee) containing trace amounts of lactam 228 was obtained in
high purity. Recrystallisation (DCM and hexane) provided crystals which were
submitted for X-ray diffraction to confirm the structure (Figure 2.1.3). Interestingly,
the crystal selected for analysis was actually racemic (determined by the diffraction
pattern). This prevented the determination of absolute configuration. Presumably,
racemic crystals formed from both enantiomers, are formed more readily than
crystals formed from only one enantiomer.
Figure 2.1.3: refined X-ray structure of 218.
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AH catalyst screen.
With these results in hand, further screening of the AH was carried out. A range of
phosphine ligands were obtained for research purposes through a collaboration with
the fine chemicals company Solvias. These included ligand derivatives of the
following types: Taniaphos, Josiphos, Walphos, Mandyphos, and MeOBiPhep.
Details on the background and use of these in asymmetric alkene hydrogenation
were reviewed in the introduction.
To enable comparison to the earlier reductions with (R,R)-Rh-Et-DuPHOS (R,R)-
229, reactions were carried out under equivalent conditions, except the temperature
was reduced from 30 °C to ambient room temperature (20-22 °C) (in the past there
were problems of maintaining a consistent temperature throughout the duration of
the reaction). Experiments were performed on a 30 mg scale. The catalyst was
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formed in situ by combination of the phosphine ligand with [Rh(COD)Cl]2,
according to a literature procedure.132 DCM was used as solvent due to insolubility
of the alkene in methanol. Conversion was determined by 1H NMR. At this point, it
was found that at a lower scale (30 mg), the hydrogenation products imide 218 and
lactam 228 could be separated (silica gel chromatography, slow elution). This
enabled the ee of the each product to be separately determined by direct HPLC
analysis. The method used to determine the absolute configuration of compounds
218 and 228 will be discussed in a later section.
Scheme 2.1.8: Asymmetric ligand screen.
Table 2.1.3: Hydrogenation of 1 with various asymmetric ligands.
entry ligand ligand type
conv.a
(%)
218
(%)a
218 ee
(%)b
228
(%)a
228 ee
(%)b
1 SL-T002-1 Taniaphos 100 trace N/A 100 98 (R)d
2 (R,R) Et-DuPhosc DuPhos 82 82 91 (S)e 0 N/A
3 SL-J001-1 Josiphos 42 42 76 (R)e 0 N/A
4 SL-J003-1 Josiphos 56 56 87 (S)e 0 N/A
5 SL-W001-1 Walphos 47 27 N/O 20 13 (R)d
6 SL-M001-1 Mandyphos 100 40 N/O 60 17 (R)d
7 SL-J005-1 Josiphos 0 0 N/A 0 N/A
8 SL-A101-1 MeOBiPhep 9 9 N/O 0 N/A
a. determined by 1H NMR; b. determined by chiral HPLC; c. [Rh((R,R)Et-DuPhos)COD]BF4 used as
catalyst; d. direct analysis of 228 following isolation; e. direct analysis of 218; N/O = not obtained;
N/A = not applicable.
The results of the ligand screen are shown above in Table 2.1.3. Use of the Josiphos
and Taniaphos ligands (entry 1, 3 and 4) resulted in high enantioselectivity (Scheme
2.1.8). Entry 1 shows major over-reduction to 228. In relation to the synthesis of
bispiperidine 6 (Scheme 2.1.3), this result was very encouraging. This is discussed
further in Section 2.1.3. Inversely, despite the high selectivity obtained with the
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Josiphos ligands (entry 3 and 4), these reactions show low consumption of the
starting material. With the long reaction time (5 days), there is limited scope for
further optimisation. The reduction with (R,R)-RhDuPhos on this low scale (30 mg)
gave incomplete conversion of the starting material, whereas at larger scales (> 50
mg, see Table 2.1.2) under the same conditions conversion is closer to 100 %.
In conclusion, these results were very encouraging and showed that this class of
enamide was affective as an AH substrate as predicted, and a novel method for the
preparation of 5-substituted glutarimides with particular relevance to the synthesis of
cytisine. This work was subsequently published.178
Section 2.1.3: Completion of the Formal Synthesis of (-)-Cytisine.
The project then moved on to the utilisation of 5-substituted glutarimide 218 in an
asymmetric synthesis of cytisine. The first approach involved attempted conversion
to cytisine precursor 230 via base-induced cyclisation (Scheme 2.1.9). Pyridone 218
was treated with a series of bases, however only the elimination product 231 was
obtained and there was no evidence for formation of the cyclised adduct 230.
Scheme 2.1.9: attempted cyclisation and conversion to cytisine precursor 5.
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From this point, the most obvious route to completion was reduction of the imide to
the cytisine precursor, lactam 5 (Scheme 2.1.10). This compound was used as a
cyclisation precursor in Gallagher’s 2nd generation synthesis (Section 1.3.2, Scheme
1.15). There is a large amount of related literature for similar carbonyl reductions.133
This reduction was initially attempted with a number of reductants, notably NaBH4
and HCl; and LiAlH4. According to the literature, regioselective reduction of imides
may be carried out with NaBH4 and HCl. HCl is thought to promote the reaction by
either the in situ generation of BH3; or by activation via protonation of the imide
carbonyl.133c,134 Indeed, this affect was observed experimentally, when the imide was
treated with NaBH4 and HCl was added periodically to maintain a pH of
approximately 7, resulting in the formation of the α-hydroxylactam isomers 232 and
233. The reaction was inconsistent, with conversions widely ranging from 30 to 69
% (determined by 1H NMR). No attempt was made to isolate the α-hydroxylactam 
isomers 232 and 233.122
Scheme 2.1.10: Reduction of 218 to cytisine precursor 5.
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Instead, the crude reaction mixture was treated with TFA and triethylsilane to give a
sample of lactam 5 and what is thought to be an inseparable mixture of the second
regioisomer 234 and unreacted starting material, following purification (silica gel
chromatography).135 The formation of this inseparable mixture prevented full
analysis of the supposed regioisomer 234, although the 1H NMR spectrum was in
agreement with its identity.
At best, the obtained yield of the two step transformation of 218 to the known
compound 5 in pure form was 50 %, although this has been inconsistent. Typically
compound 5 was obtained in ~3:1 regioselectivity over the regioisomer 234.
Compound 5 is a precursor to (-)-cytisine following the synthesis completed by
Gallagher and its synthesis secured the formal synthesis of cytisine. The optical
rotation of a sample of compound 5 derived from the reduction with (R,R)-RhEt-
DuPHOS), (R,R)-229 was shown to be + 8.8 (c0.7 in CHCl3, 25 ⁰C). Comparison
with the literature value 68 (([α]D24 = + 31.3, c0.8 in CHCl3), 98 % ee) enabled the
assignment of the absolute configuration of compound 5 as R. Retrospectively, the
absolute configuration of the precursors of compound 218 have also been assigned.
Determination of the ee of compound 5.
Following the imide reduction of 218, it was necessary to determine the ee of
compound 5 to determine whether the compound had retained its high enantiopurity.
This was carried out by the HPLC analysis of a hydrogenated (Pd/C) sample of 5
(derived from a sample of 218 from the reduction with (R,R)-Rh-Et-DuPHOS (R,R)-
229; established to be of 90 % ee) using the racemic standard, 235 (Scheme 2.1.11a).
At the time this work was carried out, this method was favoured over direct ee
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determination of 5 because of the ease of accessing the racemic standard 235.
Racemic standard 235 and regioisomer 236 were formed by the NaBH4 / Et3SiH
reduction of compound (±)-228 (Scheme 2.1.11b).
Scheme 2.1.11: a. Hydrogenation of (R)-5 for HPLC analysis;
b. Synthesis of racemic standard (±)-235
Unfortunately, HPLC analysis showed that the ee of compound 5 was only 20 %. Its
precursor, compound 218 had an ee of 90 %. This showed that partial racemisation
had taken place during the imide reduction.122 A similar result was obtained
following the LiAlH4 mediated reduction of imide (S)-218 (95 % ee) at – 78°C:
following the formation of the α-hydroxylactam and subsequent reduction with 
Et3SiH and TFA, lactam 5 was obtained in 35 % yield and 13 % ee (the same
indirect ee determination method by HPLC was used through reduction and analysis
of 235). The reducing agents BH3.SMe2, NaCNBH3, DIBAL-H and NaBH(OAc)3
were unsuccessful for this reduction.
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Luche reduction of enamide 1.
In a final effort to prepare lactam 5 without a loss of enantioselectivity, a second
approach was considered via the synthesis and hydrogenation of alkene 237 (Scheme
2.1.12a). This alkene possessed the required functionality for efficient asymmetric
reduction. It was thought that this alkene could be reached via the reduction of
enamide 1. Reduction was attempted with NaBH4 and HCl but was unsuccessful;
however treatment with CeCl3.7H2O and NaBH4 following Luche type conditions 136
resulted in the formation of the unwanted isomer, α-hydroxylactam 238. Other
reduction products were identified in the crude reaction mixture (1H NMR) but α-
hydroxylactam 238 was the only isolatable product, and the desired compound was
not identified in any form.
Scheme 2.1.12: a. Potential synthesis and hydrogenation of alkene 237; Luche type reduction of 1.
Successive purification (silica gel chromatography, followed by preparative reverse
phase HPLC, Waters XBridge Prep C18 OBD column) provided α-hydroxylactam 
238 in 20 % yield as colourless needles which were analysed by X-ray
crystallography to confirm the structure, which is shown in Figure 2.1.4. The higher
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stability of the carbonyl within the conjugated enamide system over the isolated
carbonyl may have favoured reduction of the non-conjugated carbonyl bond.
Figure 2.1.4: X-ray crystallographic structure of 238.
Section 2.1.4: The Attempted Synthesis of (-)-Sparteine.
The synthesis of sparteine precursor, enamide 216 was carried out through a
variation of the cytisine precursor route, using N-allyl glutarimide 225 as starting
material. The synthesis is shown in Scheme 2.1.13.
Following the synthesis of alkene 216, the AH was found to result in formation of an
inseparable mixture of what was characterised to be the overreduction product 242
and the desired reduction product 224 in 64 % and 36 % yields respectively (as
determined by 1H NMR).137
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Scheme 2.1.13: Synthesis and hydrogenation of 216
Consequently, no further time was spent trying to optimise this hydrogenation. By
this stage in the project, it also became clear that the substrate used in this route
would probably also have undergone the same epimerisation that had occurred in the
cytisine synthesis, preventing the proposed asymmetric synthesis.
Summary and conclusions.
On one note, the AH of enamide 1 was highly successful, achieving the formation of
glutarimide 218 in up to 94 % ee. This work was subsequently published.178 A
formal synthesis of cytisine was achieved, but the inability of glutarimide to undergo
cyclisation, and the late stage epimerisation upon conversion to lactam 5 prevented
the asymmetric synthesis from being achieved. These same underlying problems
combined with overreduction of the allyl group also prevented the success of the
asymmetric synthesis of sparteine.
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Section 2.1.5: Future Work.
The proposed synthesis and hydrogenation of pyridone 2.
At this point in the project, the focus moved towards a second strategy for
completing an asymmetric formal synthesis of cytisine, through the formation of the
precursor lactam 5. This strategy required a 5-substituted pyridone bearing a
proximal coordinating group to be asymmetrically reduced in high enantioselectivity,
to give a product that could be converted to the cytisine precursor. More specifically,
the synthesis and AH of pyridone 2 was considered (see Scheme 2.3.1). If
successful, the resulting 5-substituted lactam 274 could be converted to the cytisine
precursor lactam 5 through a known route. A more detailed explanation of this
proposal and the results and discussion are given in Section 2.3.
The synthesis of bispiperidine 6.
With the formation of lactam (S)-228 in 98 % ee, reduction to the saturated
piperidine is a unique method of forming 5-subsituted piperidine 6. This work is
continued in Section 2.4.
ATH of enamide 1 and 216.
Before moving on to the newly proposed research topics disused in the last two
paragraphs, the next section in this chapter will briefly cover an ATH study of the
enamides 1 and 216.
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Section 2.2: ATH of Enamides, β-(Acylamino)acrylates, Tetramic acids and 5-
Acetyluracil.
Due to the highly polarised alkene bond within enamides 1 and 216, during the
course of this study, these compounds were also considered as potential substrates
for alkene ATH. There are numerous examples of the transfer hydrogenation of
alkenes in the literature 138; however, there are few asymmetric examples.139 140 This
may have provided an alternative route to the formation of their corresponding 5-
substituted glutarimides. This topic led on to the second and third parts of this
section, in which the ATH of related β-substituted α,β-unsaturated carbonyl 
derivatives (243, 244, Figure 2.2.1) was also carried out. In the final section, the
ATH of 5-acetyluracil 245 was carried out. This work was not directly related to the
work outlined in this introduction, but the unexpected result was interesting and
seemed to be related to the subject of the transfer hydrogenation of alkene bonds.
This section begins with an interesting result obtained involving the ATH of
enamides 1 and 216 which were both active to reduction by the catalyst.
Figure 2.2.1: Compounds considered in this section.
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Section 2.2.1: ATH of Enamides.
When the ATH of 1 was carried out with 3 mol % (R,R)-RutethTsDPEN 248, full
conversion to glutarimide 228 (Figure 2.2.2) was observed over a period of 5 days,
with varying solvents: tBuOH, IPA and ethanol (Scheme 2.2.1 and 2.2.2, Table
2.2.1, entries 2, 3 and 4). In one case (entry 4), the ee of the sample was determined,
however the sample was found to be racemic (for details of the chiral separation, see
Section 2.1.2). To determine if this absence of ee may have been the result of
subsequent epimerisation following the formation of the chiral centre in high ee, a
control experiment was carried out. A sample of (R)-228 (95 % ee) in ethanol and
FA/TEA was stirred for 5 days (the same conditions as the results from Table 2.2.1),
after which the ee of the sample was reanalysed to show no significant change. This
confirmed that the ee of the reaction was in fact 0 % and that subsequent loss of ee
had not occurred during the reaction. Two mechanistic possibilities for this reduction
are shown later in this section, which provide an explanation for the lack of
enantioselectivity.
When methanol was used as solvent in the reduction of allyl derivative 216 (entry 1),
ring opening occurred, forming 247 alongside an impure sample of reduction product
242, in an approx. 1:1 ratio. This was most likely to have resulted from FA/TEA
catalysed methanolysis of the imide group, although ruthenium Lewis acid based
catalysts are known.141
Interestingly, a small enantioselectivity was observed in the reduction of enol imide
220.The ATH of enol imide 220, resulted in complete conversion to alcohol 246 in
31 % ee (the absolute configuration was not determined) (chiral separation was
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determined by Chiralpak IA, hexane : IPA 95:1, flow rate = 1 mL/min) (entries 6 and
7) following a reaction time of 16 h at 28 °C.
Scheme 2.2.1: ATH of enamides 1, 216 and 220.
Table 2.2.1: ATH of enamides.
entry substrate a b cat./mol % sol. time
temp.
(°C) prod. Conv. eed
1 216 (R,R)-248 2 mol% MeOH 3 d 30
242 1:1 -
247 >99 -
1 (R,R)-248 3 mol% tBuOH 5 d 30 228 >992 -
3 1 (R,R)-248 3 mol% IPA 5 d 30 228 >99 -
4 1 (R,R)-248 3 mol% EtOH 5 d rt 228 >99 0 %
5 1 249 2 mol% EtOH 5 d 28 228 >99 -
220 (R,R)-248 2 mol% MeOH 16 h 28 246 >996 32 %
7 220 (S,S)-248 2 mol% MeOH 16 h 28 246 >99 32 %
a. 0.6 M; b. 0.5 cm3 FA/TEA / mmol SM; c. determined by 1H NMR; d. determined by chiral
HPLC.
Figure 2.2.2: ATH products and catalysts.
Discussion.
There are two possible ways in which reduction of 1 could take place (Scheme
2.2.3): 1) 1,4-conjugate hydrogen transfer may take place which has been reported
for similarly polarised alkenes.139 2) Reduction proceeds through the resonance form
1b (step b). In both steps, enol 1c would be formed, which may then undergo
tautomerisation to give the product 218. Some cases in the literature have reported
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directed asymmetric protonations. From these results the exact mechanism is it not
evident.
Scheme 2.2.3: two possible mechanisms for the reduction of 1.
Enol imide 220a can also exist in the tautomeric forms 220b and 220c (Scheme
2.2.4). All three of these isomers may potentially undergo reduction by the catalyst.
Scheme 2.2.4: Possible mechanisms for the reduction of tautomers 220a, 220b and 220c.
Reduction of 220a or 220b would both result in formation of enol 250, which may
subsequently undergo tautomerisation to give the product 246. Alternatively the
reduction of tautomer 220c may take place through a kinetic resolution (KR)
resulting in the formation of product 246.
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The low ee obtained in the formation of 246 may have resulted from a poorly
controlled asymmetric protonation of 250 or from the KR of 220c. However since
seeing 218 was formed racemically via the corresponding enol 1c, the comparison
between 250 and 1c could be made to suggest that tautomerisation of 250 by this
route would also be unselective. This would suggest that the origin of the low
enantioselectivity was from the reduction of 220c. But not enough evidence is
available for any firm conclusion to be made. The ATH of enol ether 251 was
considered, however the compound could not be prepared.
Summary.
The natural progression of this work would have led to the synthesis and ATH of β-
substituted derivatives of 220d or 252, in order to create a new chiral centre
proximal to the alcohol. The synthesis of 220d was attempted following a modified
procedure of forming 220a, using ethyl acetate (Scheme 2.2.5), but this was
unsuccessful and prevented this series from being assessed.
Scheme 2.2.5: a. Attempted synthesis of 220d; b. potential β-substituted analogue of 1d which was
not possible.
Instead, two alternative compound types were considered as β-substituted 
‘surrogates’ of the enamides 1 and 220. These were aminoacrylates (analogous to
enamide 1) and tetramic acids (analogous to enamide 220). The synthesis and ATH
of these two compound types are described in the next two sections.
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Section 2.2.2: Synthesis and ATH of β-(Acylamino)acrylates. 
β-(Acylamino)acrylates were considered due to their α,β-unsaturated-β-acyl-
carbonyl conjugated system which was similar to the α,β-unsaturated-β-N-pyridone-
imidyl conjugated system present in enamide 1. The asymmetric pressure
hydrogenation of amino acrylates is a well established field and was reviewed in the
introduction. The ATH of structurally similar activated alkenes was carried out by
Xue et al. with Noyori’s catalyst with modest enantioselectivity.142 Reductions of β-
(acylamino)acrylates have not been reported by ATH. In this section, the synthesis
and ATH of a range of β-(acylamino)acrylates was briefly carried out with the 
catalyst, RutethTsDPEN 248.
Synthesis of β-(acylamino)acrylates.
The β-(acylamino)acrylates were conveniently synthesised by a known procedure 
143b
 involving the condensation of an ammonium salt to a β-keto- carbonyl (253) to
form an intermediate enamine (254) (Scheme 2.2.6). This intermediate was
subsequently acetylated to give a mixture of the E/Z β-(acylamino)acrylates, 244.
Isomers 244a, were formed via this procedure using β-keto- carbonyl 253a. Isomers
(E)-244a and (Z)-244a were isolated by silica gel chromatography in 9 % and 19 %
yields respectively (Scheme 2.2.7).
Scheme 2.2.6: General procedure for the synthesis of β-(acylamino)acrylates.
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Scheme 2.2.7: a. Synthesis of β-keto imidopyrrolidine; b. yields of obtained β-(acylamino)acrylates.
β-Keto amidopyrrolidine 253b was synthesised in 80 % yield via a 2 step procedure
involving the nucleophilic ring opening reaction of 2,2,6-trimethyl-4H-1,3-dioxin-4-
one by pyrrolidine (Scheme 2.2.7a).144 Using 253b in the condensation – acylation
sequence (Scheme 2.2.6), only the (E)-isomer of imidopyrrolidine (E)-244c was
isolated in 28 % yield. An nOe 1H NMR study indicated an interaction between H1
and the CH3 protons, supporting E geometry. Condensation and subsequent acylation
of 253a with methylamine and acetic acid enabled NMe derivative 244b to be
accessed in 29 % yield. Formation of 244d via direct methylation of (E)-244a was
not possible using NaH and MeI reagents, or through the condensation – acylation of
253b with methylamine and acetic acid.
ATH of aminoacrylates.
The ATH of the amino acrylates was carried out with (R,R)-RutethTsDPEN (R,R)-
248 (Scheme 2.2.8). β-(acylamino)acrylates (E)-244a and (Z)-244a were both
inactive to ATH. It was considered that the ester group did not induce sufficient
polarisation of the alkene bond to enable hydrogen transfer. This led to the
replacement of the ester group by an imido pyrrolidine group resulting in (E)-244c;
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however this compound also was not reduced when treated with the catalyst at 28 °C
or at a prolonged time of 3 d at 40 °C and in neat FA/TAE. The effect of any NH
bonding interaction upon the stability of the alkene bond of (E)-244a and (Z)-244a
was also considered, leading to the synthesis and ATH of methylated derivative
244b. This compound was not reduced with the catalyst.
Scheme 2.2.8: Conditions used for the ATH of β-(acylamino)acrylates.
Conclusions.
In conclusion, none of the β-(acylamino)acrylates studied reduced by ATH using the 
Ru(II) tethered catalyst. An explanation may be that the alkene bond is not
sufficiently polarised 142 to react with the catalyst, and that the conjugated system
present in these compounds was not comparable to enamide 1.
Section 2.2.3: Synthesis and ATH of N-Boc Tetramic Acids.
Following the ATH of enamide 220, in this section tetramic acids were investigated
as β-substituted ‘surrogates’ of enamide 220 due to their similar tautomeric β-keto-γ-
lactam conjugated system which was similar to the β-keto-glutarimidyl conjugated 
system present in enamide 220 (Scheme 2.2.9). Tetramic acids are substituted at the
β position, whereas the corresponding β position of enamide 220 was not substituted.
An attempted synthesis of a β-substituted derivative of enamide 220 was
unsuccessful (Scheme 2.2.5) which prevented further study into the enantioselective
formation of a chiral centre at this position. The ATH of substituted tetramic acids
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could result in the enantioselective formation of N-Boc 4-hydroxy-pyrrolidinones
(R)-257 (Scheme 2.2.10a).
Scheme 2.2.9: resonance forms of: a. 63; and b. tetramic acids.
These compounds are precursors to pharmaceuticals such as the antidepressant, (R)-
Rolipram, 259 145; the anticonvulsant, (-)-γ-amino-β-hydroxybutyric acid, 258
(GABOB)146; and Oxiracetame, 260 147 (Scheme 2.2.10b).148 Alternative methods for
the synthesis of 4-hydroxy-pyrrolidinones involve the reduction of imide 261
(obtained from (S)-malic acid) in which 262 is formed with no loss of enantiopurity
(Scheme 2.2.10c).149
Scheme 2.2.10: a. Reduction of N-Boc tetramic acids via ATH; b. Pharmaceuticals potentially derived
from N-Boc 4-hydroxy-pyrrolidinones; c. Alternative method of synthesis.
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Synthesis of N-Boc tetramic acids.
Scheme 2.2.11: General synthesis of N-Boc tetramic acids.
To accomplish this, a range of tetramic acids were synthesised. There are numerous
methods for their synthesis known in the literature, 150 but in this project the
procedure reported by Størgaard et al. was followed.186 This procedure utilises Boc-
protected amino acids as starting materials in the 2 step synthesis (Scheme 2.2.11).
The tetramic acids are known to be formed with retention of chirality. The broad
range of protected amino acids available enables the possibility of the synthesis of a
wide range of tetramic acids. The N-Boc tetramic acids 243, (S)-264, (S)-265 and
(R)-265 (Figure 2.2.3) were synthesised from N-Boc-glycine, N-Boc-(OBn)-L-serine
and N-Boc phenylalanine (both L and D natural and unnatural isomers) respectively,
through the coupling of commercially available N-Boc amino acids with Meldrum’s
acid (0°C to rt) in DCM. This resulted in formation of the intermediate adduct 263
(Figure 2.2.3) which was not isolated due to its known instability.151 Upon heating in
ethyl acetate this intermediate undergoes an intramolecular cyclisation and
subsequent loss of CO2 to give the final product. Generally the product was
sufficiently pure for further use without purification as prescribed. In some cases
decomposition has been reported following silica gel chromatography.
Serine-derived tetramic acid (S)-264 was obtained in 51 % yield (Figure 2.2.3). The
compound was found to be prone to decomposition following silica gel
chromatography or upon standing for 1 day of more. Glycine-derived tetramic acid
243 was obtained in 51 % yield. Phenylalanine-derived (both L and D) tetramic acids
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(S)-265 and (R)-265 were obtained in 54 % and 16 % yields respectively following
recrystallisation (ethyl acetate – hexane).
In all cases, variation of the 1H NMR solvent was found to alter the tautomeric form
of the tetramic acid. In deuterated chloroform, the keto tautomer was exclusively
present; whereas in deuterated DMSO, the enol tautomer was exclusively present
(Scheme 2.2.9).
O-Methylated tetramic acid 266 was synthesied in 34 % yield via alkylation of 243
with MeI and AgCO3 in MeCN at room temperature for 24 h. The product of C-
alkylation was not isolated from the reaction mixture. Enol methyl ether 266 had not
been reported in the literature, but the corresponding free NH derivative is known.152
Figure 2.2.3: Isolated yields of N-Boc tetramic acids.
ATH of tetramic acids.
The ATH of 243 was carried out using methanol as solvent and 2 mol % (R,R)-
RutethTsDPEN, 248 (Scheme 2.2.12). Following 18 h at room temperature, product
(S)-257 was obtained in complete conversion (determined by 1H NMR) (entry 1,
Table 2.2.2). Chiral separation was achieved following a literature HPLC method 148
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enabling the determination of ee to be 41 %. The absolute configuration was
assigned to S based on comparison with literature [α]D values.148
Scheme 2.2.12: ATH of tetramic acids.
Table 2.2.2: ATH of tetramic acids.
entry tetramic acid a b R cat. de (%)e Ee (%)c Prod.e d
1 243 H (R,R)-248 N/A 41 (S)-257
2 (S,S)-248 N/A 41 (R)-257
3 266 f H f (R,R)-248 N/A N/A N/A
4 (S)-264 CH2OBn (R,R)-248 100 N/D cis-267
5 (S,S)-248 100 N/D cis-267
6 (S)-265 CH2Bn (R,R)-248 100 99 (S,S)-268
7 (S,S)-248 100 >99 (S,S)-268
8 (R)-265 CH2OBn (R,R)-248 100 >99 (R,R)-268
9 (S,S)-248 100 >99 (R,R)-268
a. [SM] = 0.625 M; b. 0.5 cm3 mmol (w/r to SM); c. determined by chiral HPLC; d. config. assigned
by comparison of lit. [α]D values; e. cis config. determined by 1H NMR, as prescribed by the lit.188; f.
methyl enol ether derivative, was obtained via alkylation of 243; N/A: not applicable; N/D: not
determined.
To test whether the reduction occurred via reduction of the enol or keto tautomer of
243, it was necessary to carry out the synthesis and ATH of tetramic acid 266. If this
compound was inert to ATH it would suggest that the reduction had resulted from
ketone ATH. This compound was inert to reduction by the catalyst (entry 3, Table
2.2.2), suggesting the reduction of 243 occurs via reduction of the keto tautomer.
The low level of enantioselectivity obtained from the ATH of 243 may have resulted
from the sterically undemanding environment. The ketone is also not proximal to
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functionalisation about the heterocyclic ring. This prompted ATH of the more
sterically hindered tetramic acids 264 and 265.
The NaBH4 mediated reduction of 264 153 and 265 188 has been reported to proceed
with complete stereocontrol, forming the cis-product only. There has been dispute
over the diastereoselectivity of the reaction which required precise conditions to
achieve 100 % dr.188 The dr was studied by Kraus et al. who assigned each
diastereomer by the OH signal of the 1H NMR spectrum (DMSO).188
In this study it was found that ATH of 264 with (R,R)-RutethTsDPEN proceeded
with complete stereocontrol, forming only one diastereomer (entry 4). This was as
determined by 1H NMR through appearance of only one OH signal (as specified in
the last paragraph).188 The diastereomer was assumed to be the cis product 267 in
analogy with the corresponding NaBH4 mediated reduction of 264. Reaction of 264
with (S,S)-RutethTsDPEN also resulted in the formation of one diastereomer,
assigned as the cis product cis-267 (entry 5). These assignments of configuration
have been made on the basis that the starting material was enantiomerically pure and
the product consisted of only one diastereomer, assigned as the cis product.
These results were independent of the isomer of catalyst used – both (R,R) and (S,S)
catalysts reacted with 264 to give exclusive formation of the cis product 267,
suggesting that the reduction proceeded via a substrate controlled reduction.
However, the [α]D values of the two products of 267 formed from the (R,R) and (S,S)
isomers of the catalyst were not found to be of the same magnitude with each other
([α]D = 27 and 78 respectively) or the literature value 100 ([α]D20 + 59 (c1.00,
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MeOH)). From a substrate controlled reduction, this would be required. It was
considered that this could be an indication that the ee of the two samples of 267 were
different. A feasible explanation for this may be that during the reduction, a dynamic
kinetic resolution (DKR) involving epimerisation at C (1) could result in the
formation of both enantiomers of the cis product. A study by Oba et al. had shown
that the NaBH4 mediated reduction of 264 had occurred without epimerisation and
retention of enantiopurity.153b However it seemed important to determine the ee of
these samples.
Determination of ee required a racemic standard. This required the opposite
enantiomer starting material which was derived from the unnatural amino acid, D-
Boc serine, however this compound was not commercially available which was
problematic. The unnatural isomer, D-Boc phenylalanine was however available and
so for simplicity, the task of determining the ee of the reduction products was to be
carried out through the ATH of the model compounds, L- and D- derived tetramic
acids (S)-265 and (R)-265. This was more advantageous than alternative synthetic
methods, as full characterisation data was available for the reduction products of
265.153
The ATH of both enantiomers of 265 was carried out with both isomers of the
catalyst. ATH of (S)-265 and (R)-265 with (R,R)-RutethTsDPEN proceeded with
complete stereocontrol, each forming one diastereomer which in both cases was
assigned as the cis-product (in analogy with the literature NaBH4 reduction), (S,S)-
268 and (R,R)-268 respectively (entries 6 and 8, Scheme 2.2.13). ATH of (S)-265
and (R)-265 with (S,S)-RutethTsDPEN, formed the cis-products (S,S)-268 and (R,R)-
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268 respectively (entries 7 and 9). Chiral HPLC separation of these products was
achieved (Chiralpak IC, heptane : IPA 1:1, flow rate = 1 mL/min) enabling the ee to
be determined as 99 % in each case. The literature optical rotation values matched
the reduction products in each case, confirming that the configuration assignments
were correct. These results indicated that the reduction proceeded with retention of
enantiopurity and that a DKR had not occurred. The reductions were the result of
substrate control, independent of the isomer of catalyst.
Scheme 2.2.13: ATH of (S)- and (R)- 265 with (R,R)- and (S,S)-RutethTsDPEN.
Conclusion.
Tetramic acids were chosen as β-substituted α,β-unsaturated imido surrogates of the 
enol imide 1. The synthesis and ATH of a range of tetramic acids was carried out in
one case with low enantioselectivity (41 % ee (S)). The O-methylated tetramic acid
266 was found to be inert to ATH indicating that the reduction proceeded via the
keto form. For the 2-substituted tetramic acids, the reductions were found to proceed
by substrate control with complete stereoselectivity.
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Section 2.2.4: ATH of 5-Acetyluracil.
In a study unrelated to this chapter, the ATH of 5-acetyluracil 245 and N-benzyl 5-
acetyluracil 269 was investigated to enable comparison to other heterocyclic methyl
ketones such as pyridyl methyl ketones. There are not any direct ATH examples of
substrates of this functionality. Primarily of interest was the enantioselectivity of the
ketone reduction. Reductions of heterocycles of this type have not been reported. It
was of interest to know the enantioselectivity of this reaction. It was found that the
alkene bond of this compound as well as the ketone was reduced.
Synthesis of N-benzyl 5-acetyluracil.
5-Acetyluracil was benzylated by treatment with NaH in DMF (Scheme 2.2.14).
Using a sub-stoichiometric ratio of electrophile to starting material, slow dropwise
addition of benzyl bromide was carried out to favour mono-alkylation.
Scheme 2.2.14: alkylation of 5-acetyluracil.
Following recrystallisation from methanol, N-benzyl-5-acetyluracil, 269 was
obtained in 39 % yield as crystalline white needles which underwent X-ray
diffraction to confirm the structure (Figure 2.2.4), thus confirming that alkylation
had occurred exclusively on N (7A). Full characterisation data is shown in Appendix
II.
ATH of 5-acetyluracil and N
The ATH of 245 was
(Scheme 2.2.15). Neat
2M. The results are shown in
temperature, 245 underwent 100 % conversion to the fully reduced diastereomers
270a and 270b in a ratio of 3.1 :
the configuration of
illustration purposes only.
reduced, creating two adjacent chiral
light yellow solid, containing an inseparable
could not be separated by silica gel chromatography due to the high polarity of the
compound. Chiral separation was not possible
HPLC. To aid chiral HPLC separation (potentially by reducing polarity), analysis of
the benzylated product
acetyluracil, 269. It is important to again note, that
271b was not determined and has been included for illustration purposes only.
Catalyst structures may be seen in Appendix IV.
Figure 2.2.4: X-ray crystal structure of 269.
-benzyl 5-acetyluracil.
carried out with the catalyst (R,R)-Ru
FA/TEA was used as solvent at a substrate
Table 2.2.3. Following a reaction time of
1 (entry 1, Table 2.2.3). It is important to note, that
271a and 271b was not determined and has been included for
Interestingly, both the alkene and ketone bonds were
centres. The reaction yielded the product as a
mixture of the diastereomers
via gas chromatography (
271 was instead performed through the use of
the configuration of
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tethTsDPEN, 248
concentration of
17 h at room
which
GC) or
N-benzyl 5-
271a and
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Scheme 2.2.15: ATH of 245 and 269.
Table 2.2.3: ATH of 245 and 269.
entry ketone a R cat.e
mol
%
time
(h)
conv.
(%)b
a/b
(%)b
Ee a
(%)c
Ee b
(%)c
1 245 H (R,R)-248 2 17 100 3.1:1 N/D N/D
2 269 Bn 249 6 20 100 1:1 N/A N/A
3 269 Bn (R,R)-255 6 20 100 1.3:1d 55 36
4 269 Bn (R,R)-248 0.8 20 100 4:1d 92 33
5 269 Bn (S,S)-248 0.8 20 100 4:1d 86 49
a. [SM] = 2M, b. determined by 1H NMR (the exact configuration was not determined and has been
included for illustration purposes only); c. determined by chiral HPLC; d. the same major
diastereomer was identified by 1H NMR in these reactions; e. see Appendix IV for catalyst structures;
N/D: not determined; N/A: not applicable.
The ATH of 269 was carried out with RutethTsDPEN 248, (R,R)-RuTsDPEN, (R,R)-
255 and racemic TH catalyst, RuTsEN 249. Catalysts 249 and (R,R)-255 were used
in a higher loading (6 mol %) to achieve full conversion within the time scale of
catalyst (R,R)-RutethTsDPEN (20 h). In all cases, conversion and dr were
determined by 1H NMR. Use of catalyst (R,R)-248 resulted in formation of 271a and
271b in a 1:1 ratio and 100 % conversion (entry 2), as an inseparable mixture of
diastereomers. Substrate 269 was reduced with formation of 271a and 271b in a
1.3:1 ratio and 100 % conversion (entry 3). Chiral HPLC separation of the mixture
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of the diastereomers was achieved (Chiralpak IA, hexane : IPA 9 : 1, flow rate = 1
mL/min) using the racemic reduction product (a : b 1:1) obtained from racemic
catalyst 249 as a racemic standard to confirm the position of peaks. As the a : b ratio
had been determined by 1H NMR, it was possible to assign the chiral HPLC peaks to
the correct pairs of enantiomers. This enabled the ee of diastereomers 271a and 271b
to be determined as 55 % and 36 % respectively. The use of catalyst (R,R)-248
resulted in the formation of 271a and 271b in 4 : 1 ratio with 92 % and 33 % ee
respectively (entry 4) (Chiralpak IA, hexane : IPA 9 : 1, flow rate = 1 mL/min). The
use of catalyst (S,S)-248 resulted in the formation of 271a and 271b in 4 : 1 ratio
with 86 % and 49 % ee respectively (entry 5) (Chiralpak IA, hexane : IPA 9 : 1, flow
rate = 1 mL/min). These GC traces have been included for comparison in Appendix
III.
Comparison of the results obtained from ATH with Noyori’s catalyst (R,R)-255 and
RutethTsDPEN(R,R)-248 (entry 3 and 4) show that the same diastereomer 271a is
formed in the majority in each case. Interestingly, comparison of the HPLC retention
times for each isomer (see Appendix III) show that for 271a, the same major
enantiomer is formed. However, for 271b, the major enantiomer from each catalyst
is the opposite. These results highlight subtle differences in selectivity of the two
catalysts, resultant from the presence of the three carbon tether in RutethTsDPEN,
even though the catalysts both operate by the same reduction mechanism and share
an equivalent asymmetric environment. Comparison of the results obtained from
ATH with opposite enantiomers of RutethTsDPEN, (R,R)-248 and (S,S)-248 (entry 4
and 5) show that each catalyst favours the same diastereomer 271a. However the
opposite enantiomer catalyst forms the opposite major enantiomer of both
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diastereomers. By comparison of the HPLC retention times, it is clear that for each
diastereomer, changing the enantiomer of catalyst will favour the formation of the
opposite enantiomer: i.e. For 271a the (R,R)-248 catalyst leads to the major isomer at
Rt 43.5 min., and the minor isomer at Rt 75.3 min; whereas (S,S)-248 leads to the
minor isomer at Rt 44.1 min., and the major isomer at Rt 75.9 min. A similar affect is
observed for 271b. The configuration of diastereomers 271a and 271b was not
determined and has been included for illustration purposes only.
Discussion of mechanism.
It is possible to gain some insight into a potential mechanism of this process, from
these results. As each diastereomer was present in differing ee in each reduction, this
indicates that ketone reduction could not have occurred first. Instead, conjugate
reduction must have occurred first, resulting in formation of the enol intermediate
272 (step a, Scheme 2.2.16) which would tautomerise to give ketone 273 (step b).
The subsequent ketone reduction of ketone 273a or 273b may then proceed via a
DKR or KR, potentially leading to differing asymmetric inductions for each
enantiomer of ketone, and the subsequent formation of diastereomers 271a and 271b
(step c).154 This explanation is supported by the observed difference in ee for each
diastereomer. Attempts to independently form ketone 273 via partial reduction of
269 were unsuccessful, preventing further study.
Scheme 2.2.16: Mechanism for the reduction of 269.
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Section 2.3: 2nd Generation Formal Synthesis of Cytisine: AH of Pyridone 2.
Section 2.3.1: Introduction.
In this section, a 2nd generation formal approach to cytisine was carried out through
the AH of pyridone 2. The product of this hydrogenation, the 5-substituted lactam
274, may be converted to the cytisine precursor lactam 5 through a known route
(Scheme 2.3.1b). Following the known structural requirements for enantioselective
hydrogenation, pyridone 2 was considered to bear these necessities. The proximal
glutarimide carbonyl group to the pyridone group would be anticipated to enable
effective coordination of the catalyst, resulting in an enantioselective reduction of the
alkene (Scheme 2.3.1b). In the introduction, the AH of pyridone 67 (see Section
1.2.4) proceeded with low enantioselectivity, however this compound did not have
any proximal coordinating group, and only one catalytic system was used.
Scheme 2.3.1: a. Proposed coordination modes of 2 and 1; b. formation of 5 from 2.
This work was motivated by the availability of an extensive screen of chiral ligands
(up to 200) and rhodium, ruthenium and iridium catalysts through collaboration with
AstraZeneca. The full retrosynthetic approach and full synthesis is described in
Section 2.3.2. As discussed in the introduction, the enantioselective synthesis of δ-
lactams has not been described in detail. If successful, this methodology could also
potentially be modified for use in the asymmetric synthesis of other 5-substituted δ-
lactams.
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AH of alternative 5-substituted pyridones.
In this section, the AH of a number of 5-substituted pyridones was also carried out in
attempt to prepare the corresponding 5-substituted lactams, which are also
synthetically useful as precursors to cytisine and in other applications. The AH of the
structurally similar α,β-unsaturated δ-lactam, 110 was described in Section 1.3.2
(Scheme 1.14a).
This section is split between two parts: the first part will consist of the main subject
of this section, the synthesis and hydrogenation of pyridone 2. In the second part, the
AH of a range of 5-substituted pyridones is described.
Section 2.3.2: Synthesis and AH of Pyridone 2.
During Section 1, the AH of α,β-unsaturated imide 1 resulted in the highly
enantioselective formation of imide 228. However, the asymmetric synthesis of
cytisine could not be completed by this route, due to late state epimerisation and
subsequent loss of ee following conversion of imide 228 to the cytisine precursor 5.
To complete the asymmetric synthesis, an alternative strategy was required. In this
section, the AH of pyridone 2 was studied, as a potential entry to the cytisine
precursor 5. Lactam 274, the product of AH may also be readily converted to
cytisine precursor 5 through the method outlined in the retrosynthesis is below.
Retrosynthesis.
The intended retrosynthetic approach to cytisine precursor 5 is shown in Scheme
2.3.2. Cytisine precursor 5 should be accessible from imide 274 by the conversion of
the imide group to the pyridone through the three step method detailed by Sivaguru
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et al.155 Imide 274 may be obtained from pyridone 2 via AH, potentially through the
proposed mode of coordination (Scheme 2.3.2a). Pyridone 2 may be accessed from
two possible compounds: pyridone 277 or methoxypyridine 275 which itself may be
obtained from alcohol 276 via Mitsunobu coupling.
Scheme 2.3.2: Retrosynthesis of cytisine precursor, 5.
Synthesis of pyridone 2.
Initially the coupling of pyridone 277 with glutarimide was considered as the
primary approach to 2 (Scheme 2.3.3a); however, a second approach involving the
synthesis and benzylation of pyridine 275 was immediately more successful,
yielding the desired hydrogenation substrate.
Scheme 2.3.3: a. Attempted substitution of pyridone 277; b. alkylation of 275.
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Conversion to the desired pyridone 2 was attempted by converting 277 to the
corresponding bromide or tosylate, followed by subsequent reaction with glutarimide
(Scheme 2.3.3a), however the corresponding bromide or tosylate could not be
formed which made this approach unsuccessful.
Alternatively, it was possible to complete synthesis of the desired hydrogenation
substrate via pyridine 275. Pyridine 275 was formed by the coupling of pyridine 276
with glutarimide under Mitsunobu conditions 156 (50 % yield, Scheme 2.3.4). It was
possible to convert pyridine 275 to the corresponding pyridone 2 by treatment with
benzyl bromide.
Scheme 2.3.4: synthesis of hydrogenation substrate 2.
Following recrystallisation from ethanol, hydrogenation substrate 2 was obtained in
59 % yield as a colourless powder. Further recrystallisation provided crystals which
underwent X-ray diffraction to give confirm the structure (Figure 2.3.1), thus
confirming that alkylation had occurred exclusively on N(8). Full characterisation
data is shown in Appendix II.
Figure 2.3.1: X-ray crystal structure of 2.
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AH of pyridone 2.
The hydrogenation of pyridone 2 was carried out using a range of homogeneous and
heterogeneous catalysts (Scheme 2.3.5, Table 2.3.1). Catalyst structures may be seen
in Appendix IV. Pyridone 2 reacted with Pd / C under atmosphere of hydrogen to
give ring opened product pyridone 278 in 57 % yield (entry 1). No reduction
products were isolated. Ring opening was avoided using platinum oxide in ethanol
for 6 h at room temperature, to give the desired lactam 274 in 100 % conversion
(entry 2). Scaling up this reduction (1.0 – 1.5 g) under the same conditions lead to
incomplete conversion to the product.
Scheme 2.3.5: AH of pyridones 2.
Table 2.3.1: AH of pyridones 2.
entry cat.
scale
(mg)
mol
%
temp/
(°C) time (h) P. (bar)
conv.
(%)
1 Pd /C 185 5 rt 18 1c N/Ad
2a PtO2 40 10 30 6 1c 100
3a PtO2 1140 5 rt 18 5 95e
4 (R,R)-229 30 5 40 72 30 54f
5 (R)-37a 20 5 30 6 50 100f
6b (R,S)-279 20 1 rt 2 50 0
a. EtOH as solvent; b. DCM as solvent; c. run under a balloon of hydrogen; d. ring opened
product 278 was isolated; e. obtained yield; f. the sample was found to be racemic.
Running the hydrogenation a higher temperatures (40°C) resulted in formation of
unwanted side products which were inseparable from the desired product. Limited
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evidence suggested that debenzylation of the product was occurring. Running the
reduction at an elevated pressure of 5 bar at room temperature for 18 h was
reproducibly found to give the desired product in high yield following purification
(silica gel chromatography) typically in 90 – 95 % yield (entry 3).
Chiral separation of 274 was achieved (Chiralpak IB, hexane : IPA 8 : 2, flow rate =
1.0 mL/min). This sample was used as a racemic standard in chiral HPLC for
subsequent AHs. Partial conversion to lactam 274 was observed using (R,R)-Rh-Et-
DuPhos (R,R)-229 following a prolonged reaction time of 72 h at 40 °C under 30 bar
of hydrogen (entry 4). The ee of the sample was found to be 0 %. (R)-
Ru(OAc)2(BINAP) (R)-37a (see p 19 for catalyst structure) was remarkably active,
resulting in 100 % conversion to 274 following 6 h at 30 °C under 50 bar of
hydrogen. Again, the sample was found to be racemic. No activity was observed
with (R,S)-IrThrePHOX, (R,S)-279.
Through collaboration with AstraZeneca, the AH of pyridone 2 underwent an
extensive asymmetric ligand screen with ruthenium and rhodium catalysts. Due to
unfortunate circumstances which lead to the closure of the research facility, it has not
been possible for these results to be made available for presentation in this thesis. It
was however reported that of all the ligands screened, no significant chiral induction
was observed in any case.
This absence of any enantioselectivity with any of the ligands screened was a real set
back. This shows that the predicted coordination mode was not successful in
directing enantioselectivity. It was suggested that the absence of any
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enantioselectivity observed in the AH of pyridone 67, was due to the tautomeric
forms of the structure (Section 1.2.4).42 The AH of pyridines is generally known to
result in poor enantioselectivity, 52 with the exception of a few key examples, 53 and
this may be an explanation for the results observed here.
Section 2.3.3: Completion of the Synthesis.
Nonetheless, with lactam (±)-274 in hand, the formal synthesis of racemic cytisine
was continued following the three step method of Sivaguru (Scheme 2.3.6).155
Treatment of lactam (±)-274 with sodium borohydride and cerium chloride gave α-
hydroxylactam 280 in 70 % yield as an inseparable mixture of diastereomers which
could not be adequately purified. It was not possible to distinguish between the two
isomers by 1H NMR. Further evidence supporting the assignment was obtained
following the treatment of 280 with Et3SiH and TFA, which resulted in its
conversion to lactam 235. The use of the N-acyliminium chemistry of 280 was
briefly considered, 157 however it was reported that in similar experimentation with
α-hydroxy-δ-lactams, conversion to the corresponding γ,δ-unsaturated-δ-lactam was 
always observed as a major product.158
Scheme 2.3.6: Conversion of pyridone 2 to cytisine precursor 5.
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Advantageously, treatment of α-hydroxylactam 280 with titanium chloride and
DIPEA mediated the formation of the enamide 281.159 This method was favoured
over the use of methanesulfonyl chloride and NEt3 which resulted in co-formation of
inseparable side products.158 To complete the synthesis, oxidation of the enamide to
the pyridone was required. Although this transformation had been reported in the
literature with phenyl selenyl chloride 155, initially, less toxic alternatives to selenium
were investigated, albeit unsuccessful. Reaction with Br2 or I2 was attempted. The
oxidants, MnO2 and benzoquinone were also tried. Transition metal mediated
transfer dehydrogenation was attempted with the reagents Pd/C, [Ir(COD)dppp],
platinum black, and Raney nickel; in each case with cyclohexene as co-solvent to act
as a hydrogen acceptor. However, none of these approaches were successful. Instead,
the oxidation was achieved by the originally planned selenide oxidation –
elimination method.155 Treatment of the lithium enolate of 281 (formed with LDA)
with phenyl selenyl chloride at -78°C resulted in formation of the intermediate
selenide which was then subjected to oxidation with NaIO4 in a solution of THF :
MeOH : H2O 18 : 6 : 2, resulting in a sample containing a mixture of the desired
pyridone 5 and an unidentified product. This procedure was carried out at a small
scale (15 mg) which prevented adequate purification and isolation of 5. This was not
repeated, due to the results of the asymmetric ligand screen and time constraints.
Section 2.3.4: Synthesis and AH of 5-Substituted Pyridones.
In this part of the section, the AH of a number of 5-substituted pyridones was carried
out in attempt to achieve an enantiomerically enriched 5-substituted lactams. These
pyridones were conveniently synthesised from the equivalent 5-substituted 2-
methoxypyridine or 5-substituted 2-hydroxypyridine by known procedures involving
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the N-alkylation and subsequent demethylation / deprotonation. Two different
methods were used depending on the starting material used. Alternative synthesis
methods involve the acid hydrolysis of substituted 2-fluoropyridines.160
Pyridone 283.
Pyridine 283 underwent reaction with benzyl bromide in the presence of KOH in
methanol and water following a reaction time of 90 min at 70 °C (Scheme 2.3.7).
The crude material obtained from the reaction was not sufficiently pure and
contained traces of other alkylation products which could not be isolated or
characterised. Instead of conventional purification, a portion of the crude material
(290 mg) (for practical reasons only a fraction was used) was purified by preparative
reverse phase HPLC ((Phenomenex Gemini-NX axia Prep C18 OBD column) to give
analytically pure 283 (211 mg).
Scheme 2.3.7: Alkylation of 5-substituted 2-hydroxypyridine 282.
N-benzylpyridone-5-carboxylate 286.
Pyridone 286 was synthesied in two steps from methyl nicotinate, 284. Esterification
of methyl nicotinate 284 was achieved with H2SO4 and methanol (72 % yield,
Scheme 2.3.8). Alternatively, the product, pyridine 285, could be purchased from an
affordable commercial source. Pyridine 285 underwent reaction with benzyl bromide
in the presence of K2CO3 in acetonitrile following 47 h at 80°C to give methyl N-
benzylpyridone-5-carboxylate 286 in 29 % yield.
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Scheme 2.3.8. Synthesis of pyridone 286 from pyridine 284.
N-benzyl-5-hydroxymethylpyridone 277.
Initially the synthesis of pyridone 277 was attempted by reduction of pyridones 283
or 288 (Scheme 2.3.9); however in both cases this was hampered by the apparent co-
formation of multiple reduction products which could not be removed from the
desired product. Following reduction of pyridone 277, limited evidence by MS
suggested that formation of conjugate reduction product 287 had also occurred
(Scheme 2.3.9a).
Scheme 2.3.9: (a) Reduction of pyridone 283 with LiAlH4; (b) formation of acid chloride 40; (c)
reduction of acid 288 with NaBH4.
Alternatively, pyridone 283 was converted to acyl chloride 288 (Scheme 2.3.9b)
which was subsequently reduced with NaBH4 by the method of Thomas et al.
However, this procedure was not reproducible and resulted in multiple reduction
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products which could not be removed from the desired product.161 Limited evidence
by MS suggested the formation of conjugate reduction product 289 (Scheme 2.3.9c).
For these reasons, an alternative synthesis of pyridone 277 was completed via the
two step sequence from pyridine 285, shown in Scheme 2.3.4. Reduction of ester
285 was performed with LiAlH4 to afford pyridine 276 in 83 % yield. Pyridine 276
underwent N-alkylation and subsequent O-demethylation following 18 h at 60°C. N-
benzyl-5-hydroxymethylpyridone 277 was obtained in 32 % yield (Scheme 2.3.10).
There was some evidence for the presence of other alkylation products in the crude
reaction sample however none were isolated and identified. The analysis of alcohol
277 was in agreement with reported data. An nOe 1H NMR study also showed an
interaction between the CH2Ph protons and H3, supporting N-benzylation.
Scheme 2.3.10: Synthesis of N-benzyl-5-hydroxymethylpyridone 277.
AH of N-benzyl-5-hydroxymethylpyridone 277.
The AH of the 5-substituted pyridones was then carried out using a range of
homogeneous and heterogeneous catalysts (Scheme 2.3.11, Table 2.3.2). Pyridone
277 was reduced with Pd / C using the H-cube, an automated continuous flow
method for hydrogenations with heterogeneous catalysts. Following one pass of a
solution of the substrate in methanol (0.25 M) through the H-cube using a 10 % w/w
Pd/C cartridge, the C-O cleavage product 290 was isolated in 81 % yield (entry 1).
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Scheme 2.3.11: AH of pyridone 277.
Table 2.3.2: AH of pyridone 277.
entry
scale
(mg) cat. mol %
Temp
(°C)
time
(h)
P.
(bar) prod.
yield
(%)
1 100 Pd/Ca N/A rt N/A 5 290 81
2 30 Pd/BaSO4 10 rt 18 5 291 71
3 30 PtO2 10 rt 18 5 292 65
4 15 (R,R)-229 2.5 40 20 40 292 50b
a. Reaction performed in the H –cube; b. ee could not be determined by chiral GC or HPLC.
When Pd/BaSO4 was used, the fully hydrogenated and C-O cleaved product 291 was
obtained in 71 % yield (entry 2). The desired hydrogenation of the pyridone group
was achieved with PtO2 resulting in formation of the desired lactam 292 in 65 %
yield (entry 3). Asymmetric catalyst (R,R)-229 resulted in partial conversion to
lactam 292 (entry 4); however, chiral separation could not be achieved by GC or
HPLC. In Section 2.5.4, the ee of the similar lactam (±)-304 obtained from reduction
with (R,R)-229 was determined to be 0 %. The ee of lactam 292 formed in this
experiment was thus expected to also be 0 %. This asymmetric synthesis of lactam
292 (95 % ee) has been reported by Park et al., via the phase transfer organo-
catalytic mono-alkylation of a malonamide precursor to the lactam.162
The difference in reactivity of Pd/C in comparison to Pd/BaSO4 is unexpected as
BaSO4 is thought to deactivate Pd leading to a poorer catalyst. Comparatively, Pd/C
would have also been expected to fully reduce the pyridone ring, also resulting in
formation of product 291. However, as this experiment was run with the H-cube this
may be explained by the reduced effective time, following only one pass of the
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reaction solution through the system. The formation of 292 with PtO2 is a good
example of the catalyst’s chemoselectivity to hydrogenation over hydrogenolysis.163
AH of pyridones 283 and 285.
The attempted AH of the 5-substituted pyridones 283 and 285 was carried out using
a range of homogeneous and heterogeneous catalysts (Scheme 2.3.12, Table 2.3.3).
Pyridone 283 was reduced with Pd / C under forcing conditions (25 bar hydrogen) to
give lactam 293 in quantitative yield (entry 1). No reduction was observed with the
catalysts (R)-Ru(OAc)2(BINAP) (R)-37a or (R,R)-Rh-EtDuPhos (R,R)-229 under a
variety of conditions (entry 2 and 3). Due to the highly polarised nature of 283,
transfer hydrogenation catalyst (R,R)-RutethTsDPEN (R,R)-248 was tested with no
success (entry 4). Pyridone 283 was found to be unusually resistant to hydrogenation
with these asymmetric catalysts.
Scheme 2.3.12: AH of pyridones 283 and 285.
Table 2.3.3. AH of pyridones 283 and 285.
entry pyridonea cat. mol %
temp/
(°C) time (h) P. (bar)
conv.
(%)
1 283 Pd /C 10 30 20 25 > 99d
2 283 (R)-37a 5 30 20 20 0
3 283 (R,R)-229 5 30 20 20 0
4 283b (R,R)-248e 2 30 72 N/A 0
5 285 Pd/C 10 40 24 1 29d
6 285 W001-1e 3.2 40 120 40 0
7 285 W002-1e 3.2 40 120 40 0
8 285 T001-1e 3.2 40 120 40 0
9 285 T002-1e 3.2 40 120 40 54
10 285 (R,R)-229 3 40 120 40 75
11 285 (R,S)-279 3 40 120 40 0
a. Reactions with 283: 30 mg scale. Reactions with 285: 40 mg scale; b. 50 mg scale; c. determined
by chiral HPLC; d. isolated yield; e. used with [Rh(COD)Cl]2 (3 mol % w/r to Rh).
114
Pyridone 285 was readily reduced with Pd / C under a balloon of hydrogen to give
lactam 294 in complete conversion, although it was obtained at a low yield (29 %)
following repeated purification (silica gel chromatography) which was required due
to its use as a racemic standard. Chiral separation of 294 was achieved (Chiralpak
IA, hexane : IPA 85 : 15, flow rate = 1 mL/min). The Walphos ligands W001-1 and
W00-2-1; and Taniaphos ligands, T001-1 and T002-1 were used (3.2 mol %) in AHs
with the precatalyst Rh(COD)Cl]2 (3.0 mol % w/r to Rh) and pyridone 2 (entry 6-9).
Taniaphos T002-1 was the only active ligand resulting in 54 % conversion to 294 in
0 % ee (entry 9). (R,R)-RhDuPHOS, (R,R)-229 resulted in 75 % conversion to 294 in
0 % ee (the chiral HPLC method was shown above). No activity was observed with
the catalyst (R,S)-IrThrePHOX, (R,S)-279, although iridium catalysts of this type are
known to be deactivated by strongly coordinating substrates (entry 11).164 The
asymmetric homogeneous catalysts studied required forcing conditions to achieve
reduction. As the reduction products found were found to be racemic, further
optimisation to achieve full conversion was not attempted.
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Section 2.4: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine): AH of
Pyridone 3.
Section 2.4.1: Reduction of Imide 228.
This work carries on from Section 1, following the successful AH of enamide 1 with
Taniaphos T002-1 and [RhCODCl]2 which resulted in the formation of lactam (S)-
228 in 98 % ee (Table 2.1.3, p 72). Further reduction to the fully saturated
compound, 1-benzyl-3-(piperidin-1-ylmethyl)piperidine 6 (bispiperidine) was seen
as a desirable method of forming enantiomerically enriched 5-substituted piperidines
(Scheme 2.4.1).
Scheme 2.4.1: Synthesis of bispiperidine 6 from imide 1.
The reduction of imide (S)-228 (95 % ee) was achieved following reaction with an
excess (15 eq.) of LiAlH4 in THF for 24 h at room temperature (Scheme 2.4.2).165 A
similar glutarimide reduction with LiAlH4 from the literature resulted in the
formation of the corresponding piperidine with no reported loss of ee.166 The
reduction of 228 would be expected to have proceeded in the same manner, however
it was not possible achieve chiral separation by GC or HPLC to confirm this, which
seemed important in light of the loss of ee following the reduction of imide 228
(Section 2.1). This partly motivated the development of a second synthesis of
bispiperidine.
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Scheme 2.4.2: reduction of imide 228 to bispiperidine 6 with LiAlH4.
Alternative approach to bispiperidine 6.
Leading on from Section 3, where the AH of pyridone 2 was used as a key
component in the formal synthesis of cytisine precursor 5 (Scheme 2.4.3a), in this
section, the AH of pyridone 3 was carried out. In analogy with the rational for the
proposed enantioselective reduction of pyridone 2, the reduction of pyridone 3 was
proposed to bear the known functional requirements for successful AH via the
proximal pyridone group which may direct the reduction.
Scheme 2.4.3: a. Synthesis of cytisine precursor 2 from Section 3;
b. proposed synthesis of bispiperidine 3 in this section.
This work was largely motivated by the availability of an extensive screen of chiral
ligands and rhodium, ruthenium and iridium catalysts which was carried out
simultaneously with the screen of pyridone 2 through collaboration with
AstraZeneca. As pyridone 3 was synthetically accessible through a similar route to
pyridone 2, the opportunity of having multiple substrates screened was taken and
pyridone 3 was also put forward for screening. This was also partly motivated by the
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uncertainty of the ee of bispiperidine 6 (formed following reduction of 228, Scheme
2.4.1). As was for the motive for the AH of pyridone 2, a route to bispiperidine 6
involving a configurationally stable chiral centre was also desirable. The synthetic
use of optically pure 5-substituted lactams and piperidines has been briefly reviewed
in Section 1.5, which gives further motive for this work.
Summary.
This section starts with the main subject of this section, the synthesis and
hydrogenation of pyridone 3, and subsequent conversion to bispiperidine 6. This
section then ends with related work involving the synthesis and hydrogenation of 5-
membered enamides in attempt to access 5-membered cyclic diamines.
Section 2.4.2: Synthesis and AH of Pyridone 3.
In this retrosynthetic approach, bispiperidine 6 may be directly obtained from
bislactam 235, through reduction of the two amide groups in which the isolated
chiral centre has no risk of epimerisation (Scheme 2.4.4). Bislactam 235 is the
product of the asymmetric reduction of pyridone 3. This AH-catalysed reduction of
this compound holds the potential for a directing group effect through the pyridone
carbonyl as discussed earlier. Hydrogenation substrate, pyridone 3 may be
conveniently reached from pyridine 295 via an N-alkylation O-demethylation
sequence. Pyridine 295 may be accessed from alcohol 276 following substitution of
the corresponding halide with 2-hydroxypyridine. Due to the thermodynamic
preference of N-alkylation over O-alkylation encountered when initial formation of
the pyridone is reversible, chemoselectivity to the desired N-pyridone 295 may be
achievable possible in this process.167
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Scheme 2.4.4: Retrosynthetic of bispiperidine 6.
Synthesis of hydrogenation substrate 3.
For the initial alkylation to form pyridine 295, halides 296a and 296b were
considered. Bromide 296a was formed following treatment of alcohol 276 with PBr3
(Scheme 2.4.5a). The crude bromide was used directly in the subsequent reaction
with 2-hydroxypyridne and K2CO3. Methoxypyridine 295 was obtained in <5 %
yield (Scheme 2.4.5b). This low yield was may be due to the lability of bromide
296a (the compound has also been reported to undergo self polymerisation).
Alternatively, chloride 296b (formed from thionyl chloride) was used for the
alkylation reaction. Reaction with 2-hydroxypyridine and K2CO3 in toluene at 115
°C for 10 h, successfully gave methoxypyridine 295 in 63 % yield as the major
isomer, alongside the O-substituted isomer, 297 which was isolated in 12 % yield,
although this was inconsistent and in some cases it was not isolated (Scheme 2.4.5c).
Both isomers were readily separated from each other via silica gel chromatography.
Longer reaction times (18 h) resulted in only traces of 297 (observed by 1H NMR of
the crude reaction mixture). This has been attributed to the reversibility of the
reaction and the known thermodynamic preference for alkylation at nitrogen.
It is worth noting the similarity of the 1H NMR spectra obtained from N-substituted
pyridone 295 with that of N-substituted enamide 1 (Section 1); and those of O-
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substituted pyridol 297 with O-substituted enamide 227 (Section 2.1.2). These
comparisons are summarised in Appendix I. Their patterns are similar and appear to
be indicative of N- or O- substitution; however the conclusive evidence for each
structural assignment was obtained from the X-ray structure of 3, formed from N-
substituted imide 295 (see Figure 2.4.1).
Scheme 2.4.5: a. Synthesis of halides 296a and 296b; b. formation of 295 from 296a; c. formation of
295 and 297 from 296b; d. unsuccessful isomerisation of 297; e. benzylation of 295.
Sodium iodide mediated conversion of pyridols to pyridones have been reported.168
This was attempted following the heating of pyridol 297 with NaI in a sealed tube at
100 °C; however the reaction yielded a complex mixture from which no products
could be isolated (Scheme 2.4.5c).
With methoxypyridine
carried out. Methoxypyridine
and K2CO3 in acetonitrile at 80
obtained in 51 % yield as a colourless power, following recrystallisation from
ethanol (Scheme 2.4.5d). Further recrystallisation provided crystals which underwent
X-ray diffraction to confirm the structure (
Figure 2.4.
AH of pyridone 3.
The hydrogenation of pyridone
heterogeneous catalysts (
Pd / C under a balloon of hydrogen at 30
after 17 h (entry 1). Preferably
achieved with PtO2 under a balloon of hydrogen at 30
At a larger scale of 644 mg,
(as determined by 1H NMR) after 20 h, providing pure
following silica gel chromatography (entry 2) (for the chiral separation of lactam
235, see Section 2.1.3
295 in hand, conversion to the corresponding pyridone was
295 readily underwent alkylation with benzyl bromide
°C for 8 h. Hydrogenation substrate py
Figure 2.4.1).
1: X-ray crystallographic structure of pyridone
3 was carried out using a range of homogeneous and
Scheme 2.4.6, Table 2.4.1). Pyridone 3
°C to give lactam 235 in 90 % conversion
(due to ease of subsequent purification)
°C.
90 % conversion of the starting material was achieved
lactam
).
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ridone 3 was
3.
was reduced with
reduction was
235 in 75 % yield
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Scheme 2.4.6: AH of pyridone 3.
Table 2.4.1: AH of pyridone 3.
entry cat.
scale
(mg)
mol
%
temp/
(°C)
time
(h)
P.
(bar)
conv.
(%)
1 Pd /C 110 5 30 17 1b 90
2a PtO2 644 5 30 20 1b 90 (75c)
3 (R,R)-229 30 5 rt 18 20 40d
4 (R,S)-279a 20 1 rt 2 50 0
a. DCM used as solvent; b. run under a balloon of hydrogen; c. % yield after purification;
d. the sample was found to be racemic.
Pyridone 3 underwent partial conversion to lactam 235 with (R,R)-RhEtDuPhos,
(R,R)-229 following a reaction time of 18 h at room temperature under 20 bar
hydrogen (entry 3), however the ee of the sample was found to be 0 %. No activity
was observed with (R,S)-IrThrePHOX, (R,S)-279 (entry 4).
The AH of pyridone 3 underwent an extensive asymmetric ligand screen with
ruthenium and rhodium catalysts, through collaboration with AstraZeneca.
Unfortunately the same circumstances as detailed in Section 2.3 prevented these
results from being made available for presentation in this thesis. It was, however,
reported that of all the ligands screened, no significant chiral induction was observed
in any case.
Again, this absence of any enantioselectivity with any of the ligands screened was a
again a real set back. This shows that the predicted coordination mode was not
successful in directing enantioselectivity. As explained in Section 2.3, it is possible
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that a poorly controlled asymmetric reduction of the pyridinium tautomer of 3 is
taking place, as suggested for similar compounds (see Section 1.2.4).42
Section 2.4.3: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine) 6.
With lactam (±)-235 in hand, the racemic synthesis of bispiperidine was continued
(Scheme 2.4.7). Treatment of lactam 235 with LiAlH4 in THF (0 °C to rt) provided
the product 6 in 37 % yield following careful purification (silica gel
chromatography, eluent: CHCl3 – MeOH - NH4OH 100:2:1, visualisation by I2). This
method was not ideal, as a large amount of side products were co-formed which
required tedious purification. Alternatively, reduction with Ru3(CO)12 (2 mol %) and
Et3SiH (7 eq.) in toluene at 100 °C for 18 h resulted a clean crude reaction mixture
(1H NMR) containing bispiperidine 6 with only traces of side products.169 In this
case an alternative solvent system was used in purification (silica gel
chromatography, eluent: ethyl acetate – hexane – triethylamine 10:90:1, visualisation
by I2) to give product 6 in 57 % yield. Debenzylation of bispiperidine 6 was achieved
with Pd(OH)2 under an atmosphere of hydrogen, following 18 h at room
temperature. A sample containing the free amine was isolated through the use of an
Isolute-XL SCX amine scavenger thiol resin. The crude reaction mixture was
conveniently passed through the resin which was then washed with solvent to
remove non basic impurities. The trapped basic compounds on the resin (including
the desired product) were then released by washing flushing the resin with a
methanolic solution of ~2 % NH4OH (for details of use, see the experimental
section). A sample containing the amine 298 was obtained showing only a trace of
the starting material by 1H NMR.
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Scheme 2.4.7: Formation of bispiperidine 6 from pyridone 3.
Section 2.4.4: Synthesis and Hydrogenation of Enamide 299.
Following the synthesis and hydrogenation of enamide 1, the synthesis of alternative
heterocyclic derivatives was briefly investigated, to probe the further utility of this
synthetic route to other applications.
Through the use of a different nucleophile in the Michael addition reaction with
enamide 219 (see Section 2.1) it may also be possible to access 5-membered
enamides such as compounds 299 which could be subsequently converted to the
corresponding diamines (300) (Scheme 2.4.8).
Scheme 2.4.8: Potential synthesis of 5-membered enamides and diamines
Synthesis of pyrrolidine derived enamides.
Pyrrolidine 301 was prepared in 35 % yield following treatment of enamide 219 with
pyrrolidine and NEt3 in toluene at 40 °C for 18 h (Scheme 2.4.9). Treatment of
pyrrolidinone with tosylate 219 failed to yield the corresponding pyrollidinone 301.
An attempted synthesis of enol imide 302 using N-benzyl succinimide as starting
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material was unsuccessful, following a modified procedure used for the synthesis of
enamide 218 (see Section 2.12).
.
Scheme 2.4.9: a Synthesis of pyrrolidine 218; b. unachievable targets 300 and 302.
Surprisingly, pyrrolidine 301 was inert to pressure hydrogenation with Pd/C and
RhEtDuPHOS, (R,R)-229 and transfer hydrogenation with RutethTsDPEN, (R,R)-
248. This is presumably due to the relatively higher stability of the conjugated
system of 301 compared to enamide 1. This may result from relatively higher
donation of the pyrrolidine nitrogen lone pair into the conjugated enamide system, in
comparison with the corresponding pyridone nitrogen lone pair donation.
Conclusions.
Following an extensive ligand screen, the hydrogenation of precursor pyridone 3 did
not result in any substantial enantioselectivity. The product of this hydrogenation,
lactam 235 was however successfully converted to bispiperidine 6. The synthesis of
enamide, pyrrolidine 3 was completed; however the compound was inert to
hydrogenation.
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Section 2.5: Asymmetric Synthesis of Alcohols 7a and 7b.
Section 2.5.1: Introduction.
In sections 1-4, AH and ATH was used as a means of potentially forming
enantiomerically enriched 5-substituted lactams specific to the application in the
asymmetric formal synthesis of cytisine and bispiperidine 6. In this section, an
indirect method of asymmetrically synthesising a 5-substituted lactam cytisine
precursor was attempted, through the conversion of an enantiomerically pure alcohol
(formed via ATH) proximal to the 5-lactam position into a pair of diastereomers,
from which physical chromatographic separation may be possible. This would result
in two diastereomers which were optically enriched at the desired 5- position
(although differing in orientation). This is depicted more specifically in Scheme
2.5.1: ATH of pyridyl methyl ketone 4, may result in the highly enantioselective
formation of alcohol 303 (Scheme 2.5.1b, step a). Following conversion to the
corresponding pyridone, 304 (step b.), hydrogenation may result in the formation of
two diastereomers, 7a and 7b which may be separable by chromatography. Each
diastereomer would be optically enriched at the desired 5-lactam position, potentially
present in the enantiopurity obtained from the initial ketone ATH. There is a further
potential for diastereoselectivity in the hydrogenation of pyridone 304 (step c).176
Scheme 2.5.1: Potential strategy for the enantiomeric enrichment of 5-substituted lactams –
chromatographic separation of diastereomers 7a and 7b.
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Optically pure lactam 7 maybe subsequently converted to a derivative of the cytisine
precursor, lactam 5 through substitution with 2-hydroxypyridine (in analogy to
Gallagher’s method) 63 (step a, Scheme 2.5.2)) or via conversion to the
corresponding amine 308, which may be converted to the pyridone 307 following
reaction with 2H-pyran-2-one. However, in view of the reviewed pharmacological
limitations of structurally modified bispidine derivatives, optically pure 5-substituted
lactams are in themselves synthetically useful in other applications.170
Scheme 2.5.2: potential utilisation alcohol 7.
Various methods of forming lactam 7.
Additionally to the procedure for reaching lactam 7 shown in Scheme 2.5.1,
potentially these are also alternative routes, resulting from alternative orders of
sequential transformation steps. Each route would involve a different ketone,
expected to be reduced in differing ee, which as well as its synthetic use, may also be
mechanistically interesting. These steps are shown in Scheme 2.5.3: 1) a. ketone
reduction of 4; b. conversion to pyridone 304; c. hydrogenation of pyridone 304. 2)
d. conversion to pyridone 309; e. ketone reduction of 304; c. hydrogenation of
pyridone 304; 3) d. conversion to pyridone 309; f. hydrogenation of pyridone 310; g.
ketone reduction of 310.
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Scheme 2.5.3: Various potential routes to alcohol 7 from 4; and target ketones 4, 309 and 310.
This section is split between three main parts. In the first part, the synthesis and ATH
of ketones 4, 309 and 310 was carried out. Based on these results, a second series of
pyridyl alkyl / aryl ketenes were evaluated. In the second part, the synthesis of
diastereomers 7a and 7b was completed; and in the final section, their application in
the synthesis of amines 308a and 308b was carried out.
Section 2.5.2: Preliminary Synthesis and ATH of Ketones.
To initiate the work, the synthesis of the key ketones 4, 309 and 310 was carried out.
This required the synthesis of pyridyl methyl ketone 4 utilising the alkylation of
Weinreb amide 305.171 Weinreb amide 305 was obtained directly from the
substitution of N,O-dimethylhydroxylamine hydrochloride with methyl
methoxynicotinate 285 and isopropyl magnesium chloride in THF (-40 °C to 0 °C,
90 min). Following silica gel chromatography, Weinreb amide 305 was obtained in
68 % yield (Scheme 2.5.5a). Direct alkylation with methyl magnesium chloride gave
the pyridyl methyl ketone 4 in 61 % yield, following purification (Scheme 2.5.5b).
This yield was obtained reproducibly at reaction scales of ~ 3.5 g. Ketone 4 was
commercially available but not affordable for its use as the starting material of a
synthesis.
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Synthesis of pyridone methyl ketone 309 was achieved via treatment of pyridyl
methyl ketone 4 with benzyl bromide in acetonitrile at 80 °C. Pyridone methyl
ketone 309 was obtained in 48 % yield, following silica gel chromatography
(Scheme 2.5.5c).
Scheme 2.5.5: a. Synthesis of Weinreb amide 305, and synthesis of ketones 4, 309, and 310.
Lactam methyl ketone 310 was obtained via reduction of pyridone methyl ketone
309 with Pd/C under an atmosphere of hydrogen at room temperature. The reaction
was unselective and a large amount of side products were observed by 1H NMR.
Repeated purification (silica gel chromatography) was required to isolate the lactam
methyl ketone 310 in 9 % yield (Scheme 2.5.5d). The product has been reported in
the literature, and alternatively had been obtained from Pd/C reduction of enamide
311 in 62 % yield (Scheme 2.5.6).197 However, sufficient material was obtained (via
the procedure) for subsequent ATH and the literature work did not need to be
repeated. Notably, the reduction of 309 with PtO2 resulted in formation of alcohol 7
in 10 % yield (5 bar H2, MeOH, rt, 18 h).
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Scheme 2.5.6: Literature synthesis of lactam 310.
ATH of pyridine derived ketones.
The ATH of pyridyl ketones similar in structure to 285, has been reported with
numerous catalysts.172 Ikariya achieved the reduction of the a range of pyridyl alkyl
ketones in high enantioselectivity with (S,S)-Ru(TsDPEN), 255 (the catalyst
structure is shown in Appendix IV). Pyridyl alcohols (S)-312, (S)-313, and (S)-314
were obtained in 93 %, 98 % and 92 % ee respectively (Scheme 2.5.8b).173
Enantiofacial selection during these reductions was comparable to the reduction of
aromatic ketones. Optically pure pyridyl ketones have been useful as chiral ligands,
auxiliaries, and pharmaceuticals.
Scheme 2.5.6b: Optically pure pyridyl alcohols obtained by ATH with (S,S)-255, achieved by Ikariya.
The interaction that lactam methyl ketone 310 may have with the catalyst
RutethTsDPEN is uncertain; however, unfunctionalised ketones such as cyclohexyl
methyl ketone has been reduced in 69 % ee to form the (S) configuration alcohol (S)-
315 with (R,R)-248 by Wills.174
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For this study, the ATH of the pyridyl alkyl ketones was carried out using with
RutethTsDPEN, 248 (Scheme 2.5.9). The stereofacial selection of this catalyst would
be expected to be analogous to that of Ru(TsDPEN), 255. The ATH of ketones 4,
309 and (±)-310 was carried out with the catalyst RutethTsDPEN, 248 (Scheme
2.5.7). Neat FA/TEA was used as solvent at a substrate concentration of 1M in all
cases. Ees were determined by chiral GC or HPLC analysis. Racemic samples of the
product alcohols formed by reduction with NaBH4 were used as racemic standards to
confirm the position of the isomers in chiral GC / HPLC analysis. The results are
shown in Table 2.5.1.
Scheme 2.5.7: ATH of ketones 4, 309 and 310.
Table 2.5.1: ATH of ketones 4, 309 and 310.
entry ketonea cat. time (h) conv (%)d Prod.
Ee
(%) a : b
1 4 (S,S) 21 100 (S)-303e 82b N/A
2 4 (S,S) 18 100 (S)-303 75b g N/A
3 309 (R,R) 20 100 (R)-304e 42c N/A
4 (±)-310 (R,R) 24 100 (R,S)-7a
f
(S,S)-7bf
85b
49b 1.5:1
d
a. [SM] = 1 M; b. determined by chiral GC; c. determined by chiral HPLC; d. determined by 1H
NMR; e. config. assigned by comparison [α]D values of an authentic sample; f. config.assigned by
comparison of the GC analysis of an authentic sample; g. reaction run at rt and in methanol, [SM] =
0.16 M; N/A: not applicable.
Configurations were determined by comparison of [α]D values of a known sample, or
by comparison of HPLC/GC analysis of a known sample. Following 17 h at room
temperature, pyridyl methyl ketone 4 underwent complete conversion to alcohol, (S)-
303 in 82 % ee (entry 1, Table 2.5.1, Figure 2.3.2) (CP – ChiraSil – DEX CB, gas:
He, T = 170 °C). The ee was slightly lower (75 % ee) when run in methanol at room
temperature (entry 2). Pyridone methyl ketone 309 underwent complete conversion
to (R)-304 in 42 % ee (entry 3) (Chiralpak IC, hexane : IPA 80 : 20). The absolute
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configuration was assigned as R following comparison of the HPLC analysis of a
known sample of (R)-304 (details of the preparation of (R)-304 are shown in the next
section). Reduction of lactam methyl ketone (±)-310 resulted in formation of
diastereomers 7a and 7b in a 1.4:1 ratio. In the case of this experiment the two
diastereomers were not separated (because of the small scale of the experiment) but
directly analysed as a mixture. The dr was determined by 1H NMR analysis of the
crude product mixture. Chiral separation of the four isomers was achieved by chiral
GC: (CP – ChiraSil – DEX CB, gas: H, T = 200 °C). In the following section, a
racemic mixture of diastereomers 7a and 7b was separated chromatographically to
provide two diastereomerically pure racemic samples of (±)-7a and (±)-7b. This
enabled the assignment of the enantiomer pairs (for this experiment), and
subsequently the ees and configurations were determined. The ees of 7a and 7b
(entry 3) were 85 % and 49 % respectively. These chiral GC traces are shown in
Appendix IV. The Complete details of how the configurations of 7a and 7b have
been assigned are fully explained in a later Section 2.5.4.
Figure 2.3.2: ATH alcohol products.
Discussion.
The absolute configuration of the alcohol product obtained from reduction of ketone
4 with (S,S)-248 is in accordance with what would be expected through the standard
reduction mechanism of aryl methyl ketones such as acetophenone. Pyridone ketone
309 appeared to also follows this trend: the use of the (R,R) catalyst resulted in the
(R) alcohol, (R)-304 suggesting that an interaction between aryl C-H and pyridone
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group is occurring. Lactam methyl ketone 310 results in the formation of the (S)
configuration alcohol. This result follows what is expected from the reduction of
cyclohexyl methyl ketone.175
Section 2.5.3: Synthesis and ATH of Pyridyl Alkyl / Aryl Ketones.
With the ATH of pyridyl methyl ketone 4 giving a product of 82 % ee, a further
series of alkyl derivatives was studied. This series was chosen over the lactam alkyl
series as they may be directly obtained via alkylation of Weinreb amide 305
(Scheme 2.5.5).171
Scheme 2.5.8: Weinreb amide alkylation – ketones 316-320.
The pyridyl alkyl ketones 316-320 were synthesised via treatment of Weinreb amide
305 with the alkyl magnesium bromide or chloride reagent in a solution of THF at
variable temperatures (as stated). Acid work up yielded the ketones following silica
gel chromatography. Pyridyl butyl ketone 316 was obtained in 54 % yield following
reaction with butyl magnesium bromide at room temperature for 18 h. Pyridyl
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phenyl ketone 319 was obtained in 55 % yield following reaction with phenyl
magnesium bromide at 0°C for 3 h. Secondary alkyl Grignard reagents, cyclohexyl-
and isopropyl- magnesium bromide were lower yielding – isopyropyl ketone 317
was obtained in 16 % yield (room temperature, 18 h); and cyclohexyl ketone 318
was obtained in 23 % yield (70 °C, 2.5 h). The use of fresh Grignard reagent,
lengthening of the reaction time, or increased reaction temperature did not result in
an increased yield for these ketones.
Interestingly, in an attempt to form acetylenic ketone 321, with ethynyl magnesium
bromide, only the corresponding vinyl chlorides, 320 were obtained in 53 % yield
(Z/E = 2.7/1, determined by 1H NMR) (acetylenic ketone 321 was not identified
from the reaction mixture). This presumably occurred during the quenching of the
reaction with HCl. Alternatively, the synthesis of phenylacetylenic ketone 322 was
attempted via alkylation with lithium phenylacetylenide (formed via treatment of
phenylacetylene with nBuLi); however the resulting product was found to contain
the side-product butyl ketone 316 (formed from unreacted nBuLi) even at a
substoichiometric ratio of nBuLi to phenylacetylene. This side product could not be
adequately removed during purification.
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ATH of pyridyl ketones.
Neat FA/TEA was used as solvent at a concentration of 2M. Ees were determined by
chiral GC (CP – ChiraSil – DEX CB, gas: He) or HPLC analysis of the alcohol or
the corresponding acetate derivate. Racemic samples of the product alcohols formed
by reduction with NaBH4 were used as racemic standards to confirm the position of
the isomers in chiral GC / HPLC analysis. Results are shown in Table 2.5.2.
Scheme 2.5.9: ATH of ketones 316-320.
Table 2.5.2: ATH of ketones 316-320.
entry ketonea R time (h)h Prod. Ee (%)
1 4b methyl 21 (R)-303i 83e
2 316 n-butyl 20 (R)-323j 76e
3 317 i-propyl 22 (R)-324j 53d
4 168 cyclohexyl 24 (R)-325j 35g
5 319 phenyl 24 (-)-326 48f
6 320 cis-vinyl chloride 24 (R)-327 N/D
7c 320 cis-vinyl chloridec 3.5 (±)-328 N/A
a. [SM] = 2 M in FA/TEA; b. [SM] = 1 M in FA/TEA; c. reaction with NaBH4 in methanol at rt; d.
determined by chiral GC; e. determined by chiral GC of the acetate derivative; f. determined by chiral
HPLC; g. determined by chiral HPLC of the acetate derivative; h. completion of reaction confirmed
by 1H NMR; i. config. confirmed by lit. optical rotation reference; j. config. assigned by the expected
outcome of the theoretical model; N/A: not applicable; N/D: not determined.
NO
OH
NO
OH
NO
OH
NO
OH
(R)-323
76 % ee (R)-324
53 % ee
(R)-325
35 % ee
326
48 % ee
NO
OH
( )-328
ClNO
OH
(R)-327
Figure 4: ATH alcohol products.
In all cases the completion of the reduction was confirmed by 1H NMR. The n-alkyl
derivatives, methyl ketone 4 and n-butyl ketone 316 were reduced in highest
enantioselectivity; 83 % and 76 % ee respectively (entries 1 and 2, Table 2.5.2,
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Figure 4). In both cases, chiral separation for 323 and 324 was achieved via chiral
GC analysis of the acetate derivative. This decrease in ee following increase in alkyl
chain length as can be expected.174 The secondary alkyl ketones, isopropyl ketone
317 and cyclohexyl ketone 318 were reduced in 53 % and 35 % ee respectively
(entries 3 and 4). Again, this decrease ee is anticipated and has been reported,
following the steric increase of secondary alkyl substituent.174 In each case the
products were assigned the R configuration, in analogy with the expected outcome.
The reduction of pyridyl phenyl ketone 319 resulted in formation of the product 326
in 48 % ee. Presumably this is the result of one aromatic ring having a slightly more
dominating directing affect over the reduction. This compound is known in the
literature, however the absolute configuration of the reference was not determined.205
Interestingly, cis vinyl chloride ketone cis-320 underwent complete reduction to the
corresponding saturated ethyl alcohol 327 (entry 6). This product is likely to have
been the result of three sequential reductions (Scheme 2.5.10). In step a, 1,4-
conjugate reduction and subsequent elimination of the chloride would result in
formation of unsaturated ketone 320b. Further conjugate reduction would result in
formation of ethyl ketone 320c (step b), which again undergoes ketone reduction to
give 327, which may be tentatively assigned as the R configuration in analogy with
he expected outcome. The ee of this sample was not determined due to time
constraints. Interestingly, reduction of cis-vinyl ketone 320 with NaBH4 resulted in
the exclusive formation of vinyl chloride 328 – no conjugate reduction was
observed.
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Scheme 2.5.10: possible sequence of the ATH of cis-320.
Section 2.5.4: Asymmetric Synthesis of Diastereomers 7a and 7b.
Following the ketone ATH results, pyridyl methyl ketone 4 was chosen for the large
scale synthesis of diastereomers 7a and 7b, due to its relatively higher
enantioselectivity during ATH. To aid the explanation, the synthesis will be split
between two parts: in the first, a racemic synthesis will be shown, which is
subsequently followed by the asymmetric synthesis.
Racemic synthesis of 7a and 7b.
A larger scale reduction of pyridyl methyl ketone (scale) with achieved following
reduction with NaBH4 in methanol at room temperature for 3 h, resulting in
formation of alcohol 303 in quantitative yield (Scheme 2.5.12). This material was
sufficiently pure for use without further purification. Alcohol 303 readily underwent
alkylation with benzyl bromide and K2CO3 in acetonitrile at 80 °C for 24 h to give
the pyridone 304 in 63 % yield following purification (silica gel chromatography).
Hydrogenation of pyridone 304.
The homogeneous hydrogenation of racemic pyridone (±)-304 carried out in attempt
to diastereoselectively form 7a and 7b (Scheme 2.5.11, Table 2.5.3, entry 1-3);
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however it was only in one case (R,R)-Rh-EtDuPhos, (R,R)-229, entry 2) that any
conversion was obtained although with no diastereoselectivity. In the case of this
reaction, the starting material was recovered from the reaction, and its ee was
determined to be 0 %, indicating that no KR had occurred (for the chiral separation
of pyridone 304, see Section 6.5.1). Crabtree’s iridium based catalyst 335 was
unreactive towards the starting material.176
Scheme 2.5.11: hydrogenation of 304.
Table 2.5.3: Hydrogenation of 304.
entry cat. mol % temp (°C) time (h) P. (bar) conv. (%)a 7a:7ba
1 (R)-37a 2 40 20 40 0 N/A
2 (R,R)-229 2 40 20 40 40 1
3 335 2.5 rt 18 1 0 N/A
a. determined by 1H NMR
Gram scale hydrogenation of pyridone 304.
Following the desired chemoselectivity to hydrogenation over hydrogenolysis
observed for the PtO2 reduction of pyridone 277 (Section 2.3.4, p 112); the
hydrogenation of pyridone 304 was carried out with PtO2 in methanol under 5 bar of
hydrogen (Scheme 2.5.12). In the majority of experiments, diastereomers D1-7a and
D2-7b were obtained as major products, with only traces of the C-OH cleavage
product, ethyl lactam 331 (as determined by 1H NMR). However in one case, 331
was isolated in 14 % yield (this is detailed in following section). For the case of this
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reported reduction, diastereomers 7a and 7b were isolated in 37 and 42 % yield
respectively following careful purification (silica gel chromatography, 1 to 3 %
MeOH in DCM, visualisation by KMnO4). Interestingly, it was only in the methanol
– DCM solvent system that resolution of the diastereomers was achieved; ethyl
acetate and petroleum ether gave no resolution at any mixture ratio. Diastereopurity
was confirmed by GC analysis of the crude reaction mixture (before purification) to
be 31 % de (CP – ChiraSil – DEX CB, gas: H, T = 185 °C). These samples were
later used as racemic standards in chiral analyses of the asymmetric synthesis of the
alcohols. For explanation, the two racemic diastereomers from now will be referred
to as (±)-D1-7a and (±)-D2-7b with respect to the order of elution during
chromatography.
Scheme 2.5.12: Synthesis of diastereomers 7a and 7b via ketone 4.
Conveniently, (±)-D1-7a solidified upon standing to form a waxy solid. Further
recrystallisation (DCM – hexane) provided crystals which underwent X-ray
diffraction to confirm the structure (Figure 5a). The quality of the X-ray data was
sufficient enough for the relative orientation of the two chiral centres to be
determined. This crystal sample was racemic, and the two enantiomers are clearly
visible in the X-ray structure. This X-ray structure (Figure 5a) corresponds to the
depicted schematic structure, (Figure 5b) which may be described as syn with respect
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to the relative configuration each of the two adjacent hydrogen atoms. Accordingly,
(±)-D2-7b has assigned as the anti isomer, as depicted in Scheme 2.5.13b.
Figure 5: a. X-ray structure of D1-7a; b. corresponding schematic structure of (±)-D1-7a.
Asymmetric synthesis.
With the racemic samples, (±)-D1-7a and (±)-D2-7b in hand which could serve as
racemic standards in GC analysis, the asymmetric synthesis of alcohol 303 was
carried out. The ATH of ketone 4 at higher scale (1.0 g) proceeded to give pyridine
(R)-303 in 95 % yield following removal of the catalyst (silica gel chromatography)
with a slight loss of enantioselectivity at 78 % ee.
Pyridine (R)-303 readily underwent alkylation with benzyl bromide and K2CO3 in
acetonitrile at 80 °C for 24 h to give the pyridone (R)-304 in 71 % yield following
purification (silica gel chromatography) (Scheme 2.5.13a) however the sample
suffered from loss of enantiopurity, and the ee was determined as 45 % (the chiral
separation of 304 was stated in the last section). The use of K2CO3 in the alkylation
was therefore questioned. It was previously considered feasible that the base may
required during the O-demethylation step of this process and the control experiment
had not been carried out as the conditions had been taken from a patent procedure.
Repeating the experiment in the absence of K2CO3 resulted in formation of (R)-304
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in 63 % yield. The ee of this sample was not directly determined, but following
hydrogenation it was found to be of 78 % ee.
Scheme 2.5.13: a. Alkylation of enantiomerically enriched 303; b. reduction of 304 with PtO2.
Hydrogenation of pyridine 304 with PtO2 resulted in formation of alcohols D1-7a
and D2-7b, however a relatively higher level of hydrogenolysis had occurred
(Scheme 2.5.13b). Following purification, D1-7a and D2-7b were isolated in 20 %
and 32 % yield respectively, alongside lactam 331 in 14 % yield. The diastereopurity
of D1-7a and D2-7b were independently determined by GC to be: 100 % 7a; and 72
% 7b respectively. The ees of D1-7a and D2-7b were independently determined to
be 78 % and 78 % ee respectively, using the racemic standards described in the
previous section. The absolute configuration of both diastereomers at C (14) is
known to be R (they were derived from alcohol (R)-303). As the relative
configuration of D1-7a had been determined by X-ray crystallography in the
previous section, the following assignments were made accordingly: (S,R)-D1-7a;
(R,R)-D2-7b. This is illustrated in Scheme 2.5.14.
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Scheme 2.5.14: Reasoning for the configuration assignments of D1-7a and D2-7b.
Configuration assignment of ATH products from Section 6.5.1.
Comparison of the GC trace of these samples with the ATH product resulting from
the reduction of lactam methyl ketone (section 2.5.2, Table 2.5.1, entry 3) enabled
the configuration assignment of the ATH products. This comparison is shown in
Appendix III. Pyridone 304 (Table 2.5.1, entry 2) was also assigned as R
configuration following comparison of the chiral HPLC trace).
Section 2.5.5: Synthesis of Bromides (D1)-306a and (D2)-306b.
In this section, transformation of alcohol 7 to the desired cytisine precursor lactam
307 was attempted by two methods. In the first, direct alkylation with the
corresponding bromide was attempted in analogy with Gallagher’s method.68 In the
second, coupling of the corresponding amines 308a and 308b was attempted with
2H-pyran-2-one.
The substitution chemistry of alcohols D1-7a and D2-7b with 2-hydroxypyridine
was first investigated, however these were unreactive with a number of reagents.
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Coupling under Mitsunobu conditions 156a during test reactions with dimethyl
malonate as nucleophile were unsuccessful. No reaction occurred following reaction
of 2-hydroxypyridine with the corresponding triflate, formed in situ via reaction of 7
with triflic anhydride. Only reaction with PBr3 was successful.
Bromination of alcohols 7a and 7b.
Reaction with PBr3 was successful, providing the corresponding bromide 306.
Diastereomerically pure racemic samples of (±)-D1-7a and (±)-D2-7b underwent
reaction with PBr3 in separate reactions (Scheme 2.5.15a). (±)-D1-7a (100 % D1)
was treated with PBr3 in toluene at 80 °C resulting in the formation of a mixture of
the corresponding bromide diastereomers 306 (70 % D1, as determined by 1H
NMR). It was possible to diastereomerically enrich the samples via silica gel
chromatography, which enabled clean 1H NMR spectra of the major diastereomer
bromide, to be obtained (15 % yield, 68 % D1). For simplicity, this sample was
labelled (D1)-(±)-306 to indicate that it was obtained from D1-7a.
D2-7b (100 % D2) was treated with PBr3, again resulting in formation of a mixture
of the corresponding bromide diastereomers 306 (82 % D2, as determined by 1H
NMR). Following purification it was again possible to diastereomerically enrich the
sample providing clean 1H NMR spectra of the major diastereomer bromide. In this
case the sample (D2)-(±)-306 was obtained in 39 % yield. The 1H NMR spectra of
the two enriched diastereomer samples (D1)-(±)-306 and (D2)-(±)-306 were
distinguishable showing that although in each case a mixture was obtained, during
purification the two samples had been enriched in different isomers.
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In each case, the diastereomerically pure starting material gave a mixture of the two
diastereomer products. It is not possible to make conclusions on the mechanism of
these reactions because two independent processes may simultaneously be occurring;
formation of the bromide via an SN1 mechanism would result in loss of de. But
interconversion of the product bromide via substitution of the bromide 306 with Br-
could also occur during the reaction, also resulting in loss of de. For this reason, the
relative configurations of the diastereomers have not been assigned. What appeared
to be the elimination product, alkene 332 was also identified in the crude reaction
mixture of these bromides (alkene 332 is described in the next section).
Scheme 2.5.15: Bromination of racemic D1-7a and D2-7b.
An asymmetric synthesis of bromides D1-306a and D2-306b was carried out. D1-7a
(78 % ee, 100 % D1) underwent reaction with PBr3 to give a crude sample
containing D1-306a in 77 % yield (75 % D1, as determined by 1H NMR) (Scheme
2.5.16a). Additionally, D2-7b (78 % ee, 72 % D2) underwent reaction to give a
sample containing D2-306b in 61 % yield (67 % D2) (Scheme 2.5.16b). In this case
the sample was not purified but used directly in subsequent experimentation.
Notably the optical rotation of these samples, D1-7a and D2-7b had differing signs.
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For reasons stated, the configuration of the diastereomers at C (14) could not be
accurately determined, however as the samples were enantiomerically enriched, the
configuration at C (5) would have been retained upon the transformation from the
precursor alcohol. These have been assigned in each case. As the C (5) is
configurationally stable, no epimerisation and loss of ee would be expected during
these transformations, and so the ee has been assigned as that of the starting material
alcohol.
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Scheme 2.5.16: Bromination of enantiomerically enriched D1-7a and D2-7b.
Attempted pyridone coupling.
Bromide 306 underwent reaction with 2-hydroxypyridine, K2CO3 and Bu4NBr in
toluene in analogy with the conditions used for by Gallagher to minimise elimination
and favour N-substitution over O-substitution (Scheme 2.5.17).68 However,
substitution was not observed and only an impure sample containing what was
characterised to be the elimination product 332 was isolated from the reaction. This
absence of substitution can be explained by the relatively more sterically hindered
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secondary electrophilic centre position to Gallagher’s bromide which also suffered
from elimination during the reaction.
Scheme 2.5.17: Attempted substitution with 2-hydroxypyridine.
Section 2.5.6: Synthesis of Amines 308a and 308b.
Direct pyridone formation via amines 308a and 308b was then attempted through
formation of the corresponding azide. It was not possible to directly convert alcohols
7a or 7b to the corresponding azide with the reagent, DPPA. Reaction of bromides
306a and 306b was however successful.
A sample of diastereomerically enriched bromide D1-306a (75 % D1) was treated
with NaN3 in acetone and water at 45 °C. The reaction resulted in what appeared to
be a significant amount of decomposition (as determined by 1H NMR analysis of the
crude reaction mixture), resulting in an impure mixture of the corresponding azide
diastereomers, D1-333a (13 % yield, 82 % D1) (Scheme 2.5.18a).
The corresponding reaction of the D2 series bromide, D2-306b (66 % D2) showed
less sign of decomposition and the azide was obtained much higher purity. In this
case, an enriched sample of the diastereomers, D2-333b was obtained in 24 % yield
(86 % D2) following purification (silica gel) (Scheme 2.5.18).
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Scheme 2.5.18: a. D1-series: formation of amine D-1-308a; b. D2 series: formation of amine D2-
308b.
Reduction of azide 333 was then attempted by a number of methods: Azide 333
underwent reduction with SnCl2 in a solution of THF and water; however, poor
recovery from the aqueous phase during work up resulted in amine 308 in only 17 %
yield (Scheme 2.5.18b). It was found that even at pH 12 the amine was still too
soluble in water for effective extraction. Concentration of the aqueous layer did not
aid recovery. Alternatively, reduction with PPh3 in THF followed by subsequent
hydrolysis was successful, but resulted in formation of an inseparable mixture of the
amine 308 and Ph3PO. Reduction with PtO2 in ethyl acetate under 5 bar hydrogen
was found to be the most effective method of reduction – the solvent was simply
removed following the reaction. A drawback was limited activity of the catalyst;
complete conversion to the amine could not be achieved although it was possible to
isolate the amine from the reaction mixture by use of an Isolute-XL SCX amine
scavenger thiol resin. Through this method, a sample of azide D1-333a (82 % D1)
underwent reduction by this method to give D1-308a in 85 % yield (66 % D1);
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however the sample was in poor yield due to the inseparable contamination from
starting material, azide D1-333a (Scheme 2.5.18b). Reduction with the D2 series
resulted in a clean sample of the amine. Azide D2-333b was reduced with PtO2 to
give amine D2-308b in 62 % yield (86 % D2) following purification (thiol resin). In
each case, the ee of each azide and amine was assigned to be that of the alcohol
starting material (78 % ee).
Attempted pyridone formation.
The conversion of amine 308 to the pyridone was attempted via treatment with 2H-
pyran-2-one, following a patent procedure (Scheme 2.5.19).177 The amine was heated
in acetic acid at 140 °C for 3h under microwave irradiation resulting in the formation
of what appeared to be the corresponding amide 334 (1H NMR). The only evidence
for the formation of the desired pyridone was the [M+ H] adduct signal, observed by
MS. This procedure was repeated five times but it was not possible to achieve this
transformation with compound 308. The use of a diluted AcOH solution (1 : 9 AcOH
: MeCN) was not successful.
Scheme 2.5.19: Attempted pyridone 307 formation with 2H-pyran-2-one.
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Section 2.6: Conclusion.
The enantioselective synthesis of the diastereomers alcohol 7a and 7b was successful
through the ATH of ketone 4. The diastereomers were obtained in 78 % ee with no
loss of ee following conversion from pyridine 303. The relative and absolute
configurations were also determined via X-ray crystallography and optical rotation
respectively. These alcohols were converted to the corresponding amines 308a and
308b although it was unfortunately not possible to reach pyridone 307 via reaction
with 2H-pyran-2-one. However, as previously discussed, these 5-substituted lactams
are synthetically useful in other applications.
Through the AH of enamide 1, synthesis of the 5-substituted glutarimide 218 was
achieved in high enantioselectivity.178 Unfortunately, this compound could not be
utilised in an asymmetric synthesis of cytisine due to late stage epimerisation
following reduction to the lactam, although the formal synthesis was achieved.
An extensive ligand screen for the AH of pyridones 2 and 3 unfortunately failed to
provide an enantioselective synthesis of 5-substituted lactams. Nonetheless, a second
formal synthesis of cytisine precursor 5 was achieved. A synthetic route to the
compound bispiperidine 6 was also developed.
The asymmetric synthesis and complete characterisation of the diastereomers 7a and
7b was achieved in 78 % ee, via the ATH of pyridine methyl ketone 4. Unfortunately
it was not possible to convert the alcohols to the cytisine precursor derivative 307.
However, a co-running theme throughout this project was the underlying
methodology of enantioselectively forming 5-substituted lactams, of which there is
little report in the literature. In completing the asymmetric synthesis of 5-substituted
lactams alcohols 7a and 7b, this objective has been achieved.
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Section 3: Experimental Procedures.
General information.
All reactions unless otherwise stated were run under an atmosphere of nitrogen in
glassware (round bottomed flasks or Schlenk tubes). Room temperature refers to
ambient room temperature (20-22 °C), and 0 °C refers to an ice slush bath. Heated
experiments were conducted using thermostatically controlled oil baths. Reactions
were monitored by thin layer chromatography (TLC) using aluminium backed silica
gel 60 (F254) plates which were visualised using UV254 nm; and PMA, potassium
permanganate and ninhydrin dips as appropriate. Flash column chromatography was
carried out routinely using 60 Å silica gel (Fluorochem). NMR spectra were
recorded on Bruker DPX-300 (300 MHz), DPX-400 (400 MHz), DRX-500 (500
MHz), AV III -600 (600 MHz) and AV II-700 (700 MHz) instruments. Chemical
shifts are reported in δ units, parts per million. 
1H NMR spectra run in CDCl3 are
downfield from TMS; 1H NMR spectra run in solvents other than CDCl3, and all 13C
NMR spectra are referenced to the solvent signal. Coupling constants (J) are
measured in Hertz. IR spectra were recorded on a Nicolet Model Avatar 320 FTIR
fitted with a Specac golden gate single reflection diamond attenuated total reflection
top plate. Mass spectra were recorded on a Bruker Esquire2000 (ESI) mass
spectrometer. Determinations of ee were measured by HPLC or GC. Optical
rotations were measured on an AA-1000 polarimeter. Hydrogen gas (99.995 %
minimum) was supplied by BOC. Hydrogenations were carried out in a Parr bench-
top hydrogenator (0.3 L). HMQC, DEPT and COSY NMR experiments were
routinely used in the analysis of new compounds, to assist the assignment of 1H and
13C NMR spectra. When these methods are crucial for characterisation and the
assignment of NMR spectra, they have been shown in Appendix I.
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Section 3.1: Procedures from Section 2.1.
Section 3.1.1: Synthesis and Hydrogenation of Enamide 1.
5-(Benzylamino)-5-oxopentanoic acid, 336.
This compound has been reported but not fully characterised.179 Glutaric anhydride
(1.26 g, 11.04 mmol) was added to NEt3 (1.54 cm3, 11.05 mmol) in THF (40 cm3) at
0 °C. Benzylamine (1.21 cm3, 11.08 mmol) in THF (40 cm3) was added dropwise
over 1 h at 0 °C. The mixture was heated to 75 °C and left stirring for 24 h before
hydrochloric acid (1 M, 40 cm3) was added. Following extraction with ethyl acetate
(3 x 55 cm3), the organic extracts were washed with brine, dried (MgSO4) and
concentrated under reduced pressure to give the crude carboxylic acid 336 (2.34 g,
10.58 mmol, 96 % yield) as a white solid; (found (ESI): M+ + Na, 244.0944.
C12H15NNaO3 requires M, 244.0944); νmax 3303 (OH st.), 3031 (aryl CH st.), 1693
(C=O st.), 1638 (NH st.) cm-1; δH (300 MHz, CDCl3) 7.36-7.25 (5H, m, ArH), 5.81
(1H, s, NH), 4.42 (2H, d, J 5.5, CH2), 2.44 (2H, t, J 7.0, H3), 2.31 (2H, t, J 7.0, H1),
1.99 (2H, quin, J 7.0, H2); δC (75 MHz, CDCl3) 177.68 (CO), 172.32 (CO), 137.95
(Ar), 128.75 (Ar), 127.83 (Ar), 127.61 (Ar), 43.71 (CH2Ar), 35.21 (C3), 33.00 (C1),
20.68 (C2); m/z (ESI) 222.0 (M+ + 1). No further purification was carried out.
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1-Benzylpiperidine-2,6-dione 221.
This compound has been reported and fully characterised.180 5-(Benzylamino)-5-
oxopentanoic acid 336 (2.34 g, 10.58 mmol) was added to acetyl chloride (60 cm3)
and heated to 65 °C. The mixture was left stirring for 10 h before the mixture was
allowed to cool to room temperature. Acetyl chloride was removed under reduced
pressure and the crude material was purified by column chromatography (70/30
hexane / ethyl acetate) to give glutarimide 221 (1.93 g, 9.50 mmol, 90 %); δH (300
MHz, CDCl3) 7.35-7.32 (5H, m, ArH), 4.95 (2H, s, CH2), 2.68 (4H, t, J 6.5, H1),
2.41 (2H, quin, J 6.5, H2); δC (75 MHz, CDCl3) 173.48 (CO), 136.81 (Ar), 128.81
(Ar), 128.31 (Ar), 127.38 (Ar), 42.57 (CH2Ar), 32.80 (C1), 17.03 (C2); m/z (ESI)
204.0 (M+ + 1), 226.0 (M+ + 23).
(Z)-1-Benzyl-3-(hydroxymethylene)piperidine-2,6-dione 220.
Under an inert atmosphere, dry ethanol (1.60 cm3, 27.40 mmol) was added dropwise
to a suspension of 60 % NaH in oil (1.10 g, 27.50 mmol) in Et2O (32.0 cm3) at 0 °C
and left stirring for 20 min or until evolution of hydrogen had ceased. In a second
flask, 1-benzylpiperidine-2,6-dione 221 (2.0 g, 9.85 mmol) and ethyl formate (1.35
cm3, 16.78 mmol) in Et2O (32.0 cm3) were transferred dropwise to the first flask
over 1 h at 0 °C. The mixture was allowed to warm to room temperature and stirred
for 16 h before the solution was extracted with water (2 x 40 cm3). The aqueous
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extracts were acidified with dil. HCl (aq), followed by extraction with Et2O (3 x 50
cm3). The organic extract was washed with saturated aqueous sodium
hydrocarbonate, dried (MgSO4) and concentrated under reduced pressure to give the
product 220 (1.86 g, 8.05 mmol, 82 % yield); (found (ESI): M+ + H, 232.0964.
C13H14NO3 requires M, 232.0968); νmax 3250 (OH st.), 3033 (aryl CH st.), 1714
(C=O st.), 1670 (C=O st.), 1643 (C=C st.), 1143 (amide III) cm-1; δH (400 MHz,
CDCl3) 12.27 (1 H, d, J 12.3, OH), 7.41 - 7.21 (5 H, m, ArH), 7.18 (1 H, d, J 12.3,
H4), 4.98 (2 H, s, CH2Ph), 2.67 (2 H, t, J 7.3, H1), 2.47 (2 H, t, J 7.3, H2); δC (101
MHz, CDCl3) 171.71 (CO), 171.37 (CO), 160.88 (C4), 136.98 (Ar), 128.53 (Ar),
128.42 (Ar), 127.45 (Ar), 100.18 (C3), 42.41 (CH2Ar), 32.54 (C1), 19.73 (C2); m/z
(ESI) 232.0 (M+ +1).
(1-Benzyl-2,6-dioxopiperidin-3-ylidene)methyl-4-methylbenzene sulfonate 219.
Under nitrogen, (Z)-1-benzyl-3-(hydroxymethylene)-piperidine-2,6-dione 220 (0.859
g, 3.72 mmol) was added to a solution of NEt3 (0.62 cm3, 4.45 mmol) in dry DCM
(22.0 cm3) and cooled to 0 °C. A solution of p-toluenesulfonyl chloride (0.851 g,
4.46 mmol) in dry DCM (22.0 cm3) was added to first mixture and the mixture was
allowed to warm to room temperature and stirred for 1 h before saturated aqueous
ammonium chloride (30 cm3) was added. Following extraction with DCM (3 x 30
cm3), the organic extracts were washed with aqueous sodium hydrogen carbonate (3
x 20 cm3), dried (MgSO4) and concentrated under reduced pressure to give the
product 219 (1.323 g, 3.44 mmol, 92 % yield) as a brown solid; Mp 136 – 140 ⁰C;
(found (ESI): M+ + H, 386.1056. C20H20NO5S requires M, 386.1057); νmax 3039
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(aryl CH st.), 1721 (C=O st.), 1635 (C=C st.), 1175 (amide III) cm-1; δH (400 MHz,
CDCl3) 7.83 (2H, m, ArH), 7.73 (1H, s, H4), 7.39 (2H, m, ArH), 7.34-7.23 (5H, m,
ArH), 4.96 (2H, s, CH2), 2.60-2.54 (4H, m, H1,2), 2.47 (3H, s, CH3); δC (75 MHz,
CDCl3) 170.82 (CO), 164.62 (CO), 145.93 (Ar), 144.30 (C4), 136.38 (Ar), 131.16
(Ar), 128.22 (Ar), 127.89 (Ar), 127.64 (Ar), 126.91 (Ar), 115.08 (C3), 42.64
(CH2Ar), 30.60 (C1), 21.19 (CH3), 17.00 (C2); m/z (ESI) 386.1 (M+ + 1).
(E)-1-Benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione 1 and O-
substituted isomer 227.
Under nitrogen, (1-benzyl-2,6-dioxopiperidin-3-ylidene)methyl-4-methylbenzene
sulfonate 219 (1.32 g, 3.43 mmol) was added to a solution of 2-hydroxypyridine
(0.98 g, 10.30 mmol) and NEt3 (1.67 cm3, 11.98 mmol) in dry toluene (42.0 cm3).
The mixture was heated to 110 °C and left stirring for 20 h. Following concentration
under reduced pressure and purification by column chromatography (10/90
hexane/ethyl acetate), the product 1 (0.687 g, 2.23 mmol, 65 % yield) was obtained
as a solid; Mp 138 – 144 ⁰C; (found (ESI): M+ + H, 309.1235. C18H17N2O3 requires
M, 309.1234); νmax 3020 (aryl CH st.), 1720 (C=O st.), 1660 (C=O st.), 1630 (C=C
st.), 1580 (C=C st.), 1520 (C=C st.), 1250 (amide III) cm-1; δH (400 MHz, CDCl3)
7.97 (1 H, s, H4), 7.43-7.35 (3 H, m, ArH, H6), 7.34-7.22 (3 H, m, ArH), 7.10 (1 H,
dd, J 6.9, 1.8, H8), 6.62 (1 H, d, J 9.3, H5), 6.24 (1 H, td, J 6.9, 1.3, H7), 5.04 (2 H, s,
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CH2), 2.78-2.64 (4 H, m, H1,2); δC (101 MHz, CDCl3) 170.86 (CO), 165.16 (CO),
161.51 (CO), 140.25 (C6), 136.75 (Ar), 136.34 (C4), 135.50 (C8), 128.73 (Ar),
128.33 (Ar), 127.46 (Ar), 124.50 (C3), 121.90 (C5), 106.39 (C7), 43.37 (CH2Ar),
31.40 (C1), 20.91 (C2); m/z (ESI) 309.1 (M+ + 1), 331.1 (M+ + 23). Following
recrystallisation of a sample of 1 (EtOH), crystals suitable for crystallography were
grown and underwent X-ray diffraction to confirm the structure. Full details of the
structure are shown in Appendix II.
Initially, at shorter reaction times, the O-substituted isomer 227 was also isolated in
varying yields from the reaction mixture following column chromatography (hexane-
50/50 hexane / ethyl acetate) and recrystallisation (EtOH) as a colourless crystalline
product; (found (ESI): M+ + H, 309.1248. C18H17N2O3 requires MH+, 309.1234);
νmax 3020 (aryl CH st.), 1710 (C=O st.), 1690 (C=O st.), 1660 (C=C st.), 1580 (C=C
st.), 1250 (amide III) cm-1; δH (500 MHz, CDCl3) 8.82 (1 H, s, H4), 8.25 (1 H, dd, J
5.3, 1.3, H5), 7.75 - 7.71 (1 H, m, H7), 7.44-7.15 (5 H, m, ArH), 7.13-7.09 (1 H, m,
H6), 6.94 (1 H, d, J 8.3, H8), 5.04 (2 H, s, CH2), 2.84-2.79 (2 H, m, H1), 2.75-2.70 (2
H, m, H2); δC (126 MHz, CDCl3) 172.21 (CO), 166.84 (CO), 148.47 (C4), 147.45
(C5), 139.83 (C7), 137.50 (Ar), 128.77 (Ar), 128.34 (Ar), 127.29 (Ar), 120.25 (C6),
111.30 (C8), 43.01 (CH2Ar), 31.76 (C1), 17.75 (C2); m/z (ESI) 309.1 (M+ + 1), 331.1
(M+ + 23). Following recrystallisation of a sample of 227 (EtOH), crystals suitable
for crystallography were grown. and underwent X-ray diffraction to confirm the
structure. Full details of the structure are shown in Appendix II.
In further experiments, long reaction times (20 h as opposed to 10 h) were found to
result in an absence of O-substituted product 227 (Table 1). To determine if the N-
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product 1 was a thermodynamically favoured product, a separate isomerisation
experiment was carried out. An mixture of 1, 227, and 2-hydroxypyridine were
combined under the same reaction conditions and found to form only the N-
substituted product. This suggests that isomerisation occurs between the two O- and
N- compounds, forming the thermodynamically favoured product, 1.
Table 1: Yields of products 1 and 227.
entry scale / g N-prod. 1 (%) O-prod. 227 (%) reaction time (h).
1 0.45 14 25 10
2 0.45 32 12 10
3 0.28 75 0 20
4 1.32 65 0 20
5 4.18 48 0 20
6 1.54 62 0 20
Procedure for the isomerisation of N- and O- substituted Compounds
Under nitrogen, NEt3 (0.15 cm3, 1.08 mmol) was added to a mixture containing 1
(67 mg, 0.217 mmol), 227 (44 mg, 0.143 mmol), and 2-hydroxypridine (42 mg,
0.442 mmol) in dry toluene (3.0 cm3). The mixture was heated to 110 ⁰C for 20 h
with stirring. Removal of the solvent by reduced pressure gave the crude product
which contained the N-substituted product 1 as the major product, and only a trace of
the O- substituted product 227 (as determined by 1H NMR analysis).
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1-Benzyl-3-((2-oxopyridin-1-yl)methyl)piperidine-2,6-dione (±)-228.
Under nitrogen, a solution of (E)-1-benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)-
piperidine-2,6-dione, 1 (50.0 mg, 0.162 mmol) and palladium on charcoal (10 % Pd
w/w, 8.6 mg, 8.08 x 10-3 mmol) in dry MeOH (2.50 cm3) was hydrogenated at room
temperature under 5 bar hydrogen overnight. The catalyst was removed by filtration
with celite and the reaction mixture was passed through a short silica gel column
(10/90 hexane / ethyl acetate) to yield the crude product, (±)-228 (46 mg, 0.146
mmol, 90 % yield) as a colourless waxy solid; found (ESI): M+ + Na, 337.1522.
C18H22N2NaO3 requires M, 337.1500); νmax 3031 (aryl CH st.), 1721 (C=O st.), 1670
(C=O st.), 1629 (C=C st.), 1163 (amide III) cm-1; δH (400 MHz, CDCl3) 7.37-7.20 (5
H, m, ArH), 4.99-4.90 (2 H, m, CH2), 3.87 (1 H, dd, J 13.8, 7.7, H4A), 3.59 (1 H, dd,
J 13.8, 5.8, H4B), 3.32 - 3.43 (1 H, m, H8A), 3.23-3.13 (1 H, m, H8B), 2.85 - 2.97 (2
H, m, H3, H1A), 2.66-2.55 (1 H, m, H1B), 2.42-2.33 (2 H, m, H5), 2.08-1.97 (1 H, m,
H2A), 1.85-1.66 (5 H, m, H2B,6,7); δC (75 MHz, CDCl3) 173.53 (CO), 172.07 (CO),
170.59 (CO), 137.10 (Ar), 128.58 (Ar), 128.30 (Ar), 127.34 (Ar), 48.90 (C8), 47.52
(C4), 42.90 (CH2Ar), 40.97 (C3), 32.23 (C1), 31.58 (C5), 23.19 (C2), 21.13 (C6),
20.71 (C7); m/z (ESI) 315.2 (M+ + 1), 337.1 (M+ + 23).
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1-Benzyl-3-((2-oxopiperidin-1-yl)methyl)piperidine-2,6-dione (±)-218.
A short reaction time allowed partially reduced product 218 to be isolated before
subsequent reduction of the pyridone ring occurred. Under nitrogen, a solution of
(E)-1-benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione, 1 (30 mg,
9.74 x 10-2 mmol) and palladium on charcoal (21 mg, 9.9 x 10-3 mmol, 5 % Pd / w)
in dry MeOH (0.2 cm3) and dry DCM (0.2 cm3) was hydrogenated at room
temperature under a balloon of hydrogen for 30 min before the catalyst was removed
by filtration with celite and the reaction mixture was passed through a short silica gel
column (hexane / ethyl acetate 1:9) to yield the product, (±)-218 (20 mg, 6.5 x 10-2
mmol, 66 % yield) as a colourless solid; Mp 124 - 126 ⁰C (found (ESI): M+ + Na,
333.1208. C18H18N2NaO3 requires M, 333.1300); νmax 3035 (aryl CH st.), 1724 (C=O
st.), 1657 (C=O st.), 1584 (C=C st.), 1540 (C=C st.), 1160 (amide III) cm-1; δH (400
MHz, CDCl3) 7.42 (1 H, dd, J 6.8, 1.8, H8), 7.37-7.19 (6 H, m, ArH, H6), 6.55 (1 H,
d, J 9.3, H5), 6.14 (1 H, t, J 6.8, H7), 4.97 (1 H, d, J 13.8, CH2), 4.89 (1 H, d, J 13.8,
CH2), 4.38 (1 H, dd, J 13.3, 5.9, H4A), 4.16 (1 H, dd, J 13.3, 5.9, H4B), 3.11 (1 H, dt,
J 18.1, 5.9, H3), 2.85 (1 H, dt, J 17.6, 3.5, H1A), 2.63 (1 H, m, H1B), 2.10 (1 H, m,
H2A), 1.74 (1 H, dq, J 13.1, 4.5, H2B); δC (100 MHz, CDCl3) 173.30 (CO), 171.68
(CO), 162.84 (CO), 139.78 (C8), 138.68 (C6), 136.92 (Ar), 128.49 (Ar), 128.34 (Ar),
127.39 (Ar), 120.71 (C5), 105.89 (C7), 50.17 (C4), 41.98 (CH2Ar), 40.95 (C3), 32.24
(C1), 21.10 (C2); m/z (ESI) 311.1 (M+ + 1), 333.1 (M+ + 23).
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AH of enamide 1: (S)-1-benzyl-3-((2-oxopyridin-1(2H)-yl)methyl)piperidine-2,6-
dione, 218.
Under nitrogen, a solution of thoroughly dried (E)-1-benzyl-3-((2-oxopyridin-1(2H)-
yl)methylene)piperidine-2,6-dione, 1 (0.78 g, 2.53 mmol) and [Rh(COD)(Et-
DuPHOS)]BF4 (50.7 mg, 76.8 x 10-3 mmol) in dry DCM (10.14 cm3) was degassed
three times. The solution was divided equally into five glass test tubes which were
used in the hydrogenation procedure. To the stirred solutions, the hydrogenation was
performed at 20 °C under 25 bar hydrogen for 5 days. The reaction mixture was
passed through a short silica gel column (10/90 hexane / ethyl acetate) to remove the
catalyst, yielding product (S)-218 (0.75 g, 2.42 mmol, 96 % yield) as a colourless
solid; (Chiracel IA, 25 cm x 4.6 mm column, iPrOH : hexane 15 : 85, 1 mL/min, T =
20 ⁰C, S isomer 23.5 min, R isomer 55.8 min.) 90 % ee; [α]D25 + 11.1 (c1.00 in
CHCl3). Configuration was subsequently determined by analysis of compound (R)-5.
Full characterisation data was given in the previous section.
On the occasion of this experiment, over-reduction to lactam 228 was not observed.
This enabled the ee of 218 to be directly determined by HPLC analysis by the
procedure stated above. However, during other experiments, over-reduction was
observed in varying conversion. This resulted in the formation of a crude mixture of
218 and 228 which could not be separated by chromatography, and also prevented
accurate ee determination. In this case, the ee of 218 was not determined by the
159
procedure stated above. Instead, the mixture was hydrogenated to 228, from which
the ee was determined by HPLC analysis. The ee of this sample was taken as an
indirect indication of the ee of compound 218. The experimental procedure for this
analysis is shown in the next section.
Procedure for the hydrogenation and subsequent HPLC analysis of inseparable
asymmetric reduction mixtures.
Under nitrogen, a solution of an inseparable mixture of (S)-218 and (S)-228 (89 %
and 11 % respectively, as determined by 1H NMR analysis; (15.0 mg) and palladium
on charcoal (10 % Pd w/w, 2.6 mg, 2.44 x 10-3 mmol) in dry MeOH (1.00 cm3) was
hydrogenated at room temperature under 5 bar hydrogen overnight. The catalyst was
removed by filtration with celite and the reaction mixture was passed through a short
silica gel column (10/90 hexane / ethyl acetate) to yield the product, (S)-228 (15 mg,
0.048 mmol) as a colourless waxy solid (full characterisation is listed in the next
section); ee was determined by HPLC analysis (Chiracel IA, 25 cm x 4.6 mm
column, IPA : hexane 30 : 70, 1 mL/min, T = 15 ⁰C, S isomer (major) 10.28 min., R
isomer (minor) 23.26 min.) 94.5 % ee; [α]D
25 + 55.1 (c0.10 in CHCl3). Full
characterisation data for 228 was given in a previous section. The HPLC of the
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racemic sample (see below) was used to determine the position of the peaks for
analysis.
Procedure for the screening of AH ligands.
Under nitrogen, a solution of thoroughly dried (E)-1-benzyl-3-((2-oxopyridin-1(2H)-
yl)methylene)piperidine-2,6-dione, 1 (30.0 mg, 0.10 mmol) in dry DCM (0.39 cm3)
was purged with argon for 30 min before [Rh(COD)Cl)]2 (0.8 mg, 1.6 x 10-3 mmol)
and the ligand (3.0 x 10-3 mmol) was added. To the stirred solution, the
hydrogenation was performed at 30 °C under 25 bar hydrogen for 5 days. The
reaction mixture was purified by silica gel column chromatography (hexane - ethyl
acetate 1:9) to separate reaction products where applicable, yielding products 218
and / or product 228 as determined by 1H NMR and analysed for ee by HPLC
(conditions as described above). Results are given in Table 2. The highest ee for this
transformation was obtained using Taniaphos SL-T002-1 under the same conditions
as described above. In this case the ee of exclusive product 228 was 98 % (R) and
was determined by direct HPLC analysis, following purification by column
chromatography: (Chiracel IA, 25 cm x 4.6 mm column, iPrOH : hexane 15 : 85, 1
mL/min, T = 15 ⁰C, S isomer (minor) 31.5 min, R isomer (major) 57.3 min.) 98 %
ee. The configuration was subsequently determined by analysis of compound (R)-5.
161
Section 3.1.2: Completion of the Formal Synthesis of (-)-Cytisine
1-benzyl-3-methylidenepiperidine-2,6-dione, 231.
Under nitrogen, LDA (2M solution in THF, 6 µL, 1.20 x 10-2 mmol) was added to a
solution of 1-benzyl-3-((2-oxopiperidin-1-yl)methyl)piperidine-2,6-dione 218 (90 %
ee, 15 mg, 4.84 x 10-2 mmol) in THF (0.5 cm3) and the solution was stirred at room
temperature for 2 h before saturated aqueous ammonium chloride (2 cm3) was added.
Following extraction with Et2O (2 x 5 cm3) the organic extracts were dried (MgSO4),
concentrated under reduced pressure and purified by column chromatography (ethyl
acetate – hexane 1:1) to give an impure sample containing what was characterised to
be 231 (32 mg) as an oil. Data obtained from this mixture: δH (300 MHz, CDCl3)
7.21 - 7.39 (5 H, m, ArH), 6.31 (1 H, d, J 1.2, H4A), 5.59 (1 H, d, J 1.2, H4B), 4.99 (2
H, s, CH2), 2.62 - 2.77 (4 H, m, H1, H2); δC (101 MHz, CDCl3) 173.44 (CO), 171.78
(CO), 137.02 (Ar), 128.83 (Ar), 128.65 (Ar), 127.44 (Ar), 120.87 (C3), 106.00 (C4),
50.31 (CH2Ar), 43.15 (C1), 32.35 (C2).
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(R)-1-((1-Benzyl-6-oxopiperidin-3-yl)methyl)pyridin-2(1H)-one, (R)-5 and minor
isomer 234.
Under nitrogen, a solution of 1-benzyl-3-((2-oxopiperidin-1-yl)methyl)piperidine-
2,6-dione, (S)-218 (90 % ee, 200 mg, 0.645 mmol) in dry ethanol (6.0 cm3) was
acidified to approximately pH 7 with HCl (20 μL, 0.8 M) and cooled to 0 ⁰C. To the
stirred solution, NaBH4 (73 mg, 1.93 mmol) was added portionwise at 10 min
intervals. Throughout the reaction HCl (20 μL, 0.8 M) was added in 10 min intervals 
to maintain the reaction at approximately pH 7. After 40 min, the reaction was
neutralised and saturated aqueous sodium hydrocarbonate (10.0 cm3) was added.
Following extraction with DCM (3 x 5 cm3), the organic extracts were dried
(MgSO4) and concentrated under reduced pressure to give the crude intermediate
products 232 and 233 (~200 mg) as an oil. Approximate conversion was determined
by 1H NMR analysis. No further purification was attempted. Under nitrogen, Et3SiH
(512 µL, 3.20 mmol) was added to a solution of the crude intermediate product in
TFA (1.14 cm3) and dry DCM (1.14 cm3). The mixture was heated to 45 ⁰C and
stirred for 5 h before saturated aqueous sodium hydrocarbonate (10 cm3) was
carefully added. Following extraction with DCM (3 x 10 cm3), the organic extracts
were dried (MgSO4) and concentrated under reduced pressure to give the major
product, (R)-5 (65 mg, 0.220 mmol, 34 % yield from imide (S)-218) as a colourless
oil, following purification by column chromatography (ethyl acetate – methanol
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95:5); found (ESI): M+ + Na, 319.1417. C18H20N2NaO2 requires M, 319.1417); νmax
3066 (aryl CH st.), 1650 (C=O st.), 1629 (C=O st.), 1580 (C=C st.) cm-1; δH (400
MHz, CDCl3) 7.30-7.14 (6 H, m, ArH, H7), 6.82 (1 H, dd, J 6.8, 1.8, H9), 6.47 (1 H,
d, J 9.0, H6), 5.99 (1 H, t, J 6.8, H8), 4.65 (1 H, d, J 14.6, CH2), 4.36 (1 H, d, J 14.6,
CH2), 3.79-3.67 (2 H, m, H5), 3.17 (1 H, dd, J 12.3, 4.9, H4A), 2.94 (1 H, dd, J 12.3,
9.0, H4B), 2.50 (1 H, dt, J 17.8, 5.9, H1A), 2.44-2.31 (2 H, m, H1B, H3), 1.89 - 1.77 (1
H, m, H2A), 1.56 (1 H, dtd, J 13.4, 10.0, 5.9, H2B); δC (176 MHz, CDCl3) 169.19
(CO), 162.58 (CO), 139.60 (C9), 137.60 (C7), 136.96 (Ar), 128.69 (Ar), 128.2 (Ar),
127.54 (Ar), 121.30 (C6), 105.97 (C8), 52.21 (C5), 50.19 (CH2Ar), 49.58 (C4), 33.05
(C3), 30.58 (C1), 24.83 (C2); m/z (ESI) 319.2 (M+ + Na); [α]D25 + 8.8 (c 0.7 in
CHCl3) 20 % ee (R) (lit.68 [α]D24 + 31.3 (c0.80, CHCl3) 98 % ee (R)). The ee of 5
could not be determined directly using GC or HPLC. Instead, it was established by
chiral HPLC of 235 as described in the next section.
An attempt was made by column chromatography (hexane - ethyl acetate 1:9) to
fully purify the minor product 234 (varying yields, commonly a 3:1 ratio of 5 : 234
in the crude product) however this was not possible. Data for 234 obtained from this
mixture; δH (400 MHz, CDCl3) 7.53 (1 H, dd, J 6.8, 2.0, H9), 7.38-7.20 (6H, m, ArH,
H7), 6.55 (1 H, d, J 9.0, H6), 6.16-6.10 (1H, m, H8), 4.60-4.51 (2H, m, CH2), 4.45-
4.40 (2H, m, H5), 3.22-3.16 (1H, m, H1), 2.90-2.82 (1H, m, H4), 2.08-2.00 (1H, m,
H3A), 1.90-1.82 (1H, m, H3B), 1.80-1.68 (1H, m, H2), and 1.60-1.50 (1H, m, H2).
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(S)-1-((1-Benzyl-6-oxopiperidin-3-yl)methyl)piperidin-2-one 235.
Under nitrogen, a solution of (R)-1-((1-benzyl-6-oxopiperidin-3-yl)methyl)pyridin-
2(1H)-one, (R)-5 (20% ee, 16.0 mg, 0.054 mmol) and palladium on charcoal (6.0
mg, 2.8 x 10-3 mmol, 5 % Pd / w) in dry MeOH (0.90 cm3) was hydrogenated at
room temperature under 5 bar hydrogen overnight. The catalyst was removed by
filtration with celite and the reaction mixture was passed through a short silica gel
column (hexane - ethyl acetate 1:9) to yield the product (S)-235 (15 mg, 0.050 mmol,
93 % yield) as a colourless oil; ee was determined by HPLC analysis (Chiracel IA,
25 cm x 4.6 mm column, IPA : hexane 95 : 5, 0.8 mL/min, T = 15 ⁰C, R isomer
(minor) 15.40 min., S isomer (major) 18.56 min.) 20 % ee. Compound (±)-235 was
used as a racemic standard to establish the positions of the required peaks.
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Racemic 1-((1-Benzyl-6-oxopiperidin-3-yl)methyl)piperidin-2-one 235 and
regioisomer 236.
Under nitrogen, a solution of 1-benzyl-3-((2-oxopyridin-1-yl)methyl)piperidine-2,6-
dione, (±)-228 (56.0 mg, 0.178 mmol) in dry ethanol (1.70 cm3) was acidified to
approximately pH 7 with HCl (~ 5 μL, 0.8 M) and cooled to 0 ⁰C. To the stirred
solution, NaBH4 (13.5 mg, 0.357 mmol) was added portion-wise at 10 min intervals.
Throughout the reaction, HCl (~5 μL, 0.8 M) was added in 10 min intervals to 
maintain the reaction at approximately pH 7. After 40 min the reaction was
neutralised and saturated aqueous sodium hydrocarbonate (1.00 cm3) was added.
Following extraction with DCM (3 x 1 cm3), the organic extracts were dried
(MgSO4) and concentrated under reduced pressure to give the crude intermediate
product (52.5 mg) as an oil. No further purification was attempted. Under nitrogen,
Et3SiH (134 µL, 0.839 mmol) was added to a solution of the crude intermediate
product (53.0 mg) in TFA (0.30 cm3) and dry DCM (0.30 cm3). The mixture was
heated to 40 ⁰C and stirred for 5 h before saturated aqueous sodium hydrocarbonate
(1 cm3) was added. Following extraction with DCM (3 x 1 cm3), the organic extracts
were dried (MgSO4) and concentrated under reduced pressure to give the crude
product which was purified by column chromatography (95:5 ethyl acetate /
methanol) to give the minor amide (±)-236 (10.5 mg, 0.035 mmol, 20 % yield) as a
colourless oil; found (ESI): M+ + Na, 323.1733. C18H24N2NaO2 requires M,
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323.1730); νmax 3080 (aryl CH st.), 1624 (C=O st.), 1590 (C=C st.) cm-1; δH (700
MHz, CDCl3) 7.28-7.14 (5 H, m, ArH), 4.54-4.48 (2H, m, CH2), 4.09-4.01 (1H, m,
H5A), 3.44 (1H, dd, J 13.6, 5.0, H5B), 3.39-3.31 (1 H, m, H9A), 3.21-3.09 (3 H, m,
H9B, H4), 2.67-2.59 (1H, m, H3), 2.37-2.28 (2H, m, H6), 1.90-1.83 (1H, m, H2A), 1.79
(1H, dtd, J 13.2, 6.5, 2.7, H2B), 1.76-1.69 (2H, m, H1), 1.66-1.46 (4H, m, H7, H8); δC
(176 MHz, CDCl3) 170.84 (CO), 170.42 (CO), 137.15 (Ar), 128.60 (Ar), 127.99
(Ar), 127.36 (Ar), 50.37 (CH2Ar), 48.15, 48.01, 47.45, 40.42 (C4), 32.38 (C6), 24.62,
23.28, 21.30, 21.20; m/z (ESI) 301.2 (M+ + 1), 323.2 (M+ + 23) and the major amide
(±)-235 (15.0 mg, 0.050 mmol, 28 % yield) as a colourless oil; found (ESI): M+ + H,
301.1922. C18H25N2O2 requires M, 301.1911); νmax 1631 br. (C=O st., C=C st.) cm-1;
δH (400 MHz, CDCl3) 7.36-7.21 (5 H, m), 4.72 (1 H, d, J 14.7), 4.44 (1 H, d, J 14.7),
3.78-3.71 (1 H, m), 3.38-3.30 (1 H, m), 3.22 (1 H, dd, J 13.6, 7.3), 3.19-3.11 (2 H,
m), 3.00-2.95 (1 H, m), 2.64-2.54 (1 H, m), 2.49-2.38 (1 H, m), 2.37-2.31 (1 H, m),
2.25-2.12 (1 H, m), 1.89 - 1.80 (2 H, m), 1.79 - 1.69 (4 H, m), 1.62 - 1.50 (1 H, m);
δC (176 MHz, CDCl3) 170.18 (CO), 169.51 (CO), 137.06 (Ar), 128.59 (Ar), 128.15
(Ar), 127.39 (Ar), 50.36, 50.14, 49.78, 48.98, 32.67 (C3), 32.23 (C6), 31.19 (C1),
25.33 (C2), 23.26 (C8), 21.22 (C7); m/z (ESI) 301.2 (M+ + 1), 323.2 (M+ + 23). This
sample was used in chiral HPLC to confirm the retention times of the enantiomers.
The HPLC data is given in the following section.
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Procedure for the formation of (R)-1-((1-Benzyl-6-oxopiperidin-3-yl)methyl)pyridin-
2(1H)-one with LiAlH4.
Alternatively, LiAlH4 was used to reduce imide 218 to the intermediate α-lactam. 
The same procedure of intermediate α-lactam reduction with Et3SiH and TFA (as
detailed in the previous section) was used to form lactam 5. Under nitrogen, LiAlH4
(2M in THF, 0.05 cm3, 0.100 mmol) was added to a solution of (S)-1-benzyl-3-((2-
oxopiperidin-1-yl)methyl)piperidine-2,6-dione, 218 (95 % ee, 30 mg, 0.097 mmol)
in dry THF (1.0 cm3) and the solution was stirred at – 78°C for 2 h before water (2
cm3) was added. Following extraction with DCM (3 x 5 cm3) the organic extracts
were dried (MgSO4) and concentrated under reduced pressure to give the
intermediate product (30 mg). This intermediate was further reduced to yield product
(S)-5 via the procedure shown in the previous section, using a solution of Et3SiH (77
µL, 0.482 mmol) in TFA (1 cm3) and dry DCM (1 cm3). Following concentration
under reduced pressure, the product (S)-5 (10 mg, 0.034 mmol, 35 % yield from
imide (S)-218) was obtained as a colourless oil, as determined by 1H NMR,
following purified by column chromatography (ethyl acetate – methanol 95:5). The
ee of this sample was found to be 13 % ee via indirect reduction to product 235. Full
characterisation data and HPLC separations were listed in the previous section.
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(Z)-1-((1-Benzyl-6-hydroxy-2-oxopiperidin-3-ylidene)methyl)pyridin-2(1H)-one, 238
Under nitrogen, cerium(III) chloride heptahydrate (363 mg, 0.97 mmol) was added
to (E)-1-benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)-piperidine-2,6-dione 1 (300
mg, 0.974 mmol) in methanol (2.4 cm3) and stirred at room temperature for 5 min.
Sodium borohydride (165 mg, 4.362 mmol) was added portionwise at room
temperature and the mixture was left stirring for 3 hours before aqueous sodium
hydrocarbonate (10 cm3) was added. Following extraction with DCM (3 x 5 cm3),
the organic extracts were washed with aqueous sodium hydrocarbonate (10 cm3),
dried (MgSO4) and concentrated under reduced pressure to give the crude product
which was purified by column chromatography (ethyl acetate – heptane 9:1) and
preparative HPLC (Waters XBridge Prep C18 OBD column, 5µ silica, 19 mm
diameter, 100 mm length), using decreasingly polar mixtures of water (containing
1% NH3) and MeCN as eluents to give compound 238 (60 mg, 0.193 mmol, 20 %
yield) as a white powder; Mp 175-178 °C; (found (ESI): M+ - H2O, 293.12836.
C18H17N2O2 requires M, 293.34526); νmax 3423 (OH st.), 1656 br. (C=O st., C=C st.)
cm-1; δH (400 MHz, CDCl3) 7.91 (1 H, s, H4), 7.22 – 7.42 (6 H, m, ArH, H7), 7.19 (1
H, dd, J 7.0, 1.6, H9), 6.61 (1 H, d, J 9.2, H6), 6.23 (1 H, td, J 7.0, 1.3, H8), 5.10 (1
H, d, J 15.0, CH2), 5.02 (1 H, t, J 3.0, H1), 4.50 (1 H, d, J 15.0, CH2), 3.48 (1H, bs,
OH), 2.79 – 2.9 (1 H, m, H2A), 2.42 (1 H, m, H2B), 1.95-1.82 (2 H, m, H4); δC (101
MHz, CDCl3) 162.95 (CO), 162.10 (CO), 140.42 (C7), 137.15 (Ar), 136.54 (C9),
133.66 (C5), 128.53 (Ar), 128.04 (Ar), 127.80 (C4), 127.33 (Ar), 121.21 (C6), 106.44
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(C8), 78.05 (C1), 47.85 (CH2Ph), 29.28 (C2), 19.28 (C3); m/z (ESI) 293.04 (M+ -
H2O), 333.07 (M+ + 23).
Section 3.1.3: The Attempted Synthesis of (-)-Sparteine.
5-Oxo-5-(prop-2-en-1-ylamino)pentanoic acid, 337
This compound has been reported but not fully characterised.181 Glutaric anhydride
(2.00 g, 17.53 mmol) was added to NEt3 (2.44 cm3, 17.51 mmol) in THF (38 cm3)
and stirred for 5 min at 0 °C. Allylamine (1.32 cm3, 17.60 mmol) in THF (30 cm3)
was added dropwise over one hour at 0 °C. The mixture was heated to 75 °C and left
stirring for 24 h before hydrochloric acid (1 M, 40 cm3) was added. Following
extraction with DCM (3 x 40 cm3), the organic extracts were washed with brine (30
cm3), dried (MgSO4) and concentrated under reduced pressure to give the product
337 (1.25 g, 7.31 mmol, 42 % yield) as an oil; (found (ESI): M+ + Na, 194.0787.
C8H13NNaO3 requires M, 194.0788); νmax 3314 br. (OH st.), 1706 (C=O st.), 1620
(C=O st.), 1547 (NH st.), 1230 (C-O st.) cm-1; δH (400 MHz, CDCl3) 9.69 (1H, br s,
NH), 5.83 (1H, ddt, J 16.4, 9.6, 5.5, H4), 5.19 (1H, d, J 16.4, H6A), 5.14 (1H, d, J 9.6,
H6B), 3.89 (2H, t, J 5.5, H4), 2.43 (2H, t, J 6.5, H3), 2.31 (2H, t, J 6.5, H1), 1.99 (2H,
quin, J 6.5, H2); δC (101 MHz, CDCl3) 177.85 (CO), 171.85 (CO), 132.44 (C5),
116.61 (C6), 42.02 (C4), 35.22 (C3), 32.13 (C1), 20.35 (C2); m/z (ESI) 193.8 (M+ +
Na). No further purification was carried out.
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1-Allylpiperidine-2,6-dione, 225.
This compound has been reported but not fully characterised.182 5-Oxo-5-(prop-2-en-
1-ylamino)pentanoic acid 337 (2.34 g, 13.68 mmol) was added to acetyl chloride (33
cm3) and the solution was left stirring 65 °C for 8 h. Following concentration under
reduced pressure, product 225 (0.675 g, 4.41 mmol, 32 %) was obtained as a
colourless oil, following purification by column chromatography (hexane - ethyl
acetate 1:1); (found (ESI): M+ + Na, 176.0683 C8H11NaNO2 requires M, 176.0682);
νmax 3090 (alkene CH st.), 1760 (C=O st.), 1722 (C=O st.), 1667 (C=C st.), 1172
(amide III), 1022 (=CH b.), 925 (=CH b.) cm-1; δH (400 MHz, CDCl3) 5.65 (1H, ddt,
J 16.7, 9.7, 5.7, H4), 5.01 (1H, d, J 16.7, H5A), 4.98 (1H, d, J 9.7, H5B), 4.19 (2H, d, J
5.7, H3), 2.52 (4H, t, J 6.5, H1), 1.84 (2H, q, J 6.5, H2); δC (100 MHz, CDCl3) 171.90
(CO), 131.87 (C4), 116.54 (C5), 41.00 (C3), 32.27 (C1), 16.67 (C2); m/z (ESI) 154.2
(M+ + 1).
(Z)-1-Allyl-3-(hydroxymethylene)piperidine-2,6-dione, 240.
Dry ethanol (2.33 cm3, 39.90 mmol) was added dropwise to a suspension of NaH
(60% in oil, 1.60 g, 40.00 mmol) in Et2O (46.5 cm3) at 0 °C and left stirring for 20
min. A solution of 1-allylpiperidine-2,6-dione 225 (2.14 g, 13.98 mmol) and ethyl
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formate (1.96 cm3, 24.24 mmol) in Et2O (46.5 cm3) was added dropwise over 1 h at
0 °C, then left to warm to room temperature and stirred for 16 h before extraction
with water (2 x 40 cm3). The aqueous extracts were acidified with HCl (30 cm3, 2M),
followed by extraction with Et2O (3 x 50 cm3). The organic extract was washed with
saturated aqueous sodium hydrocarbonate, dried (MgSO4), concentrated under
reduced pressure and purified by column chromatography (hexane - ethyl acetate 1 :
1), to give product 240 (1.63 g, 9.00 mmol, 64 % yield) as an oil; (found (ESI): M+ +
Na, 204.0640. C9H11NNaO3 requires M, 204.0631); νmax 3250 (OH st.), 3090 (alkene
CH st.), 1715 (C=O st.), 1678 (C=O st.), 1642 (C=C st.), 1600 (C=C st.), 1153
(Amide III), 990 (alkene CH b.), 926 (alkene CH b.) cm-1; δH (400 MHz, CDCl3)
12.24 (1H, d, J 12.2, OH), 7.18 (1H, d, J 12.2, H4), 5.83 (1H, ddt, J 13.6, 7.5, 5.8,
H6), 5.19 (1H, d, J 13.6, H7A), 5.16 (1H, d, J 7.5, H7B), 4.40 (2H, d, J 5.8, H5), 2.66
(2H, t, J 7.0, H1), and 2.47 (2H, t, J 7.0, H2); δC (100 MHz, CDCl3) 171.37 (CO),
170.87 (CO), 160.64 (C4), 131.87 (C6), 117.10 (C7), 99.95 (C3), 41.13 (C5), 32.29
(C1), 19.61 (C2); m/z (ESI) 204.1 (M+ +1).
(Z)-(1-Allyl-2,6-dioxopiperidin-3-ylidene)methyl 4-methylbenzenesulfonate, 241.
(Z)-1-Allyl-3-(hydroxymethylene)piperidine-2,6-dione, 240 (1.40 g, 7.73 mmol) was
added to NEt3 (1.29 cm3, 9.26 mmol) in dry DCM (25.0 cm3) and cooled to 0 °C. A
solution of p-toluenesulfonyl chloride (1.77 g, 9.28 mmol) in dry DCM (25.0 cm3)
was added and the mixture was allowed to warm to room temperature and stir for 1 h
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before saturated ammonium chloride (40 cm3) was added. Following extraction with
DCM (3 x 40 cm3), the organic extracts were washed with saturated hydrogen
carbonate (3 x 40 cm3), dried (MgSO4) and concentrated under reduced pressure to
give product 241 (2.38 g, 7.10 mmol, 92 % yield) as a dark purple solid; (found
(ESI): M+ + Na, 358.0725. C16H17NNaO5S requires M, 358.0720); νmax 3090 (alkene
CH st.), 1718 (C=O st.), 1678 (C=O st.), 1643 (C=C st.), 1593 (C=C st.), 1372 (SO
st.), 1343 (SO st.), 1197 (SO st.), 1173 (Amide III), 1114 (SO st.), 957 (alkene CH
b.), 934 (alkene CH b.) cm-1; δH (400 MHz, CDCl3) 7.84-7.82 (2H, m, ArH), 7.72
(1H, s, H4), 7.41-7.38 (2H, m, ArH), 5.77 (1H, ddt, J 16.3, 9.5, 5.8, H6), 5.16 (1H, d,
J 16.3, H7A), 5.14 (1H, d, J 9.5, H7B), 4.38 (2H, d, J 5.8, H5), 2.59 (4H, m, H1,2), and
2.47 (3H, s, CH3); δC (100 MHz, CDCl3) 170.76 (CO), 164.66 (CO), 146.23 (Ar),
144.42 (C4), 131.66 (C6), 131.59 (Ar), 130.13 (Ar), 127.91 (Ar), 117.42 (C7), 115.48
(C3), 41.87 (C5), 30.87 (C1), 21.54 (CH3), 17.54 (C2); m/z (ESI) 358.0 (M+ + Na).
(Z)-1-Allyl-3-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione, 216.
(Z)-(1-Allyl-2,6-dioxopiperidin-3-ylidene)methyl 4-methylbenzenesulfonate 241
(2.35 g, 7.01 mmol) was added to 2-hydroxypridine (1.33 g, 13.99 mmol) and NEt3
(2.44 cm3, 17.51 mmol) in dry toluene (70.0 cm3) at room temperature. The mixture
was heated to 110 °C and stirred for 20 h before concentration under reduced
pressure and purification by column chromatography (ethyl acetate – hexane 9 : 1),
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to give the product 216 (1.29 g, 5.00 mmol, 71 % yield) as an oil; (found (ESI): M+ +
Na, 281.0902. C14H14N2NaO3 requires M, 281.0897); νmax 3020 (alkene CH st.),
1721 (C=O st.), 1661 (C=O st.), 1640 (C=C st.), 1586 (C=C st.), 1533 (C=C st.),
1268 (Amide III), 992 (alkene CH b.), 916 (alkene CH b.) cm-1; δH (400 MHz,
CDCl3) 7.96 (1H, s, H4), 7.40 (1H, ddd, J 9.3, 6.8, 1.7, H6), 7.13 (1H, dd, J 6.8, 1.7,
H8), 6.64 (1H, d, J 9.3, H5), 6.26 (1H, t, J 6.8, H7), 5.82 (1H, ddt, J 17.1, 9.5, 5.8,
H4), 5.24 (1H, d, J 17.1, H11A), 5.18 (1H, d, J 9.5, H11B), 4.47 (2H, d, J 5.8, H9),
2.75-2.67 (4H, m, H1,2); δC (100 MHz, CDCl3) 170.57 (CO), 164.91 (CO), 161.54
(CO), 140.26 (C6), 136.27 (C4), 135.54 (C8), 131.70 (C10), 124.58 (C3), 121.95 (C5),
117.83 (C11), 106.42 (C7), 42.31 (C9), 31.38 (C1), 21.01 (C2); m/z (ESI) 259.1 (M+ +
H), 281.1 (M+ + Na). The O-substituted isomer was not observed.
Asymmetic hydrogenation of (Z)-1-Allyl-3-((2-oxopyridin-1(2H)-
yl)methylene)piperidine-2,6-dione 216.
A solution of thoroughly dried (Z)-1-Allyl-3-((2-oxopyridin-1(2H)-yl)methylene)-
piperidine-2,6-dione 216 (143.0 mg, 0.554 mmol) and [Rh(COD)((R,R)-Et-
DuPHOS)]BF4 (9.3 mg, 1.41 x 10-2 mmol) in dry DCM (1.86 cm3) was degassed
three times. To the stirred solution, the hydrogenation was performed at 30 °C under
25 bar hydrogen for 5 days. The reaction mixture was passed through a short silica
gel column to remove the catalyst to give an unseparable mixture of what was
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characterised to be the desired allyl imide 224 and the over reduced propyl derivative
242 (36 % and 63 % respectively as determined by comparison of the allyl and
propyl group integrals by 1H NMR): δH (400 MHz, CDCl3) 7.45-7.40 (1H, m, H8),
7.30-7.25 (1H, m, H6), 6.50-6.44 (1H, m, H5), 6.14-6.10 (1H, m, H7), 5.70-5.65 (1H,
m, H10), 5.10-5.02 (2H, m, H11), 4.35–4.25 (2H, m, H4A, H9), 4.12-4.05 (1H, m, H4B),
3.68-3.58 (1H, m, H12), 3.10–2.98 (1H, m, H3), 2.80-2.70 (1H, m, H1A), 2.60-2.48
(1H, m, H1B), 2.08-1.96 (1H, m, H2A), 1.75-1.60 (1H, m, H2B), 1.50-1.38 (2H, q, J
7.0, H13), 0.88-0.78 (3H, t, J 7.0, H14).
Section 3.2: Procedures from Section 2.2.
Section 3.2.1: ATH of Enamides.
General procedure for the transfer hydrogenation of α,β-unsaturated imides. 
Under nitrogen, a solution of α,β-unsaturated imide (1 mmol) and [Ru(teth-
TsDPEN)] in dry methanol (1.6 cm3) was stirred at 28 ⁰C for 5 min before FA/TEA
(5:2, 0.5 cm3) was added. The solution was left stirring at 28 ⁰C for the specified
time before saturated aqueous hydrogen carbonate was added. Following extraction
with DCM (3 x 5 cm3), the organic extracts were dried (MgSO4) and concentrated
under reduced pressure to give the crude product which was analysed by 1H NMR.
Where applicable the crude material was purified by column chromatography and
analysed by chiral HPLC to determine the ee. The synthesis of all subsequently
listed compounds was carried out by this procedure at equivalent stoichiometric
ratios.
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The formation of 1-benzyl-3-((2-oxopyridin-1(2H)-yl)methyl)piperidine-2,6-dione,
(±)-218 via ATH.
This compound was prepared following the general procedure for transfer
hydrogenation of α,β-unsaturated imides, using (E)-1-benzyl-3-((2-oxopyridin-
1(2H)-yl)methylene)piperi-dine-2,6-dione, 1 (10 mg, 3.2 x 10-2 mmol) and (S,S)-
Ruteth-TsDPEN, (S,S)-248 (0.6 mg, 9.7 x 10-4 mmol), following a reaction time of 5
d. Following solvent removal and column chromatography, the product 218 (8 mg,
2.6 x 10-2 mmol, 81 % yield) was obtained as colourless oil. The product was found
to be racemic. Full characterisation data for 218 was stated in the previous section.
Procedure for the transfer hydrogenation of (E)-1-benzyl-3-((2-oxopyridin-1(2H)-
yl)methylene)piperidine-2,6-dione 218 with RuTsEN, 249.
This method conveniently used the racemic TH catalyst, Ru(TsEN) to carry out the
TH. The material was otherwise formed by ATH in racemic form by using the chiral
catalyst, RutethTsDPEN. The catalyst was formed in situ by combination of the
precatalyst and diamine ligand by a known procedure.
Under nitrogen, a solution of [Ru(cymene)Cl2]2 (0.4 mg, 6.5 x 10-4 mmol) and TsEN
(0.8 mg, 2.2 x 10-3 mmol) in dry ethanol (1.0 cm3) and FA/TEA (5:2) (78 μL) were 
stirred for 20 min at 28 ⁰C. (E)-1-benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)-
piperidine-2,6-dione 1 (20 mg, 6.5 x 10-2 mmol) was added and the solution was
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stirred at 28 ⁰C for 5 days before saturated aqueous hydrogen carbonate (1 cm3) was
added. Following extraction with DCM (3 × 2 cm3), the organic extracts were dried
(MgSO4) and concentrated under reduced pressure to give the product 218 (18 mg,
5.8 x 10-2 mmol, 89 % yield) as determined by 1H NMR. Full characterisation data
for 218 was stated in Section 1.
The formation of 1-benzyl-3-((2-oxopyridin-1(2H)-yl)methyl)piperidine-2,6-dione
and methyl 5-oxo-2-[(2-oxopyridin-1(2H)-yl)methyl]-5-(prop-2-en-1-
ylamino)pentanoate.
(Z)-1-Allyl-3-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione, 216 (566
mg, 2.19 mmol) was added to [Ru(R,R)teth-TsDPEN] (27.2 mg, 4.4 x 10-2 mmol) in
dry MeOH (3.50 cm3) at 28 °C before FA/TEA (5:2) (1.10 cm3) was added. The
solution was stirred at 28 °C for 3 days before saturated aqueous hydrogen carbonate
(5 cm3) was added. Following extraction with DCM (3 × 5 cm3), the organic extracts
dried (Mg2SO4), concentrated under reduced pressure and purified by column
chromatography (ethyl acetate – methanol 95:5) to give product 247 (100 mg, 0.34
mmol, 16 % yield), as an oil, following; (found (ESI): M+ + Na, 315.1314.
C15H20N2NaO4 requires M, 315.1315); νmax 3078 (alkene CH st.), 1732 (C=O st.),
1655 (C=O st.), 1580 (C=C st.), 1540 (C=C st.), 993 (alkene CH b.), 924 (alkene CH
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b.) cm-1; δH (600 MHz, CDCl3) 7.32 - 7.37 (2 H, m, H5’’, H3’’), 6.54 (1 H, d, J 9.0,
H2’’), 6.39 (1 H, bs, NH), 6.14 - 6.18 (1 H, td, J 7.0, 1.0, H4’’), 5.80 - 5.87 (1 H, ddt, J
17.0, 10.0, 4.5, H2’), 5.19 (1 H, dd, J 17.0, 1.5, H3’A), 5.12 (1 H, dd, J 10.0, 1.5,
H3’B), 4.35 (1 H, dd, J 13.0, 4.5, H1’A), 3.85 - 3.91 (3 H, m, H1’B, H6), 3.66 (3 H, s,
Me), 2.93 - 2.99 (1 H, m, H2), 2.49 - 2.42 (1 H, m, H4A), 2.38 - 2.30 (1 H, m, H4B),
2.12 - 2.04 (1 H, m, H3A), 1.90 - 1.83 (1 H, m, H3B); δC (151 MHz, CDCl3) 174.16
(CO), 171.69 (CO), 162.68 (CO), 140.04 (C5’’), 138.52 (C3’’), 134.21 (C2’), 120.81
(C2’’), 116.27 (C3’), 106.10 (C4’’), 52.10 (CH3), 50.44 (C1’), 43.82 (C2), 41.98 (C6),
33.92 (C4), 26.31 (C3); m/z (ESI) 293.2 (M+ + H), 315.1 (M+ + Na); followed by an
impure sample containing what was characterised to be product 242 (400 mg);
(found (EI): M+ + Na, 283.1058. C14H16N2NaO3 requires M, 283.1053); νmax 3084
(aryl CH st.), 1715 (C=O st.), 1662 (C=O st.), 1647 (C=O st.), 1581 (C=C st.), 1538
(C=C st.), 1157 (amide III) cm-1; δH (400 MHz, CDCl3) 7.48 (1 H, dd, J 7.0, 2.5,
H13), 7.38 - 7.32 (1 H, m, H11), 6.56 (1 H, d, J 9.0, H10), 6.21 - 6.16 (1 H, m, H12),
5.83 - 5.71 (1 H, m, H15), 5.16 (1 H, dd, J 8.0, 1.5, H16A), 5.14 - 5.11 (1 H, m, H16B),
4.40 - 4.34 (1 H, m, H7A), 4.19 (1 H, dd, J 13.5, 5.5, H7B), 3.12 (1 H, ddd, J 18.0,
10.5, 5.5, H5), 2.87 (1 H, dt, J 16.0, 7.0, H3A), 2.63 (1 H, m, H3B), 2.18 - 2.08 (1 H,
m, H4A), 1.82 - 1.69 (1 H, m, H4B); δC (101 MHz, CDCl3) 173.15 (CO), 171.41 (CO),
162.89 (CO), 139.84 (C13), 138.81 (C11), 133.73 (C15), 131.89, 120.72 (C10), 117.38
(C16), 105.92 (C12), 50.35 (C7), 41.91 (C14), 41.68 (C5), 32.26 (C3), 21.30 (C4); m/z
(ESI) 283.1 (M+ + Na).
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1-Benzyl-3-(hydroxymethyl)piperidine-2,6-dione, 246
This compound was prepared following the general procedure (A) for transfer
hydrogenation of α,β-unsaturated imides using (Z)-1-benzyl-5-(hydroxyl-
methylene)piperidine-2,6-dione 220 (32 mg, 0.139 mmol) and Ru(S,S)teth-TsDPEN
(1.7 mg, 2.7 x 10-3 mmol), for 16 h. Following column chromatography (ethyl
acetate – hexane 1:1), the product 246 (25 mg, 0.107 mmol, 77 % yield) was
obtained as an oil; [α]D
24 + 19 (c0.09 in CHCl3) 31 % ee; (found (ESI): M+ + Na,
256.0942. C13H15NNaO3 requires M, 256.0944); νmax 3387 (OH st.), 3033 (aryl CH
st.) 1722 (C=O st.), 1667 (C=O st.), 1165 (amide III) cm-1; δH (300 MHz, CDCl3)
7.33 - 7.13 (5 H, m, ArH), 4.88 (2 H, s, CH2Ph), 3.90 - 3.73 (2 H, m, H4), 2.98 - 2.73
(2 H, m, H1), 2.68 - 2.49 (1 H, m, H3), 1.93 - 1.71 (2 H, m, H2); δC (101 MHz,
CDCl3) 175.00 (CO), 171.99 (CO), 137.03 (Ar), 128.59 (Ar), 128.48 (Ar), 127.52
(Ar), 63.03 (C4), 44.62 (CH2Ar), 42.94 (C3), 32.41 (C1), 20.22, (C2); m/z (ESI) 256.1
(M+ + Na). The ee was determined by HPLC analysis (Chiralpak IA, 4.6 mm x 250
mm, hexane : IPA 95:1, 1 mL/min, T = 30 °C, minor isomer 57.34 min, major
isomer 62.04 min.) 31 % ee. For HPLC analysis, a racemic standard was used to
establish the position of the two enantiomers. This standard was obtained from the
combination of an equal amount of two samples of the alcohol product which were
both opposite enantiomers. These had been formed by ATH through the (R,R) and
(S,S) forms of the catalyst respectively.
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Section 3.2.2: Synthesis and ATH of β-(Acylamino)acrylates.  
Ethyl-3-(amino)but-2-enoate, 254a.
This compound has been reported and characterised.183 A solution of ammonium
acetate (1.59 g, 20.62 mmol) and ethyl acetoacetate (0.50 g, 3.84 mmol) in ethanol
(5.3 cm3) were stirred at room temperature for 60 h, before the solution was
concentrated under reduced pressure and chloroform (10 cm3) was added. The
resulting salt precipitate was removed by filtration and the filtrate was washed with
water (15 cm3), and brine (15 cm3); dried (MgSO4) and concentrated under reduced
pressure to give the product, 254a (0.300 g, 2.32 mmol, 61 %) as an oil; δH (300
MHz, CDCl3) 4.52 (1 H, s, H3), 4.11 (2 H, q, J 7.0, H4), 1.91 (3 H, s, H1), 1.25 (1 H,
t, J 7.0, H5) A resonance attributable to NH2 was not observed; δC (101 MHz,
CDCl3) 170.18 (CO), 159.67 (C2), 83.96 (C3), 58.41 (C4), 22.21 (C1), 14.48 (C5).
This data was in agreement with the literature.
Ethyl-3-[acetylamino]but-2-enoate, 244a.
This compound is been reported and characterised.184 Under nitrogen, acetic
anhydride (6.00 cm3, 6.48 g, 63.47 mmol) and pyridine (2.00 cm3, 1.96 g, 24.73
mmol) were added to a solution of ethyl-3-(amino)but-2-enoate 254a (1.55 g, 12.01
mmol) in THF (15.0 cm3) at room temperature. The solution was left stirring at 65
°C for 15 h before being concentrated under reduced pressure. The residue was re-
dissolved in ethyl acetate (10 cm3), washed with water (5 cm3), HCl (1M, 5 cm3),
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saturated aqueous sodium hydrocarbonate (5 cm3) and saturated aqueous brine (5
cm3). The organic extracts were dried (MgSO4), concentrated under reduced pressure
and purified by column chromatography (ethyl acetate – hexane 1 : 9) to give the
products (Z/E = 2.2:1, as determined by 1H NMR) (Z)-244a (0.40 g, 2.34 mmol, 19
%) and (E)-244a (0.18 g, 1.05 mmol, 9 %) as colourless solids; (Z)-244a: δH (300
MHz, CDCl3) 11.13 (1 H, bs, NH), 4.90 (1 H, s, H3), 4.15 (2 H, q, J 7.0, H4), 2.38 (3
H, s, H1), 2.14 (3 H, s, H2), 1.28 (3 H, t, J 7.0, H5); δC (75 MHz, CDCl3) 169.16
(CO), 168.95 (CO), 110.15 (C6), 96.40 (C3), 59.60 (C4), 25.41 (CH3), 21.88 (CH3),
14.98 (C5). (E)-244a: δH (300 MHz, CDCl3) 6.75 (1 H, s, H3), 6.70 (1 H, bs, NH),
4.14 (2 H, q, J 7.0, H4), 2.35 (3 H, s, H1), 2.13 (3 H, s, H2), 1.27 (1 H, t, J 7.0, H5); δC
(75 MHz, CDCl3) 169.77 (CO), 168.41 (CO), 149.16 (C6), 102.34 (C3), 59.39 (C4),
24.66 (CH3), 18.10 (CH3), 14.11 (C5). This data was in agreement with the literature.
1-(2-Oxopyrrolidin-1-yl)butane-1,3-dione, 253b.
This compound has been reported but not fully characterised.185 A solution of
pyrrolidin-2-one (0.90 cm3, 1.01 g, 11.84 mmol) and 2,2,6-trimethyl-4H-1,3-dioxin-
4-one (1.87 cm3, 2.00 g, 14.08 mmol) in xylene (9.0 cm3) stirred at 140 °C for 90
min. Following concentration under reduced pressure and purification by column
chromatography (ethyl acetate – heptanes 1:1), the product 253b (1.61 g, 9.52 mmol,
80 %) was obtained as a pale yellow liquid; (found (ESI): M+ + H, 169.0728.
C8H11NO3 requires M, 169.0739); νmax 1728 (C=O st.), 1693 (C=O st.), 1630 (C=O
st.), 1192 (amide III) cm-1; δH (400 MHz, CDCl3) 3.98 (2 H, s, H3), 3.90 – 3.77 (2 H,
m, H6), 2.56 (2 H, t, J 8.0, H8), 2.25 (3 H, s, H1), 2.11 – 1.98 (2 H, m, H7); δC (101
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MHz, CDCl3) 201.37 (C2), 175.79 (C4), 167.12 (C9), 52.46 (C3), 45.33 (C6), 33.37
(C8), 30.30 (C1), 17.16 (C7); m/z (ESI) 169 (M+ +1).
(Z)-N-(4-Oxo-4-(2-oxopyrrolidin-1-yl)but-2-en-2-yl)acetamide, 253c.
Under nitrogen, a solution of ammonium acetate (3.28 g, 42.55 mmol) and 1-(2-
oxopyrrolidin-1-yl)butane1,3-dione 253b (1.44 g, 8.52 mmol) in methanol (10.64
cm3) were left stirring at room temperature for 24 h before solution was concentrated
under reduced pressure and chloroform (30 cm3) was added. The resulting precipitate
of salt was removed by filtration and the resulting filtrate was washed with water (30
cm3) and brine (30 cm3), then dried (MgSO4) and concentrated under reduced
pressure to give the intermediate product (1.95 g) as a solid; δH (400 MHz, CDCl3)
6.12 (1 H, s, CH), 4.91 (2 H, bs, NH2), 4.14 – 4.07 (2 H, m, CH2), 3.09 (2 H, t, J 8.0,
CH2), 2.27 (3 H, s, CH3), 2.02 – 1.93 (2 H, m, CH2); δC (101 MHz, CDCl3) 174.88
(CO), 168.42 (CO), 162.83 (CO), 110.08 (=CH), 46.88 (NCH2), 32.76 (CH2), 23.78
(CH3), 19.12 (CH2). A solution of the intermediate product (1.95 g), acetic anhydride
(5.61 cm3, 6.06 g, 59.35 mmol) and pyridine (1.92 cm3, 23.74 mmol) in THF (14.9
cm3) was stirred at 70 °C for 15 h before the solution was concentrated under
reduced pressure. The residue was re-dissolved in EtOAc (30 cm3) and washed with
H2O (10 cm3), 1 M HCl (10 cm3), saturated aqueous sodium hydrocarbonate (10
cm3) and saturated aqueous brine (10 cm3). The organic extracts were dried
(MgSO4), concentrated under reduced pressure and purified by column
chromatography (ethyl acetate – hexane 3 : 7) to give the product 253c (0.50 g, 2.38
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mmol, 28 % over two steps) as a colourless solid; Mp 118-120 °C; (Found (ESI): M+
+ H, 211.10762. C10H15N2O3 requires M, 211.10772); νmax 1727 (C=O st.), 1614 br.
(C=O st., C=C st.) cm-1; δH (400 MHz, CDCl3) 11.86 (1 H, s, NH), 6.54 (1 H, d, J
1.0, H4), 3.91 – 3.80 (2 H, m, H7), 2.61 (2 H, t, J 8.0, H5), 2.46 (3 H, d, J 1.0, H1),
2.16 (3 H, s, H2), 2.09 – 1.97 (2 H, m, H6); δC (101 MHz, CDCl3) 175.08 (CO),
169.37 (CO), 169.15 (CO), 157.68 (C3), 97.13 (C4), 45.58 (C7), 34.17 (C5), 25.62
(C1), 22.74 (C2), 17.10 (C6); m/z (ESI) 211 (M+ + H), 233 (M+ +Na). The assignment
of E alkene geometry was supported by an 1H NMR nOe experiment. Irradiation of
H3 resulted in the excitation of protons H2.
Ethyl-3-[acetyl(methyl)amino]but-2-enoate, 244b.
Acetic acid (1.23 cm3, 1.29 g, 21.49 mmol) and methylamine (33 % w/w ethanol
solution, 2.12 cm3, 0.70 g, 22.52 mmol) were added to a solution of ethyl
acetoacetate (0.5 g, 3.84 mmol) in ethanol (5.4 cm3) and stirred at room temperature
for 24 h, before the solution was concentrated under reduced pressure to give the
intermediate product (2.10 g) as an oil; δH (300 MHz, CDCl3) 4.47 (1 H, s, CH), 4.08
(2 H, d, J 7.0 Hz, CH2), 2.90 (3 H, s, CH3), 2.92 (3 H, s, CH3), 1.92 (3 H, s, CH3),
1.25 (3 H, t, J 7.0 Hz, CH3); δC (75 MHz, CDCl3) 177.56 (CO), 170.55 (NC=),
81.65(=CH), 58.12 (OCH2), 29.41 (CH3), 24.38 (CH3), 14.47 (CH3). A solution of
acetic anhydride (2.04 cm3, 2.20 g, 21.58 mmol), pyridine (0.70 cm3, 0.68 g, 8.65
mmol) and the intermediate product (2.10 g) in THF (5.4 cm3) were stirred at 40 °C
for 8 h before the solution was concentrated under reduced pressure. The residue was
re-dissolved in EtOAc (10 cm3) and washed with water (5 cm3), 1 M HCl (5 cm3),
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saturated aqueous sodium hydrocarbonate (5 cm3) and saturated aqueous brine (5
cm3). The organic extracts were dried (MgSO4), concentrated under reduced pressure
and purified by column chromatography (ethyl acetate – hexane 3:7) to give the
product 244b (205 mg, 1.11 mmol, 29 %) as a colourless solid; Mp 140-144 °C;
Found (ESI): M+ + Na, 208.0944. C9H15NNaO3 requires M, 208.0944); νmax 1678
(C=O st.), 1569 (C=O st.), 766 (alkene CH b.) cm-1; δH (400 MHz, CDCl3) 12.36 (1
H, bs, H5), 4.23 (2 H, q, J 7.0, H6), 3.01 (s, H2), 2.25 (3 H, s, H1), 2.18 (3 H, s, H3),
1.33 (3 H, t, J 7.0, H7); δC (126 MHz, CDCl3) 170.00 (CO), 168.19 (CO), 117.13
(C4), 103.89 (C5), 59.81 (C6), 29.36 (CH3), 28.29 (CH3), 16.02 (CH3), 13.48 (C7);
m/z (ESI) 208.1 (M+ + Na).
Section 3.2.3: Synthesis and ATH of N-Boc Tetramic Acids.
General procedure for the synthesis of tetramic acids.
These tetramic acids were observed as both keto and enol tautomer forms, by 1H and
13C NMR depending upon the solvent used. It was found that in d6-DMSO, the
enolic tautomer was exclusively observed; and in chloroform the keto tautomer was
exclusively observed. This was consistent for each tetramic acid synthesised. The
reported NMR spectra for each tetramic acid synthesised have been reported in both
CDCl3 and d6 DMSO. The tetramic acids included in the following experimental
section were synthesised according to the following general procedure stated by
Størgaard et al.186
184
Under nitrogen, a solution of the Boc-protected amino acid (6.25 mmol), Meldrum’s
acid (9.20 mmol) and DMAP (9.20 mmol) in dry DCM (82 cm3) was cooled to 0 °C.
EDC.HCl (9.20 mmol) was added and the mixture was stirred at 0 °C for 15 m. The
mixture was allowed to warm to room temperature and stirred for 4 h before ethyl
acetate (245 cm3) was added. This solution was washed with brine (2 x cm3), 5 %
citric acid (2 x 125 cm3), and by brine (125 cm3), then dried (MgSO4) and
concentrated under reduced pressure to give the intermediate adduct. Ethyl acetate
(50 cm3) was added and the mixture was stirred at 75 °C for 30 min before the
solvent was removed by reduced pressure to give the crude product which was
purified as stated.
Tert-butyl 4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate, 243.
This compound has been reported but not fully characterised.188 This compound was
prepared following the general procedure for the synthesis of tetramic acids using
Boc-glycine (1.10 g, 6.28 mmol), Meldrum’s acid (1.35 g, 9.37 mmol), DMAP (1.15
g, 9.41 mmol) and EDC.HCl (1.80 g, 9.39 mmol). Following concentration under
reduced pressure, the product 243 (1.27 g, 6.38 mmol) was obtained as a solid; Mp
120-124 °C (lit Mp 123-127°C); (Found (ESI): M+ + Na, 222.0743. C9H13NNaO4
requires M, 222.0737); νmax 1751 (C=O st.), 1597 (C=C st.) cm-1; enol form, 243a:
δH (300 MHz, DMSO-d6) 12.16 (1H, bs, OH), 4.89 (1H, s, H3), 4.14 (2H, s, H1), 1.44
(9H, s, tBu); δC (75 MHz, DMSO-d6) 174.38 (CO), 169.20 (CO), 148.88 (C2), 94.27
(C3), 80.76 (C(CH3)3), 49.33 (C1), 27.72 (C(CH3)3); keto form, 243b: δH (300 MHz,
CDCl3) 4.25 (2 H, s, H1), 3.25 (2 H, s, H3), 1.57 (9 H, s, tBu); δC (101 MHz, CDCl3)
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200.59 (C2), 167.33 (CO), 148.93 (CO), 84.44 (C(CH3)3), 57.08 (C1), 43.59 (C3),
27.95(C(CH3)3); m/z (ESI) 222.1 (M+ + Na), 421.0 (M2+ + Na). The compound was
used in its crude form as prescribed.186 This data was in agreement with the
literature.
Tert-butyl (2S)-2-[(benzyloxy)methyl]-3-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate, 264.
This compound has been reported but not fully characterised.187 This compound was
prepared following the general procedure for the synthesis of tetramic acids using O-
benzyl Boc-L-serine (1.00 g, 3.39 mmol), Meldrum’s acid (0.747 g, 5.18 mmol),
DMAP (0.635 g, 5.20 mmol) and EDC.HCl (0.996 g, 5.20 mmol). Following
concentration under reduced pressure the product 264 (1.07 g, 3.35 mmol, 99 %
yield) was obtained as an oil; [α]D25 + 73.25 (c0.40 in MeOH) (S) > 99 % ee (lit.187
[α]D
20 + 55 (c1.00, MeOH) (S), > 99 % ee); (Found (ESI): M+ + Na, 342.1309.
C17H21NNaO5 requires M, 342.1312); νmax 1753 (C=O st.), 1712 (C=O st.), 1618
(C=C st.) cm-1; enol form, 264a: δH (400 MHz, DMSO-d6) 12.29 (1 H, br. s, OH),
7.36 - 7.22 (5 H, m, ArH), 4.90 (1 H, s, H3), 4.53 - 4.40 (3 H, m, H6, H1), 3.96 (1 H,
dd, J 10.3, 2.9, H5A), 3.76 (1 H, dd, J 10.3, 1.8, H5B), 1.41 (9 H, s, tBu); δC (101
MHz, DMSO-d6) 174.95 (CO), 169.29 (CO), 148.79 (C2), 138.05 (Ar), 128.24 (Ar),
127.48 (Ar), 127.28 (Ar), 94.74 (C3), 80.96 (C(CH3)3), 72.33 (C6), 65.53 (C5), 60.31
(C1), 27.74 (C(CH3)3); keto form, 264b: δH (400 MHz, CDCl3) 7.37 - 7.18 (5 H, m,
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ArH), 4.52 (1 H, d, J 12.4, H6A), 4.45 (1 H, d, J 12.4, H6B), 4.40 - 4.36 (1 H, m, H1),
3.93 (1 H, dd, J 9.8, 2.3, H5A), 3.83 (1 H, dd, J 9.8, 2.0, H5B), 3.27 (1 H, dd, J 22.1,
1.5, H3), 3.10 (1 H, d, J 22.1, H3), 1.50 (9 H, s, tBu); δC (101 MHz, CDCl3) 202.92
(C2), 167.99 (CO), 148.72 (CO), 136.87 (Ar), 128.43 (Ar), 127.84 (Ar), 127.38 (Ar),
84.02 (C(CH3)3), 73.28 (C6), 67.85 (C5), 67.75 (C1), 43.66 (C3), 27.82 (C(CH3)3);
m/z (ESI) 342.1 (M+ + Na), 660.9 (M2+ + Na).
Tert-butyl (2S)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate,
(S)-265.
Both enantiomers of tetramic acid 265 were synthesised to enable comparison of
their ATH products, to establish whether a DKR may have occurred. This compound
has been reported with full characterisation.188
This compound was prepared following the general procedure for the synthesis of
tetramic acids using Boc-L-phenyl alanine (4.33 g, 16.32 mmol), Meldrum’s acid
(0.655 g, 4.54 mmol), DMAP (0.350 g, 2.86 mmol) and EDC.HCl (0.549 g, 2.86
mmol). Following concentration under reduced pressure, the product (S)-265 (2.53 g,
8.75 mmol, 54 %) was obtained as a fine white powder, following recrystallisation
(ethyl acetate – hexane); [α]D25 + 227.3 (c1.00 in MeOH) (S) > 99 % ee (lit.188 [α]D25
+ 230 (c1.00, MeOH) (S), > 99 % ee); enol form, (S)-265a: δH (400 MHz, DMSO)
12.34 (1 H, s, OH), 7.29 – 7.17 (3 H, m, ArH), 7.01 – 6.98 (2 H, m, ArH), 4.65 (1 H,
s, H3), 4.62 (1 H, m, H1), 3.36 (1 H, dd, J 13.5, 5.5, H5A), 3.08 (1 H, dd, J 13.5, 2.5,
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H5B), 1.52 (9 H, s, tBu); δC (101 MHz, DMSO-d6) 175.51 (CO), 168.74 (CO), 149.02
(C2), 134.54 (Ar), 129.55 (Ar), 127.94 (Ar), 126.69 (Ar), 94.87 (C3), 81.00
(C(CH3)3), 59.74 (C1), 34.21 (C5), 27.87 (C(CH3)3); keto form, (S)-265b: δH (300
MHz, CDCl3) 7.35 - 7.23 (3 H, m, ArH), 7.08 – 6.98 (2 H, m, ArH), 4.70 – 4.63 (1
H, m, H1), 3.38 (1 H, dd, J 14.0, 5.3, H5A), 3.24 (1 H, dd, J 14.0, 3.0, H5B), 2.87 (1 H,
d, J 22.4, H3A), 2.27 (1 H, dd, J 22.4, 1.9, H3B), 1.63 (9 H, s, tBu); δC (101 MHz,
CDCl3) 204.22 (C2), 167.32 (CO), 149.09 (CO), 133.82 (Ar), 129.79 (Ar), 128.94
(Ar), 127.83 (Ar), 84.33 (C(CH3)3), 68.12 (C1), 43.31 (C3), 36.52 (C5),
27.98(C(CH3)3).
Tert-butyl (2R)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate,
(R)-265.
The enantiomer (R)-265 was obtained using the unnatural amino acid, Boc-D-phenyl
alanine as starting material. This compound was prepared following the general
procedure for the synthesis of tetramic acids using Boc-D-phenyl alanine (1.00 g,
3.77 mmol), Meldrum’s acid (0.815, 5.65 mmol), DMAP (0.691 g, 5.66 mmol) and
EDC.HCl (1.08 g, 5.65 mmol). Following concentration under reduced pressure, the
product (R)-265 (0.15 g, 0.52 mmol, 14 %) was obtained as a fine white powder,
following recrystallisation (ethyl acetate – hexane); [α]D20 – 253.8 (c1.00 in MeOH)
(R) > 99 % ee (lit.188 [α]D25 - 230 (c1.00, MeOH) (R) > 99 % ee). Full
characterisation was stated in the previous section.
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Tert-butyl 4-methoxy-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate, 266.
This compound has been reported but not fully characterised.189 Methyl iodide (18
µL, 41.0 mg, 0.289 mmol) was added to a solution of tert-butyl 4-hydroxy-2-oxo-
2,5-dihydro-1H-pyrrole-1-carboxylate 243 (50 mg, 0.251 mmol) and silver carbonate
(69 mg, 0.250 mmol) in dry acetonitrile (0.50 cm3) at room temperature and left
stirring for 24 h before saturated aqueous sodium hydrocarbonate (5 cm3) was added.
Following extraction with DCM (3 x 10 cm3) the organic extracts were dried
(MgSO4), concentrated under reduced pressure and purified by column
chromatography (ethyl acetate – hexane 8:2) to give product 266 (18 mg, 0.084
mmol, 34 % yield) as a colourless oil; (Found (ESI): M+ + Na, 236.0893.
C10H15NNaO4 requires M, 236.0893); νmax 1775 (C=O st.), 1624 (C=C st.), 1325 (C-
O-C st.), 1157 (amide III) cm-1;  (400 MHz, CDCl3) 5.11 (1 H, s, H3), 4.18 (2 H, s,
H1), 3.84 (3 H, s, CH3), 1.55 (9 H, s, tBu); δC (101 MHz, CDCl3) 174.60 (CO),
169.20 (CO), 149.34 (C2), 94.92 (C3), 82.60 (C(CH3)3), 58.48 (CH3), 49.16 (C1),
28.05 (C(CH3)3); m/z (ESI) 236.1 (M+ +23), 449.0 (M2+ + 23). The C-alkylation
product was not obtained from the reaction.
General procedure for the transfer hydrogenation of tetramic acids.
The following compounds were prepared using the following general procedure: A
solution of the tetramic acid (1 mmol) and Ru(teth-TsDPEN (2 mol %) in dry
methanol (0.625 M w/r to the tetramic acid) was stirred at room temperature for 5
min. before FA/TEA (5:2, 0.5 cm3 / mmol substrate) was added. The solution was
left stirring at room temperature for 18 h before saturated aqueous hydrogen
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carbonate was added. Following extraction with DCM (3 x 5 cm3) the organic
extracts were dried (MgSO4), concentrated under reduced pressure and purified by
column chromatography (where applicable) to give the product.
(S)-Tert-butyl 4-hydroxy-2-oxopyrrolidine-1-carboxylate, 257.
This compound has been reported but not fully characterised.190 This compound was
prepared following the general procedure for the ATH of tetramic acids using tert-
butyl 4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate 243 (70 mg, 0.352
mmol) and Ru(R,R)teth-TsDPEN (4.4 mg, 7.11 x 10-3 mmol). Following
concentration under reduced pressure and purification by column chromatography
(ethyl acetate – hexane 9:1), the product (S)-257 (43 mg, 0.214 mmol, 61 % yield)
was obtained as a colourless solid; [α]D
23 + 2.15 (c0.77 in CHCl3) 41 % ee (S) (lit.190
[α]D
25 + 2.1 (c1.86, CHCl3) 99.9 % ee (S).); (Found (ESI): M+ + Na, 224.0899.
C9H15NNaO4 requires M, 224.0893); νmax 3454 (OH st.), 1773 (C=O st.) cm-1; 
(500 MHz, DMSO-d6) 5.27 (1 H, d, J 3.6, OH), 4.24 - 4.16 (1 H, m, H2), 3.76 (1 H,
dd, J 11.3, 4.7, H1A), 3.51 (1 H, d, J 11.3, H1B), 2.74 (1 H, dd, J 17.2, 5.8, H3A), 2.18
(1 H, d, J 17.2, H3B), 1.45 (9 H, s, tBu); δC NMR (126 MHz, DMSO-d6) 173.27
(CO), 149.16 (CO), 81.46 (C(CH3)3), 61.83 (C2), 55.05 (C1), 42.41 (C3), 27.64
(C(CH3)3); m/z (ESI) 224.1 (M+ + Na), 425.0 (M2Na+). The ee was determined by
HPLC analysis (Chiralpak OB, 4.6 mm x 250 mm, heptane : IPA 9:1, 1 mL/min, T =
25 °C, R (minor) isomer 12.1 min, S (major) isomer 15.3 min.) 41 % ee.
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Tert-butyl (2S)-2-[(benzyloxy)methyl]-3-hydroxy-5-oxocyclopentanecarboxylate,
(S,S)-267.
This compound has been reported but not fully characterised.153 This compound was
prepared following the general procedure for the ATH of tetramic acids using tert-
butyl (2S)-2-[(benzyloxy)methyl]-3-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-1-
carboxylate, (R)-264 (52 mg, 0.163 mmol) and Ru(R,R)teth-TsDPEN (2.0 mg, 3.22 x
10-3 mmol). Following concentration under reduced pressure and purification by
column chromatography (methanol - ethyl acetate 5:95), the product (S,S)-267 (40
mg, 0.125 mmol, 76 % yield) was obtained as an oil; [α]D
30 + 27 (c0.10 in MeOH)
(lit.153 [α]D20 + 59 (c1.00, MeOH)); Found (ESI): M+ + Na, 344.1465. C17H23NNaO5
requires M, 344.1468); νmax 3459 (OH st.), 1772 (C=O st.), 1713 (C=O st.) cm-1; δH
(400 MHz, DMSO-d6) 7.36 - 7.24 (5 H, m, ArH), 5.45 (1 H, d, J 4.5, OH), 4.53 (1 H,
d, J 12.5, H7A), 4.54 - 4.44 (2 H, m, H7B, H3), 4.08 (1 H, dt, J 7.5, 3.5, H2), 3.77 (1 H,
dd, J 9.7, 3.5, H6A), 3.72 (1 H, dd, J 9.7, 3.5, H6B), 1.38 (9 H, s, tBu); δC (75 MHz,
DMSO-d6) 171.53 (CO), 149.25 (CO), 138.42 (Ar), 128.21 (Ar), 127.33 (Ar),
127.08 (Ar), 81.58 (C(CH3)3), 72.38 (C7), 66.09 (C6), 63.51 (C2), 60.43 (C3), 40.63
(C4), 27.57 (C(CH3)3); m/z (ESI) 344.1 (M + Na), 665.1 (M2+ + Na). The ee of this
sample was not determined.
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ATH of (R)-265 with (R,R)-Ru(teth-TsDPEN).
This compound has been reported and fully characterised.188 This compound was
prepared following the general procedure for the ATH of tetramic acids using tert-
butyl (2R)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (R)-265
(60 mg, 0.208 mmol) and Ru(R,R)teth-TsDPEN (2.6 mg, 4.19 x 10-3 mmol).
Following concentration under reduced pressure the product (R,R)-268 (40 mg,
0.137 mmol, 66 % yield) was obtained as colourless solid, following column
chromatography (ethyl acetate – hexane 9:1); [α]D
28 – 44.5 (c1.00 in MeOH) > 99 %
ee (lit.188 [α]D25 – 43.5 (c1.00, MeOH)); δH (500 MHz, DMSO-d6) 7.36 - 7.24 (5 H,
m, ArH), 5.50 (1 H, d, J 4.5 Hz, OH), 4.32 - 4.22 (2 H, m, H2,3), 3.06 (1 H, dd, J
13.5, 7.0, H6A), 2.93 (1 H, dd, J 13.5, 5.0, H6B), 2.43 - 2.49 (1 H, m, H4A), 2.23 (1 H,
dd, J 17.0, 8.0, H4B), 1.34 (9 H, s, tBu); δC (126 MHz, DMSO-d6) 171.36 (CO),
149.26 (CO), 138.34 (Ar), 129.80 (Ar), 128.05 (Ar), 126.02 (Ar), 81.53 (C(CH3)3),
63.91 (C2), 62.43 (C3), 33.15 (C6), 27.46 (C(CH3)3). The ee was determined by
HPLC analysis (Chiralpak IC, 4.6 mm x 250 mm, heptane : IPA 1:1, 1 mL/min, T =
25 °C, (S,S) (minor) isomer 5.18 min, (R,R) (major) isomer 5.97 min.) > 99 % ee.
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ATH of (R)-265 with (S,S)-Ru(teth-TsDPEN).
This compound was prepared following the general procedure for the ATH of
tetramic acids using tert-butyl (2R)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (R)-265 (100 mg, 0.346 mmol) and Ru(S,S)teth-TsDPEN (4.4
mg, 7.09 x 10-3 mmol). Following concentration under reduced pressure and column
chromatography (ethyl acetate – hexane 9:1), the product (R,R)-268 (70 mg, 0.240
mmol, 69 % yield) was obtained as colourless solid; [α]D
25 - 59.3 (c0.34 in MeOH) >
99 % ee (lit.188 [α]D25 – 43.5 (c1.00, MeOH)); ee determined by HPLC analysis
(Chiralpak IC, 4.6 mm x 250 mm, heptane : IPA 1:1, 1 mL/min, T = 25 °C, (S,S)
(minor) isomer 5.18 min, (R,R) (major) isomer 5.98 min) > 99 % ee.
ATH of (S)-265 with (R,R)-Ru(teth-TsDPEN).
This compound was prepared following the general procedure for the ATH of
tetramic acids using tert-butyl (2S)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (S)-265 (50 mg, 0.172 mmol) and Ru(R,R)teth-TsDPEN (2.1
mg, 3.39 x 10-3 mmol). Following concentration under reduced pressure and
purification by column chromatography (ethyl acetate – hexane 9:1), the product
(S,S)-268 (25 mg, 0.086 mmol, 50 % yield) was obtained as colourless solid; [α]D25 +
56 (c0.10 in MeOH) 99 % ee (lit.188 [α]D25 + 43 (c1.00, MeOH)); ee determined by
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HPLC analysis (Chiralpak IC, 4.6 mm x 250 mm, heptane : IPA 1:1, 1 mL/min, T =
25 °C, (S,S) (major) isomer 5.57 min, (R,R) (minor) isomer 6.56 min.) 99 % ee.
ATH of (S)-265 with (S,S)-Ru(teth-TsDPEN).
This compound was prepared following the general procedure for the ATH of
tetramic acids using tert-butyl (2S)-2-benzyl-3-hydroxy-5-oxo-2,5-dihydro-1H-
pyrrole-1-carboxylate (S)-265 (55 mg, 0.19 mmol) and Ru(S,S)teth-TsDPEN (2.4
mg, 3.87 x 10-3 mmol). Following concentration under reduced pressure, and
purification by column chromatography (ethyl acetate – hexane 9:1), the product
(R,R)-268 (49 mg, 0.168 mmol, 89 % yield) was obtained as colourless solid; [α]D26
+ 43.5 (c1.00 in MeOH) > 99 % ee (lit.188 [α]D25 + 43 (c1.00, MeOH)); Ee
determined by HPLC analysis (Chiralpak IC, 4.6 mm x 250 mm, heptane : IPA 1:1,
1 mL/min, T = 25 °C, (S,S) (major) isomer 5.17 min, (R,R) (minor) isomer 5.95
min.) > 99 % ee.
Section 3.2.4: ATH of 5-Acetyluracil.
5-Acetyl-1-benzylpyrimidine-2,4(1H,3H)-dione, 269
This compound has been reported but not fully characterised.191 Under nitrogen, a
suspension of 5-acetyluracil (200 mg, 1.298 mmol) and NaH (60 % in oil, 52 mg,
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1.300 mmol) in DMF (6.5 cm3) was stirred at room temperature for 90 m. A solution
of benzyl bromide (200.6 mg, 1.173 mmol) in DMF (6.5 cm3) was added dropwise
over 30 min and the mixture was stirred at room temperature for 3 d. Following
concentration under reduced pressure, purification by column chromatography (ethyl
acetate - petroleum ether 1:1) and recrystallisation (methanol), product 269 (123 mg,
0.504 mmol, 39 % yield) was obtained as colourless needles; Mp 196-198 °C; (found
(ESI): M+ + Na, 267.0740. C13H12N2NaO3 requires M, 267.0740); νmax 3486 (NH
st.), 3408 (alkene CH st.), 1724 (C=O st.), 1640 (C=O st.), 1599 (C=O st.), 1554
(NH b.), 1510 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.63 (1 H, bs, NH), 8.26 (1 H, s,
H4), 7.44 - 7.30 (5 H, m, ArH), 4.99 (2 H, s, CH2), 2.59 (3 H, s, H1); δC (151 MHz,
DMSO-d6) 193.54 (C2), 161.73 (CO), 151.49 (C4), 150.36 (CO), 136.24 (Ar), 128.70
(Ar), 127.86 (Ar), 127.66 (Ar), 111.82 (C3), 51.04 (CH2Ph), 30.26 (CH3); m/z (ESI)
267.1 (M+ +Na). The crystals obtained were of sufficient quality for X-diffraction,
enabling confirmation of the structure. Full details are shown in Appendix II.
5-(1-hydroxyethyl)dihydropyrimidine-2,4(1H,3H)-dione, 270.
This compound was prepared following the general procedure for ketone transfer
hydrogenation, using 5-acetyluracil (100 mg, 0.641 mmol) and Ru(R,R)teth-
TsDPEN (8.1 mg, 1.31 x 10-2 mmol) in neat FA/TEA (700 µL, 2M). Following a
reaction time of 17 h, DCM (2 cm3) was added and the resulting suspension was
cooled and filtered. The resulting powder was dried to give an inseparable mixture of
the diastereomers (D1/D2 = 3.1:1, as determined by 1H NMR) (D1)-270a and (D2)-
270b (80 mg, 0.506 mmol, 79 % yield) as a powder; (Found (ESI): M+ + Na,
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181.0588. C6H10N2NaO3 requires M, 181.0584); Mp 226-230 °C; νmax 3400 (OH st.),
3219 (NH st.), 1708 br. (C=O st.), 1674 (NH b.), 1225 (C-O st.) cm-1; (D1)-270a: δH
(600 MHz, DMSO-d6) 9.90 (1 H, bs, NH), 7.42 (1 H, bs, NH), 4.82 (1 H, d, J 6.0,
OH), 4.03 (1 H, sxt, J 6.0, H2), 3.32 - 3.15 (2 H, m, H4), 2.31 (1 H, q, 6.0, H3), 1.13
(3 H, d, J 6.0, H1); δC (151 MHz, DMSO-d6) 171.78 (CO), 153.53 (CO), 62.71 (C2),
46.80 (C4), 36.02 (C3), 21.75 (C1); (D2)-270b: δH (600 MHz, DMSO-d6) 9.93 (1 H,
bs, NH), 7.43 (1 H, bs, NH), 4.84 - 4.83 (1 H, m, OH), 4.10 - 4.09 (1 H, m, H2), 3.32
- 3.15 (2 H, m, H4), 2.57 (1 H, dt, J 7.2, 6.0, H3), 1.06 (3 H, d, J 6.4, H1); δC (151
MHz, DMSO-d6) 171.81 (CO), 153.50 (CO), 64.77 (C2), 45.80 (C4), 36.08 (C3),
19.16 (C1); m/z (ESI) 159.0 (M+ - H). No further purification or separation of the
diastereomers was carried out.
1-Benzyl-5-(1-hydroxyethyl)dihydropyrimidine-2,4(1H,3H)-dione, 271.
This compound was prepared following the general procedure (C) for ketone transfer
hydrogenation, using 5-acetyl-1-benzylpyrimidine-2,4(1H,3H)-dione 269 (30 mg,
0.123 mmol) and Ru(R,R)teth-TsDPEN (0.6 mg, 9.67 x 10-4 mmol) following a
reaction time of 20 h. Following concentration under reduced pressure and
purification by column chromatography (ethyl acetate – petroleum ether 9:1), an
inseparable mixture of diastereomers 271a and 271b (D1/D2 = 3.48:1, as determined
by 1H NMR) (23 mg, 0.093 mmol, 75 % yield) was obtained as a colourless oil;
(found (ESI): M+ + Na, 271.1049. C13H16N2NaO3 requires M, 271.1053); νmax 3400
(OH st.), 3199 (NH st.), 1670 br. (C=O st.), 1491 cm-1; m/z (ESI) 270.8 (M+ +23);
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271a: δH (400 MHz, CDCl3) 8.22 (1 H, bs, NH), 7.41 - 7.25 (5 H, m, ArH), 4.67 (1
H, d, J 14.8, CH2), 4.58 (1 H, d, J 14.8, CH2), 4.33 (1 H, sxt, J 6.3, H2), 3.48 (1 H,
dd, J 12.6, 10.8, H4A), 3.28 (1 H, dd, J 12.6, 6.1, H4B), 2.66 - 2.59 (1 H, m, H3), 1.20
(3 H, d, J 6.3, H1); A resonance attributable to OH was not observed; δC (101 MHz,
CDCl3) 171.62 (CO), 152.69 (CO), 136.01 (Ar), 128.81 (Ar), 127.90 (Ar), 128.02
(Ar), 63.95 (C2), 50.64 (C4), 46.67 (CH2Ph), 41.66 (C3), 19.92 (C1). Enantiomeric
separation was achieved by HPLC analysis (Chiralpak IA, 4.6 mm x 250 mm,
hexane : IPA 90 : 10, 1 mL/min, T = 30 °C, minor isomer 72.6 min, major isomer
41.8 min.) 69 % ee; 271b: δH (400 MHz, CDCl3) 8.26 (1 H, bs, NH), 7.40 - 7.27 (5
H, m, ArH), 4.92 (1 H, d, J 1.8, OH), 4.68 (1 H, d, J 14.8, CH2), 4.57 (1 H, d, J 14.8,
CH2), 4.01 (1 H, quind, J 6.6, 1.8, H2), 3.25 - 3.15 (2 H, m, H4), 2.66 - 2.59 (1 H, m,
H3), 1.14 (3 H, d, J 6.6, H1); A resonance attributable to OH was not observed; δC
(101 MHz,CDCl3) 172.74 (CO), 152.59 (CO), 135.76 (Ar), 128.85 (Ar), 128.06
(Ar), 127.93 (Ar), 66.21 (C2), 50.52 (CH2Ph), 46.41 (C4), 43.37 (C3), 19.99 (C1);
Enantiomeric separation was achieved by HPLC analysis (Chiralpak IA, 4.6 mm x
250 mm, hexane : IPA 90 : 10, 1 mL/min, T = 30 °C, minor isomer 46.0 min, major
isomer 51.9 min.) 19 % ee.
Section 3.3: Procedures from Section 2.3.
Section 3.3.1: Synthesis and AH of Pyridone 2.
1-((6-Methoxypyridin-3-yl)methyl)piperidine-2,6-dione, 275.
Under nitrogen, a solution of triphenylphosphine (6.73 g, 25.66 mmol), (6-
methoxypyridin-3-yl)methanol 276 (3.50 g, 25.17 mmol) and glutarimide (2.90 g,
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25.64 mmol) in THF (75 cm3) was stirred at 0 °C for 5 min. A solution of
diisopropyl azodicarboxylate (4.99 cm3, 5.19 g, 25.66 mmol) in THF (50 cm3) was
added dropwise over 1 h at 0 °C and the solution was allowed to warm to room
temperature and stirred for 18 h. Following concentration under reduced pressure
and purification by column chromatography (ethyl acetate – hexane 1:1), product
275 (3.03 g, 12.94 mmol, 51 % yield) was obtained as a colourless oil; (found (ESI):
M+ + H, 235.10750. C12H15N2O3 requires M, 235.10772); νmax 3010 (aryl CH st.),
1716 (CO), 1607 (aryl C=C st.), 1491 (aryl C=C st.) cm-1; δH (400 MHz, CDCl3)
8.22 (1 H, d, J 2.5, H5), 7.63 (1 H, dd, J 8.5, 2.5, H3), 6.67 (1 H, d, J 8.5, H2), 4.87 (2
H, s, H6), 3.90 (3 H, s, CH3), 2.65 (4 H, t, J 6.7, H7), 1.92 (2 H, quin, J 6.7, H8); δC
(101 MHz, DMSO) 172.68 (CO), 162.69 (C1), 146.22 (C5), 138.98 (C3), 126.22 (C4),
109.99 (C2), 52.99 (CH3), 40.18 (C6), 32.02 (C7), 16.43 (C8); m/z (ESI) 234.97 (M+
+1). The synthesis of the starting material, 276 is shown in the next section.
1-[(1-Benzyl-6-oxo-1,6-dihydropyridin-3-yl)methyl]piperidine-2,6-dione, 2.
Under nitrogen, a mixture of benzyl bromide (1.02 cm3, 1.47 g, 8.59 mmol), 1-((6-
methoxypyridin-3-yl)methyl)piperidine-2,6-dione, 275 (1.82 g, 7.77 mmol) and
potassium carbonate (2.15 g, 15.56 mmol) in dry acetonitrile (31 cm3) was stirred at
80 °C for 24 h before the solution was filtered. The resulting filtrate was
concentrated under reduced pressure and recrystallised (ethanol), to give product 2
(1.42 g, 4.58 mmol, 59 % yield) as a white powder; Mp 154-156 °C; (found (ESI):
M+ + Na, 333.1205. C18H18N2NaO3 requires M, 333.1210); νmax 1722 (C=O st.),
1666 (C=O st.), 1601 (pyridone C=C st.), 1537 (pyridone C=C st.) cm-1; δH (400
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MHz, CDCl3) 7.49 - 7.41 (2 H, m, H2, H4), 7.37 - 7.25 (5 H, m, ArH), 6.52 (1 H, d, J
9.3, H1), 5.10 (2 H, s, CH2), 4.62 (2 H, s, CH2), 2.64 (4 H, t, J 6.4, H6), 1.93 (2 H,
quin, J 6.4, H7); δC (101 MHz, CDCl3) 172.36 (CO), 161.90 (CO), 141.49 (C4),
138.61 (C2), 136.23 (Ar), 128.69 (Ar), 128.05 (Ar), 127.85 (Ar), 120.60 (C1), 115.36
(C3), 52.03 (CH2Ph), 39.20 (C5), 32.60 (C6), 16.85 (C7); m/z (ESI) 333.1 (M+ +23).
Further recrystallisation (EtOH) provided crystals of sufficient quality for X-
diffraction, enabling confirmation of the structure. Full details are shown in
Appendix II.
1-[(1-Benzyl-6-oxopiperidin-3-yl)methyl]piperidine-2,6-dione, (±)-274.
This compound was prepared following the general procedure for alkene
hydrogenation, using 1-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-methyl]-
piperidine-2,6-dione, 2 (1.14 g, 3.68 mmol) and platinum oxide (42 mg, 0.185
mmol) following a reaction time of 20 h, at 30 °C. Following concentration under
reduced pressure, product (±)-274 (1.10 g, 3.50 mmol, 95 % yield) was obtained as
colourless oil, following column chromatography (methanol - ethyl acetate 2:8);
(found (ESI): M+ + Na, 337.1522. C18H22N2NaO3 requires M, 337.1523); νmax 1668
(C=O st.), 1634 (C=O st.) cm-1; δH (400 MHz, CDCl3) 7.36 - 7.19 (5 H, m, ArH),
4.73 (1 H, d, J 14.6, CH2), 4.42 (1 H, d, J 14.6, CH2), 3.77 (1 H, dd, J 12.4, 7.3,
H5A), 3.68 (1 H, dd, J 12.4, 7.5, H5B) 3.11 (1 H, ddd, J 11.0, 5.0, 1.3, H4A), 2.98 (1 H,
t, J 11.0, H4B), 2.63 (4 H, t, J 6.6, H6), 2.58 (1 H, ddd, J 18.0, 5.8, 3, H1A), 2.39 (1 H,
ddd, J 18.0, 11.5, 6.2, H1B), 2.20 - 2.07 (1 H, m, H3), 1.89 (2 H, quin, J 6.6, H7), 1.53
(2 H, dtd, J 13.1, 11.5, 6.2, H2); δC (101 MHz, CDCl3) 172.33 (CO), 169.03 (CO),
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136.50 (Ar), 128.13 (Ar), 127.53 (Ar), 126.90 (Ar), 50.08 (CH2Ph), 49.72 (C5),
41.05 (C4), 32.84 (C3), 32.26 (C8), 30.65 (C1), 24.77 (C2), 16.57 (C7); m/z (ESI)
337.1 (M+ +Na). Enantiomeric separation was achieved by HPLC analysis
(Chiralpak IB, 4.6 mm x 250 mm, hexane : IPA 80 : 20, 1.0 mL/min, T = 30 °C, 38.1
min, 41.0 min). This sample was used as a racemic standard in chiral HPLC to
confirm the retention times of the enantiomers of the AH products prepared in the
next section.
AH screen of 1-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-methyl]piperidine-2,6-
dione, 2.
The AH catalyst screen of 1-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-
methyl]piperidine-2,6-dione 2 was carried out using the general procedure for alkene
hydrogenation. Conversions were determined by 1H NMR. Ees were determined by
HPLC analysis using compound (±)-274 as a racemic standard.
Methyl 5-oxo-5-{[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)methyl]amino}-
pentanoate, 278.
This compound was prepared following the general procedure for alkene
hydrogenation, using 1-[(1-benzyl-6-oxo-1,6-dihydropyridin-3-yl)-methyl]-
piperidine-2,6-dione 2 (185 mg, 0.587 mmol) and palladium on carbon (10 % Pd
w/w, 32 mg, 3.01 x 10-2 mmol) following a reaction time of 18 h, at room
temperature. Following concentration under reduced pressure and purification by
column chromatography (methanol - ethyl acetate 5:95), product 278 (115 mg, 0.336
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mmol, 57 % yield) was obtained as colourless oil; (found (ESI): M+ + Na, 365.1474.
C19H22N2NaO4 requires M, 365.1472); νmax 3281(NH st.), 3062 (aryl CH st.) 1731
(CO), 1661 (CO), 1593 (CO), 1536 (pyridone C=C st.) cm-1; δH (400 MHz, CDCl3)
7.38 - 7.21 (7 H, m, ArH, H2, H4), 6.59 (1 H, d, J 9.3, H1), 5.77 (1 H, bs, NH), 5.11
(2 H, s, CH2), 4.12 (2 H, d, J 6.0, H5), 3.66 (3 H, s, CH3), 2.35 (2 H, t, J 7.1, H8),
2.24 (2 H, t, J 7.1, H6), 1.95 (5 H, quin, J 7.1, H7); δC (151 MHz, CDCl3) 173.55
(CO), 172.26 (CO), 162.04 (CO), 140.22 (C4), 136.14 (Ar), 135.92 (C2), 128.85
(Ar), 128.09 (Ar), 127.95 (Ar), 121.16 (C1), 116.83 (C3), 51.98 (CH2Ph), 51.55
(CH3), 39.95 (C5), 35.14 (C8), 32.97 (C6), 20.73 (C7); m/z (ESI) 365.1 (M+ +Na).
Section 3.3.2: Completion of the Synthesis.
1-Benzyl-5-[(2-hydroxy-6-oxopiperidin-1-yl)methyl]piperidin-2-one, (±)-280.
Under nitrogen, a solution of cerium chloride heptahydrate (574 mg, 1.54 mmol) and
1-[(1-benzyl-6-oxopiperidin-3-yl)methyl]piperidine-2,6-dione, (±)-274 (484 mg,
1.54 mmol) in dry methanol (3.85 cm3) was stirred at 0 °C for 5 min. Sodium
borohydride (118 mg, 3.12 mmol) was added and the mixture was stirred at 0 °C for
4 h before saturated aqueous sodium hydrocarbonate (5 cm3) was added. Following
extraction with DCM (3 x 10 cm3), the organic extracts were dried (MgSO4),
concentrated under reduced pressure and purified by column chromatography
(methanol - ethyl acetate 5:95), to give an impure sample containing what was
characterised to be the inseparable diastereomers (±)-280 (343 mg, 1.08 mmol, 70 %
yield). Data obtained for the mixture of diastereomers is as follows: (found (ESI):
M+ + Na, 339.1683. C18H24N2NaO3 requires M, 339.1679); νmax 3303 (OH st.), 1613
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(C=O st.) cm-1; δH (400 MHz, CDCl3) 7.38 - 7.15 (5 H, m, ArH), 4.79 - 4.33 (3 H, m,
CH2, H6), 3.65 - 3.43 (1 H, m, H5A), 3.29 - 3.04 (2 H, m, H5B, H4A), 3.03 - 2.87 (1 H,
m, H4B), 2.61 - 2.10 (5 H, m, H1, H9, H3), 2.10 - 1.42 (6 H, m, H2, H8, H7); δC (101
MHz, CDCl3) 171.02 (CO), 169.84 (CO), 137.18 (Ar), 128.58 (Ar), 128.41 (Ar),
128.36 (Ar), 79.92 (C6), 50.49 (CH2Ph), 46.64 (C5), 41.44 (C4), 32.79 (C1), 31.55
(C9), 30.84 (C3), 24.99 (C8), 24.75 (C7), 15.47 (C2); m/z (ESI) 339.1 (M+ +Na).
1-[(1-Benzyl-6-oxopiperidin-3-yl)methyl]-3,4-dihydropyridin-2(1H)-one, (±)-281.
Under nitrogen, a solution of 1-benzyl-5-[(2-hydroxy-6-oxopiperidin-1-
yl)methyl]piperidin-2-one, (±)-280 (240 mg, 0.759 mmol) in dry DCM (19 cm3) was
stirred at - 10 °C for 10 min. Titanium chloride (92 µL, 159 mg, 0.839 mmol) was
added and the solution was stirred at -10 °C for 10 min before DIPEA (147 µL, 109
mg, 0.844 mmol) was added. The solution was allowed to warm to 0 °C and left
stirring for 4 h before saturated aqueous ammonium chloride (5 cm3) was added.
Following extraction with DCM (3 x 10 cm3), the organic extracts were dried
(MgSO4) and concentrated under reduced pressure to give product (±)-281 (203 mg,
0.681 mmol, 90 % yield) as an oil; (found (ESI): M+ + H, 299.1743. C18H23N2O2
requires M, 299.1754); νmax 1616 br. (C=O st., C=C st.) cm-1; δH (600 MHz, CDCl3)
7.21 - 7.36 (5 H, m, ArH), 5.85 (1 H, d, J 7.7, H9), 5.10 (1 H, dt, J 7.7, 4.1, H8), 4.67
(1 H, d, J 14.7, CH2), 4.49 (1 H, d, J 14.7, CH2), 3.37 (2 H, m, H4), 3.18 (1 H, ddd, J
12.0, 4.9, 1.5, H5A), 2.95 (1 H, dd, J 12.0, 9.8, H5B), 2.58 (1 H, ddd, J 18.0, 6.0, 3.8,
H1A), 2.47 (2 H, t, J 7.9, H6), 2.43 (1 H, ddd, J 18.0, 11.3, 6.8, H1B), 2.23 - 2.28 (2 H,
m, H7), 2.13 - 2.21 (1 H, m, H3), 1.85 - 1.90 (1 H, m, H2A), 1.50 - 1.58 (1 H, m, H2B);
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δC (151 MHz, CDCl3) 169.58 (CO), 169.39 (CO), 136.96 (Ar), 130.04 (C9), 128.60
(Ar), 128.13 (Ar), 127.41 (Ar), 106.45 (C8), 50.18 (C5), 50.10 (CH2Ph), 48.74 (C4),
31.26 (C1), 31.02 (C6), 30.91 (C7), 25.06 (C2), 20.16 (C7); m/z (ESI) 299.2 (M+ +1).
The selenide oxidation – elimination of enamide (±)-281, yielding (±)-1-((1-benzyl-
6-oxopiperidin-3-yl)methyl)pyridin-2(1H)-one, (±)-5.
This compound has been reported and fully characterised.68 Under nitrogen, LDA
(1.5M solution in THF, 70 µL, 0.105 mmol) was added to a solution of 1-[(1-benzyl-
6-oxopiperidin-3-yl)methyl]-3,4-dihydropyridin-2(1H)-one, (±)-281 (15 mg, 0.050
mmol) in freshly distilled THF (0.7 cm3) and the solution was stirred at -78 °C for 1
h. A solution of phenyl selenyl chloride (9.6 mg, 0.050 mmol) in freshly distilled
THF (1.0 cm3) was added and the solution was stirred at -78 °C for 45 min before
saturated ammonium chloride was added and the solution was allowed to warm to
room temperature. Following extraction with ethyl acetate (3 x 5 cm3), the organic
extracts were dried (MgSO4) and concentrated under reduced pressure to give the
intermediate product (25 mg). A solution of the intermediate product (25 mg) in
THF : methanol : H2O 18:6:2 (1 cm3) and NaIO4 (37 mg, 0.173 mmol) was stirred at
room temperature for 24 h before water was added and the solution was concentrated
under reduced pressure. Following extraction with ethyl acetate (3 x 5 cm3), the
organic extracts were dried (MgSO4) and concentrated under reduced pressure to
give a sample containing the product, (±)-5 (10 mg) as a colourless oil, as
determined by 1H NMR. At this small scale, further purification was not possible.
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This data was in accordance the characterisation data for 5 which was given in
Section 1.
Section 3.3.3: Synthesis and AH of 5-Substituted Pyridones.
1-Benzyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid, 283.
This compound has been reported but not fully characterised.192 Under nitrogen, a
solution of 6-hydroxynicotinic acid (2.10 g, 15.07 mmol) and potassium hydroxide
(2.96 g, 52.74 mmol) in water (3.59 cm3) and methanol (17.94 cm3) was stirred at 70
°C for 5 min before benzyl bromide (3.58 cm3, 5.15 g, 30.13 mmol) was added. The
mixture was stirred at 70 °C for 90 min before the reaction was cooled to room
temperature and concentrated under reduced pressure. The resulting residue was
diluted with water (10 cm3) and washed diethyl ether (2 x 10 cm3). The aqueous
phase was acidified to pH 1 with HCl (2M) and the resulting white precipitate was
washed with water and dried under reduced pressure to give the crude product (2.68
g) as a white solid. Purification by silica gel chromatography was not possible.
A portion of the crude product (0.290 g) was purified by preparative reverse phase
HPLC (Phenomenex Gemini-NX axia Prep C18 OBD column, 5µ silica, 50 mm
diameter, 150 mm length), using decreasingly polar mixtures of water (containing
0.1% formic acid) and MeCN as eluents. Following concentration under reduced
pressure, product, 283 (0.210 g, 0.916 mmol) was obtained as a white powder; Mp
210-214 °C; (found (ESI): M+ + H, 230.0807. C13H12NO3 requires M, 230.0812);
νmax 3325 (OH st.), 1708 (C=O st.), 1638 (C=O st.), 1568 (pyridone C=C st.), 1539
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(pyridone C=C st.) cm-1; δH (400 MHz, DMSO-d6) 12.86 (1 H, bs, OH), 8.56 (1 H, d,
J 2.5, H4), 7.80 (1 H, dd, J 9.5, 2.5, H2), 7.39 - 7.24 (5 H, m, ArH), 6.46 (1 H, d, J
9.5, H1), 5.20 (2 H, s, CH2); δC (101 MHz, DMSO) 165.19 (CO), 161.46 (CO),
149.34 (C4), 138.88 (C2), 136.80 (Ar), 128.61 (Ar), 127.74 (Ar), 127.67 (Ar), 118.91
(C3), 109.57 (C1), 51.52 (CH2Ph); m/z (ESI) 229.9 (M+ - 1).
Methyl 6-methoxynicotinate, 285.
This compound has been reported but not fully characterised.193 A suspension of 6-
methoxynicotinic acid 284 (2.90 g, 18.94 mmol) in methanol (28.0 cm3) and sulfuric
acid (16 M, 1.1 cm3, 20.64 mmol) was stirred at 80 °C for 16 h before the mixture
was allowed to cool. The mixture was neutralised by careful addition of sodium
bicarbonate. Following concentration under reduced pressure, water (20 cm3) and
aqueous sodium bicarbonate (10 cm3) were added. Following extraction with DCM
(3 x 50 cm3), the organic extracts were dried (MgSO4) and concentrated under
reduced pressure to give the product 285 (2.480 g, , 14.84 mmol, 72 %) as a white
powder; (Found: C, 57.11; H, 5.36; N, 8.30. C8H9NO3 requires C, 57.48; H, 5.43; N,
8.38 %); νmax 1720 (CO), 1603 (C=C st.), 1568 (C=C st.), 1604 (C=C st.) cm-1; δH
(400 MHz, CDCl3) 8.83 (1H, s, H5), 8.14 (1H, d, J 8.7, H3), 6.76 (1H, d, J 8.7, H2),
4.00 (3H, s, CH3), 3.91 (3H, s, CH3); δC (101 MHz, CDCl3) 167.00 (CO), 150.18
(C1), 143.35 (C5), 139.90 (C3), 119.79 (C4), 110.75 (C2), 54.09 (CH3), 52.17 (CH3);
m/z (ESI) 168.1 (M+ +1).
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Methyl 1-benzyl-6-oxo-1,6-dihydropyridine-3-carboxylate, 286.
This compound has been reported and fully characterised.194 A mixture of benzyl
bromide (4.40 cm3, 6.34 g, 37.05 mmol), methyl 6-methoxynicotinate 285 (3.00 g,
17.96 mmol) and potassium carbonate (4.96 g, 35.89 mmol) in dry acetonitrile (72
cm3) was stirred at 80 °C for 48 h. The mixture was filtered and concentrated under
reduced pressure and purified by column chromatography (ethyl acetate – hexane
1:1) to give product 286 (1.25 g, 5.14 mmol, 29 % yield) as an oil; δH (300 MHz,
CDCl3) 8.18 (1 H, d, J 2.4, H4), 7.83 (1 H, dd, J 9.6, 2.4, H2), 7.40 - 7.29 (5 H, m,
ArH), 6.58 (1 H, d, J 9.6, H1), 5.17 (2 H, s, CH2), 3.83 (3 H, s, CH3); 13C NMR (101
MHz, CDCl3) 164.57 (CO), 162.32 (CO), 142.59 (C4), 138.43 (C2), 135.46 (Ar),
128.96 (Ar), 128.30 (Ar), 128.11 (Ar), 119.93 (C3), 109.87 (C1), 52.66 (CH2Ph),
51.99 (CH3). This data was in agreement with the literature.
1-benzyl-6-oxo-1,6-dihydropyridine-3-carbonyl chloride, 288.
This compound has been reported but not fully characterised.161 Under nitrogen,
potassium carbonate (193 mg, 1.40 mmol) and thionyl chloride (111 µL, 181 mg,
1.52 mmol) were added to a solution of 1-benzyl-6-oxo-1,6-dihydropyridine-3-
carboxylic acid 283 (100 mg, 0.436 mmol) in toluene (4.36 cm3) and the mixture
was heated to 110 °C for 2.5 h. The mixture was allowed to cool before the mixture
was filtered and concentrated under reduced pressure to yield the crude product 288
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(49 mg, 0.198 mmol, 45 %) as a colourless oil; (found (ESI): M+ + H, 248.0471.
C13H1135ClNO2 requires M, 248.0473); νmax 1741 (CO), 1656 (CO), 1617 (C=C st.),
1542 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.30 (1 H, d, J 2.8, H4), 7.72 (1 H, dd, J
9.5, 2.8, H2), 7.19 - 7.32 (5 H, m, ArH), 6.49 (1 H, d, J 9.5, H1), 5.09 (2 H, s, CH2);
δC (101 MHz, CDCl3) 163.64 (CO), 161.90 (CO), 146.86 (C4), 138.15 (C2), 134.71
(Ar), 129.26 (Ar), 128.80 (Ar), 128.39 (Ar), 120.19 (C3), 113.42 (C1), 53.22
(CH2Ph); m/z (ESI) 248.0 (M[35Cl]+ +1), 250.0 (M[37Cl]+ +1).
(6-Methoxypyridin-3-yl)methanol, 276.
This compound has been reported but not fully characterised.195 Under nitrogen, a
suspension of lithium aluminum hydride solution in THF (1M, 6.58 cm3, 6.58 mmol)
in THF (3.39 cm3) was stirred at 0 °C for 5 min. Methyl 6-methoxynicotinate 285
(1.0 g, 5.98 mmol) was added portionwise and the mixture was stirred for 10 m. The
suspension was allowed to warm to room temperature and stirred for 2 h before the
solution was cooled to 0 °C. The suspension was carefully quenched with water
(0.04 cm3), 15 % NaOH (0.04 cm3) followed by water (0.12 cm3). The resulting
precipitate was filtered with celite and washed with ethyl acetate. The filtrate was
concentrated under reduced pressure to give product 276 (0.690 g, 4.96 mmol, 83 %
yield) as an oil; (found (ESI): M+ + H, 140.0711. C7H10NO2 requires M, 140.0706);
νmax 3298 (OH st.), 1608 (CO), 1573 (C=C st.) cm-1; δH (400 MHz, DMSO) 8.07
(1H, s, H5), 7.64 (1H, d, J 8.5, H3), 6.77 (1H, d, J 8.5, H2), 5.11 (1H, t, J 5.6, OH),
4.43 (2H, d, J 5.6, H6), 3.83 (3H, s, CH3); δC (101 MHz, DMSO) 162.70 (C1), 144.99
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(C5), 138.29 (C3), 130.63 (C2), 109.94 (C4), 60.20 (C6), 52.94 (CH3); m/z (ESI) 139.8
(M+ +1).
1-Benzyl-5-(hydroxymethyl)pyridin-2(1H)-one, 277.
This compound has been reported and fully characterised.196 A mixture of benzyl
bromide (0.56 cm3, 0.81 g, 4.71 mmol), 6-methoxypyridin-3-yl)methanol 276 (1.00
g, 7.19 mmol) and potassium carbonate (1.30 g, 9.40 mmol) in dry acetonitrile (17
cm3) was stirred at 60 °C for 18 h. The mixture was filtered, concentrated under
reduced pressure and purified by column chromatography (methanol - ethyl acetate 5
: 95), to give product 277 (0.500 g, 2.32 mmol, 32 % yield) as an oil; δH (300 MHz,
CDCl3) 7.38 - 7.18 (7 H, m, ArH, H4, H1), 6.50 (1 H, d, J 9.2, H2), 5.03 (2 H, s,
CH2), 4.33 (2 H, d, J 5.5, H5), 4.00 - 3.94 (1 H, m, OH); δC (75 MHz, CDCl3) 162.33
(CO), 140.10 (C4), 136.11 (Ar), 135.12 (C2), 128.75 (Ar), 127.95 (Ar), 127.90 (Ar),
120.61 (C1), 120.06 (C3), 61.26 (C5), 52.03 (CH2Ph). The O-benzylation product was
not isolated from the reaction mixture. An nOe 1H NMR experiment supported the
structural assignment: irradiation of the CH2Ph protons (5.03 ppm) resulted in the
excitation of proton H3 only. This data was also in agreement with the literature.
General procedure A - alkene hydrogenation with hydrogen balloons.
Under nitrogen, the alkene (1.00 mmol) was loaded into a round bottomed flask
containing a magnetic stirrer and the specified solvent was added. The heterogeneous
catalyst (at the specified catalytic loading) was carefully added before the flask was
evacuated with hydrogen and a balloon of hydrogen was attached. The solution was
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stirred vigorously for the specified time and temperature before the catalyst was
removed by filtration with celite. Following solvent removal under reduced pressure
the product was obtained, following purified by column chromatography (where
applicable).
General procedure B - alkene hydrogenation in a hydrogenator.
The alkene (1 mmol) and catalyst (at the specified catalytic loading) were added to a
small glass hydrogenation vial. A suba seal was attached and the contents were
flushed with nitrogen for 10 min before the dry solvent (as specified) was added. The
suba seal was removed and the vial was quickly placed into the hydrogenation
apparatus. The hydrogenator was filled with hydrogen to the appropriate pressure
before the pressure was nearly completely released. The hydrogenator was then filled
again with hydrogen and the pressure was released. This fill release cycle carried out
for a total of 3 times to ensure the vessel was sufficiently charged with hydrogen at
the stated pressure. A magnetic stirrer box was placed under the hydrogenator to
enable stirring for the specified time before the hydrogen was carefully released and
the apparatus was disassembled. Following concentration under reduced pressure,
the product was obtained, following purified by column chromatography (where
applicable).
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Methyl 1-benzyl-6-oxopiperidine-3-carboxylate, (±)-294.
This compound has been reported and fully characterised.197 This compound was
prepared following the general procedure for alkene hydrogenation, using methyl 1-
benzyl-6-oxo-1,6-dihydropyridine-3-carboxylate, 277 (100 mg, 0.411 mmol) and
palladium on carbon (5 % w/w, 88 mg, 4.13 x 10-2 mmol) in methanol (1 cm3)
following a reaction time of 1 d, at 40 °C under a balloon of hydrogen. Following
solvent removal and purification by column chromatography (ethyl acetate – hexane
9:1), the product (±)-294 (30 mg, 0.121 mmol, 30 % yield) was obtained as
colourless oil; δH (400 MHz, CDCl3) 7.30 - 7.14 (5 H, m, ArH), 4.62 (1 H, d, J 14.6,
CH2), 4.46 (1 H, d, J 14.6, CH2), 3.59 (3 H, s, CH3), 3.42 - 3.28 (2 H, m, H4), 2.78 -
2.65 (1 H, m, H3), 2.54 (1 H, dt, J 17.8, 5.3, H1A), 2.47 - 2.35 (1 H, m, H1B), 2.13 -
2.02 (1 H, m, H2A), 2.00 - 1.89 (1 H, m, H2B); C (75 MHz, CDCl3) 172.51 (CO),
168.79 (CO), 136.68 (Ar), 128.54 (Ar), 128.06 (Ar), 127.41 (Ar), 52.13 (CH3), 50.08
(CH2Ph), 47.92 (C4), 38.99 (C3), 30.65 (C1), 23.86 (C2); Enantiomeric separation
was achieved by HPLC analysis (Chiralpak IA, 4.6 mm x 250 mm, hexane : IPA 85 :
15, 1 mL/min, T = 30 °C, 13.3 min, 14.9 min.). This sample was used as a racemic
standard in chiral HPLC to confirm the retention times of the enantiomers of the AH
products prepared in the next section.
AH screen of pyridone 285.
The AH catalyst screen of pyridone 285 was carried out using the general procedure
for alkene hydrogenation. Conversions were determined by 1H NMR. Ees were
determined by HPLC analysis using compound (±)-294 as a racemic standard.
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1-Benzyl-6-oxopiperidine-3-carboxylic acid, (±)-293.
This compound has been reported and fully characterised.197 This compound was
prepared following the general procedure for alkene hydrogenation, using 1-benzyl-
6-oxo-1,6-dihydropyridine-3-carboxylic acid, 283 (30 mg, 0.131 mmol) and
palladium on carbon (10 % w/w, 13 mg, 1.22 x 10-2 mmol) in methanol (1 cm3),
following a reaction time of 20 h, at room temperature and 25 bar. Following
concentration under reduced pressure, (±)-293 (30 mg, 0.129 mmol, 98 % yield) was
obtained as a colourless oil. δH (400 MHz, CDCl3) 10.40 (1 H, bs, OH), 7.28 - 7.10
(5 H, m, ArH), 4.68 (1 H, d, J 14.7, CH2), 4.36 (1 H, d, J 14.7, CH2), 3.47 - 3.25 (2
H, m, H4), 2.75 - 2.62 (1 H, m, H3), 2.56 (1 H, dt, J 17.9, 4.5, H1A), 2.42 (1 H, dt, J
17.9, 6.5, H1B), 2.11 - 1.99 (1 H, m, H2A), 1.98 - 1.82 (1 H, m, H2B); δC (101 MHz,
CDCl3) 176.85 (CO), 170.43 (CO), 136.11 (Ar), 128.61 (Ar), 128.06 (Ar), 127.58
(Ar), 50.59 (CH2Ph), 48.05 (C4), 38.83 (C3), 31.48 (C1), 25.52 (C2).
1-Benzyl-6-oxopiperidine-3-carboxylic acid, (±)-292.
1
N
Bn
4
3
2
O
5
OH
( )-292
This compound has been reported and fully characterised.198 This compound was
prepared following the general procedure for alkene hydrogenation, using 1-benzyl-
5-(hydroxymethyl)pyridin-2(1H)-one 277 (30 mg, 0.139 mmol) and platinum oxide
(3 mg, 1.32 x 10-2 mmol) in methanol (1 cm3), following a reaction time of 18 h at
room temperature under 5 bar of hydrogen. Following concentration under reduced
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pressure, (±)-292 (20 mg, 0.091 mmol, 66 % yield) was obtained as an oil; δH (400
MHz, CDCl3) 7.37 - 7.19 (5 H, m, ArH), 4.60 (2 H, s, CH2Ph), 3.64 - 3.54 (1 H, m,
H4A), 3.53 - 3.45 (1 H, m, H4B), 3.32 (1 H, ddd, J 12.1, 5.1, 1.8, H5A), 3.02 (1 H, dd,
J 12.1, 10.0, H5B), 2.57 (1 H, ddd, J 17.8, 6.3, 3.5, H1A), 2.44 (1 H, ddd, J 17.8, 11.1,
6.5, H1B), 2.11 - 1.97 (1 H, m, H3), 1.94 - 1.85 (1 H, m, H2A), 1.53 (1 H, dtd, J 13.1,
11.1, 6.3, H2B). A signal attributable to OH was not observed; δC (75 MHz, CDCl3)
170.00 (CO), 136.93 (Ar), 128.53 (Ar), 127.93 (Ar), 127.33 (Ar), 64.34 (C5), 50.26
(CH2Ph), 49.78 (C4), 36.34 (C3), 31.16 (C1), 23.75 (C2). This data was in agreement
with the literature.
1-benzyl-5-methylpyridin-2(1H)-one, 290.
This compound has been reported and fully characterised.199 A solution of 1-benzyl-
5-(hydroxymethyl)pyridin-2(1H)-one 277 (100 mg, 0.465 mmol) in methanol (1.83
cm3) were hydrogenated in the H-Cube hydrogenation cell using a 30 mm 10% Pd/C
cartridge at room temperature, with a hydrogen pressure of 5 bar and a flow rate of 1
ml/minute. Following one circulation of the alkene solution through the H-Cube, the
solvent was removed to give 1-benzyl-5-methylpyridin-2(1H)-one 290 (75 mg, 0.377
mmol, 81 % yield) as a white waxy solid; δH (400 MHz, CDCl3) 7.21 – 7.38 (5 H, m,
ArH), 7.16 (1 H, dd, J 9.3, 2.3, H4), 7.01 (1 H, d, J 2.3, H1), 6.56 (1 H, d, J 9.3, H2),
5.11 (2 H, s, CH2Ph), 2.02 (3 H, d, J 0.9, H5); δC (101 MHz, CDCl3) 161.70 (CO),
141.80 (C4), 136.48 (Ar), 134.35 (C2), 128.57 (Ar), 127.79 (Ar), 127.63 (Ar), 120.58
(C1), 114.92 (C3), 51.45 (CH2Ph), 16.83 (C5).
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1-benzyl-5-methylpiperidin-2-one, (±)-291.
This compound was prepared following the general procedure for alkene
hydrogenation, using 1-benzyl-5-(hydroxymethyl)pyridin-2(1H)-one 277 (30 mg,
0.139 mmol) and palladium on barium sulfate (5 % w/w, 30 mg, 1.41 x 10-2 mmol)
in methanol (1 cm3), following a reaction time of 18 h at room temperature and 5 bar
of hydrogen. Following concentration under reduced pressure and purification by
column chromatography (ethyl acetate – hexane 8:2), (±)-291 (20 mg, 0.098 mmol,
71 % yield) was obtained as an oil; (found (ESI): M+ + Na, 226.1203. C13H17NNaO
requires M, 226.1202); νmax 1619 (C=O st.) cm-1; δH (400 MHz, CDCl3) 7.22 - 7.36
(5 H, m, ArH), 4.67 (1 H, d, J 14.6, CH2), 4.50 (1 H, d, J 14.6, CH2), 3.16 (1 H, ddd,
J 12.0, 5.1, 2.0, H4A), 2.83 (1 H, dd, J 12.0, 10.4, H4B), 2.55 (1 H, ddd, J 17.7, 6.0,
3.0, H1A), 2.44 (1 H, ddd, J 17.7, 11.5, 6.3, H1B), 1.88 - 1.99 (1 H, m, H3), 1.84 (1 H,
dddd, J 13.2, 6.3, 3.0, 2.0, H2A), 1.47 (1 H, dtd, J 13.2, 11.5, 6.0, H2B), 0.95 (3 H, d,
J 6.5, H5) δC (100 MHz, CDCl3) 169.78 (CO), 137.27 (Ar), 129.02 (Ar), 128.58 (Ar),
127.33 (Ar), 60.27 (CH2Ph), 54.17 (C4), 31.72 (C1), 29.49 (C2), 29.02 (C3), 18.55
(C5); m/z (ESI) 203.8 (M+ +1). The 1H NMR spectrum of this sample is shown in
Appendix I.
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Section 3.4: Procedures from Section 2.4.
Section 3.4.1: Reduction of Imide 228.
This method was used to form the product 6 from an optically pure sample of imide
228. Under nitrogen, LDA (1M solution in THF, 0.72 cm3, 0.720 mmol) was added
to a solution of 1-benzyl-3-((2-oxopiperidin-1-yl)methyl)piperidine-2,6-dione (R)-
228 (95 % ee, 15 mg, 4.84 x 10-2 mmol) in THF (0.17 cm3) and the solution was
stirred at room temperature for 24 h before water (14 µL) was added, followed by 15
% aqueous NaOH (14 µL), and water (42 µL). The resulting precipitate was filtered
and the resulting filtrate was concentrated under reduced pressure to give a sample
containing product 6 (10 mg, 3.67 x 10-2 mmol, 76 %), as determined by 1H NMR.
Full characterisation data for 6 is given in the next section. The ee of this sample
could not be determined by chiral GC or HPLC.
Section 3.4.2: Synthesis and AH of Pyridone 3.
5-Bromomethyl-2-methoxypyridine, 296a.
This compound has been reported but not fully characterised.200 Under nitrogen,
phosphorus tribromide (68 μL, 196 mg, 0.723 mmol) was added to a solution of (6-
methoxy-pyridin-3-yl)methanol 276 (50 mg, 0.360 mmol) in dry toluene (0.83 cm3)
and the solution was stirred at room temperature for 1 h before water (5 cm3) was
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added. Following extraction with toluene (2 x 5 cm3) the organic extracts were
concentrated under reduced pressure to give the product 296a (50 mg, 0.248 mmol,
69 % yield) as an oil; (found (ESI): M+ + H, 201.9865. C7H979BrNO requires M,
201.9862); νmax 3019 (aryl CH st.), 1658 (C=C st.), 1585 (C=C st.), 1537 (C=C st.)
cm-1; δH (400 MHz, DMSO) 8.25 (1 H, d, J 2.4, H5), 7.78 (1 H, dd, J 8.6, 2.4, H3),
6.83 (1 H, d, J 8.6, H2), 4.71 (2 H, s, H6), 3.85 (3 H, s, CH3); δC (100 MHz, CDCl3)
162.05 (C1), 145.41 (C5), 140.96 (C3), 126.98 (C2), 111.68 (C4), 54.69 (CH3), 29.74
(C6); m/z (ESI) 202.0 (M[79Br]+ +1), 204.0 (M[81Br]++1).
5-Chloromethyl-2-methoxypyridine, 296b.
This compound has been reported and fully characterised.201 Under nitrogen, thionyl
chloride (2.05 cm3, 3.34 g, 28.09 mmol) was added to a solution of (6-methoxy-
pyridin-3-yl)methanol 276 (3.56 g, 25.60 mmol) in dry toluene (10.6 cm3) and the
solution was stirred at room temperature for 1 h before NaOH (2M, 10 cm3) was
added. The solution was stirred for 10 min before extraction with toluene (2 x 20
cm3). The organic extracts were washed (water) and concentrated under reduced
pressure to give the product 296b (3.85 g, 24.52 mmol, 96 % yield) as an oil; δH (400
MHz, CDCl3) 8.15 (1 H, d, J 2.7, H5), 7.62 (1 H, dd, J 8.5, 2.7, H2), 6.75 (1 H, d, J
8.5, H1), 4.55 (2 H, s, H6), 3.94 (3 H, s, CH3); δC (101 MHz, CDCl3) 163.56 (C1),
146.66 (C5), 139.16 (C3), 126.12 (C2), 111.25 (C4), 53.57 (CH3), 43.34 (C6). This
data is in agreement with the literature.
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1-((6-methoxypyridin-3-yl)methyl)pyridin-2(1H)-one 295 and 2-methoxy-5-((pyridin-
2-yloxy)methyl)pyridine, 297.
Under nitrogen, a mixture of 5-chloromethyl-2-methoxypyridine 296b (0.342 g, 2.18
mmol), 2-hydroxypyridine (0.413 g, 4.34 mmol) and potassium carbonate (0.601 g,
4.35 mmol) in toluene (22 cm3) was stirred at 115 °C for 1 d, before the solution was
allowed to cool. Following filtration, the filtrate was concentrated under reduced
pressure and purified by column chromatography (ethyl acetate), to give the O-
substituted product 297 (58 mg, 0.268 mmol, 12 % yield) as a colourless oil; (found
(ESI): M+ + H, 216.0891. C12H12N2O2 requires M, 216.0899); νmax 1610 (C=O st.),
1596 (C=C st.), 1571 (C=C st.), 1495 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.27 (1
H, d, J 2.3, H7), 8.17 (1 H, d, J 7.8, H5), 7.70 (1 H, dd, J 8.5, 2.5, H3), 7.55 – 7.60 (1
H, m, H9), 6.88 (1 H, t, J 6.0, H8), 6.76 (2 H, m, H2, H10), 5.31 (2 H, s, H6), 3.94 (3
H, s, CH3); δC (176 MHz, CDCl3) 164.00 (C11), 163.36 (C1), 147.04 (C5), 146.56
(C7), 139.20 (C10), 138.56 (C2), 125.60 (C3), 117.28 (C9), 111.36 (C4), 111.04 (C8),
64.96 (C6), 53.60 (CH3); m/z (ESI) 215.97 (M+ +1).
Increasing the polarity of the eluent (methanol – ethyl acetate 5:95) gave the N-
substituted product, 295 (0.299 g, 1.384 mmol, 63 % yield) as a colourless oil;
(found (ESI): M+, 216.0887. C12H12N2O2 requires M, 216.0899); νmax 3018 (aryl CH
st.), 1657 (C=O st.), 1587 (C=C st.), 1568 (C=C st.), 1490 (C=C st.) cm-1; δH (400
MHz, CDCl3) 8.14 (1 H, d, J 2.5, H5), 7.63 (1 H, dd, J 8.7, 2.5, H2), 7.34 - 7.25 (2 H,
m, H8, H10), 6.72 (1 H, d, J 8.7, H3), 6.60 (1 H, dd, J 9.2, 1.2, H7), 6.15 (1 H, td, J
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6.8, 1.5, H9), 5.06 (2 H, s, H6), 3.92 (3 H, s, CH3); δC (101 MHz, DMSO-d6) 163.09
(CO), 161.38 (C1), 146.65 (C5), 140.09 (C3), 139.24 (C10), 138.80 (C8), 126.10 (C4),
119.83 (C7), 110.44 (C2), 105.62 (C9), 53.14 (C6), 48.36 (CH3); m/z (ESI) 215.97
(M+ +1).
1-Benzyl-5-[(2-oxopyridin-1(2H)-yl)methyl]pyridin-2(1H)-one, 3.
Under nitrogen, a mixture of benzyl bromide (1.60 cm3, 2.30 cm3, 13.53 mmol), 1-
((6-methoxypyridin-3-yl)methyl)pyridin-2(1H)-one, 295 (1.45 g, 6.71 mmol) and
potassium carbonate (1.85 g, 13.39 mmol) in dry acetonitrile (27 cm3) was stirred at
80 °C for 24 h before the solution was allowed to cool. Following filtration, the
resulting filtrate was concentrated under reduced pressure and recrystallised
(ethanol), to give product 3 (1.00 g, 3.42 mmol, 51 % yield) as a white powder; 140-
142 °C; (found (ESI): M+ + Na, 315.1102. C18H16N2NaO2 requires M, 315.1104);
νmax 3034 (aryl CH st.), 1714 (C=O st.), 1666 (C=O st.), 1649 (C=C st.), 1595 (C=C
st.), 1568 (C=C st.), 1493 (C=C st.) cm-1; δH (400 MHz, CDCl3) 7.45 (1 H, d, J 2.5,
H3), 7.37 - 7.27 (7 H, m, ArH, H6, H2), 7.23 (1 H, dd, J 6.8, 2.0, H8), 6.58 (2 H, d, J
9.3, H1, H5), 6.16 (1 H, td, J 6.8, 1.4, H7), 5.12 (2 H, s, CH2), 4.78 (2 H, s, CH2); δC
(101 MHz, CDCl3) 162.41 (CO), 161.83 (CO), 139.93 (C9), 139.70 (C4), 137.53
(C7), 136.57 (C2), 135.93 (Ar), 128.72 (Ar), 127.91 (Ar), 127.85 (Ar), 121.16 (C6),
121.07 (C1), 114.51 (C3), 106.58 (C8), 52.02 (C5), 49.17 (CH2Ph); m/z (ESI) 293.1
(M+ +1), 315.1 (M+ + 23). Further recrystallisation (EtOH) provided crystals of
sufficient quality for X-diffraction, enabling confirmation of the structure. Full
details are shown in Appendix II.
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1-((1-Benzyl-6-oxopiperidin-3-yl)methyl)piperidin-2-one, (±)-235.
This compound was prepared following the general procedure for alkene
hydrogenation, using 1-benzyl-5-[(2-oxopyridin-1(2H)-yl)methyl]pyridin-2(1H)-one,
3 (0.644 g, 2.20 mmol) and platinum oxide (25 mg, 0.110 mmol) following a
reaction time of 20 h, at 30 °C. Following concentration under reduced pressure and
purification by column chromatography (ethyl acetate – methanol 95:5), product (±)-
235 (497 mg, 1.66 mmol, 75 % yield) was obtained as an oil, Full characterisation
data was listed in Section 1.
AH screen of 1-benzyl-5-[(2-oxopyridin-1(2H)-yl)methyl]-pyridin-2(1H)-one, 6.
The AH catalyst screen of 1-benzyl-5-[(2-oxopyridin-1(2H)-yl)methyl]pyridin-
2(1H)-one 3 was carried out using the general procedure (B) for alkene
hydrogenation. Conversions were determined by 1H NMR. Ees were determined by
HPLC analysis using compound (±)-235 as a racemic standard.
Section 3.4.3: Synthesis of (1-Benzyl-3-(piperidin-1-ylmethyl)piperidine) 6.
1-Benzyl-3-(piperidin-1-ylmethyl)piperidine, (±)-6.
Under nitrogen, triethyl-silane (1.41 cm3, 8.79 mmol) was added to a solution of 1-
((1-benzyl-6-oxopiperidin-3-yl)methyl)piperidin-2-one, (±)-235 (377 mg, 1.256
mmol) and triruthenium dodecacarbonyl (16 mg, 2.50 x 10-2 mmol) in dry toluene
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(2.5 cm3) and the mixture was stirred at 100 °C for 18 h. The solution was
concentrated under reduced pressure and purified by column chromatography (ethyl
acetate – hexane – triethylamine 10:90:1) to give product (±)-6 (194 mg, 0.713
mmol, 57 % yield) as a colourless oil; (found (ESI): M+ + H, 273.2323. C18H29N2
requires M, 273.2325); νmax 2928 (alkyl CH st.), 2849 (alkyl CH st.), 2793 (alkyl CH
st.), 2754 (alkyl CH st.) cm-1; δH (700 MHz, CDCl3) 7.33 - 7.20 (5 H, m, ArH), 3.57
(1 H, d, J 13.2, CH2), 3.40 (1 H, d, J 13.2, CH2), 2.90 (1 H, d, J 10.1, H5A), 2.76 (1
H, d, J 10.5, H1A), 2.37 - 2.21 (4 H, m, H7), 2.13 - 2.06 (2 H, m, H6), 1.89 (1 H, m,
H1B), 1.87 - 1.81 (1 H, m, H4), 1.74 (1 H, dq, J 13.0, 3.4, H3A), 1.71 - 1.65 (1 H, m,
H5B), 1.62 (1 H, dquin, J 13.0, 3.4, H2A), 1.58 - 1.48 (5 H, m, H8, H2B), 1.43 - 1.36 (2
H, m, H9), 0.89 (1 H, qd, J 13.0, 3.4, H3B); δC (75 MHz, CDCl3) 136.62 (Ar), 129.20
(Ar), 128.06 (Ar), 126.80 (Ar), 63.76 (CH2Ph), 63.60 (C6), 59.36 (C5), 55.08 (C1),
54.10 (C7), 33.63 (C4), 29.77 (C3), 25.89 (C8), 25.14 (C2), 24.50 (C9); m/z (ESI)
273.0 (M+ +1). The assignments of these proton signals were supported by 13C
HMQC and COSY correlation NMR experiments. These can be found in Appendix
I.
1-(Piperidin-3-ylmethyl)piperidine, (±)-298.
This compound was prepared following the general procedure for alkene
hydrogenation, using 1-benzyl-3-(piperidin-1-ylmethyl)piperidine (±)-6 (22 mg,
0.081 mmol) and palladium hydroxide on carbon (20 % w/w, 6 mg, 8.55 x 10-3
mmol) following a reaction time of 18 h, at room temperature. Following filtration
with celite, the resulting filtrate was passed through an Isolute-XL SCX amine
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scavenger resin and the resin was washed with DCM (3 x 1 cm3). The free amine
was liberated by passing a solution of approx. 2 % NH4OH in methanol through the
resin, followed by washing with DCM (3 x 1 cm3). Following concentration under
reduced pressure, product (±)-298 (20 mg, 0.110 mmol) was obtained as a colourless
oil; (found (ESI): M+ + H, 183.1857. C11H23N2 requires M, 183.1856); νmax 3400
(NH st.), 2927 (alkyl CH st.), 2848 (alkyl CH st.), 2795 (alkyl CH st.), 2758 (alkyl
CH st.) cm-1; δH (700 MHz, CDCl3) 3.14 (1 H, dd, J 11.9, 1.5, H1A), 3.01 (1 H, d, J
11.9, H5A), 2.54 (1 H, td, J 11.8, 2.8, H5B), 2.19 - 2.43 (5 H, m, H7, H1B), 2.09 (1 H,
dd, J 12.3, 8.1, H6A), 2.05 (1 H, dd, J 12.3, 6.2, H6B), 1.81 (1 H, dq, J 12.7, 3.5, H3A),
1.67 - 1.73 (1 H, m, H4), 1.64 (1 H, dquin, J 12.8, 3.5, H2A), 1.54 (4 H, quin, J 6.4,
H8), 1.46 (1 H, qt, J 12.8, 3.5, H2B), 1.42 - 1.37 (2 H, m, H9), 1.01 (1 H, qd, J 12.8,
3.5, H3B); δC (101 MHz, CDCl3) 63.88 (C6), 55.17 (C7), 51.96 (C1), 47.21 (C5), 34.61
(C4), 30.34 (C3), 26.39 (C8), 26.03 (C2), 24.55 (C9); m/z (ESI) 182.9 (M+ +1).
Section 3.4.4: Synthesis and Hydrogenation of Enamide 301.
(3E)-1-Benzyl-3-(pyrrolidin-1-ylmethylidene)piperidine-2,6-dione 301.
Under nitrogen, (1-benzyl-2,6-dioxopiperidin-3-ylidene)methyl-4-methyl-benzene
sulfonate 219 (0.46 g, 1.19 mmol) was added to a solution of pyrrolidine (0.20 cm3,
0.170 g, 2.40 mmol) and NEt3 (0.41 cm3, 0.298 g, 2.94 mmol) in dry toluene (14.0
cm3) and the mixture stirred at 125 ⁰C for 8 h. The mixture was concentrated under
reduced pressure and purified by column chromatography (hexane - ethyl acetate
220
1:9), to give the product 301 (0.119 g, 0.419 mmol, 35 %) as an oil; (found (ESI):
M+ + Na, 307.1410. C17H20N2NaO2 requires M, 307.1417); νmax 3020 (aryl CH st.),
1716 (C=O st.), 1668 (C=O st.), 1608(C=C st.) cm-1; δH (400 MHz, CDCl3) 7.64 (1
H, s, H3), 7.33-7.08 (5 H, m, ArH), 4.94 (2 H, s, CH2), 3.50-3.40 (4 H, m, H4), 2.72
(2 H, t, J 7.2, H1), 2.52 (2 H, t, J 7.2, H2), 1.88-1.77 (4 H, m, H5); δC (101 MHz,
CDCl3) 172.68 (CO), 168.92 (CO), 146.75 (C4), 138.55 (Ar), 128.37 (Ar), 128.20
(Ar), 126.82 (Ar), 92.99 (C3), 51.70 (CH2Ph), 42.93 (C5), 33.03 (C1), 25.37 (C2),
19.25 (C6); m/z (ESI) 307.1 (M+ + 23).
Section 3.5: Procedures from Section 5.
Section 3.5.1: Synthesis of Ketones.
N,6-Dimethoxy-N-methylpyridine-3-carboxamide, 305
Under nitrogen, a solution of methyl 6-methoxynicotinate 285 (3.00 g, 17.96 mmol)
and N,O-dimethylhydroxylamine hydrochloride (5.36 g, 54.95 mmol) in THF (40
cm3) was stirred at – 40 °C for 10 min. Isopropyl magnesium chloride (2 M solution
in THF, 26 cm3, 52.00 mmol) was added dropwise over 15 min and the reaction was
stirred at – 40 °C for 90 min before aqueous acetic acid (20 %, 20 cm3) was added.
This solution was extracted with diethyl ether (3 x 20 cm3) and the organic extracts
were set aside. The remaining aqueous phase was then basified with saturated
aqueous sodium hydrocarbonate and extracted with DCM (2 x 10 cm3). The
combined organic extracts were dried (MgSO4), concentrated under reduced pressure
and purified by column chromatography (petroleum ether – ethyl acetate 9:1), to
give the product 305 (2.38 g, 12.14 mmol, 68 % yield) as a colourless oil; (found
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(ESI): M + Na, 219.0740. C9H12N2NaO3 requires M, 219.0740); νmax 1635 (C=O st.),
1600 (C=C st.), 1566 (C=C st.), 1495 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.65 (1
H, d, J 2.5, H5), 7.99 (1 H, dd, J 8.7, 2.5, H3), 6.76 (1 H, d, J 8.7, H2), 3.99 (3 H, s,
CH3), 3.58 (3 H, s, CH3), 3.38 (3 H, s, CH3); δC (75 MHz, CDCl3) 167.29 (CO),
165.28 (C1), 148.24 (C5), 139.32 (C3), 122.73 (C4), 110.14 (C2), 61.00 (CH3), 53.71
(CH3), 33.29 (CH3); m/z (ESI) 196.8 (M+ + 1).
1-(6-Methoxypyridin-3-yl)ethanone, 4.
This compound has been reported but not fully characterised.202 Under nitrogen, a
solution of N,6-dimethoxy-N-methylpyridine-3-carboxamide 305 (3.66 g, 18.67
mmol) in THF (64 cm3) was stirred at 0 °C for 15 m. Methyl magnesium bromide
(3M solution in THF, 6.42 cm3, 19.26 mmol) was added dropwise over 5 min and
the solution was stirred at 0 °C for 1 h. The solution was allowed to warm to room
temperature and stirred for 1 d before the solution was concentrated under reduced
pressure and HCl (2 M, 10 cm3) was added. Following extraction with diethyl ether
(3 x 30 cm3), the organic extracts were washed with brine, dried (MgSO4),
concentrated under reduced pressure and purified by column chromatography
(petroleum ether – ethyl acetate 2:8), to give product 4 (1.73 g, 11.48 mmol, 61 %
yield) as a colourless solid; Mp 60 – 64 °C; (found (ESI): M+ + Na, 174.0525.
C8H9NNaO2 requires M, 174.0525); νmax 1671 (C=O st.), 1597 (C=C st.), 1562 (C=C
st.), 1494 (C=C st.) cm-1; δH (300 MHz, CDCl3) 8.78 (1 H, dd, J 2.5, 0.6, H6), 8.14 (1
H, dd, J 8.8, 2.5, H4), 6.79 (1 H, dd, J 8.8, 0.6, H3), 4.01 (3 H, s, H1), 2.71 - 2.55 (3
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H, s, H7); δC (101 MHz, CDCl3) 195.64 (CO), 166.76 (C2), 149.39 (C6), 138.13 (C4),
126.96 (C5), 111.12 (C3), 54.03 (C1), 26.32 (C7); m/z (ESI) 152.1 (M+ +1).
5-Acetyl-1-benzylpyridin-2(1H)-one, 309.
This compound has been reported but not fully characterised.203 A mixture of benzyl
bromide (0.43 cm3, 0.62 g, 3.62 mmol), 1-(6-methoxypyridin-3-yl)ethanone 4 (0.500
g, 3.31 mmol) and potassium carbonate (0.914 g, 6.61 mmol) in dry acetonitrile (17
cm3) was stirred at 80 °C for 2 d before the mixture was allowed to cool to room
temperature. Following filtration, concentration under reduced pressure and
purification by column chromatography (ethyl acetate - hexane 8:2), the product 309
(0.395 g, 1.74 mmol, 48 % yield) was obtained as a colourless oil; (found (ESI): M+
+ Na, 250.0837. C14H13NNaO2 requires M, 250.0838); νmax 3063 (aryl CH st.), 1640
(C=O st.), 1542 (C=C st.), 1496 (C=C st.) cm-1; δH (300 MHz, CDCl3) 8.10 (1 H, d, J
2.5, H4), 7.85 (1 H, dd, J 9.6, 2.5, H3), 7.42 - 7.25 (5 H, m, ArH), 6.60 (1 H, d, J 9.6,
H1), 5.19 (2 H, s, CH2), 2.39 (3 H, s, H5); δC (75 MHz, CDCl3) 193.01 (CO), 162.25
(CO), 142.05 (C4), 137.56 (C2), 135.31 (Ar), 129.07 (Ar), 128.45 (Ar), 128.14 (Ar),
120.11 (C3), 117.98 (C1), 52.71 (CH2Ph), 25.69 (C5); m/z (ESI) 227.8 (M+ +1), 249.8
(M++ 23). Insufficient literature characterisation data was reported for comparison.
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5-Acetyl-1-benzylpiperidin-2-one, (±)-310.
This compound has been reported and fully characterised.197 This compound was
prepared following the general procedure for alkene hydrogenation, using 5-acetyl-1-
benzylpyridin-2(1H)-one, 309 (260 mg, 1.14 mmol) and palladium on carbon (10 %
w/w, 61 mg, 5.73 x 10-2 mmol) following a reaction time of 36 h, at room
temperature. Following concentration under reduced pressure and purification by
column chromatography (ethyl acetate – hexane 9:1), product (±)-310 (23 mg, 0.010
mmol, 9 % yield) was obtained as a colourless oil; δH (400 MHz, CDCl3) 7.23 - 7.35
(5 H, m, ArH), 4.74 (1 H, d, J 14.6, CH2), 4.47 (1 H, d, J 14.6, CH2), 3.43 (1 H, dd, J
12.4, 9.5, H4A), 3.30 (1 H, ddd, J 12.4, 5.6, 1.5, H4B), 2.80 (1 H, tdd, J 9.5, 5.6, 3.5,
H3), 2.59 (1 H, ddd, J 17.8, 5.8, 4.5, H1A), 2.50 (1 H, ddd, J 17.8, 10.0, 6.0, H1B),
2.16 (3 H, s, H5), 1.82 - 1.94 (2 H, m, H2); δC (75 MHz, CDCl3) 206.79 (CO), 168.19
(CO), 136.16 (Ar), 127.95 (Ar), 127.56 (Ar), 126.93 (Ar), 49.59 (CH2Ph), 46.66
(C4), 46.08 (C3), 34.17 (C5), 30.47 (C1), 23.30 (C2).
(6-Methoxypyridin-3-yl)(phenyl)methanone, 319.
This compound has been reported but not fully characterised.204 Under nitrogen, a
solution of N,6-dimethoxy-N-methylpyridine-3-carboxamide, 305 (100 mg, 0.510
mmol) in THF (0.96 cm3) was cooled to 0 °C and left stirring for 5 min. Phenyl
magnesium bromide (1M solution in THF, 0.79 cm3, 0.79 mmol) was added
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dropwise over 5 min and the solution was stirred at 0 °C for the 3 h before the
solution was concentrated under reduced pressure and HCl (2 M, 5 cm3) was added.
Following extraction with DCM (3 x 5 cm3), the organic extracts were dried
(MgSO4), concentrated under reduced pressure and purified by column
chromatography (petroleum ether – ethyl acetate 9:1), to give product 319 (60 mg,
0.282 mmol, 55 % yield) as an oil; (found (ESI): M+ + H, 214.0860. C13H12NO2
requires M, 214.0863); νmax 1651 (CO), 1592 (C=C st.), 1492 (C=C st.) cm-1; δH
(400 MHz, CDCl3) 8.62 (1 H, d, J 2.4, H5), 8.10 (1 H, dd, J 8.9, 2.4, H3), 7.83 - 7.73
(2 H, m, H7), 7.63 - 7.56 (1 H, m, H9), 7.54 - 7.43 (2 H, m, H8), 6.85 (1 H, d, J 8.9,
H2), 4.03 (3 H, s, CH3); δC (101 MHz, CDCl3) 193.63 (CO), 166.50 (C1), 150.79
(C5), 140.00 (C3), 137.50 (C6), 129.68 (C7), 128.41 (C8), 126.90 (C9), 126.50 (C4),
111.01 (C2), 54.04 (CH3); m/z (ESI) 214.1 (M+ +1).
Cyclohexyl(6-methoxypyridin-3-yl)methanone, 318.
Under nitrogen, cyclohexyl magnesium bromide (1 M solution in Et2O, 1.5 cm3, 1.5
mmol) was added to a solution of N,6-dimethoxy-N-methylpyridine-3-carboxamide,
305 (200 mg, 1.02 mmol) in THF (1.9 cm3) and the solution was stirred at room
temperature for 5 min. The solution was stirred at 70 °C for 2.5 h, before the solution
was concentrated under reduced pressure and HCl (2 M, 5 cm3) was added.
Following extraction with DCM (5 x 10 cm3), the organic extracts were washed with
brine (10 cm3), dried (MgSO4) and concentrated under reduced pressure and purified
by column chromatography (petroleum ether – ethyl acetate 1:9), to give product 318
(51 mg, 0.233 mmol, 23 % yield) as an oil; (found (ESI): M+ + H, 220.1331.
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C13H18NO2 requires M, 220.1332); νmax 2926 (alkyl CH st.), 2853 (alkyl CH st.),
1677 (C=O st.), 1600 (C=C st.), 1565 (C=C st.), 1494 (C=C st.) cm-1; δH (400 MHz,
CDCl3) 8.79 (1 H, d, J 2.2, H5), 8.14 (1 H, dd, J 8.8, 2.2, H3), 6.79 (1 H, d, J 8.8,
H2), 4.01 (3 H, s, CH3), 3.16 (1 H, tt, J 11.3, 3.3, H6), 1.94 - 1.79 (4 H, m, H7), 1.60 -
1.18 (6 H, m, H8-9); δC (101 MHz, CDCl3) 201.46 (CO), 166.51 (C1), 148.90 (C5),
138.52 (C3), 125.72 (C4), 111.13 (C2), 53.94 (CH3), 45.71 (C6), 33.32 (C7), 29.33
(C8), 25.85 (C9); m/z (ESI) 219.9 (M+ +1).
1-(4-Methoxyphenyl)pentan-1-one, 316.
Under nitrogen, n-butyl magnesium bromide (2 M solution in THF, 0.77 cm3, 1.54
mmol) was added to a solution of N,6-dimethoxy-N-methylpyridine-3-carboxamide,
305 (200 mg, 1.02 mmol) in THF (1.15 cm3) and the solution was stirred at room
temperature for 18 h before HCl (2 M, 3 cm3) was added. Following extraction with
DCM (3 x 5 cm3), the organic extracts were washed with brine (5 cm3), dried
(MgSO4), concentrated under reduced pressure and purified by column
chromatography (petroleum ether – ethyl acetate 1:9), to give product 316 (107 mg,
0.554 mmol, 54 % yield) as a colourless oil; (found (ESI): M+ + H, 194.1172.
C11H16NO2 requires M, 194.1176); νmax 2955 (alkyl CH st.), 2872 (alkyl CH st.),
1678 (C=O st.), 1593 (C=C st.), 1562 (C=C st.), 1493 (C=C st.) cm-1; δH (400 MHz,
CDCl3) 8.79 (1 H, d, J 2.4, H3), 8.14 (1 H, dd, J 8.7, 2.4, H1), 6.79 (1 H, d, J 8.7,
H2), 4.00 (3 H, s, H8), 2.91 (2 H, t, J 7.7, H4), 1.72 (2 H, quin, J 7.7, H5), 1.40 (2 H,
sxt, J 7.7, H6), 0.96 (3 H, t, J 7.7, H7); δC (101 MHz, CDCl3) 198.22 (CO), 166.59
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(C2), 148.90 (C6), 138.12 (C4), 126.73 (C5), 111.06 (C3), 53.96 (C1), 38.15 (C7),
26.45 (C8), 22.43 (C9), 13.85 (C10); m/z (ESI) 193.9 (M+ +1).
1-(6-Methoxypyridin-3-yl)-2-methylpropan-1-one, 317.
Under nitrogen, isopropyl magnesium bromide (2 M solution in THF, 0.77 cm3, 1.54
mmol) was added to a solution of N,6-dimethoxy-N-methylpyridine-3-carboxamide,
305 (200 mg, 1.02 mmol) in THF (1.53 cm3) and the solution was stirred at room
temperature for 18 h before the solution was concentrated under reduced pressure
and HCl (2 M, 5 cm3) was added. Following extraction with DCM (5 x 10 cm3), the
organic extracts were washed with brine (5 cm3), dried (MgSO4), concentrated under
reduced pressure and purified by column chromatography (petroleum ether – ethyl
acetate 15:85), to give ketone 317 (30 mg, 0.168 mmol, 16 % yield) as an oil; (found
(ESI): M+ + H, 180.1017. C10H14NO2 requires M, 180.1019); νmax 2973 (alkyl CH
st.), 2944 (alkyl CH st.), 1679 (C=O st.), 1601 (C=C st.), 1562 (C=C st.), 1493 (C=C
st.) cm-1; δH (400 MHz, CDCl3) 8.80 (1 H, d, J 2.5, H6), 8.15 (1 H, dd, J 8.8, 2.5,
H3), 6.80 (1 H, d, J 8.8, H4), 4.02 (3 H, s, H1), 3.46 (1 H, spt, J 7.0, H7), 1.22 (6 H, d,
J 7.0, H8); δC (75 MHz, CDCl3) 202.18 (CO), 166.59 (C2), 148.98 (C6), 138.60 (C4),
125.66 (C5), 111.21 (C3), 54.00 (C1), 35.43 (C7), 19.06 (C8); m/z (ESI) 180.1 (M+
+1).
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3-Chloro-1-(6-methoxypyridin-3-yl)prop-2-en-1-one, 320.
Under nitrogen, ethynyl magnesium bromide (0.5 M solution in THF, 1.53 cm3,
0.765 mmol) was added to N,6-dimethoxy-N-methylpyridine-3-carboxamide, 305
(100 mg, 0.510 mmol) and the solution was stirred at room temperature for 5 min.
The solution was stirred at 70 °C for 1 h before the solution was concentrated under
reduced pressure and HCl (2 M, 5 cm3) was added. Following extraction with DCM
(3 x 5 cm3), the organic extracts were washed with brine (10 cm3), dried (MgSO4),
concentrated under reduced pressure and purified by column chromatography
(petroleum ether – ethyl acetate 9:1), to give the isomers (Z/E = 2.7:1, as determined
by 1H NMR of the crude reaction mixture) (E)-320 (21 mg, 0.107 mmol, 21 %) and
(Z)-320 (32 mg, 0.162 mmol, 32 %) as a colourless solids; (E)-320: Mp 82-84 °C;
(found (ESI): M+ + Na, 220.0136. C9H835ClNNaO2 requires M, 220.0136); νmax 3075
(alkene CH st.), 1652 (C=O st.), 1608 (C=C st.), 1581 (C=C st.), 1504 (C=C st.),
1497 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.69 (1 H, d, J 2.5, H5), 8.07 (1 H, dd, J
8.6, 2.5, H3), 7.41 (1 H, d, J 13.3, H7), 7.19 (1 H, d, J 13.3, H6), 6.75 (1 H, d, J 8.6,
H2), 3.95 (3 H, s, CH3); δC (101 MHz, CDCl3) 185.57 (CO), 167.04 (C1), 149.43
(C5), 138.52 (C3), 138.24 (C7), 127.81 (C6), 126.47 (C4), 111.54 (C2), 54.16 (CH3);
m/z (ESI) 197.8 (M[35Cl]+ +1), 199.8 (M[37Cl]+ + 1). (Z)-320: Mp 120-122 °C;
(found (ESI): M+ + Na, 220.0144. C9H835ClNNaO2 requires M, 220.0136); νmax 3069
(alkene CH st.), 1658 (C=O st.), 1603 (C=C st.), 1580 (C=C st.), 1564 (C=C st.),
1498 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.75 (1 H, d, J 2.5, H3), 8.16 (1 H, dd, J
8.8, 2.5, H2), 6.93 (1 H, d, J 8.3, H5), 6.82 (1 H, d, J 8.8, H1), 6.77 (1 H, d, J 8.3, H4),
4.02 (3 H, s, CH3); δC (75 MHz, CDCl3) 187.25 (CO), 166.98 (C1), 149.92 (C5),
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138.46 (C3), 129.21 (C7), 126.73 (C4), 125.84 (C6), 111.47 (C2), 54.20 (CH3); m/z
(ESI) 197.7 (M[35Cl]+ +1), 199.8 (M[35Cl]+ + 1).
Section 3.5.2: ATH of Ketones.
General procedure for the ATH of ketones.
All ketones in the following section were asymmetrically reduced using the
following general procedure: Under nitrogen, FA/TEA (5:2, concentration w/r to
ketone as specified) was added to a mixture of the ketone (1 mmol) and [Ru(teth-
TsDPEN)Cl] (1 mol %). The solution was left stirring at 45 °C for the specified time
before the product was obtained, following removal of the catalyst (the reaction
mixture directly through a plug of silica gel using ethyl acetate - petroleum ether
(1:1) as eluent). Conversion was primarily determined by 1H NMR. Ee was
determined by chiral GC or HPLC via direct analysis, or alternatively indirectly via
acetate derivatisation of the product.
General procedure for the preparation of acetate derivatives.
All acetate derivatives of alcohols obtained from asymmetric ketone reduction, and
of alcohols used as racemic standards were prepared using the following general
procedure, for subsequent chiral analysis by GC or HPLC. A solution of acetic
anhydride (1 drop), the alcohol (10 mg) and DMAP (1 mg) in DCM (1 cm3) was
stirred at room temperature for 18 h. Following concentration under reduced pressure
and purification by column chromatography, the product was obtained. The product
was used directly in subsequent GC or HPLC analysis.
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General procedure for the formation of racemic standards: reduction of ketones with
NaBH4.
Racemic standards for the determination of the ee of asymmetrically reduced ketones
were prepared (unless otherwise specified) via reduction with NaBH4, using the
following procedure: Under nitrogen, NaBH4 (1.1 mmol) was added to a solution of
the ketone (1 mmol) in methanol and the solution was stirred at room temperature
until the reaction reached completion. Saturated aqueous hydrogen carbonate was
then added. Following extraction with DCM (3 x 5 cm3) the organic extracts were
dried (MgSO4), concentrated under reduced pressure and purified by column
chromatography (ethyl acetate – petroleum ether 1:1), to give the product. The
sample was directly used as a racemic standard for chiral GC or HPLC analysis.
In some cases this was not appropriate. Instead, two samples of the alcohol formed
from opposite isomers of the catalyst respectively were equally combined. This
approximately racemic sample was then used as a racemic standard for subsequent
chiral GC or HPLC analysis of asymmetrically formed alcohols.
ATH of ketones.
(R)-1-(6-Methoxypyridin-3-yl)-2-methylpropan-1-ol, (R)-324.
This compound was prepared following the general procedure for ketone transfer
hydrogenation, using 1-(6-methoxypyridin-3-yl)-2-methylpropan-1-one, 317 (11.3
mg, 6.31 x 10-2 mmol), Ru(R,R)teth-TsDPEN (0.4 mg, 6.45 x 10-4 mmol) in FA/TEA
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(32 µL, 2M), following a reaction time of 22 h. Following concentration under
reduced pressure and purification by column chromatography (ethyl acetate – hexane
1:1), product (R)-324 (6.9 mg, 0.038 mmol, 60 % yield) was obtained as colourless
oil; [α]D
21 + 23.2 (c0.35 in CHCl3) 53 % ee; (found (ESI): M+ + H, 182.1176.
C10H16NO2 requires M, 182.1176); νmax 3398 (OH st.), 1609 (C=C st.), 1575 (C=C
st.), 1493 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.05 (1 H, d, J 2.4, H6), 7.57 (1 H,
dd, J 8.6, 2.4, H4), 6.74 (1 H, d, J 8.6, H3), 4.34 (1 H, d, J 6.9, H7), 3.93 (3 H, s, H1),
1.94 (1 H, oct, J 6.9, H8), 1.02 (3 H, d, J 6.9, H9), 0.79 (3 H, d, J 6.9, H10); δC (126
MHz, CDCl3) 163.85 (C2), 150.22 (C6), 145.18 (C4), 137.00 (C5), 110.53 (C3), 77.65
(C1), 53.42 (C7), 35.15 (C8), 18.72 (C9), 18.37 (C9); m/z (ESI) 181.9 (M+ +1);
Enantiomeric separation was determined by GC analysis (CP – ChiraSil – DEX CB
25 m x 0.25 mm x 0.25 µm, gas: He, T = 140 °C, P = 18 psi He, det = 220 °C, inj =
220 °C, major isomer 21.54 min., minor isomer 22.56 min.) 53 % ee (R). The
absolute configuration was assigned analogy with the expected outcome of the
theoretical model.
(6-Methoxypyridin-3-yl)(phenyl)methanol, (-)-326.
This compound has been reported but not fully characterised.205 This compound was
prepared following the general procedure for ketone transfer hydrogenation, using
(6-methoxypyridin-3-yl)(phenyl)methanone, 319 (15 mg, 0.070 mmol) and
Ru(R,R)teth-TsDPEN (0.4 mg, 6.45 x 10-4 mmol) in FA/TEA (58 µL, 2M),
following a reaction time of 24 h. Following concentration under reduced pressure
and purification by column chromatography (ethyl acetate – petroleum ether 1:1),
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product (-)-326 (10 mg, 0.046 mmol, 66 % yield) was obtained as colourless oil;
[α]D
20 – 9.8 (c0.365 in CHCl3) 48 % ee (lit.205 [α]D22 - 26.2 (c0.26, CHCl3) 96.0 %
ee); (found (ESI): M+ + H, 216.1019. C13H14NO2 requires M, 216.1019); νmax 3340
(OH st.) 1607 (C=C st.), 1573 (C=C st.), 1491 (C=C st.) cm-1; δH (400 MHz, CDCl3)
8.13 (1 H, d, J 2.5, H6), 7.54 (1 H, dd, J 8.3, 2.5, H4), 7.32 - 7.38 (3 H, m, ArH), 7.26
- 7.30 (2 H, m, ArH), 6.70 (1 H, d, J 8.3, H3), 5.81 (1 H, d, J 3.3, H7), 3.91 (3 H, s,
H1), 2.47 (1 H, d, J 3.5, OH); δC (75 MHz, CDCl3) 158.57 (C2), 145.13 (C6), 143.21
(C5), 137.38 (C4), 132.11 (C8), 128.62 (C9), 127.77 (C10), 126.26 (C11), 110.94 (C3),
73.81 (C7), 53.47 (C1); m/z (ESI) 216.1 (M+ +1), 238.1 (M++23). Enantiomeric
separation was achieved by HPLC analysis (Chiralpak IC, 4.6 mm x 250 mm,
hexane : IPA 90 : 10, 1 mL/min, T = 30 °C, minor isomer 12.2 min, major isomer
14.9 min.) 48 % ee.
(S)-1-(6-Methoxypyridin-3-yl)ethanol, (S)-303.
This compound has been reported but not fully characterised.206 This compound was
prepared following the general procedure for ketone transfer hydrogenation, using 1-
(6-methoxypyridin-3-yl)ethanone, 4 (30 mg, 0.199 mmol) and Ru(S,S)teth-TsDPEN
(1.2 mg, 1.93 x 10-3 mmol) in FA/TEA (199 µL, 1 M), following a reaction time of
22 h. Following concentration under reduced pressure and purification by column
chromatography (ethyl acetate – hexane 1:1), product (S)-303 (21 mg, 0.137 mmol,
69 % yield) was obtained as colourless oil; [α]D15 – 42.4 (c1.05 in CHCl3) 82 % ee
(lit.206 [α]D23 + 33.7 (c2.70, CHCl3) 98.0 % ee (R)); (found (ESI): M+ + H, 154.0861.
C8H12NO2 requires M, 154.0863); νmax 3300 (OH st.), 1607 (C=C st.), 1574 (C=C
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st.), 1492 (C=C st.) cm-1; δH (400 MHz, DMSO) 8.09 (1 H, d, J 2.5, H6), 7.66 (1 H,
dd, J 8.5, 2.5, H4), 6.76 (1 H, d, J 8.5, H3), 5.12 (1 H, d, J 4.5, OH), 4.76 – 4.65 (1 H,
qd, J 6.5, 4.5, H7), 3.82 (3 H, s, H1), 1.32 (3 H, d, J 6.5, H8); δC (101 MHz, DMSO)
162.55 (C2), 143.74 (C6), 136.62 (C4), 135.32 (C5), 109.84 (C3), 65.60 (C1), 52.91
(C7), 25.41 (C8); m/z (ESI) 154.0 (M+ +1), 176.0 (M++23). Enantiomeric separation
was determined by GC analysis of the acetate derivative: (CP – ChiraSil – DEX CB
25 m x 0.25 mm x 0.25 µm, gas: He, T = 170 °C, P = 18 psi He, det = 250 °C, inj =
220 °C, S (major) isomer 3.82 min., R (minor) isomer 3.95 min.) 82 % ee (S). The
configuration was primarily assigned by comparison the reported optical rotation.
This was also in agreement with that expected from the theoretical model. This
characterisation data was in agreement with the literature.
(R)-1-(6-Methoxypyridin-3-yl)pentan-1-ol, (R)-323.
This compound was prepared following the general procedure for ketone transfer
hydrogenation, using 1-(4-methoxyphenyl)pentan-1-one, 316 (30 mg, 0.155 mmol)
and Ru(R,R)teth-TsDPEN (1.0 mg, 1.61 x 10-3 mmol) in FA/TEA (78 µL, 2M),
following a reaction time of 20 h. Following concentration under reduced pressure
and purification by column chromatography (ethyl acetate – hexane 1:1), product
(R)-323 (15 mg, 0.077 mmol, 50 % yield) was obtained as colourless oil; [α]D22 +
28.5 (c0.61 in CHCl3) 76 % ee; (found (ESI): M+ + H, 196.1329. C11H18NO2
requires M, 196.1332); νmax 3339 (OH st.), 2931(alkyl CH st.), 2859 (alkyl CH st.),
1607 (C=C st.), 1573 (C=C st.), 1491 (C=C st.) cm-1; δH (300 MHz, CDCl3) 8.09 (1
H, d, J 2.3, H3), 7.61 (1 H, dd, J 8.7, 2.3, H2), 6.75 (1 H, d, J 8.7, H1), 4.64 (1 H, td, J
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6.7, 3.2, H4), 3.93 (3 H, s, CH3), 1.90 - 1.76 (2 H, m, H5A, OH), 1.78 - 1.63 (2 H, m,
H5B), 1.47 - 1.17 (4 H, m, H6-7), 0.93 - 0.85 (3 H, m, H8); δC (101 MHz, CDCl3)
163.81 (C2), 144.69 (C6), 136.62 (C4), 132.77 (C5), 110.89 (C3), 72.07 (C1), 53.43
(C7), 38.44 (C8), 27.85 (C9), 22.51 (C10), 13.96 (C11); m/z (ESI) 195.9 (M+ +1).
Enantiomeric separation was determined by GC analysis for the acetate derivative:
(CP – ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: He, T = 140 °C, P = 18
psi He, det = 220 °C, inj = 220 °C, major isomer 21.30 min., minor isomer 22.33
min.) 76 % ee (R). The absolute configuration was assigned analogy with the
expected outcome of the theoretical model.
(R)-1-(6-Methoxypyridin-3-yl)propan-1-ol, (R)-327.
This compound was prepared following the general procedure (C) for ketone transfer
hydrogenation, using (2E)-3-chloro-1-(6-methoxypyridin-3-yl)prop-2-en-1-one, (E)-
320 (7 mg, 3.55 x 10-2 mmol) and Ru(R,R)teth-TsDPEN (0.2 mg, 3.22 x 10-4 mmol)
in FA/TEA (18 µL, 2M), following a reaction time of 24 h. Following concentration
under reduced pressure and purification by column chromatography (ethyl acetate –
hexane 1:1), product (R)-327 (8 mg, 4.79 x 10-2 mmol) was obtained as colourless
oil; (found (ESI): M+ + H, 168.1021. C9H14NO2 requires M, 168.1019); νmax 3325
(OH st.), 1607 (C=C st.), 1574 (C=C st.), 1492 (C=C st.) cm-1; δH (400 MHz, CDCl3)
8.01 (1 H, d, J 2.3, H3), 7.53 (1 H, dd, J 8.5, 2.3, H2), 6.67 (1 H, d, J 8.5, H1), 4.50 (1
H, t, J 7.1, H4), 3.86 (3 H, s, CH3), 1.81 - 1.61 (2 H, m, H5), 0.84 (2 H, t, J 7.1, H6);
δC (101 MHz, CDCl3) 160.98 (C2), 144.77 (C6), 136.64 (C4), 132.43 (C5), 110.88 (C-
3), 73.46 (C1), 53.44 (C7), 31.60 (C8), 10.02 (C9). The ee of this sample was not
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determined due to time constraints. The absolute configuration was assigned analogy
with the expected outcome of the theoretical model.
Cyclohexyl(6-methoxypyridin-3-yl)methanol,(±)-328.
This compound was prepared following the general procedure for the reduction of
ketones with NaBH4, using (2E)-3-chloro-1-(6-methoxypyridin-3-yl)prop-2-en-1-
one, E-320 (5 mg, 2.54 x 10-2 mmol) and NaBH4 (1 mg, 2.64 x 10-2 mmol) in
methanol (1 cm3) following a reaction time of 3½ h. Following concentration under
reduced pressure, product (±)-328 (4.2 mg, 2.11 x 10-2 mmol, 80 %) was obtained as
colourless oil; (found (ESI): M+ + H, 200.0476. C9H1135ClNO2 requires M,
200.0473); νmax 3348 (OH st.), 1608 (C=C st.), 1574 (C=C st.), 1493 (C=C st.) cm-1;
δH (400 MHz, CDCl3) 8.05 (1 H, s, H6), 7.52 (1 H, dd, J 8.5, 2.3, H4), 6.69 (1 H, d, J
8.8, H3), 6.29 (1 H, d, J 13.3, H9), 6.04 (1 H, dd, J 13.3, 6.3, H8), 5.17 (1 H, d, J 5.8,
H7), 3.91 - 3.82 (3 H, m, H1), 1.97 (1 H, s, OH); δC (101 MHz, CDCl3) 164.18 (C2),
145.08 (C6), 137.02 (C4), 134.78 (C9), 129.85 (C5), 120.73 (C8), 111.20 (C3), 70.85
(C1), 53.57 (C7); m/z (ESI) 200.0 (M[35Cl]+ +1), 202.0 (M[37Cl]+ +1).
(R)-Cyclohexyl(6-methoxypyridin-3-yl)methanol, (R)-325.
This compound was prepared following the general procedure for ketone transfer
hydrogenation, using cyclohexyl(6-methoxypyridin-3-yl)methanone 318 (26 mg,
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0.119 mmol) and Ru(R,R)teth-TsDPEN (0.7 mg, 1.13 x 10-3 mmol) in FA/TEA (58
µL, 2M) , following a reaction time of 24 h. Following concentration under reduced
pressure and purification by column chromatography (ethyl acetate – hexane 1:1),
product (R)-325 (27 mg, 0.122 mmol) was obtained as colourless oil; [α]D21 + 18.2
(c0.70 in CHCl3) 35 % ee; (found (ESI): M+ + H, 220.1490. C13H20NO2 requires M,
220.1489); νmax 3335 (OH st.), 2922 (alkyl CH st.), 2850 (alkyl CH st.), 1606 (C=C
st.), 1573 (C=C st.), 1492 (C=C st.) cm-1; δH (400 MHz, CDCl3) 8.03 (1 H, d, J 2.4,
H6), 7.56 (1 H, dd, J 8.5, 2.4, H4), 6.74 (1 H, d, J 8.5, H3), 4.34 (1 H, dd, J 7.3, 3.0,
H7), 3.93 (3 H, s, H1), 1.87 (1 H, bs, OH), 1.83 - 1.73 (1 H, m, H8), 1.73 - 1.53 (4 H,
m, H9), 1.32 - 0.82 (6 H, m, H10-11); δC (101 MHz, CDCl3) 163.69 (C2), 145.16 (C6),
137.10 (C4), 131.55 (C5), 110.64 (C3), 76.65 (C1), 53.38 (C7), 44.71 (C8), 29.00 (C9),
26.30 (C10), 25.92 (C11); m/z (ESI) 220.1 (M+ +1). Enantiomeric separation was
determined by HPLC analysis of the acetate derivative: (Chiralpak IA, 4.6 mm x 250
mm, hexane : IPA 98 : 2, 0.5 mL/min, T = 28 °C, 13.0 min, 17.2 min.) 35 % ee (R).
The absolute configuration was assigned analogy with the expected outcome of the
theoretical model.
1-Benzyl-5-(1-hydroxyethyl)piperidin-2-one, (R)-304.
This compound was prepared following the general procedure (C) for ketone transfer
hydrogenation, using 5-acetyl-1-benzylpyridin-2(1H)-one, 309 (45 mg, 0.198 mmol)
and Ru(R,R)teth-TsDPEN (1.2 mg, 1.93 x 10-3 mmol) in FA/TEA (198 µL, 1M),
following a reaction time of 20 h. Following concentration under reduced pressure
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and purification by column chromatography (ethyl acetate – hexane 9:1), product
(R)-304 (17 mg, 0.074 mmol, 37 %) was obtained as colourless oil; [α]D22 + 3.6
(c0.35 in CHCl3) 42 % ee; (found (ESI): M+ + Na, 252.0995. C14H15NNaO2 requires
M, 252.0995); νmax 3356 (OH st.), 1661 (C=O st.), 1578 (C=C st.), 1542 (C=C st.),
1497 (C=C st.) cm-1; δH (400 MHz,) 7.41 - 7.22 (7 H, m, ArH, H2, H4), 6.60 (1 H, d,
J 9.5, H1), 5.05 - 5.17 (2 H, s, CH2), 4.63 (1 H, q, J 6.2, H5), 2.02 - 2.11 (1 H, bs,
OH), 1.40 (3 H, d, J 6.2, H6); δC (101 MHz, CDCl3) 162.43 (CO), 138.30 (C4),
136.21 (Ar), 133.70 (C2), 128.80 (Ar), 128.01 (Ar), 127.96 (Ar), 124.30 (C1), 120.89
(C3), 66.76 (CH2Ph), 52.10 (C5), 24.14 (C6); m/z (ESI) 229.8 (M+ +1). Enantiomeric
separation was determined by HPLC analysis of the acetate derivative: (Chiralpak
IC, 4.6 mm x 250 mm, hexane : IPA 80 : 20, 1.0 mL/min, T = 30 °C, S (minor)
isomer 41.0 min, R (major) isomer 44.3 min.) 42 % ee. The configuration was
determined by comparison of the optical rotation of a sample of (R)-304, formed
from (R)-303. The synthesis of this compound is in the following section.
AH of 1-benzyl-5-(1-hydroxyethyl)pyridin-2(1H)-one, 304.
The AH catalyst screen of 1-benzyl-5-(1-hydroxyethyl)-pyridin-2(1H)-one 304 was
carried out using the general procedure for alkene hydrogenation. Conversions were
determined by 1H NMR.
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1-Benzyl-5-(1-hydroxyethyl)pyridin-2(1H)-one, 7.
This compound was prepared following the general procedure for ketone transfer
hydrogenation, using 5-acetyl-1-benzylpiperidin-2-one (±)-310 (7.5 mg, 0.032
mmol) and Ru(R,R)teth-TsDPEN (0.2 mg, 3.22 x 10-4 mmol) in FA/TEA (32 µL,
1M), following a reaction time of 24 h. Following concentration under reduced
pressure and removal of the catalyst by column chromatography (ethyl acetate –
hexane 9:1), a mixture containing diastereomers (anti / syn = 1.39:1, as determined
by GC) (D1)-7a and (D2)-7b (10 mg, 0.043 mmol) was obtained as a colourless oil.
No separation of the diastereomers was attempted. De and ee was determined by GC
analysis of the isolated mixture of diastereomers: (CP – ChiraSil – DEX CB 25 m x
0.25 mm x 0.25 µm, gas: He, T = 200 °C, P = 18 psi He, det = 220 °C, inj = 220 °C,
(S,R) (minor) isomer 24.70 min., (R,S) (major) isomer 25.25 min., (S,S) (major)
isomer 25.83 min., (R,R) (minor) isomer 26.19 min.) 20 % de; (R,S), 85 % ee; (S,S),
49 % ee. Full characterisation of the isomers 7a and 7b is detailed in the next
section. Assignments of absolute and relative configurations were made through
comparison of the GC traces of two enantiomerically enriched samples of (R,R)-7b
and (S,R)-7a. Racemic samples of D2-7b and D1-7a prepared through the procedure
shown in the next section were used as racemic standards during chiral GC analysis.
238
Section 3.5.3: Asymmetric Synthesis of Diastereomers 7a and 7b.
(R)-1-(6-Methoxypyridin-3-yl)ethanol, (R)-303.
This procedure was used for the large scale asymmetric reduction of 1-(6-
methoxypyridin-3-yl)ethanone 4. Under nitrogen, FA/TEA (5:2, 9.93 cm3, 1M) was
added to 1-(6-methoxypyridin-3-yl)ethanone, 4 (1.00 g, 6.62 mmol). Dissolution was
aided by gently heating the mixture at 45 °C. The mixture was then allowed to cool
to room temperature for 30 min. Ru(R,R)teth-TsDPEN (41.0 mg, 6.61 x 10-2 mmol)
was added and the solution was left stirring at room temperature for 5 min. The
mixture was heated to 45 °C and stirred for 24 h before saturated aqueous sodium
hydrocarbonate (20 cm3) was added. Following extraction with DCM (3 x 20 cm3),
the solution was concentrated under reduced pressure and purified by column
chromatography (petroleum ether – ethyl acetate 1:1), to give the product (R)-303
(0.960 g, 6.27 mmol, 95 % yield) as an oil; [α]D15 + 27.8 (c0.60 in CHCl3) 78 % ee
(lit. [α]D206 + 33.7 (c 2.70, CHCl3) 98.0 % ee (R)); Enantiomeric separation was
determined by GC analysis of the acetate derivative: (CP – ChiraSil – DEX CB 25 m
x 0.25 mm x 0.25 µm, gas: He, T = 180 °C, P = 18 psi He, det = 250 °C, inj = 220
°C, S (minor) isomer 3.23 min., R (major) isomer 3.30 min.) 78 % ee. Full
characterisation data was given in the previous section.
239
1-Benzyl-5-(1-hydroxyethyl)pyridin-2(1H)-one,(R)-304.
1
N
Bn
3
2
O
4 (R)-3045
OH
NO
(R)-303
78 % ee
OH BnBr
MeCN
80 °C
16 h
A solution of benzyl bromide (0.77 cm3, 1.12 g, 6.47 mmol) and (R)-1-(6-
methoxypyridin-3-yl)ethanone 303 (78 % ee, 0.910 g, 5.94 mmol) in dry acetonitrile
(14 cm3) was stirred at 80 °C for 16 d before the mixture was concentrated under
reduced pressure and purified by column chromatography (ethyl acetate – petroleum
ether 1:1 to 1:0), to give product (R)-304 (0.852 g, 3.72 mmol, 63 % yield) as a
colourless oil; [α]D
20 + 15.4 (c1.40 in CHCl3). The ee was not determined at this
point and it was assumed to be unchanged. Conditions for chiral HPLC separation
and full characterisation data were given in the previous section.
(5R)-1-benzyl-5-[(1R)-1-hydroxyethyl]piperidin-2-one (R,R)-(D2)-7b and (5S)-1-
benzyl-5-[(1R)-1-hydroxyethyl]piperidin-2-one, (S,R)-(D1)-7a.
These compounds were prepared following the general procedure for alkene
hydrogenation, using syn - 1-benzyl-5-(1-hydroxyethyl)pyridin-2(1H)-one, (R)-304
(78 % ee, 0.810 g, 3.54 mmol) and platinum oxide (40 mg, 0.176 mmol) following a
reaction time of 18 h, at room temperature and 5 bar of hydrogen. Following
concentration under reduced pressure and purification by column chromatography (1
to 3 % methanol – DCM, slow gravity elution), two diastereomerically enriched
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samples of the isomers D2-(R,R)-7b and D1-(S,R)-7a were obtained: D1-(S,R)-7a
(100 % syn as determined by GC) (165 mg, 0.708 mmol, 20 % yield) was obtained
as a colourless oil which solidified upon standing; 110-112 °C; [α]D22 – 30.1 (c0.75
in CHCl3) 78 % ee; (found (ESI): M+ + Na, 256.1306. C14H19NNaO2 requires M,
256.1308); νmax 3354 (OH st.), 1614 (C=O st.) cm-1; δH (400 MHz, CDCl3) 7.36 -
7.20 (5 H, m, ArH), 4.60 (1 H, d, J 14.6, CH2), 4.56 (1 H, d, J 14.6, CH2), 3.61 (1 H,
quin, J 6.4, H5), 3.40 (1 H, ddd, J 12.2, 5.1, 1.8, H4A), 3.10 (1 H, dd, J 12.2, 10.2,
H4B), 2.54 (1 H, ddd, J 18.1, 5.5, 3.0, H1A), 2.41 (1 H, ddd, J 18.1, 11.5, 6.0, H1B),
1.98 (1 H, bs, OH), 1.87 - 1.71 (2 H, m, H2), 1.60 - 1.47 (1 H, m, H3), 1.20 (3 H, d, J
6.4, H6); δC (101 MHz, CDCl3) 169.86 (CO), 136.91 (Ar), 128.39 (Ar), 127.78 (Ar),
127.17 (Ar), 68.91 (C5), 50.27 (CH2Ph), 49.39 (C4), 41.14 (C3), 31.27 (C1), 23.82
(C2), 21.14 (C6); m/z (ESI) 234.1 (M+ +1), 256.1 (M+ + 23). Enantiomeric separation
was determined by GC analysis: (CP – ChiraSil – DEX CB 25 m x 0.25 mm x 0.25
µm, gas: H, T = 185 °C, P = 18 psi H, det = 250 °C, inj = 220 °C, (S,R) (major)
isomer 18.61 min., (R,S) (minor) isomer 19.24 min.) 78 % ee. A racemic sample of
the diastereomer D1-7a was used as a racemic standard during chiral GC analysis.
Recrystallisation of a racemic sample of D1-7a (DCM-hexane) provided crystals of
sufficient quality to undergo X-ray diffraction. Full details of this X-ray structure are
shown in Appendix II. This confirmed the structure and enabled the relative
configuration of this sample to be assigned as cis with respect to H3 and H5. As the
configuration at C(5) was known to be R (due to the configuration of the starting
material), and the ee of the sample was known, this enabled the assignment of the
configurations to be made. The 1H NMR spectrum of this compound has been shown
in Appendix I.
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(R,R)-7b (72 % anti, as determined by GC) (266 mg, 1.14 mmol, 32 % yield) was
obtained as a colourless oil; [α]D
22 + 11.0 (c1.00 in CHCl3) 78 % ee; (found (ESI):
M+ + Na, 256.1306. C14H19NNaO2 requires M, 256.1308); νmax 3368 (OH st.) 1612
(C=O st.) cm-1; δH (400 MHz, CDCl3) 7.37 - 7.22 (5 H, m, ArH), 4.64 (1 H, d, J
14.7, CH2), 4.55 (1 H, d, J 14.7, CH2), 3.68 (1 H, quin, J 5.8, H5), 3.17 (1 H, ddd, J
11.5, 5.8, 1.5, H4A), 3.07 (1 H, t, J 11.5, H4B), 2.61 (1 H, ddd, J 17.9, 5.5, 3.0, H1A),
2.42 (1 H, ddd, J 17.9, 11.8, 6.0, H1B), 1.79 (1 H, dqd, J 11.5, 5.8, 3.1, H3), 1.66 -
1.53 (2 H, m, H2), 1.15 (3 H, d, J 5.8, H6); δC (101 MHz, CDCl3) 169.91 (CO),
137.05 (Ar), 128.58 (Ar), 127.99 (Ar), 127.36 (Ar), 68.55 (C5), 50.27 (CH2Ph),
49.19 (C4), 40.91 (C3), 31.53 (C1), 22.37 (C2), 20.97 (C6); m/z (ESI) 234.1 (M+ +1),
256.1 (M+ + 23). Enantiomeric separation was determined by GC analysis: (CP –
ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: He, T = 200 °C, P = 18 psi He,
det = 250 °C, inj = 220 °C, (S,R) (minor) isomer 24.70 min., (R,S) (major) isomer
25.25 min., (S,S) (minor) isomer 25.54 min., (R,R) (major) isomer 26.09 min.) 78 %
ee. A racemic sample of the diastereomer D2-7b was used as a racemic standard
during chiral GC analysis. The relative configuration of this sample was assigned in
analogy to D1-7b. As configuration at C(5) was known, the absolute configuration
of this sample was assigned accordingly. De was determined by GC analysis of the
crude reaction mixture with the chiral GC method stated above: 31 % de. The 1H
NMR spectrum of this compound has been shown in Appendix I.
For future reference, enantiomerically and diastereomerically enriched samples of 7
will be referred to in terms of the absolute configuration of the major component
present, with indication of the degree of purity, with the prefix of D2 or D1 for
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clarity. Racemic and diastereomerically enriched samples of 7 will be referred to in
terms of D2 and D1 with a prefix of (±).
The hydrogenolysis product 1-benzyl-5-ethylpiperidin-2-one, 331 was also isolated
from this reaction in variable yields. For the case of this experiment, 1-benzyl-5-
ethylpiperidin-2-one (110 mg, 0.507 mmol, 14 % yield) was obtained as a colourless
oil; (found (ESI): M+ + Na, 240.1357. C14H19NNaO requires M, 240.1359); νmax
2959 (alkyl CH st.), 2923 (alkyl CH st.), 2874 (alkyl CH st.), 1636 (C=O st.) cm-1;
δH (400 MHz, CDCl3) 7.36 - 7.22 (5 H, m, ArH), 4.63 (1 H, d, J 14.2, CH2), 4.55 (1
H, d, J 14.2, CH2), 3.20 (1 H, ddd, J 12.0, 5.1, 1.8, H4A), 2.85 (1 H, dd, J 12.0, 10.3,
H4B), 2.56 (1 H, ddd, J 17.8, 5.8, 3.3, H1A), 2.42 (1 H, ddd, J 17.8, 11.4, 6.5, H1B),
1.97 - 1.87 (1 H, m, H2A), 1.75 - 1.61 (1 H, m, H3), 1.43 (1 H, dtd, J 13.1, 11.4, 5.8,
H2B), 1.34 - 1.25 (2 H, m, H5), 0.87 (3 H, t, J 7.5, H6); δC (101 MHz, CDCl3) 170.02
(CO), 137.22 (Ar), 128.51 (Ar), 127.96 (Ar), 127.25 (Ar), 52.52 (CH2Ph), 50.15
(C4), 35.49 (C3), 31.60 (C2), 26.01 (C5), 11.29 (C6); m/z (ESI) 240.0 (M+ +1).
Synthesis of amines 308a and 308b, and attempted pyridone formation.
Two separate syntheses of diastereomerically enriched samples of 5-(1-aminoethyl)-
1-benzylpiperidin-2-one 308 originating from diastereomerically and
enantiomerically enriched samples of the precursors, (R,R)-(D2)-7b and (S,R)-(D1)-
7a. For simplicity, these have been shown in two separate sections. For future
reference, enantiomerically and diastereomerically enriched samples of 306, 333 or
308 will be referred to with an additional prefix of (D1) or (D2) to indicate that the
sample had originated from a diastereomericaly enriched sample of D1-7a, or (D2)-
7b respectively; additionally, the sign of the optical rotation will also be used.
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Section 3.5.4: Synthesis of Amine 308a.
1-Benzyl-5-(1-bromoethyl)piperidin-2-one, (D1)-(-)-306 via precursor alcohol D1-
(S,R)-7a.
Under nitrogen, phosphorus tribromide (73 µL, 210 mg, 0.777 mmol) was added to a
solution of 1-benzyl-5-(1-hydroxyethyl)-piperidin-2-one (S,R)-(D1)-7a (100 % syn,
as determined by GC) (78 % ee, 150 mg, 0.643 mmol) in toluene (6.00 cm3) and the
solution was stirred at 0 °C for 5 min. The solution was stirred at 80 °C for 50 min
before water (5 cm3) was added. Following extraction with ethyl acetate (3 x 10
cm3), the organic extracts were dried (MgSO4) and concentrated under reduced
pressure to give a sample enriched in one diastereomer (75 % D1, as determined by
1H NMR), (D1)-(-)-306 (147 mg, 0.498 mmol, 77 % yield) as an oil; [α]D22 – 12.9
(c0.52 in CHCl3). This sample was characterised through the synthesis and
purification of the racemic sample, (D1)-(±)-306. This is shown in the next section.
For the case of this experiment, no further purification of separation of the
diastereomers was attempted.
Synthesis of 1-benzyl-5-(1-bromoethyl)piperidin-2-one, (D1)-(±)-306 via precursor
alcohol D1-(±)-7a.
Under nitrogen, phosphorus tribromide (97 µL, 279 mg, 1.03 mmol) was added to a
solution of anti-1-benzyl-5-(1-hydroxyethyl)piperidin-2-one anti-D1-(±)-7a (100 %
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anti, as determined by GC) (198 mg, 0.850 mmol) in toluene (4.3 cm3) and the
solution was stirred at 0 °C for 5 min. The solution was stirred at 80 °C for 1 h
before water (5 cm3) was added. Following extraction with DCM (3 x 5 cm3), the
organic extracts were dried (MgSO4), concentrated under reduced pressure and
purified by column chromatography (ethyl acetate – petroleum ether 1:1), to give a
sample enriched in one diastereomer (68 % D1, as determined by 1H NMR), (D1)-
(±)-306 (38 mg, 0.129 mmol, 15 % yield) as an oil; (found (ESI): M+ + Na,
318.0465. C14H1879BrNNaO requires M, 318.0464); νmax 1636 (C=O st.), 1494 (C=C
st.) cm-1; δH (400 MHz, CDCl3) 7.38 - 7.20 (5 H, m, ArH), 4.73 (1 H, d, J 14.7,
CH2), 4.46 (2 H, d, J 14.7, CH2), 4.11 - 3.99 (1 H, m, H5), 3.27 - 3.10 (2 H, m, H4),
2.68 - 2.54 (1 H, m, H1A), 2.51 - 2.39 (1 H, m, H1B), 2.09 - 1.92 (2 H, m, H2), 1.66 (3
H, d, J 7.5, H6) 1.80 - 1.62 (1 H, m, H3); δC (101 MHz, CDCl3) 169.35 (CO), 136.86
(Ar), 128.61 (Ar), 127.99 (Ar), 127.43 (Ar), 59.52 (CH2Ph), 51.59 (C5), 50.03 (C4),
41.53 (C3), 31.19 (C1), 24.08 (C2), 23.57 (C6); m/z (ESI) 318.0 (M[79Br]+ +23).
5-(1-Azidoethyl)-1-benzylpiperidin-2-one, (D1)-(-)-333.
Under nitrogen, a solution of (-)-1-benzyl-5-(1-bromoethyl)piperidin-2-one, (D1)-(-
)-306 (75 % D1, as determined by 1H NMR) (78 % ee, 137 mg, 0.464 mmol) and
NaN3 (45 mg, 0.692 mmol) in acetone (0.9 cm3) and water (0.6 cm3) was stirred at
45 °C for 24 h before water (5.0 cm3) was added. Following extraction with ethyl
acetate (3 x 10 cm3), the organic extracts were dried (MgSO4), concentrated under
reduced pressure and purified by column chromatography (ethyl acetate - petroleum
ether 1:9 to 1:1), to give the product (D1)-(-)-333 (82 % D1, as determined by 1H
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NMR) (16 mg, 0.062 mmol, 13 % yield) as an oil; [α]D22 – 24.0 (c0.70 in CHCl3);
(found (ESI): M+ + Na, 281.1373. C14H18N4NaO requires M, 281.1373); νmax 2101
(N3 st.), 1637 (C=O st.), cm-1; δH (400 MHz, CDCl3) 7.30 - 7.14 (5 H, m, ArH), 4.66
(1 H, d, J 14.8, CH2), 4.39 (1 H, d, J 14.8, CH2), 3.99 (1 H, quin, J 6.9, H5), 3.20 -
3.05 (2 H, m, H4), 2.56 (1 H, ddd, J 17.7, 5.8, 3.5, H1A), 2.39 (1 H, ddd, J 17.7, 11.5,
6.3, H1B), 2.01 - 1.85 (2 H, m, H2), 1.73 - 1.62 (1 H, m, H3), 1.59 (3 H, d, J 6.9, H6);
δC (101 MHz, CDCl3) 169.40 (CO), 136.89 (Ar), 128.62 (Ar), 128.02 (Ar), 127.43
(Ar), 59.60 (CH2Ph), 51.60 (C4), 50.07 (C5), 41.57 (C1), 31.14 (C3), 24.14 (C6),
23.60 (C2); m/z (ESI) 259.0 (M+ + 1), 281.0 (M+ + 23).
5-(1-aminoethyl)-1-benzylpiperidin-2-one, (D1)-(-)-308.
This compound was prepared following the general procedure for alkene
hydrogenation, using (D1)-(-)-(1-azidoethyl)-1-benzyl-piperidin-2-one, (D1)-(-)-333
(82 % D1, as determined by 1H NMR) (78 % ee, 14 mg, 0.054 mmol) and platinum
oxide (0.6 mg, 2.64 x 10-3 mmol) following a reaction time of 14 h, at room
temperature and 5 bar of hydrogen. Following filtration with celite, the resulting
filtrate was passed through an Isolute-XL SCX amine scavenger resin and the resin
was washed with DCM (3 x 1 cm3). The free amine was liberated by passing a
solution of approx. 2 % NH4OH in methanol through the resin, followed by washing
with DCM (3 x 1 cm3). Following concentration under reduced pressure, an impure
sample containing what was characterised to be the product (D1)(-)-308 (67 % D1,
as determined by 1H NMR) (78 % ee, 10.6 mg, 0.046 mmol, 85 % yield) was
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obtained as colourless oil; [α]D
22 – 24.0 (c0.05 in CHCl3); (found (ESI): M+ + H,
233.1643. C14H21N2O requires M, 233.1648); νmax 3441 (NH st.), 1638 (C=O st.) cm-
1; δH (400 MHz, CDCl3) 7.40 - 7.19 (5 H, m, ArH), 4.73 (1 H, d, J 14.8, CH2), 4.46
(1 H, d, J 14.8, CH2), 4.11 - 4.01 (1 H, m, H5), 3.30 - 3.08 (2 H, m, H4), 2.68 - 2.55
(1 H, m, H1A), 2.52 - 2.39 (1 H, m, H1B), 2.10 - 1.91 (2 H, m, H2), 1.66 (3 H, d, J 7.0,
H6), 1.71 - 1.56 (1 H, m, H3); δC (101 MHz, CDCl3) 162.55 (CO), 136.88 (Ar),
128.81 (Ar), 127.91 (Ar), 127.47 (Ar), 51.56 (C5), 50.40 (CH2Ph), 50.13 (C4), 41.54
(C1), 31.23 (C6), 24.14 (C3); m/z (ESI) 233.1 (M+ +1).
Section 3.5.5: Synthesis of Amine 308b.
1-Benzyl-5-(1-bromoethyl)piperidin-2-one, (D2)-(+)-306.
Under nitrogen, phosphorus tribromide (120 µL, 346 mg, 1.28 mmol) was added to a
solution of 1-benzyl-5-(1-hydroxyethyl)piperidin-2-one, (R,R)-7b (72 % anti, as
determined by GC) (78 % ee, 246 mg, 1.06 mmol) in toluene (10.6 cm3) and the
solution was stirred at 0 °C for 5 min. The solution stirred at 80 °C for 50 min before
water (5 cm3) was added. Following extraction with ethyl acetate (3 x 10 cm3), the
organic extracts were dried (MgSO4) and concentrated under reduced pressure to
give a sample enriched in one diastereomer (68 % D2, as determined by 1H NMR),
the product (D2)-(+)-306 (190 mg, 0.644 mmol, 61 % yield) as an oil; [α]D22 + 10.6
(c0.50 in CHCl3). Full characterisation data was shown in the previous section. This
sample was characterised through the synthesis and purification of the racemic
sample, (D2)-(±)-306 which is shown in the next section. For the case of this
experiment, no further purification of separation of the diastereomers was attempted.
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Synthesis of 1-benzyl-5-(1-bromoethyl)piperidin-2-one, (D2)-(±)-306 via precursor
alcohol D2-(±)-7b.
Under nitrogen, phosphorus tribromide (95 µL, 274 mg, 1.01 mmol) was added to a
solution of racemic anti-1-benzyl-5-(1-hydroxyethyl)-piperidin-2-one syn-D2-(±)-7b
(100 % syn, as determined by GC) (194 mg, 0.832 mmol) in toluene (4.0 cm3) and
the solution was stirred at 0 °C for 5 min. The solution was stirred at 80 °C for 1 h
before water (5 cm3) was added. Following extraction with DCM (3 x 5 cm3), the
organic extracts were dried (MgSO4) and concentrated under reduced pressure and
purified by column chromatography (ethyl acetate – petroleum ether 1:1), to give a
sample enriched in one diastereomer (74 % D2, as determined by 1H NMR), (D2)-
(±)-306 (95 mg, 0.322 mmol, 39 % yield) as an oil; (found (ESI): M+ + Na,
318.0461. C14H1879BrNNaO requires M, 318.0464); νmax 1636 (C=O st.) cm-1; δH
(400 MHz, CDCl3) 7.37 - 7.23 (5 H, m, ArH), 4.68 (1 H, d, J 14.6, CH2), 4.53 (1 H,
d, J 14.6, CH2), 4.04 (1 H, quin, J 6.9, H5), 3.42 (1 H, ddd, J 12.1, 5.1, 1.9, H4A),
3.15 (1 H, dd, J 12.1, 10.3, H4B), 2.60 (1 H, ddd, J 17.6, 5.8, 3.3, H1A), 2.45 (1 H,
ddd, J 17.6, 11.5, 6.3, H1B), 2.11 - 1.92 (2 H, m, H2A, H3), 1.71 (3 H, d, J 6.9, H6),
1.75 - 1.62 (1 H, m, H2B); δC (176 MHz, CDCl3) 169.25 (CO), 136.91 (Ar), 128.65
(Ar), 128.06 (Ar), 127.45 (Ar), 52.17 (C5), 50.53 (CH2Ph), 50.25 (C4), 42.00 (C3),
31.19 (C1), 25.44 (C2), 23.92 (C6); m/z (ESI) 296.0 (M[79Br]+ +1), 298.0 (M[81Br]+
+1).
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5-(1-Azidoethyl)-1-benzylpiperidin-2-one, (D2)-(+)-333.
Under nitrogen, a solution of (+)-1-benzyl-5-(1-bromoethyl)piperidin-2-one, (D2)-(-
)-306 (66 % D2, as determined by 1H NMR) (78 % ee, 180 mg, 0.610 mmol) and
NaN3 (60 mg, 0.923 mmol) in acetone (1.2 cm3) and water (0.8 cm3) was stirred at
45 °C for 24 h before water (5.0 cm3) was added. Following extraction with ethyl
acetate (3 x 10 cm3), the organic extracts were dried (MgSO4), concentrated under
reduced pressure and purified by column chromatography (ethyl acetate - petroleum
ether 1:0 to 1:1), to give a diastereomerically enriched sample of (D2)-(+)-333 (86 %
D2, as determined by 1H NMR) (38 mg, 0.147 mmol, 24 % yield) as an oil; [α]D22 +
17.9 (c0.76 in CHCl3); (found (ESI): M+ + Na, 281.1370. C14H18N4NaO requires M,
281.1373); νmax 2107 (N3 st.), 1637 (CO) cm-1; δH (400 MHz, CDCl3) 7.31 - 7.14 (5
H, m, ArH), 4.61 (1 H, d, J 14.5, CH2), 4.46 (1 H, d, J 14.5, CH2), 3.97 (1 H, quin, J
6.8, H5), 3.35 (1 H, ddd, J 12.1, 5.1, 1.8, H4A), 3.07 (1 H, dd, J 12.1, 10.0, H4B), 2.52
(1 H, ddd, J 17.8, 5.8, 3.3, H1A), 2.38 (1 H, ddd, J 17.8, 11.8, 6.3, H1B), 2.03 - 1.85 (2
H, m, H2A, H3), 1.63 (3 H, d, J 6.8, H6), 1.68 - 1.55 (1 H, m, H2B); δC (101 MHz,
CDCl3) 169.25 (CO), 136.86 (Ar), 128.62 (Ar), 128.02 (Ar), 127.43 (Ar), 59.60 (C5),
52.18 (C4), 50.54 (CH2Ph), 50.39 (C4), 41.92 (C3), 31.15 (C1), 25.39 (C2), 23.90
(C6); m/z (ESI) 258.9 (M+ +1), 280.9 (M+ +23).
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5-(1-aminoethyl)-1-benzylpiperidin-2-one, (D2)-(+)-308
This compound was prepared following the general procedure for alkene
hydrogenation, using (D2)-(1-azidoethyl)-1-benzylpiperidin-2-one, (D2)-(+)-333
(86% D2, as determined by 1H NMR) (78 % ee, 38 mg, 0.147 mmol) and platinum
oxide (1.6 mg, 7.05 x 10-3 mmol) following a reaction time of 14 h, at room
temperature and 5 bar of hydrogen. Following filtration with celite, the resulting
filtrate was passed through an Isolute-XL SCX amine scavenger resin and the resin
was washed with DCM (3 x 1 cm3). The free amine was liberated by passing a
solution of approx. 2 % NH4OH in methanol through the resin, followed by washing
with DCM (3 x 1 cm3). Following concentration under reduced pressure, the product
(D2)-(+)-308 (86% D2, as determined by 1H NMR) (78 % ee, 21 mg, 0.090 mmol,
62 % yield) was obtained as a colourless oil; [α]D
22 + 16.4 (c0.21 in CHCl3); (found
(ESI): M+ + H, 233.1643. C14H21N2O requires M, 233.1648); νmax 3412 (NH st.),
1638 (C=O st.) cm-1; δH (400 MHz, CDCl3) 7.37 - 7.19 (5 H, m, ArH), 4.68 (1 H, d,
J 14.8, CH2), 4.53 (1 H, d, J 14.6, CH2), 4.04 (1 H, quin, J 6.8, H5), 3.42 (1 H, ddd, J
12.1, 5.1, 1.9, H4A), 3.15 (1 H, dd, J 12.0, 10.3, H4B), 2.60 (1 H, ddd, J 18.1, 6.0, 3.0,
H1A), 2.45 (1 H, ddd, J 17.6, 11.8, 6.0, H1B), 2.10 - 1.93 (2 H, m, H2, H3), 1.70 (3 H,
d, J 6.8, H6), 1.74 - 1.62 (1 H, m, H2B); δC (176 MHz, CDCl3) 169.29 (CO), 136.88
(Ar), 128.65 (Ar), 128.05 (Ar), 127.45 (Ar), 52.16 (C5), 50.53 (CH2Ph), 50.37 (C4),
41.97 (C3), 31.18 (C1), 25.42 (C2), 23.92 (C6); m/z (ESI) 233.1 (M+ +1).
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Section 3.5.6: Attempted Synthesis of Pyridone 307.
1-benzyl-5-ethylidenepiperidin-2-one, 332.
Under nitrogen, a solution of 2–hydroxypyridine (80 mg, 0.841 mmol), 1-benzyl-5-
(1-bromoethyl)piperidin-2-one (±)-306 (250 mg, 0.847 mmol), tetrabutylammonium
bromide (27 mg, 0.084 mmol) and potassium carbonate (234 mg, 1.69 mmol) in
toluene (7.0 cm3) and water (36 µL) was heated at 110 °C for 18 h before the
solution was allowed cool. Following filtration, concentration under reduced
pressure and purification by column chromatography (ethyl acetate – petroleum ether
1:1 to 1:0), an impure and inseparable mixture of what was characterised to be
isomers E-332 and Z-332 (100 mg, 0.465 mmol) was obtained as a colourless oil;
(found (ESI): M+ + Na, 238.1198. C14H17NNaO requires M, 238.1202); νmax 1636
(C=O st.), 1489 (C=C st.) cm-1; δH (400 MHz, CDCl3) 7.38 - 7.20 (5 H, m, ArH),
5.41 - 5.31 (1 H, m, H5), 4.64 (2 H, s, CH2), 3.83 (2 H, s, Z-H4), 3.75 - 3.68 (2 H, m,
E-H4), 2.55 - 2.39 (4 H, m, H1, H2), 1.62 (3 H, d, J 6.8, H6); δC (101 MHz, CDCl3)
170.59 (CO), 136.98 (Ar), 128.50 (Ar), 127.95 (Ar), 127.28 (Ar), 119.56 (C3),
119.39 (C5), 53.40 (CH2Ph), 47.29 (C4), 33.30 (C1), 30.17 (C2), 22.93 (C6); m/z (ESI)
215.8 (M+ +1).
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Procedure for the attempted formation of pyridone (±)-307.
Under nitrogen, a solution of 5-(1-aminoethyl)-1-benzylpiperidin-2-one, (D2)-(±)-
308 (30 mg, 0.129 mmol) and 2H-pyran-2-one (37 mg, 0.390 mmol) in acetic acid
(0.8 cm3) was irradiated at 140 °C for 3 h before saturated sodium hydrogen
carbonate (5 cm3) was added. Following extraction with ethyl acetate (3 x 5 cm3), the
organic extracts were dried (MgSO4) and concentrated under reduced pressure to
give a sample containing an inseparable mixture of what was characterised to be the
product 334 (30 mg). Data for 334 obtained from this mixture: δH (400 MHz, CDCl3)
7.31 - 7.14 (5 H, m, ArH), 4.61 (1 H, d, J 14.5, CH2), 4.46 (1 H, d, J 14.5, CH2), 3.90
(1 H, quin, J 6.8, H5), 3.20 - 3.10 (1 H, m, H4A), 3.00 – 2.90 (1 H, m, H4B), 2.55 –
2.45 (1 H, m, H1A), 2.40 – 2.30 (1 H, m, H1B), 1.80 (3 H, s, CH3), 1.90 - 1.70 (2 H,
m, H2), 1.50 - 1.40 (1 H, m, H3), 1.00 (3 H, d, J 6.8, H6); m/z (ESI) 275.1 (M+ +1),
297.1 (M+ +23). A signal corresponding to the indented product 307 was observed by
MS; m/z (ESI) 313.1 (M+ +1), 333.1 (M+ +23).
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Appendix I: NMR Spectra: Spectra from Section 2.1.
(E)-1-benzyl-4-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione, 1.
Figure 1: 1H NMR spectrum of 1, 400 MHz, CDCl3.
265
1-benzyl-3-[(pyridin-2-yloxy)methyl]piperidine-2,6-dione, 227.
Figure 2: 1H NMR spectra of 227, 500 MHz, CDCl3.
266
Specta from Section 2.4.
1-((6-methoxypyridin-3-yl)methyl)pyridin-2(1H)-one 295.
Figure 3: 1H NMR spectra of 295, 400 MHz, CDCl3.
267
2-methoxy-5-((pyridin-2-yloxy)methyl)pyridine, 297.
Figure 4: 1H NMR spectra of 297, 400 MHz, CDCl3.
268
1-Benzyl-3-(piperidin-1-ylmethyl)piperidine, (±)-6.
Figure 5: 1H NMR spectra of 6, 700 MHz, CDCl3.
269
Figure 6: HMQC spectra of 6, 700 MHz (1H), 176 MHz (13C) CDCl3.
Figure 7: COSY spectra of 6, 700 MHz (1H1,1H2), CDCl3.
270
Specta from Section 2.5.
1-benzyl-5-(1-hydroxyethyl)piperidin-2-one, D1-7.
Figure 8: 1H NMR spectra of (D1)-7, 400 MHz, CDCl3.
271
1-benzyl-5-(1-hydroxyethyl)piperidin-2-one, D2-7.
Figure 9: 1H NMR spectra of 7, 400 MHz, CDCl3.
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Appendix II: X-Ray Crystal Structures.
1-Benzyl-3-((2-oxopyridin-1-yl)methyl)piperidine-2,6-dione,(±)-218.
This structure was obtained from the diffraction of a crystal of racemic 218 which
had formed from a sample of enatiomerically enriched 13 (90 % ee). The structure
was found to have weak data, due to the overlapping presence of the two
enantiomers. The pyridone ring was modeled due to disordered over these two
positions. Crystallographic data for 218: C18H18N2O3, M = 310.34, Monoclinic,
space group P2(1)/c, a = 10.80640(10), b = 9.82230(10), c = 14.8463(2) Ǻ, α = 90 
deg., β = 98.1460(10) deg., γ = 90 deg., U = 1559.94(3) A
3 (by least squares
refinement on 14247 reflection positions), T =100(2)K, lambda = 1.54178 Ǻ, Z =  4, 
D(cal) = 1.321 Mg/m3, F(000) = 656. mν(MoK-α) = 0.741 mm-1. Crystal character:
colourless block. Crystal dimensions 0.24 x 0.20 x 0.10 mm. 19357 reflections
measured, 2425 unique [R(int) = 0.0293].
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(E)-1-Benzyl-3-((2-oxopyridin-1(2H)-yl)methylene)piperidine-2,6-dione, 1.
This structure was obtained by Akira Shiibashi. Crystallographic data for 1
(CCDC873751): C18H16N2O3, M = 308.33, Monoclinic, space group P21/c, a =
13.8161(4), b = 9.6613(2), c = 11.7717(3) Å,  = 90 deg.,  = 107.2680(10) deg.,  =
90 deg. U = 1500.48(7) Å3 (by least squares refinement on 9224 reflection
positions), T =120(2) K, lambda = 071073 Å, Z = 4, D(cal) = 1.365 Mg/m3, F(000)
= 648. m(MoK-) = 0.094 mm-1. Crystal character: colourless block. Crystal
dimensions 0.60 x 0.38 x 0.05 mm. 20600 reflections measured, 3425 unique
[R(int) = 0.0430].
274
(3E)-1-benzyl-3-[(pyridin-2-yloxy)methylidene]piperidine-2,6-dione, 227.
This structure was obtained by Akira Shiibashi. Crystallographic data for 227
(CCDC873752): C18H16N2O3, M = 308.33, Monoclinic, space group P21/c, a =
14.0338(5) b = 8.3474(3), c = 13.1017(3) Å,  = 90 deg.,  = 96.381(2) deg.,  = 90
deg. U = 1525.30(8) Å3 (by least squares refinement on 13564 reflection positions),
T =298(2) K, lambda = 0.71073 Å, Z = 4, D(cal) = 1.343 Mg/m3, F(000) = 648.
m(MoK-) = 0.093 mm-1. Crystal character: pale block. Crystal dimensions 0.58 x
0.38 x 0.25 mm. 27338 reflections measured, 3487 unique [R(int) = 0.0544].
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(Z)-1-((1-Benzyl-6-hydroxy-2-oxopiperidin-3-ylidene)methyl)pyridin-2(1H)-one, 238
Crystallographic data for 238 (CCDC873750): C18H18N2O3, M = 310.34,
Tetragonal, space group P4122, a = 8.92910(10), b = 8.92910(10), c = 39.0823(7) Å,
α = 90 deg., β = 90 deg., γ = 90 deg. U = 3115.99(7) Å
3 (by least squares refinement
on 6800 reflection positions), T =298(2) K, lambda = 1.54184 Å, Z = 8, D(cal) =
1.323 Mg/m3, F(000) = 1312. m (MoK-α) = 0.741 mm-1. Crystal character:
colourless block. Crystal dimensions 0.20 x 0.20 x 0.20 mm. 18002 reflections
measured, 1852 unique [R(int) = 0.0443].
5-Acetyl-1-benzylpyrimidine
This structure was determined by the
Crystallographic data for
P2(1)/n, a = 9.680(15), b = 23.71(3), c = 10.025(13)
97.78(3) deg., gamma = 90 deg., U = 2280(5)
reflection positions), T =100(2)K, lambda = 0.71075
Mg/m3, F(000) = 1024. m
needle. Crystal dimensions 0.20 x 0.01 x 0.01 mm,
5220 unique [R(int) = 0.0623].
-2,4(1H,3H)-dione, 269.
EPSRC Crystallographic Service
269: C13H12N2O3, M = 244.25, Monoclinic, space group
Ǻ, alpha = 90 deg., beta =
Ǻ
3 (by least squares refinement on 453
Ǻ, Z = 8, D(cal) = 1.423
ν (MoK-alpha) =  0.103 mm
-1. Crystal character
25462 refl
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.
: colourless
ections measured,
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1-[(1-Benzyl-6-oxo-1,6-dihydropyridin-3-yl)methyl]piperidine-2,6-dione, 2.
Crystallographic data for 2: C18H18N2O3, M = 310.34, Orthorhombic, space group
Pbca, a = 8.60003(9), b = 17.41730(19), c = 20.1379(3)Ǻ, α = 90 deg., β = 90 deg., γ 
= 90 deg., U = 3016.45(6) 3 Ǻ (by least squares refinement on 9775 reflection 
positions), T =100(2)K, lambda = 1.54184 Ǻ, Z =  8, D(cal) = 1.367 Mg/m
3, F(000)
= 1312. mν(MoK-alpha) = 0.766 mm
-1. Crystal character: colourless block. Crystal
dimensions 0.40 x 0.40 x 0.28 mm, 15826 reflections measured, 2892 unique [R(int)
= 0.0173].
1-Benzyl-5-[(2-oxopyridin
Crystallographic data for
P2(1)/n, a = 13.0964(3), b = 7.73187(14), c = 15.1103(3)
108.983(2) deg., gamma = 90 deg., U = 1446.85(5) A
on 2682 reflection positions), T =150(2)K, lambda = 1.54184
1.342 Mg/m3, F(000) = 616. m
colourless plate. Crystal dimensions 0.20 x 0.20 x 0.01 mm. 5296 reflections
measured, 2543 unique [R(int) = 0.0216].
-1(2H)-yl)methyl]pyridin-2(1H)-one, 3.
3. C18H16N2O2, M = 292.33, Monoclinic, space group
Ǻ, alpha = 90 deg., beta =
3 (by least squares
Ǻ
ν (MoK-alpha) =  0.714 mm
-1. Crystal character:
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refinement
, Z = 4, D(cal) =
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1-benzyl-5-(1-hydroxyethyl)piperidin-2-one, anti-D1-7a.
Crystal Data for 7a: C14H19NO2, M = 233.30, Orthorhombic, space group Pna2(1), a
= 10.7915(2), b = 21.1078(5), c = 5.64620(18) Ǻ, alpha = 90 deg., beta = 90 deg., 
gamma = 90 deg., U = 1286.11(6) Ǻ
3 (by least squares refinement on 5741 reflection
positions), T =150(2)K, lambda = 1.54184 Ǻ, Z =  4, D(cal) = 1.205 Mg/m^3, 
F(000) = 504. Mν (MoK-alpha) = 0.638 mm
-1. Crystal character: colourless needle.
Crystal dimensions 0.50 x 0.01 x 0.01 mm, 10079 reflections measured, 2146 unique
[R(int) = 0.0250].
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Appendix III: Chiral HPLC and GC Traces.
HPLCs from Section 2.2: ATH of N-benzyl-5-acetyluracil.
In this section the HPLC traces of the reduction products formed by the ATH of N-
benzyl-5-acetyluracil are shown. These reductions were shown in Table 2, section
2.2.3.
HPLC trace 1.
Reduction with the racemic catalyst, RuTsEN 249, (entry 2, Table 2, section 2.2.3);
chiral separation details: (Chiralpak IA, 4.6 mm x 250 mm, hexane : IPA 90 : 10, 1
mL/min, T = 30 °C, minor isomer 46.0 min, major isomer 51.9 min.) 271a : 271b dr
= 1:1.
HPLC trace 2.
Reduction with the Noyori’s catalyst (R,R)-248, (entry 3, Table 2, section 2.2.3);
chiral separation details: (Chiralpak IA, 4.6 mm x 250 mm, hexane : IPA 90 : 10, 1
mL/min, T = 30 °C) 271a: 55 % ee; 271b: 36 % ee. a : b dr = 1.3:1.
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HPLC trace 3.
Reduction with (R,R)-RutethTsDPEN, (R,R)-248, (entry 4, Table 2, section 2.2.3);
chiral separation details: (Chiralpak IA, 4.6 mm x 250 mm, hexane : IPA 90 : 10, 1
mL/min, T = 30 °C) 271a: 92 % ee; 271b: 33 % ee. a : b dr = 4:1.
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HPLC trace 4.
Reduction with (S,S)-RutethTsDPEN, (S,S)-248, (entry 5, Table 2, section 2.2.3);
chiral separation details: (Chiralpak IA, 4.6 mm x 250 mm, hexane : IPA 90 : 10, 1
mL/min, T = 30 °C) 271a: 86 % ee; 271b: 49 % ee. a : b dr = 4:1.
GC traces from Section 2.5:
GC trace 1: crude reduction mixture of 7a and 7b
This GC trace was obtained from the crude reaction mixture of (D1)-7a and (D2)-7b
resulting from the PtO2 reduction of pyridone (R)-304 (78 % ee). This was used to
determine the dr of the reaction. Chiral separation details: (CP – ChiraSil – DEX CB
25 m x 0.25 mm x 0.25 µm, gas: He, T = 200 °C, P = 18 psi He, det = 250 °C, inj =
220 °C, (S,R) isomer 24.49 min., (R,S) isomer 25.04 min., (S,S) isomer 25.57 min.,
(R,R) isomer 25.99 min.) 31 % de.
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The following chromatography of this crude mixture, the diastereomers D1-7a and
D2-7b were obtained. The GC traces of these isomers are shown in the next two GC
traces.
GC trace 2: D1-7a, 78 % ee.
This GC trace was obtained from a chromatographically separated sample of D1-7a.
Different GC conditions (to those in GC trace 1) were required for adequate
separation. The racemic standard for this run is shown in GC trace 3. Chiral
separation details: (CP – ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: H, T
= 185 °C, P = 18 psi H, det = 250 °C, inj = 220 °C, (S,R) isomer 18.61 min., (R,S)
isomer 19.24 min.) 78 % ee.
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GC trace 3: (±)-(D1)-7a (racemic standard).
This GC trace of (D1)-7a was used as a racemic standard for GC trace 2: (CP –
ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: H, T = 185 °C, P = 18 psi H,
det = 250 °C, inj = 220 °C, (S,R) isomer 18.64 min., (R,S) isomer 19.16 min.).
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GC trace 4: (±)-D1-7a (in reference to GC 1).
This GC trace of racemic (D1)-7a was run at the same conditions as GC trace 1 to
enable comparison. Chiral separation details: (CP – ChiraSil – DEX CB 25 m x 0.25
mm x 0.25 µm, gas: He, T = 200 °C, P = 18 psi He, det = 250 °C, inj = 220 °C, (S,R)
isomer 24.62 min., (R,S) isomer 25.11 min.).
GC trace 5: D2-7b, 78 % ee.
This GC trace was obtained from a chromatographically enriched sample of D2-7b
(72 % D2). The racemic standard is shown in GC trace 6. Chiral separation details:
(CP – ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: H, T = 200 °C, P = 18
psi He, det = 250 °C, inj = 220 °C, (S,R) isomer 24.48 min., (R,S) isomer 25.00 min.
(S,S) isomer 25.54 min., (R,R) isomer 26.09 min.) 78 % ee.
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GC trace 6: (±)-D2-7b.
This GC trace of (±)-D2-7b was used as a racemic standard for GC trace 5. Chiral
separation details: (CP – ChiraSil – DEX CB 25 m x 0.25 mm x 0.25 µm, gas: He, T
= 200 °C, P = 18 psi He, det = 250 °C, inj = 220 °C, (S,S) isomer 25.52 min., (R,R)
isomer 25.99 min.).
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GC trace 7: the ATH products of methyl lactam ketone 310.
This GC trace was obtained from the unseparated mixture of diastereomers obtained
from the ATH of methyl lactam ketone 310. (CP – ChiraSil – DEX CB 25 m x 0.25
mm x 0.25 µm, gas: He, T = 200 °C, P = 18 psi He, det = 220 °C, inj = 220 °C, (S,R)
(minor) isomer 24.70 min., (R,S) (major) isomer 25.25 min., (S,S) (major) isomer
25.83 min., (R,R) (minor) isomer 26.19 min.) 20 % de; (R,S), 85 % ee; (S,S), 49 %
ee.
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Appendix IV: Catalyst and Ligand Structures from Section 2.
Asymmetric hydrogenation catalysts:
Non-chiral hydrogenation catalysts:
Asymmetric transfer hydrogenation catalysts:
